" 10 " on
" 10 "
" 10
" 15 " on
" 15 "
" 15
" 30 " on
" 30 "
" 30
" 5 " on
" 5 "
" 5
" 640 " on
" 640 "
" 641 " on
" 641 "
" 643 " on
" 643 "
" A "
" A
" A " over
" A
" A-007 " and "
" A-007 " and
" A-007 "
" A-007
" A-008 " and "
" A-008 " and
" A-008 "
" A-008
" A-009 " and "
" A-009 " and
" A-009 "
" A-009
" A-011 " and "
" A-011 " and
" A-011 "
" A-011
" on the other
" on one side .
" on one side
" on
" and " 10 "
" and " 10
" and " 15 "
" and " 15
" and " 30 "
" and " 30
" and " 5 "
" and " 5
" and "
" and
"
" over " 640 "
" over " 641 "
" over " 643 "
" over
% ( 10
% ( 101
% ( 141
% ( 28 % ;
% ( 28 %
% ( 75
% ( 95 % CI
% ( 95 %
% ( 95
% ( 96
% ( N = 30
% ( N =
% ( N
% (
% )
% )
% ) .
% ) than
% ) of
% ) were receiving cardiovascular
% ) were receiving
per weight loss category for
per weight loss category
per weight loss
per weight
% ) and +0.1
% ) and placebo (
% ) and placebo
% ) and a
% ) and
% ) and
% ) of EPS including
% ) of EPS
% ) of
% ) following the
% ) following
% ) of
% )
7.8 % )
% , and suicidal ideation
% , and
% ,
% .
% ; 0.5
% ; 1.0
% ; 19 % )
% ; 19 %
% ;
% Actraphane 20 : soluble
% Actraphane 20 :
% Actraphane 20
% Actraphane 30 : soluble
% Actraphane 30 :
% Actraphane 30
% Actraphane 40 : soluble
% Actraphane 40 :
% Actraphane 40
% Actraphane 50 : soluble
% Actraphane 50 :
% Actraphane 50
% Actraphane
% of unchanged aripiprazole was
% CI :
% CI ] ( weeks
% CI ] (
% CI ]
% CI
% isophane insulin .
% isophane insulin
% Caucasian and 9 %
% Caucasian and 9
% ] ) .
% ] ) and placebo
% ] ) and
% ] )
% ]
% ansteigt . Die
% ansteigt . Die
% ansteigt .
% ansteigt
% in men treated with
% in bisphosphonate-naïve patients and
% in bisphosphonate-naïve patients
% in bisphosphonate-naïve
% for
% in
% and 73 %
% being
%
% being
%
% of aripiprazole AUC
% of patients )
% of the patients .
% of the patients
% of the patients .
% of the patients
percent received study medicinal product
percent of the patients received
percent received study
% of patients .
% of the patients .
% of patients
% of the patients
% of patients had a
percent of the patients had
percent of the patients had
% of patients
% of the patients
% of the population were
% of the population
% of the administered dose
% of the administered
% of the
% of the
% of
%
% had had a stroke
% ,
%
% for Aclasta-treated
% for Aclasta-treated
% for placebo .
% for placebo
% for both groups )
% for both groups
% for both
% for
% dissolved insulin and 50
% dissolved insulin and 60
% dissolved insulin and 70
% dissolved insulin and 80
% dissolved insulin and 90
% dissolved insulin and
% dissolved insulin
% dissolved
%
% had > 3 sites
% had > 3
% had >
% had >
% had >
% relative to baseline
% in
% with aripiprazole and 3.0
% with aripiprazole and 3.2
% with aripiprazole and
% with aripiprazole
% with placebo .
% with placebo
% with
% after the first
% after
% Black .
% Black
% seines Ausgangsgewichtes reduzierte ,
% und 10
% and haloperidol 73 %
% and haloperidol 73
% and haloperidol
% and isophane insulin 50
% and isophane insulin 60
% and isophane insulin 70
% and isophane insulin 80
% and isophane insulin 90
% and isophane insulin
% and consists of 165
% and consists of
% and AUC
% and
% and 47 %
% and 47
% and
% und
% below baseline levels
% below baseline levels at
% below
%
% for
% in the
% in
% of the
% of
%
7.8 %
percent
was
% .
& Co KG , Kuhloweg
& Co KG ,
& Co KG Kuhloweg 37
& Co KG Kuhloweg
& Co KG
& Co
& D Centre ( Europe
& D Centre (
& D Centre Limited
& D Centre
& D
&
per weight loss category
per weight loss
per weight
reactions ( * ) :
reactions ( * )
( 0 ) 241 941-0
( 0 ) 241
( 0 ) 30 60
( 0 ) 30
( 0 )
( 0
( 0)1 46 25 16
( 0)1 46 25
( 0)1 46
( 0)1 47 56 69
( 0)1 47 56
( 0)1 47
( 0)1 580 00 10
( 0)1 580 00
( 0)1 580
( 0)1
( 0)1628 537 900
( 0)1628 537
( 0)1628
( 0)20 3116 8000
( 0)20 3116 8950
( 0)20 3116 8951
( 0)20 3116 8952
( 0)20 3116 8953
( 0)20 3116 8954
( 0)20 3116
( 0)20
( 0)21 272 16 00
( 0)21 272 16
( 0)21 272
( 0)21
( 0)810 410 500
( 0)810 410
( 0)810
( 0)9 8545250
( 0)9
( 0.5 to
( 0.5
( 0.6 % ) (
( 0.62 mmol/ l )
( 0.62 mmol/ l
( 0.62
( 0.7 ml )
( 0.7 ml
( 0.7
( 0800 ) 731 1736
( 0800 ) 731
( 0800 )
( 0800
( 1 ) 524 40
( 1 ) 524
( 1 )
( 1 800 ) 749
( 1 800 )
( 1 800
( 1 mg/ ml )
( 1 mg/ ml
( 1 ml )
( 1 ml
( 1 to
( 1
( 1.25 mmol/ l )
( 1.25 mmol/ l
( 1.25
( 1.3 % ) (
( 1.3 ml ) aripiprazole
( 1.3 ml ) for
( 1.3 ml ) ,
( 1.3 ml )
( 1.3 ml
( 1.3
( 1/ 100 )
( 1/ 100
( 10 000
( 10
( 1000 IU ) of
( 1000
( 101
( 139 out of 1,062
( 139 out of
( 139 out of
( 139
( 141
( dose 15 mg )
( dose 15 mg
( 16 % ) of
( 16 % )
( 16 %
( 16
( 172 breast , 64
( 172 breast ,
( 172 breast
mg/
( 2 )
( dose 2 mg )
( dose 2 mg
( 2
2
( 2.1 % )
( 2.1 %
( 2.1
( 2.5 % ) of
( 2.5 % )
( 2.5 % ; 0.5
( 2.5 % ;
( 2.5 %
( 2.5
( 2000 IU ) of
( 2000
( 221 multiple
( 23 mg )
( 24-hour
( 24-hour
( 25
( 28
( 29 [ 2.7 %
( 29 [ 2.7
( 29 [
( 29
( 2°C - 8°C )
( 2°C - 8°C
( 2°C -
( 2°C - 8°C )
( 2°C - 8°C
( 2°C -
( 2°C
( 3 ml ) .
( 3 ml )
( 3 ml
( 3
, 3
3
( 3.5
( 30 % )
( 30 % ) .
( 30 % )
( 30 %
( 30 mg )
( 30 mg
( 30
( 300 mg/ m2 ;
( 300 mg/ m2
( 300
( 3000 IU ) of
( 3000
( 31 % )
( 31 %
( 31
( 34 [ 3.2 %
( 34 [ 3.2
( 34 [
( 34
repeated (
( 4 to 6 weeks
( 4 to 6 weeks
( 4 to 6
( 4 to
( 4 or more units
( 4 or more
( 4 or
( 4
( 4000 IU ) of
( 4000
( 44-20 ) 74 18
( 44-20 ) 74
( 44-20 )
( 44-20
( 45 % )
( 5 ) 2649600
( 5 )
( 5 mg in 100
( 5 mg in
( 5 mg
( 5 mg/
( 5 mg/ ml )
( 5 mg/ ml
( 5
( 5.1 % ) .
( 5.1 % )
( 5.1 %
( 5.1
( 5.9 - 6.8
( 5.9 -
( 5.9
( 50
(
( 5000 IU ) of
( 5000
( 53 % ) .
( 53 % )
( 53 %
( 53
( 55 % ) and
( 55 % )
( 55 %
( 55
( 6 % )
( 6 %
( 6 , 12 ,
( 6 , 12
( 6 ,
( 6
( 6.2 - 7.5
( 6.2 -
( 6.2 mmol/ l )
( 6.2 mmol/ l
( 6.2
( 6000 IU ) of
( 6000
( 65 years )
( 65 years
( 65
( 683 breast
( 7.5 mg/ ml )
( 7.5 mg/ ml
( 7.5 mmol/ l )
( 7.5 mmol/ l )
( 7.5 mmol/ l )
( 7.5 mmol/ l
( 7.5 mmol/
( 7.5
( 7000 IU ) of
( 7000
( 75 out of 3,852
( 75
( 8.1 mmol/ l )
( 8.1 mmol/ l
( 8.1
( 8000 IU ) of
( 8000
( 9 weeks )
( 9 weeks
( 9
( 9000 IU ) of
( 9000
( 91 ) 663 50
( 91 ) 663
( 91 )
( 91
( 92
( 95 % )
( 95 % CI :
( 95 % CI
( 95 %
( 95
( 95 % CI :
( 95 % CI
( 96
( > 99 % )
( > 99 %
( > 99
( >
enzyme ( ACE ) inhibitors
enzyme (
( ALT ) ,
( ALT )
( ALT
( AQ ) , Italy
( AQ ) ,
( AQ )
( AQ
( AST ) , increased
( AST ) ,
( AST )
( AST
( AUC ) increased
( AUC ) increased
( AUC )
( AUC
( antibiotics
( aripiprazole
( anti-fungal medicines )
( anti-fungal medicines
( baseline 7.2 % )
( baseline 7.2 %
( baseline 7.2
( baseline 7.3 % )
( baseline 7.3 %
( baseline 7.3
( baseline
( BSAP ) ,
( BSAP ) ,
( BSAP )
( BSAP
( CB1 ) receptors .
( CB1 ) receptors
( CB1 )
( CHMP )
( CHMP
( CLAS ) .
( CLAS )
( CLAS
( CYP3A4-Substrat )
( CYP3A4-Substrat
( quinidine )
CYP2D6 ( quinidine )
( Cmax =
( Cmax =
( Cmax
( dextromethorphan ) .
( dextromethorphan )
( dextromethorphan
( dextromethorphan/ 3-methoxymorphinan ratio )
( dextromethorphan/ 3-methoxymorphinan ratio
( mean age :
( mean age
( E 320 ) 2
( E 320 ) Yarvitan
( E 320 )
( E 320
Tablet core :
Tablet core
Tablet
aluminium lake ( E132 )
aluminium lake ( E132
( E216 ) ,
( E216 ) Sodium hydroxide
( E216 ) per
( E216 )
( E216
( E218 ) Propylene glycol
( E218 ) per ml
( E218 ) per
( E218 )
( E218
( E951 ) Acesulfame potassium
( E951 ) per
( E951 )
( E951
MULTI-PACK ( INCLUDING BLUE BOX
MULTI-PACK ( INCLUDING BLUE
MULTI-PACK ( INCLUDING
( ESAs ) have shown
( iron deficiency ,
( iron deficiency
( inflammation of
( inflammation
( colds )
( colds
( Europe ) , Royaume-Uni
( Europe ) , Storbritannia
( Europe ) , Storbritannien
( Europe ) , Te
( Europe ) , Wielka
( Europe ) ,
( Europe ) , µ
( Europe ) Ltd ,
( Europe ) Ltd 61
( Europe ) Ltd
( Europe )
( Europe
( FACT-An ) general scale
( FACT-An )
( FACT-An
( FINLAND ) AB
( FINLAND )
( FINLAND
( SPC )
characteristics ( SPC )
( fever ) .
( fever )
( fever
flushes ,
flushes
( G-CSF and GM-CSF
( GGT ) , increased
( GGT ) ,
( GGT )
( GGT
( heparin )
( heparin
( heparinisation ) may
( heparinisation )
( heparinisation
before and
before
before and
before
( hydrolysis ) sites on
( hydrolysis ) sites
( hypoglycaemia ) , sugar
( hypoglycaemia ) ,
( hypoglycaemia )
( hypoglycaemia
( haematocrit of 33 -
( haematocrit of 33
( haematocrit of
( haematocrit
( IU ) corresponding to
( IU )
( IU ) per
( IU )
( IU
( infusion )
( infusion
( injection )
( injection
( insulin
( International Unit )
( International Unit
( International
( 0 1 year )
( 0 1 year
( 0 2 year )
( 0 2 year
( ketoconazole )
( ketoconazole
fibrosis ( bone marrow fibrosis
(
( M-II , M-III ,
( M-II
( MAOI ) ,
( MAOI )
( MAOI
( WITH BLUE BOX )
( WITH BLUE BOX
( WITH BLUE
( WITH
( NMS
( MTP ) .
( MTP )
( MTP
( Madrid ) Spain
( Madrid )
( Madrid
( metformin , gliclazide
( metformin ,
( metformin
( medicine to suppress
( medicine to
(
( 45 mg monotherapy
( parent
( mouse spleen cell
( N = 225 )
( N = 225
( N = 229 )
( N = 229
( N = 30 )
( N = 30
( N =
( N
reduction ( N=3,861 )
reduction ( N=3,861
( N = 789 )
( N = 789
iliac crest 1
iliac crest 1
( NPH ) insulin .
( NPH ) insulin
( NPH )
( NPH
THE WEEK (
( NYHA stages I to
( NYHA stages I
( renal
( NovoLet ,
( NovoLet
( omeprazole )
( omeprazole
( PFT ) The
( PFT )
( PFT
Update Report ( PSUR )
( PVC/ aluminium ) Blister
( PVC/ aluminium )
( PVC/ aluminium
phosphate dihydrate , sodium chloride
sodium hydroxide ,
phosphate dihydrate ,
phosphate dihydrate
sodium
plasma concentration
plasma concentration
lips (
( RFT ) The incidence
( RFT ) The
( RFT )
( RFT
( rhabdomyolysis ) , and
( rhabdomyolysis ) ,
tartaric acid ,
( SBECD ) Tartaric acid
( SBECD )
( SBECD
( Serenade ) ,
( Serenade )
( Serenade
Safety
Safety
( heartburn ) , vomiting
( heartburn ) ,
( heartburn )
( heartburn
( study CZOL446M2308 )
( study CZOL446M2308
( study
( sulphonylureas , insulin ,
( sulphonylureas , insulin
( sulphonylureas ,
( sulphonylureas
( symptoms , emergency procedures
( symptoms ,
( symptoms
( tablets
( days 21 , 14
( days 21 ,
( days 21
platelets ( thrombocytes )
platelets ( thrombocytes )
platelets ( thrombocytes
( drip into a vein
( drip
( type 1 )
( type 1 ) ,
( type 1 )
( type 1
( type III ) with
( type III )
( type III
( type
( low blood
( EXP
( atrial fibrillation ) has
( atrial fibrillation )
( atrial fibrillation
( warfarin )
( warfarin
( weeks )
( weeks
( zoledronic acid ) ,
( zoledronic acid ) ,
( zoledronic acid )
( zoledronic acid
( all formulations ) should
( all formulations )
( all formulations
mg tablets
( as hydrochloride ) .
( as hydrochloride )
( as hydrochloride
( as hydrochloride ) .
( as hydrochloride )
( as hydrochloride
( as
( also called serotonin )
( also called serotonin
( also known as non
( also known as
( also known as non
( also known as
( also known
( also
of the
the
of the
the
( behandelte ) Dyslipidämie eingeschlossen
( behandelte )
( behandelte
( reported in 79 %
( reported in 79
( reported in
(
( ca . 16
( approximately 43-55 %
( ca . Me
( ca .
( ca
( i.
(
( i. e.
(
( this should be
( this
(
( also part of
( an antidiabetic medicine )
( an antidiabetic medicine
(
Digoxin ( ein
( another antipsychotic medicine )
( another antipsychotic medicine
( another
( an
(
( a disease
( for a cumulative dose
( for a cumulative
( a
( for a
( a
( an
( once daily )
( once daily
( once
( including all formulations of
( including all formulations
( including
solution ( containing
( produced by
( pooled data* ) :
( pooled data* )
( pooled data*
( glycosylated haemoglobin
substance ( glycosylated haemoglobin
( glycosylated haemoglobin ,
substance ( glycosylated haemoglobin ,
( glycosylated haemoglobin
substance ( glycosylated haemoglobin
( mostly
( human ) .
( human )
( human
( within 90 days
( within 90
( within
( particularly
( particularly overweight patients )
( particularly overweight patients )
( particularly overweight patients
( particularly overweight patients
( particularly overweight
( particularly overweight
( intravenously ) .
( intravenously )
(
( local )
( local
systems ( durable
( with a baseline of
( with a baseline
( with
in
( mean difference to placebo
( mean difference to
( mean difference
( mean
( possibly delayed )
( possibly delayed
( possibly
( possibly delayed ) .
( possibly delayed )
( possibly delayed
( possibly
( n = 131 )
( n = 131
( n = 132 )
( n = 132
( n = 135 )
( n = 135
( n = 136 )
( n = 136
( n =
( n= 938 ;
( n= 938 ;
( not
( low blood calcium levels
( low blood calcium
( low blood
( low
( normal and anaemic rats
( normal and anaemic
( normal and
( normal
( or if
( or
orchiectomy ( surgical castration )
orchiectomy ( surgical castration
orchiectomy (
, oral
oral
, oral
oral
mortality ( p=0.01 ) .
mortality ( p=0.01 )
mortality ( p=0.01
( peripheral arterial
( peripheral
day ;
( rDNA ) .
( rDNA ) or
( rDNA )
day
( rDNA
day
( see section 4.2 )
( see section 4.2 Treatment
( see section dic
( see also section 4.2
( see section 4.2
( see section dic
populations ( see section 4.2
( see section 4.3 )
( see section 4.3
( see section 4.3 )
( See section 4.4 )
( see section 4.4 )
( see section 4.4 -
( see section 4.4 and
( siehe Abschnitt 4.4 und
( See section 4.4
( please see section 4.4
( see section 4.4
( siehe Abschnitt 4.4
( see section 4.5 )
( see section 4.5
( see section 4.6 )
( see section 4.6
( see section 4.8 )
( see section 4.8
( see section 5.1 )
( see section 5.1
( see section 5.2 )
( see also section 5.2
( see section 5.2
( see section 5.3 )
( see section 5.3
( see section 6.1 )
( see section 6.1
( See section
( please see section
( see also section
( see section 4.4 )
( see section
( see sections 4.4 and
( see sections 4.4
Special populations ( see section
is
populations ( see section
( see sections 4.3 and
( see sections 4.3
( see sections 4.8 and
( see sections 4.8
( see sections
( see Annex I )
( See Annex I :
( See Annex I
( see Annex I
( see Table 2 )
( see Table 2
( see Table
( See also section 4.4
( See also section
( See also
( See
( please see
( see also
( see sections
( see
( siehe Abschnitt
Special populations ( see
populations ( see
( subcutaneously ) .
( subcutaneously ) .
( subcutaneously )
( subcutaneously ) .
( subcutaneously )
( thrombotic vascular events
( thrombotic vascular
clotting disorders ( thrombotic vascular
( thrombotic
clotting disorders ( thrombotic
( deep venous thrombosis )
( deep venous thrombosis
( t½ ) is therefore
( t½ ) is
( t½ )
( t½
( and , with
( and ,
( and
, ( and
following
following
(
( below 25°C ) .
( below 25ºC ) .
( below 25°C )
( below 25ºC )
( below 25°C
( below 25ºC
( below 30°C ) .
( below 30°C )
( below 30°C
( injection under the skin
( below
( decreased sensitivity to a
( decreased sensitivity
( decreased
(
( anhydrous ) .
( anhydrous )
( anhydrous
( affecting less than 1
( affecting less than 10
( less than
range ( less than
reference range ( less than
( affecting less
( less
( such as
( such as
( e. g. aminoglycosides or
( e. g. aminoglycosides
( e. g. rifampicin
induce ( e. g. rifampicin
( e. g. stenoses
( e. g. diminished
( e. g. diminished
( e. g. increased exercise
( e. g. increased
( e. g.
( e. g.
treated ( e. g.
( e. g. increased
( e. g.
( e. g.
( e. g.
( e.
induce ( e. g.
( e.
treated ( e.
( e. g. stroke
( e. g. gemfibrozil
( e. g. hypothermia ,
( e. g. hypothermia
( e. g. ,
( e. g.
( e. g.
( e.
( e. g.
( e. g. anaphylactic reaction
( e. g. anaphylactic
( cerebrovascular
( zum
( for pH-adjustment ) ,
( for pH-adjustment )
( for pH-adjustment
( two studies
( two relate
( two
( Clcr
( aluminium
( for
( i. e.
( i.
( new
( reduced
( the
(
)
, (
1
120 (
22 (
29 (
36 (
64 (
Special populations (
Use (
characteristics (
conditions (
day
full
index (
induce (
injections of
injections
populations (
substance (
system (
treated (
vessels (
( oedema ) .
( oedema )
( oedema
nausea ( feeling
) )
)
) , 2C9 ( warfarin
) , 2C9 (
) , 2C9
) , anaemia (
) , anaemia
) , chest pain ,
) , chest pain
) , vomiting ,
) , vomiting
) , weight increase ,
) , grand mal convulsion
) , Italy
) , macrogol 3000
) , macrogol
) , monoamine oxidase inhibitors
) , myalgia (
) , myalgia
) , sodium hydroxide (
) , sodium hydroxide ,
hydroxide , and
) , sodium hydroxide
hydroxide ,
) , ritonavir
) , Royaume-Uni Tél/ Tel
) , Royaume-Uni
) , Storbritannia Tlf :
) , Storbritannia Tlf
) , Storbritannia
) , Storbritannien Tel :
) , Storbritannien Tel
) , Storbritannien Tlf :
) , Storbritannien Tlf
) , Storbritannien
) , Te . :
) , Te .
) , Te
) , and water for
) , and water
) , tartaric acid ,
) , Wielka Brytania Tel
) , Wielka Brytania
) , Wielka
) , sugar
) , as
) ,
) that dissolve the paclitaxel
) inadequately controlled by diet
) which are normally
)
, corresponding to 0.0533 mg
, corresponding to 0.0533
) corresponding to 16.8 micrograms
) corresponding to 16.8
) corresponding to 25.2 micrograms
) corresponding to 25.2
) corresponding to 33.6 micrograms
) corresponding to 33.6
) corresponding to 42.0 micrograms
) corresponding to 42.0
, corresponding to 5.330 mg
, corresponding to 5.330
) corresponding to 50.4 micrograms
) corresponding to 50.4
) corresponding to 58.8 micrograms
) corresponding to 58.8
) corresponding to 67.2 micrograms
) corresponding to 67.2
) corresponding to 75.6 micrograms
) corresponding to 75.6
) corresponding to 8.4 micrograms
) corresponding to 8.4
) corresponding to 84.0 micrograms
) corresponding to 84.0
) corresponding to
, corresponding to
) , increased Aspartate Aminotransferase
) , increased Gamma
) , increased alkaline phosphatase
) , increased alkaline
) , increased
) , if necessary
) , if
) , where prophylaxis against
) , where prophylaxis
) , where
) , where prophylaxis against
) , where prophylaxis
) , where
)
) , contact
) , with an
) , with
) or
) , see section 4.5
) , see section
) , see
) sealed in a
) sealed in
) sealed
) is
) ,
) and
) at
)
,
,
;
move ) ,
to move ) ,
) , µ : +44
) , µ :
) , µ
) . vomiting diarrhoea softened
) . vomiting diarrhoea
) . vomiting
) .
) . dic
) . no
) .
)
)
. ) .
.
received
weight ) .
) 2 mg/ ml
) 2
) 20 501 76 03
) 20 501 76
) 20 501
) 20
) 241 941-0
) 241
) 2649600
) 30 60 25 800
) 30 60 25
) 30 60
) 30
) 524 40 64
) 524 40
) 524
) 663 50 00
) 663 50
) 663
) 731 1736
) 731
) 74 18 84 00
) 74 18 84 16
) 74 18 84
) 74 18 86 68
) 74 18 86
) 74 18
) 74
) 749 749
) 749
Psychiatric disorder : psychotic disorders
) :
) ,
) AB Puh/ Tel :
) AB Puh/ Tel
) AB
) Acesulfame potassium Vanilla
) Acesulfame potassium
) Aclasta
) aripiprazole .
) aripiprazole
ACTIVE SUBSTANCE(S ) AND
ACTIVE SUBSTANCE(S )
ACTIVE SUBSTANCE(S
) Blister ( PVC/ aluminium
) Blister (
) Blister
) OF ADMINISTRATION
) OF
) The incidence of clinical
) The incidence of
) The incidence
) The
) Dyslipidämie eingeschlossen waren ,
) Dyslipidämie eingeschlossen
) No dose adjustment is
) No dose adjustment
) erythropoietin treatment .
) erythropoietin treatment
) erythropoietin
) general scale
) In
) insulin .
) insulin
) Ltd , 61 Aldwych
) Ltd , 61
) Ltd ,
) Ltd 61 Aldwych London
) Ltd 61 Aldwych
) Ltd 61
) Ltd
) Sodium hydroxide (
) Sodium hydroxide Sucrose Purified
) Sodium hydroxide Sucrose
) Sodium hydroxide
) pioglitazone concentration is unchanged
) pioglitazone
) in fracture event
with a
) Propylene glycol Propyl parahydroxybenzoate
) Propylene glycol
) Protamine sulphate Water for
) Protamine sulphate Water
) Hydrochloric acid ( for
) Spain
) AND BOTTLE LABEL FOR
) AND BOTTLE
) AND OTHER INGREDIENT(S )
) AND
) Tartaric acid Sodium
) Tartaric acid
) Yarvitan is a colourless
) Yarvitan is a
) Yarvitan is
) Yarvitan
) als bei Patienten ohne
) als bei Patienten
) than for haloperidol
) als bei
in
) als
) as
) than
) in 384 patients
) in 384
) in
) to insulin human (
) to insulin human
) to pioglitazone or any
) to pioglitazone or
) to pioglitazone
) to
to
) .
blood ) .
)
blood )
) in patients
at the maximum recommended clinical
at the maximum recommended
) with a maintenance dose
) in
) beobachtet . For lp
) beobachtet
) have been reported
) regularly
) regularly and
) regularly
) were 2 5 %
) were 2 5
) were
) to 12 g/ dl
) to 12
) to
) is the current standard
) of
up to 2 years .
up to 2 years
to
significantly greater
taken
) once a day .
) once a day
) once a
) corresponds to 0.035 mg
) corresponds to 0.035
) corresponds to
) were receiving cardiovascular
) were receiving
) increased linearly from
) increased linearly
) increased
) increased
) for the first injection
) for the first
) for the
) for
) to pioglitazone
) to
) in the jaw .
) in the jaw
) compared with patients
) , compared
) compared with
)
) presented in Module
) in the placebo group
) in the
) in vitro .
) in vitro
) in
) is fever .
) is fever
) is therefore
) is
) per orodispersible tablet
) per ml
) per ml 0.2 mg
) per ml 0.2
) per ml
) per
) may be
) may be
) may
) shortly
) may
)
)
metabolised
metabolised
) in women with
) with a
) with
) at six months
) after
) or CYP2D6
) or coma ,
) or coma
or placebo (
or placebo
) , or to other
) or the
) or to any
PenFill ) or pre-filled pens
) , or as
) , or
) or
) , or to
) , or
) or
or
) Excluding finger , toe
)
) per kilogram bodyweight .
) per kilogram bodyweight
) per month , or
) per month ,
) per month
) per month
) per month
) per
) presumably represent rapid
) presumably
) presumably
) are neutropenia (
) are neutropenia
) should be alerted about
) should be alerted about
) are extrapyramidal
, are not sufficient .
are not sufficient .
, are not sufficient
are not sufficient
) are
) should
) should be avoided .
) should be avoided
) should
) should not
) should be
) should
) and +0.1 on placebo
) and +0.1
rat ) and 29 (
rat ) and
) and 6.1 months (
) and 6.1 months
) and 6.1
) and 802 with
) and 802
) and NovoFine needles
) and placebo ( 2.1
) and placebo ( 29
) and placebo (
) and placebo
) and as
) in September 2005 and
) and binding is
) and binding
) and
lymphocytes ) and
) , and was rapidly
) , and was
) and a
) and
) , and
) and
) und
) and/
) .
) should be investigated .
) should be investigated
) .
)
) of EPS including parkinsonism
) of EPS including
) of EPS
) of
) prior to
) is
) is
) has
) was
) were
) during
l ) .
l )
) are too high
) are too high
for
(
) ,
) That
) and
) at
) confirmed
) following the
) following
) in
) low- trauma
) low-
) of
) was
) with
)
,
.
blood )
blood calcium levels )
breaks )
calcium levels )
factors (
levels )
mouth )
move )
rabbit )
received
to move )
weight )
symptoms of
the symptoms of
symptoms
the symptoms
rabbit )
rabbit )
* : in
* : in line with
* : in line
* :
* data from 360 dogs
* data from 360
* data from
* This data
* This
* Additional adverse events
* Additional adverse
* Additional
*
*frequency is based only on
*frequency is based only
*frequency is based
*frequency
* Produced in CHO
* Produced
*Median time to disease progression
*Median time to
*Median time
*Median
*Median Progression Free
*Median Progression Free Survival [
*Median Progression Free Survival
*Survival [ 95 % CI
*Survival [ 95 %
*Survival [ 95
*Survival [
*Survival
+ 31 ( 0 )
+ 31 ( 0
+ 31 (
+ 31 34 857 42
+ 31 34 857
+ 31 34
+ 31
+ 32 2 352 74
+ 32 2 352
+ 32 2
+ 32
+ 33 ( 0)1 47
+ 33 ( 0)1
+ 33 ( 0)810 410
+ 33 ( 0)810
+ 33 (
+ 33
+ 34 ( 91 )
+ 34 ( 91
+ 34 (
+ 34
+ 351 21 412 6600
+ 351 21 412
+ 351 21
+ 351
+ 353 ( 1 800
+ 353 ( 1
+ 353 (
+ 353
+ 354 535 7000
+ 354 535
+ 354
+ 358 ( 0)9 8545250
+ 358 ( 0)9
+ 358 (
+ 358 9 251 21
+ 358 9 251
+ 358 9
+ 358
+ 36(0 ) 20 501
+ 36(0 ) 20
+ 36(0 )
+ 36(0
+ 39 06 5026 01
+ 39 06 5026
+ 39 06
+ 39
+ 40 ( 0)21 272
+ 40 ( 0)21
+ 40 (
+ 40
+ 43 ( 1 )
+ 43 ( 1
+ 43 (
+ 43 1 60 14
+ 43 1 60
+ 43 1
+ 43
+ 43-(0)800 29 5193
+ 43-(0)800 29
+ 43-(0)800
+ 44 ( 0)1628 537
+ 44 ( 0)1628
+ 44 ( 0)20 3116
+ 44 ( 0)20
+ 44 ( 0800 )
+ 44 ( 0800
+ 44 (
+ 44
+ 45 45 93 05
+ 45 45 93
+ 45 45
+ 45
+ 46 8 704 71
+ 46 8 704
+ 46 8
+ 46
+ 47 67 55 53
+ 47 67 55
+ 47 67
+ 47
+ 49 ( 0 )
+ 49 ( 0
+ 49 (
+ 49
+
+0.1 on placebo ( baseline
+0.1 on placebo (
+0.1 on placebo
+0.1
+33 ( 0)1 46 25
+33 ( 0)1 46
+33 ( 0)1
+33 (
+33
+353 1 260 12 55
+353 1 260 12
+353 1 260
+353 1
+353
+358 9 61 33 22
+358 9 61 33
+358 9 61
+358 9
+358
+36 1 457 65 00
+36 1 457 65
+36 1 457
+36 1
+36
+370 ( 5 ) 2649600
+370 ( 5 )
+370 ( 5
+370 (
+370
+371 7364000
+371
+3726441100
+386 ( 0)1 580 00
+386 ( 0)1 580
+386 ( 0)1
+386 (
+386
+43 1 86 6570
+43 1 86
+43 1
+43
+44 ( 0)20 3116 8000
+44 ( 0)20 3116
+44 ( 0)20
+44 (
+44
+45 39 16 84 00
+45 39 16 84
+45 39 16
+45 39
+45
+46 8 732 32 00
+46 8 732 32
+46 8 732
+46 8
+46
+47 23 05 20 00
+47 23 05 20
+47 23 05
+47 23
+47
+49 911 273 0
+49 911 273
+49 911
+49
, -3A4 , and both
, 008 , 010 ,
150/ 001-003 ,
150/ 001-003
150/ 004-006 ,
150/ 004-006
, 007 , 009 ,
, 10 mg , 15
, 10 mg ,
, 10 mg
, 10
, 12 , 24 and
, 12 , 24
, 12 ,
, 12
, 14 and 7 )
, 14 and 7
, 14 and
, 14
, 15 mg and 30
, 15 mg and
, 15 mg
, 15
, 150 or 480 ml
, 150 or 480
, 150 or
, 150
, 17
, 174 gynaecological
, 22 prostate
, 22
, 23 lung , 22
, 23 lung ,
, 23 lung
, 23
, 24 and 36 months
, 24 and 36
, 24 and 36 months
, 24 and
, 24
; 27 % had
; 27 %
27
, 28 , 30 ,
, 28 , 30
, 28 , 56 ,
, 28 , 56
, 28 ,
, 28
, 28
,
, 2C8/ 9
, 2C9 ( warfarin )
, 2C9 ( warfarin
, 2C9 (
, 2C9
, 30 or 45 mg
, 30 or 45
, 30 or
, 30
, 30-36 Avenue Gustave Eiffel
, 30-36 Avenue Gustave
, 30-36 Avenue
, 30-36
, 300 gastro-intestinal ,
, 4 , 8 and
, 4 , 8
, 4 ,
,
49 , 56 ,
, 49 x 1 ,
, 49 x 1
, 49 x
, 49
49 ,
, 5 and 10
, 5 and
, 5
, 56 , 84 ,
, 56 , 84 AND
, 56 , 84
, 56 ,
56 ,
, 56 x 1 ,
, 56 x 1
, 56 x
, 56
, 61 Aldwych , London
, 61 Aldwych ,
, 61 Aldwych
, 61
, 64 gynaecological ,
, 64 gynaecological
, 64
, 67019 Scoppito ( AQ
, 67019 Scoppito (
, 67019 Scoppito
, 67019
79
, 84 , 90 and
, 84 , 90
, 84 , 90 and
, 84 , 90 and
, 84 , 90
, 84 ,
, 84 AND 98
, 84 AND
, 84
, 87 %
, 87
, 9.6 for lorazepam ,
, 90 and 98
, 90 and
, 90
, 90 and 98 tablets
, 90 and 98
, 90 and
, 90 and
, 90
, 98 and 500
, 98 and
, 98
, 98 x 1 tablets
, 98 x 1
, 98 x
, 98 and
, 98
common
100 , , 1/
, ABILIFY orodispersible tablets ,
, ROUTE(S ) AND METHOD
, ROUTE(S ) AND
, ROUTE(S )
, Section 4.2 ) .
, section 4.2 )
, Section 4.2 )
, Section 4.2
, section 4.2
, Section
, section
, akathisia , tremor ,
, akathisia , tremor ,
, akathisia , tremor
, akathisia ,
, akathisia
, akathisia , nausea and
, akathisia , nausea
, akathisia Gastrointestinal disorders
, akathisia
, aneurysms , etc.
, aneurysms
, angiotensin converting enzyme (
, angiotensin converting
, angioedema including swollen tongue
, feeling anxious ,
, feeling anxious
in clinical trials .
, anorexia , hyponatremia
, anorexia ,
, anorexia
, anaemia (
, anaemia
, pharmacist or nurse
, pharmacist or nurse .
, pharmacist or nurse
, pharmacist or
, pharmacist
, anorexia
, areflexia , dyskinesia ,
, areflexia , dyskinesia
, areflexia ,
, areflexia
, aripiprazole , is an
, aripiprazole , is
, aripiprazole ,
, aripiprazole
, ataxia , sensory
, ataxia ,
, ataxia
, respiratory
,
, eye pain Uveitis ,
, eye pain Uveitis
, eye
, eye pain , abnormal
, eye
, BP 27166 , F-37071
, BP 27166 ,
, BP 27166
, BP
, abdominal discomfort ,
,
sweats , hyperhydrosis
, exertional dyspnoea ,
, exertional dyspnoea
, light-headedness , trouble sleeping
, reports of
, reports
, blood in urine
, blood
, blood loss and haemolysis
, flatulence , glossodynia
, flatulence ,
, flatulence
, bradycardia
, joint swelling ,
, chest pain , peripheral
, chest pain ,
status , chest pain
, chest pain , and
, chest pain ,
, chest pain
, County Wicklow .
, County Wicklow
, County
, D-58638 Iserlohn , Germany
, D-58638 Iserlohn ,
, D-58638 Iserlohn
, D-58638
NAMES , PHARMACEUTICAL FORM ,
NAMES , PHARMACEUTICAL FORM
NAMES ,
THAT THE MEDICINAL PRODUCT MUST
THAT THE MEDICINAL PRODUCT
THAT THE
, SUPPLY AND/ OR
HOLDER
HOLDER(S )
,
OF THE
IMPOSED ON
HOLDERS
appearance , dehydration and pale
appearance , dehydration and
appearance , dehydration
with Abraxane at any dose
, Germany
, diabetes mellitus , diabetic
, diabetes mellitus ,
, diabetes mellitus
, diabetes
, diarrhoea
, nitrates , diuretics
, diarrhoea , vomiting ,
, diarrhoea , vomiting
, diarrhoea ,
, diarrhoea ,
, diarrhoea
mean age :
mean age
, dysgeusia , dizziness ,
, dysgeusia , dizziness
, dysgeusia ,
, dysgeusia
, dyskinesia , hyporeflexia ,
, dyskinesia , hyporeflexia
, dyskinesia ,
, dyskinesia
, night sweats , hyperhydrosis
, Gastrointestinal dyspepsia
, night
, dysphagia
E218 , and E216 .
E218 , and E216
E218 , and
E218 ,
, yellow
aluminium intoxication
, episcleritis , iritis
, episcleritis ,
, episcleritis
, vomiting , constipation ,
, vomiting , constipation
, vomiting , an
, vomiting ,
, vomiting , nausea ,
, vomiting , nausea
, vomiting and diarrhoea .
, vomiting and diarrhoea
, vomiting and
, vomiting
, inflammation of
, inflammation
, F-37071 Tours Cedex 2
, F-37071 Tours Cedex
, F-37071 Tours
, F-37071
, FACT-An fatigue scale ,
, fibrates ) .
, fibrates )
, fibrates
, fluid retention , hypoalbuminaemia
, fluid retention ,
, fluid retention
, France
, antidotes ) , if
, antidotes ) ,
, antidotes )
, antidotes
indigestion , abdominal
, gender , and
,
, face oedema
, weight decreased , anorexia
, weight decreased ,
, weight decreased
, weight increase , and
, weight gain and oedema
, weight increase ,
, gliclazide ) .
, gliclazide )
, gliclazide
, glucocorticoids , thyroid hormones
, glucocorticoids ,
, glucocorticoids
, glucose-galactose malabsorption or
, glucose-galactose malabsorption
, glycine ,
, glycine
glycine ,
, HORIZON
, polyuria , urinary incontinence
, urinary tract
, urinary
, hoarseness ,
, hoarseness
, hepatitis ,
, hepatitis
-cyclodextrin ( SBECD )
-cyclodextrin ( SBECD
-cyclodextrin (
-cyclodextrin
b-cyclodextrin ,
, hydroxylation , and N-dealkylation
, hydroxylation , and
, hydroxylation ,
, hyperglycaemia , hypocalcaemia ,
, hyperglycaemia , hypocalcaemia
, hyperglycaemia ,
, hyperglycaemia and diabetes mellitus
, hyperglycaemia and diabetes mellitus
, hyperglycaemia and diabetes
, hyperglycaemia and
, hyperglycaemia
hypertension , lymphoedema
hypertension ,
, hypoalbuminaemia , polydipsia ,
, hypoalbuminaemia , polydipsia
, hypoalbuminaemia ,
, hypoalbuminaemia
, hypoglycaemia , hyponatraemia Common
, hypoglycaemia , hyponatraemia
, hypoglycaemia ,
, hypoglycaemia
, hypocalcaemia , hypoglycaemia ,
, hypocalcaemia , hypoglycaemia
, hypocalcaemia ,
, hypocalcaemia
, hyponatremia
, hyponatraemia Common :
, hyponatraemia Common
, hyponatraemia
, hyporeflexia , neuralgia
, hyporeflexia ,
, hyporeflexia
like and contents of the
like and contents of
like and contents
, hyprolose , carmellose calcium
like
, hydroxypropyl
, hypoaesthesia , paraesthesia .
, hypoaesthesia , paraesthesia
, hypoaesthesia ,
, hypoaesthesia
, haemolysis , blood loss
haemolysis , and bone marrow
haemolysis , and
haemolysis ,
spine , hip , and
spine , hip ,
to breast-feed your baby
your dose of
your dose
your
infection , folliculitis ,
infection , folliculitis ,
, upper respiratory tract infection
, infection or
, infection
, insulin ( human )
, insulin ( human
, insulin (
, insulin , metformin )
, insulin , metformin
, insulin ,
, insulin
, iritis
, Italy
, itching , rash )
, itching , rash
, itching ,
, itching , hives ,
, itching , hives
, itching ,
, itching
achieved during the Coordination group
, keratoconjunctivitis sicca , madarosis
, keratoconjunctivitis sicca ,
, keratoconjunctivitis sicca
, keratoconjunctivitis
, ketoacidosis (
ketoacidosis (
, ketoacidosis
ketoacidosis
, Kilruddery , County Wicklow
, Kilruddery , County
, Kilruddery ,
, Kilruddery
, Km 22 , 67019
, Km 22 ,
, Km 22
, Km
, concentrations and protein binding
, concentrations and
, concentrations
, headache , akathisia ,
, headache , akathisia
, headache , dysgeusia ,
, headache , dysgeusia
, headache , tiredness ,
, headache , tiredness
, headache ,
, headache
, headache Eye disorders Common
, headache Eye disorders
, headache
,
, creatinine and
, creatinine
, Kuhloweg 37 , D-58638
, Kuhloweg 37 ,
, Kuhloweg 37
, Kuhloweg
, lactation or lay
, lactation or
, lactation or
, lactation
, Lda Tel : +
, Lda Tel :
, Lda Tel
, Lda
, London , WC2B 4AE
, London , WC2B
, London ,
, London
pulmonary embolism ,
, pulmonary
,
, M-III , and M-IV
, M-III , and
, M-III ,
, macrogol 3000
, macrogol
, madarosis Eye disorders :
, madarosis Eye disorders
, madarosis
,
, magnesium stearate , yellow
stearate , indigo carmine
, magnesium stearate ,
magnesium stearate , red
stearate ,
, magnesium stearate
, maize starch , microcrystalline
, maize starch , microcrystalline
, maize starch ,
, maize starch ,
, maize starch ,
, maize starch
, Neuroleptic Malignant Syndrome (
, Neuroleptic Malignant Syndrome
, Neuroleptic
, brand ( manufacturer )
, brand ( manufacturer
use machines have
use machines have
, metformin ) were
, metformin ) .
, metformin )
, metformin
, monoamine oxidase inhibitors (
, monoamine oxidase inhibitors
, muscle pain
muscle pain
Gliedern , Muskelschwäche
, myalgia (
, myalgia
myalgia
, myoglobinuria (
, myoglobinuria
, tiredness ,
, tiredness , nausea ,
, tiredness , nausea
, tiredness
, sodium chloride , glycine
, sodium chloride ,
, sodium chloride
, sodium citrate and water
, sodium citrate and
, sodium citrate
, sodium hydroxide (
, sodium hydroxide , sucrose
, sodium hydroxide ,
hydroxide , and
, sodium hydroxide
hydroxide ,
, nausea ( feeling sick
, nervousness ; suicide attempt
, nervousness
difficulty breathing ,
, hives , swelling and
site within a given area
, hives , swelling
, hives ,
site within a
, hives
, neuralgia , sensory loss
, neuralgia , sensory
, neuralgia
, neuropathy , hypoaesthesia ,
, neuropathy , hypoaesthesia
, neuropathy ,
, neuropathy
channel blockers ,
channel blockers
, emergency procedures , antidotes
, emergency procedures ,
, emergency procedures
, nocturia
,
, osteoporosis and QT prolongation
, osteoporosis and QT prolongation
, Oxford Road Uxbridge -
, Oxford Road Uxbridge
, Oxford Road
, Oxford
free from particles and
free from particles
free
, paraesthesia .
, paraesthesia
, cartridges (
, cartridges
, phenprocoumon and metformin
, Nevirapin und Johanniskraut
, pleural effusion , allergic
, pleural effusion ,
, pollakiuria , haematuria
, polydipsia , hyperglycaemia ,
, polydipsia , hyperglycaemia
, polydipsia ,
, polydipsia
polysorbate 80 , hydrochloric acid
, pruritus , or urticaria
, pruritus , or
, pruritus ,
, pulse , respiratory rate
, pyrexia ) ,
, pyrexia )
, pyrexia
, RH12 5AB United Kingdom
, RH12 5AB United
, RH12 5AB
, RH12
, raloxifene
, race or body weight
, race or
, race
, rigors ,
, rigors , oedema ,
, rigors , oedema
, rigors
, rimonabant , is a
, rimonabant , is
, rimonabant ,
, ritonavir (
, ritonavir
, Royaume-Uni Tél/ Tel :
, Royaume-Uni Tél/ Tel
, Royaume-Uni
, restlessness , feeling anxious
, restlessness ,
, restlessness
, redness , pain and
, redness , pain
, redness ,
, S. A.
ACE ) inhibitors ,
ACE ) inhibitors
, thyroid hormones and beta-sympathomimetics
, thyroid hormones and
, thyroid hormones
, insomnia ,
, insomnia
, mucosal inflammation , pain
, mucosal
, somnolence , sedation ,
, somnolence , sedation
, somnolence , tachycardia ,
, somnolence , tachycardia
, somnolence , tremor ,
, somnolence , tremor
, sleepiness , shaking and
, sleepiness , shaking
, somnolence ,
, somnolence ,
, somnolence
inflammation , pain , rigors
inflammation , pain
, swelling and inflammation .
, swelling and inflammation
, swelling and
, swelling and/ or pain
, swelling and/ or
, swelling
, dizziness , headache ,
, dizziness , headache
, dizziness , somnolence ,
, dizziness , somnolence
, dizziness , peripheral motor
, dizziness , peripheral
, dizziness ,
, dizziness
, diaphoresis and cardiac dysrhythmia
, feeling of weakness ,
, feeling of weakness
, sedation , headache
, sedation ,
, sedation
, visual disturbance ,
, visual disturbance
, Spain
, salivation , anorexia ,
, salivation , anorexia
, salivation ,
,
, salivary hypersecretion Vascular
, salivary hypersecretion
taste disturbance ,
, stomatitis
, Storbritannia Tlf : +
, Storbritannia Tlf :
, Storbritannia Tlf
, Storbritannia
, Storbritannien Tel : +
, Storbritannien Tel :
, Storbritannien Tel
, Storbritannien Tlf : +
, Storbritannien Tlf :
, Storbritannien Tlf
, Storbritannien
, injection route
, sucrose , E218 ,
, sucrose ,
, sucrose
, suicidal ideation , and
, suicidal ideation ,
, and suicidal ideation in
, and suicidal ideation
, syncope
, tachycardia ,
, tachycardia ,
, tachycardia
, tamoxifen , hormone replacement
, tamoxifen , hormone
, Te . : +44
, Te . :
, Te .
, Te
, or telithromycin or clarithromycin
, thiazides , glucocorticoids ,
, thiazides , glucocorticoids
, thiazides ,
, thiazides
, tibolone ;
, tibolone
humans
, tremor , dizziness ,
, tremor , dizziness
, tremor , syncope
, tremor ,
, tremor Common :
, tremor Common
, tremor
, urticaria and angioedema ,
, United Kingdom .
, United Kingdom
, United
, sensory loss ,
, sensory loss
, constipation , salivary hypersecretion
, constipation , stomatitis
, constipation , increased
, constipation ,
, constipation ,
, constipation
, vitamin B12 or
, vitamin B12
, WC2B 4AE , United
, WC2B 4AE ,
, WC2B 4AE
, WC2B
HOLDER
HOLDER
, growth hormone and danazol
, growth hormone and
, growth hormone
, delusion and paranoia .
, delusion and paranoia
, delusion and
, delusion
, warfarin ,
, warfarin
, and water for injections
, and water for
, and water
, tartaric acid , sodium
, tartaric acid ,
, Wielka Brytania Tel :
, Wielka Brytania Tel
, Wielka Brytania
, Wielka
, indigestion , abdominal
,
, toothache
, zoledronic acid , is
, zoledronic acid ,
, zoledronic acid
, sugar
, glossodynia , dry mouth
, glossodynia , dry
, glossodynia
but no
but not
but unpreserved product and
but unpreserved product
but unpreserved
but prescribers
but prescribers should be alert
, but with
, but
but
but
loss , emaciated appearance ,
loss , emaciated
, decreased breath sounds ,
, decreased breath sounds
, must be discontinued .
, must be discontinued
pain , abnormal vision ,
pain , abnormal vision
pain , abnormal
, as 10 mg ,
, as 10 mg
, as 10
, as
than
involving 460 women
involving 460
involving
involving
.
, strenuous physical exercise may
, arterial
to learn how
to learn
learn
, including
the request of the EMEA
the request of the
dosing ,
,
,
in 2.3 % of
in 2.3 %
in 2.3
95 % in
patients scheduled for major
scheduled for major
, having a high
patients scheduled
who for any reason cannot
in which
patients scheduled
scheduled for
in which overweight or
in which overweight
in which the body
in which the
,
in which
in
patients
, for example
been observed .
been observed
reported (
were reported (
reported
were reported
, especially in patients
, especially in
, especially when
, especially
before
carefully before
until your condition
until your condition
until your
of Abraxane until
until a stable level
until it
until
until
Abraxane until
until
until
, i. e.
as this will
, since
as
as
, and therefore
, this medicinal product must
should not be
, as a mitosis-stimulating factor
, as a mitosis-stimulating
containing the active
trained in the handling of
trained in the handling
which
risk
, which involved
, which
,
containing
enter
human
risk
the
which
that Abseamed
that aripiprazole
that aripiprazole
that epoetin alfa
that epoetin
that erythropoietins
that your haemoglobin
that your
that pioglitazone
that rimonabant is
make you
that you are
that the dose selector returns
that the effect of
that the effect
indicated that
that the
that
in exposures is
need to
need to
need to
that the
that
containing
indicate that
make
sure
that the
that
that
to
defined by a decrease in
defined by a decrease
defined by a decrease in
defined by a decrease
defined
, the active metabolite ,
, the active metabolite
, the cannabinoid type 1
, the cannabinoid type
, the
, osteoporosis in men
, osteoporosis in
which also
,
, der nach einem Jahr
, der nach einem
, der
, which
in blood
of
the
the
with insufficient glycaemic
glycaemic control despite
, non- smoking
, diabetic ketoacidosis ,
, diabetic ketoacidosis
, diabetic
, diabetic hyperosmolar coma
, diabetic hyperosmolar
(
receiving > 1st-line therapy
receiving Aclasta
receiving Aclasta
receiving aripiprazole solution for injection
, although development of severe
, although development of
the haemoglobin target range of
the haemoglobin target range
to you by your doctor
to you by
that dissolve the paclitaxel ,
that dissolve the paclitaxel
to performing the
those receiving placebo (
receiving placebo
those receiving placebo
to protect the environment
to protect the
, which gives an indication
, which gives an indication
on
, die aus
related to 229 patients
who
to lower the blood pressure
, which produces three active
inadequately controlled by diet and
inadequately controlled by diet
by
as naturally
of one year or
of one year or
of one year
of one year
a
, given weekly
activities detailed in the Pharmacovigilance
activities detailed in the Pharmacovigilance
who have shown an
, but made
, but
, each
recent (
recent
treated with Abraxane
treated with Abseamed
treated with haloperidol
4.3 and
section 4.3 and
4.3
section 4.3
with a bromobutyl/ polyisoprene
with
, not necessarily in association
insufficiency not yet
which are normally
scheduled for major elective
, which is potentially lethal
, which
, micro-ophthalmia ,
,
resulting in discontinuation
( the
, die
, that
, the
, which
, who
,
,
58 The
70 The
The
as
dose of
high risk from
high risk
high
of
related to
that of
that
that
the
to 15
to
to
which
who
, but it attaches to
, but it attaches
, but it
, but
randomised
hypoglycaemia whilst driving .
hypoglycaemia whilst driving
increased risk of
increased risk
, an
a mean total
, a
a 0.69
a
, a potent inducer
both a calibrated
both a
, a cardiovascular
undergo periodic
, a
, a known marker of
, including ABILIFY ,
use , including ABILIFY
, including ABILIFY
including isolated cases of angioedema
including isolated cases of
including isolated cases
, including zoledronic acid
, including those with
, including those
, including dose reduction
including rare cases of
including rare cases
including rare
, including
including
dated Final (
dated Final
corresponding to 16.8 micrograms epoetin
corresponding to 16.8 micrograms
corresponding to 16.8
corresponding to 25.2 micrograms epoetin
corresponding to 25.2 micrograms
corresponding to 25.2
corresponding to 33.6 micrograms epoetin
corresponding to 33.6 micrograms
corresponding to 33.6
corresponding to 42.0 micrograms epoetin
corresponding to 42.0 micrograms
corresponding to 42.0
, corresponding to 5.330 mg
, corresponding to 5.330
corresponding to 50.4 micrograms epoetin
corresponding to 50.4 micrograms
corresponding to 50.4
corresponding to 58.8 micrograms epoetin
corresponding to 58.8 micrograms
corresponding to 58.8
corresponding to 67.2 micrograms epoetin
corresponding to 67.2 micrograms
corresponding to 67.2
corresponding to 75.6 micrograms epoetin
corresponding to 75.6 micrograms
corresponding to 75.6
corresponding to 8.4 micrograms epoetin
corresponding to 8.4 micrograms
corresponding to 8.4
corresponding to 84.0 micrograms epoetin
corresponding to 84.0 micrograms
corresponding to 84.0
, corresponding to
corresponding to
experienced the development
revealed no medically important
revealed no medically
revealed no
revealed
appropriate you will receive
, increase the risk of
, increase the risk
, increase
increased
, increased Alanine Aminotransferase (
, increased Alanine Aminotransferase
, increased Aspartate Aminotransferase (
, increased Aspartate Aminotransferase
, increased Gamma Glutamyl Transferase
, increased Gamma
, increased alkaline phosphatase
, increased alkaline
, increased
, increased risk of
, increased risk
, increased
unless
unless
.
, if necessary
, if
, colourless , aqueous solution
, colourless , aqueous
, colourless ,
, colourless solution for injection
, colourless solution
, colourless
this product , ask your
this product , ask
for
, there were no
, there were
, give
, followed by
administered intravenously
to
, purified water , and
, purified water ,
,
was well
well
well tolerated in
well tolerated
was well
well
, but had no effect
, but had no
, but had
, binding primarily to albumin
, but more frequently
, but more frequently
, but more frequently when
, but more frequently
, ideally starting before the
, ideally starting before
, ideally starting
, ideally
, compared
as compared to
as compared
in patients
in both groups
similar in both groups
in both
, in denen Midazolam (
, in denen Midazolam
in which pioglitazone was
, in
in which
the pharmacokinetics
the
, where prophylaxis against
, where prophylaxis
, where
, in some cases
, in some
, in
, where prophylaxis against
, where prophylaxis
, where
,
in
looking at
by pinching the
by pinching
by
shown to
shown
, tell your doctor
, inform your
, please tell your
, inform
, please tell
, tell
, including PANSS and the
, including PANSS and
, including PANSS
, especially infections and
, especially infections
, especially those
, especially
, particularly if
, especially
, particularly
particularly
, intermediate-acting combined with
, intermediate-acting combined
, intermediate-acting
, intestinal calcium malabsorption )
, intestinal calcium malabsorption
, intestinal calcium
, the treatment
, therapy should be discontinued
, therapy
, is a bisphosphonate .
, is a bisphosphonate
, is an antipsychotic medicine
, is a
, is an
, it is
, is
,
baseline body weight after
baseline body weight
is
, but this is
osteoporosis , but not other
osteoporosis , but not
, but
but
osteoporosis , but
, both via subcutaneous administration
, both via subcutaneous
, both via
, both
,
, both via
, both
,
, the dose may
, it may
clinical
,
study ,
, causal relationship has
,
study ,
, contact
randomised , controlled ,
, controlled ,
controlled
, controlled
controlled
may occur .
may occur
, may
, may
may
, long-acting insulin
, long-acting
, read the
, read
, lesen Sie bitte
, read
, median time to
headaches as a
like headaches as
, microcrystalline
, marked with A-007
, marked with A-008
, marked with A-009
, marked with A-011
, marked with
, marked with
, marked with
, engraved with "
, marked with "
, engraved with
, marked with
, with an
, with or
, with
has to be
should be carefully
should be carefully monitored
should be
you
, take the
, take
, neuropathic pain , tremor
, neuropathic pain ,
, neuropathic pain
, neuropathic
lon Hypoaesthesia Sciatica Paresthesia
lon Hypoaesthesia Sciatica
, but not in monkeys
, but not in
, but not
not
, non-selective beta- blocking agents
decreases with subsequent doses
decreases with subsequent
with subsequent doses
with subsequent
if paclitaxel
whether pioglitazone
whether zoledronic acid
considered
whether to
whether or not there
if
whether or
whether
, although
, or if you are
, or if
, or
or
, open-label studies , 2697
, open-label studies ,
without
, orthostatic hypotension Rare :
, orthostatic hypotension Rare
, orthostatic hypotension
, orthostatic
in patients who received dic
patients who received dic
in patients who
patients who
who
continuing surveillance of
continuing surveillance
, peripheral coldness , orthostatic
, peripheral coldness ,
, peripheral coldness
, peripheral motor neuropathy ,
, peripheral motor neuropathy
, peripheral motor
, peripheral
, peripheral oedema
, placebo-controlled trial
, placebo-controlled trial
, sudden unexplained death ,
, sudden unexplained
, sudden
, polycythaemic mice ) .
, polycythaemic mice )
, polycythaemic mice
, postural dizziness , neuropathic
, postural dizziness ,
, postural dizziness
, postural
, rDNA ( produced by
, rDNA (
, rDNA
, randomised , double-blind
, reduced visual acuity ,
, reduced visual acuity
, reduced
is based on your
based
, round tablets contain 15
, round tablets contain
, round tablets
, round
,
plan to become pregnant .
plan to become pregnant
, severe weight loss ,
, severe weight
, severe
usual , talking very
, sensory disturbance , somnolence
, sensory
, please contact
, please contact
please contact
about hurting yourself .
about hurting yourself
to adhere strictly
but its occurrence is very
but its occurrence
, see section 4.5 .
, see section 4.5
, see section
, see the
, see
, liver enzyme levels should
, are shown below .
, are shown below
, are shown
, are
,
as soon as
, if applicable
, the aripiprazole dose should
the dose should
, the dose should
should be
should
should be
,
should
treated with antidepressants ,
and
, and
reflected differences in
reflected differences
, sterile ,
highly palatable , sweet or
highly palatable ,
Tell
, deep vein thrombosis ,
, deep vein thrombosis
, deep vein
, nasal dryness , wheezing
, dry mouth
, pruritus , erythema
, dry
, teardrop- shaped tablets .
, teardrop- shaped tablets
to maintain urea , creatinine
to maintain urea ,
to maintain urea
draw conclusions regarding
to minimise the risk of
accordingly to minimise the risk
to minimise the risk
in order
to expose the tablet
in order to avoid microbial
to ensure that
to ensure
draw conclusions
in order to
in order
, and doses
, and doses above 45
, and doses above
, and Vantas
and the median
, and the majority
, and the
and a negative impact
and a negative
and a
, und
, and
, und
, which showed a
, which showed
, which
,
and its
and
of sugar
sugar
.
, incoherent speech
vascular events , such as
vascular events ,
, ventricular arrhythmias , sudden
, ventricular arrhythmias ,
, ventricular arrhythmias
, ventricular
.
compared
compared to
compared to
compared
, decreased by
,
of
, decreased performance
, decreased
, blurred vision ,
, blurred vision
sealed in a blister
sealed in a
sealed in
sealed
per week
system . lp
, cases
,
to
, flushing
was lower in a smaller
was
were : nausea ,
, indicating extensive
, which
, however
, which
direct- acting
direct-
on the type of food
the type of food
type of food
on the type of
the type of
type of
to increase the effectiveness of
to increase the effectiveness
to increase the
to
that permitted recovery from
that permitted
that
that
questions , ask
, less than 1
, less than 1
, less than
, less
when concomitant administration of ABILIFY
when Aclasta
when erythropoiesis stimulating agents (
when erythropoiesis stimulating agents
when haemoglobin values exceeding 12
when haemoglobin values exceeding
when pioglitazone
when pioglitazone
if you are having any
while you are using Abseamed
while you are using
if you are pregnant
if you are breast-feeding .
if you are breast-feeding
if you are
if you are
if you are
if you
if you
you are
when treatment with
when treatment
when a rapid
when a
if they
behaviour when
if
if
intervals unless
when
when
, you may not
,
how your anaemia
how your
how
how
how the anaemia
how the
benefit
of how well the
how well
, such as fever
such as unusual
, such as
such as
, as
,
as instructed
as
decide how
how
how
your doctor may
, the treatment will
, the use
, the
, no information will
is
effective than
effective
and this
this
and this
this
unit dose blisters
unit dose
of
, whilst the relative efficacy
, whilst the relative
, whilst the
of
, whilst
was
in
, were
, while approximately 86 %
, while approximately 86
, while approximately
, while the
levels , while
levels , while
levels , while
, while
while
, aqueous solution .
, aqueous solution
, aqueous
, a
, cerebrovascular
to pioglitazone or placebo
to pioglitazone or
to pioglitazone
, may lead to hyperglycaemia
,
to
, serotonin 5HT2c and 5HT7
, ,
, and
, around
, as
, cases
, decreased breath
, donate
, drug interactions
, drug
, feeling of
, feeling
, for
, given the
, given
, influenza-like
, non-
, pain in the
, pain in
, pain
, reduced
, salivation
, sensory
, some
, the
, typically
, when
, which showed a
, which showed
, which
,
0.69
3 , and
3 ,
:
;
ACOMPLIA and
ACOMPLIA
HbA1c ,
Human Use
Human
advised during
advised
appearance ,
appropriate preventive
as
at risk of
at risk
blood
body
cancer before ,
combination
containing
dated
determined ,
disorder ,
disturbance ,
enzyme involved
enzyme
exceeding
glycerin ,
high risk from
high risk
high
in combination
in exposures
in
increased ,
intervals
it , donate
it ,
its
looking
loss ,
necessary for
necessary
of ACOMPLIA and
of ACOMPLIA
of
osteoporosis ,
risk of
risk
serious
shortness of breath
smaller
study ,
that
the
there is
there
to be
to it , donate
to it ,
to
ulceration ,
unless
use of ACOMPLIA and
use of ACOMPLIA
well
when
where there is
where there
which
who
with
, µ : +44 (
, µ : +44
, µ :
, µ
, oedema ,
, oedema
, oesophagitis , toothache
, oesophagitis ,
, oesophagitis
, nausea , vomiting ,
, nausea , vomiting and
, nausea , vomiting
, nausea , constipation ,
, nausea , constipation
, nausea ,
, nausea and vomiting
, nausea and vomiting
, nausea and
, nausea
have similar effects and similar
, anxious or tense
, anxious or tense .
, anxious or tense
, anxious or
, anxious
, usually in
, usually
- 100
- 14 g/ dl (
- 14 g/ dl .
- 14 g/ dl
- 14
- 150 30 - 100
- 150 30 -
- 150 30
- 150 60 - 150
- 150 60 -
- 150 60
034 - 150 ml bottle
- 150 ml
- 150
2 g/ dl per month
2 g/ dl per
to 2 g/ dl per
2 g/ dl
to 2 g/ dl
- 200 mg
- 200
to 23 hours .
to 23 hours
to 23
- 300 mg Fe2+/ day
- 300 mg
- 300
- 39 % )
- 39 %
- 39
035 - 480 ml bottle
035 - 480 ml
035 - 480
- 50 ml bottle
- 50 ml
- 50
6.2 months ) and
6.2 months )
6.2 months
6.2
- 6.8 mmol/ l )
- 6.8 mmol/ l
- 6.8
- 7.5 mmol/ l )
- 7.5 mmol/ l
- 7.5
- 8°C ) .
- 8°C )
- 8°C
- Aclasta 5 mg
- Aclasta 5
- Aclasta
- General )
- General
- Keep out of the
- Treatment of anaemia associated
- Treatment of
- Treatment
- In pregnant or
- In
- raised blood pressure which
- raised blood pressure which
- blood clotting ( thrombotic
- blood clotting (
- blood clotting
- Diabetic retinopathy Long-term improved
- Diabetic retinopathy
- Diabetic
- The other ingredients are
- The other ingredients
- The other ingredients
- The
- This medicine has been
- This medicine
- This
- Occlusion in the connection
Pure Red Cell Aplasia )
- The unopened bottle does
- a small reduction in
- a small
- flu-like symptoms ,
- flu-like symptoms
- flu-like
- cardiac failure or
- cardiac failure
Method of administration )
Method of administration
Method
- Store and transport refrigerated
- Store
- metformin , in patients
- metformin , in
- metformin and a sulphonylurea
- metformin and
- metformin ,
- metformin
- Middlesex UB8 1HU -
- Middlesex UB8 1HU
- Middlesex UB8 1HU -
- Middlesex UB8
- Middlesex
- After
- After opening the bottle
- After opening the
- After opening
- oral iron substitution of
- chronic renal failure patients
- Peripheral neuropathy
- Peripheral
- Produtos Farmacêuticos , Lda
- Produtos Farmacêuticos ,
- Produtos Farmacêuticos
- Produtos
- Refraction disorders
- Do not use Aclasta
- Do not use
- Do not use
- United Kingdom
- United
- decreased blood sugar (
- decreased blood sugar
- decreased
- if you are
- If you are
- If you have
- If you
- if you are
- if you have
- if you
- if you
- if you have had
- if you have
- If
- in patients ( particularly
- in patients (
- in patients
- in
- a sulphonylurea , only
- a sulphonylurea ,
- a sulphonylurea
- increased risk
- shortened overall survival and
- shortened overall survival
- shortened
- to minimise the risk
- decreased locoregional control
- if you have high
- If you
- if you are
- if you have developed
- if you
- if you cannot receive
- if
- if the solution
- if the
- if
even several weeks prior to
, even several weeks
even several weeks
, even several
even several
- if
- in
-
ACOMPLIA is indicated in
to
works by blocking specific receptors
- Oedema Oedema may
- hypersensitivity
-0.6 for rimonabant 20 mg
-0.6 for rimonabant 20
-0.6 for rimonabant
-0.6 for
-0.6
-2.9 kg ) .
-2.9 kg )
-2.9 kg
-2.9
-2C8 and -3A4 respectively .
-2C8 and -3A4 respectively
-2C8 and
-2C8
-3A4 respectively .
-3A4 respectively
-hydroxypaclitaxel and 3 -p-hydroxypaclitaxel ,
-hydroxypaclitaxel and 3 -p-hydroxypaclitaxel
-hydroxypaclitaxel and 3
-hydroxypaclitaxel ; and
-hydroxypaclitaxel and
-hydroxypaclitaxel ;
-hydroxypaclitaxel
inducers ( e. g. rifampicin
g. insulin dosage ,
g. insulin dosage
-3 -p-dihydroxypaclitaxel
-3 -p-dihydroxypaclitaxel
-p-hydroxypaclitaxel ,
-p-hydroxypaclitaxel and 6 -3 -p-dihydroxypaclitaxel
-p-hydroxypaclitaxel and 6
-p-hydroxypaclitaxel
) .
. 16
5.2 ) .
. : + 36(0 )
. : + 36(0
. : +
. : +36 1 457
. : +36 1
. : +36
. : +44 ( 0)20
. : +44 (
. : +44
. :
Abseamed 3000 IU/ 0.3 ml
Abseamed 3000 IU/ 0.3
Abseamed 3000
Abseamed 4000 IU/
Abseamed 5000 IU/
Abseamed 6000 IU/ 0.6 ml
Abseamed 6000 IU/ 0.6
Abseamed 6000 IU/
Abseamed 7000
Abseamed 8000 IU/ 0.8 ml
Abseamed 8000 IU/ 0.8
Abseamed 8000
Abseamed 9000
Abseamed
the request of the EMEA
the request of the
with
with
medication .
Date of last
Date of
Date
ABILIFY dose should be reduced
patients should be
3 trials
trials
. Die
. Die
.
The pharmacokinetic parameters
The pharmacokinetic
. Die
.
The
. of
.
but this dose should be
this dose should be
this dose
as measured
as measured
and such patients
such patients
and such
such
this
This
a trend
trend
a trend
trend
efficacy or other
loss of efficacy or other
of efficacy or other
efficacy or
loss of efficacy or
of efficacy or
efficacy
loss of efficacy
of efficacy
. vomiting diarrhoea softened stools
. vomiting diarrhoea softened
. vomiting diarrhoea
. vomiting
. It can be
. It
hypothermia , pyrexia )
hypothermia , pyrexia
hypothermia ,
hypothermia
.
Within 60 days of
Within
.
European
testing did not
testing
OF THE
) .
. For lp
. The
. no
. of
.
Me
action .
be a
be
between .
conditions .
day ) .
days.
disorders .
effects .
for resorption
in between .
infusion .
levels .
occur .
other .
period .
prescribed .
resorption
studies .
swallowing .
to
treatment .
treatment in between .
years .
and/ or dark urine ,
and/ or dark urine
and/ or dark
. europa . eu/
/
stopper .
stopper
0 ) 241 941-0
0 ) 241
0 ) 30 60 25
0 ) 30 60
0 ) 30
0 )
0 )
0
0)1 46 25 16 16
0)1 46 25 16
0)1 46 25
0)1 46
0)1 47 56 69 00
0)1 47 56 69
0)1 47 56
0)1 47
0)1 580 00 10
0)1 580 00
0)1 580
0)1
0)1628 537 900
0)1628 537
0)1628
0)20 3116 8000
0)20 3116 8950
0)20 3116 8951
0)20 3116 8952
0)20 3116 8953
0)20 3116 8954
0)20 3116
0)20
0)21 272 16 00
0)21 272 16
0)21 272
0)21
0)810 410 500
0)810 410
0)810
0)9 8545250
0)9
received dic
received dic
dic
sulphone 0.0471 µg/ ml
0.01
0.02 mg/ kg daily was
0.02 mg/ kg daily
0.02 mg/ kg
0.02
0.035 mg of anhydrous
0.035 mg
0.035
0.05 mg zoledronic acid anhydrous
0.05 mg zoledronic acid
0.05 mg zoledronic acid anhydrous
0.05 mg
0.05
0.0533 mg zoledronic acid monohydrate
0.0533 mg
0.0533
0.05330 mg zoledronic acid monohydrate
0.05330 mg
0.05330
0.1 mg/ kg
0.1
0.14 % in
0.14 %
0.14
0.2 mg propyl parahydroxybenzoate (
0.2 mg propyl parahydroxybenzoate
0.2 mg
0.2 mg/ kg
0.2
0.25 mg/ kg
0.25
0.3 ml ( 3000
0.3 ml (
0.3 ml 6
of 0.3 ml 6
0.3 ml solution for injection
0.3 ml contains 3000 international
0.3 ml contains 3000
of 0.3 ml contains 3000
0.3 ml contains
of 0.3 ml contains
0.3 ml
of 0.3 ml
0.3
of 0.3
0.35 %
0.35
0.4 ml ( 4000
0.4 ml (
of 0.4 ml 6
0.4 ml contains 4000 international
0.4 ml contains 4000
of 0.4 ml contains 4000
of 0.4 ml contains 4000
0.4 ml contains
of 0.4 ml contains
of 0.4 ml contains
0.4 ml
of 0.4 ml
of 0.4 ml
0.4
of 0.4
of 0.4
0.45
of 0.45
0.5 % ) of
0.5 % )
0.5 %
0.5 to
0.5 ml ( 1000
0.5 ml ( 5000
0.5 ml (
0.5 ml 6
of 0.5 ml 6
0.5 ml contains 1000 international
0.5 ml contains 1000
of 0.5 ml contains 1000
0.5 ml contains 5000 international
0.5 ml contains 5000
of 0.5 ml contains 5000
0.5 ml contains
of 0.5 ml contains
0.5 ml
of 0.5 ml
0.5
of 0.5
0.6 % )
0.6 %
0.6 mg/ kg
0.6 ml ( 6000
0.6 ml (
of 0.6 ml 6
0.6 ml solution for injection
0.6 ml contains 6000 international
0.6 ml contains 6000
of 0.6 ml contains 6000
of 0.6 ml contains 6000
0.6 ml contains
of 0.6 ml contains
of 0.6 ml contains
0.6 ml
of 0.6 ml
of 0.6 ml
0.6
of 0.6
of 0.6
0.62 mmol/ l ) or
0.62 mmol/ l )
0.62 mmol/ l
0.62
0.63 mg mitratapide/ kg bodyweight
0.63 mg mitratapide/
0.63 mg
0.63
0.7 ml ( 7000
0.7 ml (
0.7 ml ) may be
0.7 ml )
of 0.7 ml 6
of 0.7 ml contains 7000
of 0.7 ml contains
0.7 ml
of 0.7 ml
0.7
of 0.7
0.8 % of
0.8 % for placebo .
0.8 % for placebo
0.8 % for
0.8 %
0.8 ml ( 8000
0.8 ml (
of 0.8 ml 6
0.8 ml solution for injection
0.8 ml contains 8000 international
0.8 ml contains 8000
of 0.8 ml contains 8000
0.8 ml contains
of 0.8 ml contains
0.8 ml
of 0.8 ml
of 0.8 ml
0.8
of 0.8
of 0.8
0.9 ml ( 9000
0.9 ml (
of 0.9 ml 6
of 0.9 ml contains 9000
of 0.9 ml contains
0.9 ml
of 0.9 ml
0.9
of 0.9
0.94
0.99 , 1,18 ; 42
0.99 , 1,18 ;
0.99
0 1
00 10
00
000 IU ) of solution
000 IU ) of
000 IU of epoetin alfa*
000 IU
000 IU/ 1 ml
000 IU/ 1 ml
000 IU/ 1
000 IU/
000 international units ( IU
000 international units (
000 international units
000 international
to 125,000 international units
000
8,000
008 , 010 , 019-021
008 , 010 ,
150/ 001-003 ,
150/ 001-003
150/ 004-006 ,
150/ 004-006
007 , 009 , 016-018
007 , 009 ,
01
016-018
019-021
03
05 06
05 20 00
05 20
05
06 5026 01
06 5026
06
1,062 ) .
1,062 )
1,062
0800 ) 731 1736
0800 ) 731
0800 )
0800
1 %
1 % of
1 %
1 ( CB1 ) receptors
1 ( CB1 )
1 )
1 )
1 ) 524 40 64
1 ) 524 40
1 ) 524
1 ) ,
1 )
1 , 49 x 1
1 , 49 x
1 , 49
1 , 5 and 10
1 , 5 and
1 , 5
1 , 56 x 1
1 , 56 x
1 , 56
1 , 98 x 1
1 , 98 x
1 , 98
1 ,
1 to 2 g/ dl
1,062 ) .
1,062 )
1,062
1 260 12 55
1 260 12
1 260
1 457 65 00
1 457 65
1 457
1 60 14 30
1 60 14
1 60
1 800 ) 749 749
1 800 ) 749
1 800 )
1 800
1 86 6570
1 86
1 CONDITIONS OR RESTRICTIONS WITH
1 CONDITIONS OR
1 CONDITIONS
1 diabetes ,
1 diabetes
1 The
1 vial contains 10
1 vial contains
1 vial
1 pre-filled syringe of 0.3
1 pre-filled syringe of 0.4
1 pre-filled syringe of 0.4
1 pre-filled syringe of 0.5
1 pre-filled syringe of 0.6
1 pre-filled syringe of 0.6
1 pre-filled syringe of 0.7
1 pre-filled syringe of 0.8
1 pre-filled syringe of 0.8
1 pre-filled syringe of 0.9
1 pre-filled syringe of 1
1 pre-filled syringe of
1 pre-filled syringe
1 film-coated
1 bottle
1 bottle - 100 ml
1 bottle - 100
1 bottle contains 5 mg
1 bottle contains 5
1 bottle contains
1 bottle
1 month after
1 month
1 orodispersible tablets 28 x
1 orodispersible tablets 28
1 orodispersible tablets 49 x
1 orodispersible tablets 49
1 orodispersible tablets
1 tablets .
1 tablets 28 x 1
1 tablets 28 x
1 tablets 28
1 tablets 49 x 1
1 tablets 49 x
1 tablets 49
1 tablets 56 x 1
1 tablets 56 x
1 tablets 56
1 tablets 98 x 1
1 tablets 98 x
1 tablets 98
1 tablets in
1 tablets
1 and 10
1 and 10
1 g/ dl ( 0.62
1 g/ dl (
1 g/ dl
1 mg/ ml ) and
1 mg/ ml )
1 mg/ ml oral solution
1 mg/ ml
1 ml ( 10 000
1 ml ( 10
1 ml ( 2000
1 ml (
1 ml )
1 ml 6
of 1 ml 6
1 ml of the product
1 ml contains 10 000
1 ml contains 10
of 1 ml contains 10
1 ml contains 100
1 ml contains 2000 international
1 ml contains 2000
of 1 ml contains 2000
1 ml contains 40
1 ml contains
of 1 ml contains
1 ml
of 1 ml
1 or 2 ) at
1 or 2 )
1 or 2 ) at
1 or 2 )
1 or 2
1 or
1
1 and 5 vials
1 and 5
1 and
1
once weekly
1 and
1 patient
1 to
1
of 1
IU/ kg/ day .
IU/ kg/ day
, 1.0
1.0
of 1.0
in favour
1.1
, 1,18 ; 42 trials
, 1,18 ; 42
, 1,18 ;
1.2
1.25 mmol/ l ) per
1.25 mmol/ l )
1.25 mmol/ l
1.25 and 2.47 in favour
1.25 and 2.47 in
1.25 and
1.25
1.3 % )
1.3 %
1.3 ml ) aripiprazole .
1.3 ml ) aripiprazole
1.3 ml ) for the
1.3 ml ) for
1.3 ml ) ,
1.3 ml )
1.3 ml
1.3 ml
1.3
1.35 , 2.06 , 35
1.35 , 2.06 ,
ml
1.44 % for Aclasta-treated
1.44 % for Aclasta-treated
1.44 % for
1.44 %
1.44
reached
1.5 x 109/ l
1.5 x
1.5
95 % CI :
95 % CI
95
1.8 %
1.8 mg methyl parahydroxybenzoate (
1.8 mg methyl parahydroxybenzoate
1.8 mg
1.8
1.87
1.9 % ( 75
1.9 % (
1.9 %
1.9
in every 1,000 patients )
in every 1,000 patients
1/
1/ 100 )
1/ 100
10 " on one side
10 " on
10 "
10 % ( 101
10 % (
10 % , and
10 % ,
10 % ; 19 %
10 % being
10 %
10 % being
10 %
10 % dissolved insulin and
10 % dissolved insulin
10 % dissolved
10 % and isophane insulin
10 % and
10 %
10 000 IU ) of
10 000 IU
10 000 IU/ 1 ml
10 000 IU/ 1 ml
10 000 IU/ 1
10 000 IU/
10 000 international units (
10 000 international units
10 000 international
10 000
10 : soluble insulin 10
10 : soluble insulin
10 : soluble
10 :
10 ACTRAPHANE 20 ACTRAPHANE 30
10 ACTRAPHANE 20 ACTRAPHANE
10 ACTRAPHANE 20
10 ACTRAPHANE
Dosage adjustment Concomitant illness
Effect on all clinical
Effect on all
Effect on
Effect
9 In a
In a
9 In
In
Following intravenous administration of
Following intravenous administration
Following intravenous
Following
10 NovoLet 100
10 NovoLet
patient in 10 ) is
patient in 10 )
patient in 10
10 cartridges x 3
10 cartridges x
10 cartridges
10 Penfill 100
10 Penfill
10 days after
10 days following
days after
10 days
days
10 days
10 on one side .
10 on one side
10 on
10 consists of 10 %
10 consists of 10
10 consists of
10 g/ dl ( 6.2
10 g/ dl (
10 g/ dl - 12
10 g/ dl
10 g/ dl
10 kg BW 120 ml
10 kg BW 120
10 kg BW
10 kg
10 mg , 15 mg
10 mg , 15
10 mg ,
10 mg of aripiprazole .
10 mg of aripiprazole
10 mg orodispersible tablets are
10 mg orodispersible tablets
10 mg tablets are rectangular
10 mg tablets are
10 mg tablets
10 mg of
10 mg
10 mg/ kg
10 ml equivalent to 1000
10 ml equivalent to 400
10 ml equivalent to
10 ml and a multipack
10 ml and a
10 ml and
10 ml
10 or 15 mg/ day
10 or 15 ml solution/
10 or 15
10 or more
10 or
10 and 12 g/ dl
10 and 12
10 to 30 mg/ day
10 to 30
of 10 to 30
10 and
10 to
of 10 to
10 pre-filled pens x
10 pre-filled pens
10 x ULN ) should
10 x ULN )
10 x ULN
10 x
10
and 10
of 10
10.4
100 % .
100 %
100 , less than 1
100 , less than
100 , less
100 ,
Not all pack
Not
100 IU of insulin human
100 IU of insulin
100 IU of
in every 100 patients )
in every 100 patients
100 mg paclitaxel .
100 mg paclitaxel
100 mg
100 ml .
of 100 ml .
100 ml ready-to-infuse solution )
100 ml ready-to-infuse solution
100 ml of solution contains
100 ml of solution contains
100 ml of solution
100 ml of solution
- 100 ml Component
- 100 ml
100 ml of
100 ml
of 100 ml
100 ml infusion , lasting
100 ng/ ml
100 x
- 100
100
of 100
1000 IU ) of solution
1000 IU ) of
1000 IU .
1000 IU/ 0.5 ml
1000 IU/ 0.5
1000 international units ( IU
1000 international units (
1000 international units
1000 international
1000 IU/
1000
101
Phlebotomy may be performed
Phlebotomy may be
During
In animal studies , epoetin
,
,
,
6.6 Special
6.6
A gastric
454
by 107 % ,
by 107 %
4.2 Posology
4.2
The following undesirable effects occurred
The following
The
107
by 107
109/ l and
109/ l and
109/ l
109/ l.
10
Usual warning symptoms may
The efficacy
The
11 g/ dl ( 5.9
11 g/ dl (
11 g/ dl
, the
,
11
11.6 63.8 31.0 65.1 26.7
11.6 63.8 31.0 65.1
11.6 63.8 31.0
11.6 63.8
11.6
11.9 47.3 11.6 63.8 31.0
11.9 47.3 11.6 63.8
11.9 47.3 11.6
11.9 47.3
11.9
10/ 20 PARTICULARS
10/ 20
The recommended dosing regimen is
The recommended dosing regimen
The
and disturbed behaviours ,
and disturbed behaviours
and
104 The recommended
104 The
In
104
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
In patients with
In patients
In
106 A MANUFACTURING AUTHORISATION
106 A MANUFACTURING
106 A
Phlebotomy may be performed
Phlebotomy may be
109 PARTICULARS TO
109 PARTICULARS TO APPEAR
109 PARTICULARS
In animal studies , epoetin
109
11
resulting
12 , 24 and 36
12 , 24 and
12 , 24
12 ,
12 - 14 g/ dl
12 - 14
12 -
12 55
Sporadic malformations (
Sporadic malformations
Sporadic malformations (
Sporadic malformations
Phlebotomy may be performed
Phlebotomy may be
12 months
12 weeks the level
12 weeks the
12 weeks
12 g/ dl ( 6.2
12 g/ dl ( 7.5
12 g/ dl (
- 12 g/ dl :
- 12 g/ dl
12 g/ dl
- 12
12
was 12.1 % with aripiprazole
was 12.1 % with
was 12.1 %
was 12.1
6.6 Special
6.6
120 ml : 22 kg
120 ml : 22
120 ml :
120 ml
120
111 MINIMUM PARTICULARS TO APPEAR
111 MINIMUM PARTICULARS
111
122 % ( N =
122 % ( N
122 % (
122 %
4.2 Posology
4.2
112 PARTICULARS TO
112 PARTICULARS TO APPEAR
112 PARTICULARS
112
122
114 MINIMUM PARTICULARS TO APPEAR
114 MINIMUM PARTICULARS
114
115 PARTICULARS TO
115 PARTICULARS TO APPEAR
115 PARTICULARS
The recommended dosing regimen is
The recommended dosing regimen
115
dosing
118 The recommended
118 The
118
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
117 MINIMUM PARTICULARS TO APPEAR
117 MINIMUM PARTICULARS
2,127 men
involved 2,127 men
117
2,127
involved 2,127
118 PARTICULARS TO
118 PARTICULARS TO APPEAR
118 PARTICULARS
In patients with
In patients
In
118
13 % ( 141
13 % (
13 % of the
13 %
13
13 days
13 g/ dl , the
13 g/ dl ,
13 g/ dl
13 g/ dl
13 July
13
13.2 [ 7.54
13.2 [
13.2
12/ 20 MINIMUM PARTICULARS TO
12/ 20
120 MINIMUM PARTICULARS TO APPEAR
120 MINIMUM PARTICULARS
131 )
121 PARTICULARS TO
121 PARTICULARS TO APPEAR
121 PARTICULARS
121
131
132 )
Phlebotomy may be performed
Phlebotomy may be
132
123 MINIMUM PARTICULARS TO
123
124 PARTICULARS TO
124 PARTICULARS TO APPEAR
124 PARTICULARS
In animal studies , epoetin
124
135 )
6.6 Special
6.6
135
136 )
126 MINIMUM PARTICULARS TO
126
136
4.2 Posology
4.2
127 PARTICULARS TO
127 PARTICULARS TO APPEAR
127 PARTICULARS
127
129 MINIMUM PARTICULARS TO
139 out of 1,062 )
139 out of 1,062
139 out of
139 out of
129
139
14 , 28 , 56
14 , 28 ,
14 , 28
of 14 , 28
14 , 28
14 ,
14 30
In animal studies , epoetin
Patients with
Patients
14 tablets 28 tablets 30
14 tablets 28 tablets
14 tablets 28
14 tablets
14 g/ dl ( 7.5
14 g/ dl (
14 g/ dl .
14 g/ dl
12 d ise or uth
12 d ise
12 d
14 and 7 )
14 and 7
14 and
14 x 1 ,
14 x 1 orodispersible tablets
14 x 1 tablets 28
14 x 1 tablets in
14 x 1 tablets
14 x 1
14 x
12
14
Fourteen
of 14
14.2 % ( 10
14.2 % (
14.2 %
14.2
13/ 20 PARTICULARS TO
13/ 20
130 PARTICULARS TO APPEAR ON
130 PARTICULARS
The recommended dosing regimen is
The recommended dosing regimen
The
130
132 The recommended
132 The
132
141
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
In patients with
In patients
143 Aclasta-treated
143
134 MINIMUM PARTICULARS TO
134
146 hours .
146 hours
146
of
Phlebotomy may be performed
Phlebotomy may be
In animal studies , epoetin
15 " on one side
15 " on
15 "
15 , 30 or 45
15 , 30 or
15 , 30
15 ,
15
6.6 Special
6.6
15 minutes .
15 minutes
15-minute infusions of
15 minutes .
15 minutes
15 minutes caused
15 minutes
Tardive Dyskinesia : in clinical
Tardive Dyskinesia : in
Tardive Dyskinesia :
Tardive Dyskinesia
15 on one side .
15 on one side
15 on
15 l/ hr/ m2 .
15 l/ hr/ m2
15 mg , 30
15 mg aripiprazole )
15 mg of aripiprazole .
15 mg aripiprazole
15 mg of aripiprazole
dose 15 mg )
dose 15 mg
15 mg pioglitazone ( as
15mg of pioglitazone ( as
15 mg pioglitazone (
15mg of pioglitazone (
15 mg of pioglitazone as
15 mg of pioglitazone
15 mg pioglitazone
15mg of pioglitazone
15 mg orodispersible tablets are
15 mg orodispersible tablets
15mg tablets
15mg tablets
15mg tablets is pioglitazone
15mg tablets is
15 mg tablets may
15mg tablets can be
15mg tablets with
15 mg tablets are round
15 mg tablets are
15mg tablets are
15 mg tablets
15mg tablets
15 mg once a day
15 mg once a
15 mg or 30 mg
15 mg or 30
15 mg or
15 mg and 30 mg
15 mg and 30
15 mg and
15 mg were
15 mg has not
15 mg has
15 mg of
15 mg
15mg of
15mg
15 mg/ day (
15 mg/ day
15 ml solution ( corresponding
15 ml solution/
15
15mg
less than 15
15.0 , 18.3 ] (
15.0 , 18.3 ]
15.0 , 18.3
15.0 , 19.3 ] (
15.0 , 19.3 ]
15.0 , 19.3
15.0 ,
15.7 % for
15.7 %
15.7 , 25.9 ] (
15.7 , 25.9 ]
15.7 , 25.9
15.7 ,
15.7
of 10
of
infusion
150 30 - 100
150 30 -
150 30
6.6 Special
6.6
150 60 - 150 30
150 60 - 150
150 60 -
150 60
at 150 IU/ kg 3
150 IU/ kg given subcutaneously
103 150 IU/ kg
117 150 IU/ kg
131 150 IU/ kg
150 IU/ kg
19 150 IU/ kg
33 150 IU/ kg
47 150 IU/ kg
5 150 IU/ kg
61 150 IU/ kg
75 150 IU/ kg
89 150 IU/ kg
150 International Units ( IU
150 International Units (
150 International Units
150 International
150 ml oral solution
150 ml
150 or 480 ml per
150 or 480 ml
150 or 480
150 or
103 150
117 150
131 150
150
19 150
47 150
5 150
61 150
75 150
89 150
148 MINIMUM PARTICULARS TO APPEAR
148 MINIMUM PARTICULARS
148
149 MINIMUM PARTICULARS TO
149 MINIMUM
16 % ) of
16 % )
16 % of the administered
16 % of the
16 %
16 to 23 hours .
16 to 23 hours
16 to 23
16 to
16 00
16 16
16 84 00
16 84
Weight gain : weight gain
Weight gain :
16 mg zoledronic acid
16 mg
16
16.1 [ 15.0 , 18.3
16.1 [ 15.0 , 19.3
16.1 [ 15.0 ,
16.1 [
16.1
HDL-C and triglycerides in
HDL-C and triglycerides
in HDL-C and triglycerides in
in HDL-C and triglycerides
44.7
16.8 micrograms epoetin alfa
16.8 micrograms epoetin
corresponding to 16.8 micrograms epoetin
16.8 micrograms
corresponding to 16.8 micrograms
16.8
to 16.8
in 160 patients whose
in 160 patients
152 MINIMUM PARTICULARS TO APPEAR
152 MINIMUM PARTICULARS
152
153 MINIMUM PARTICULARS TO
153 MINIMUM
165 amino acids .
165 amino acids
165
156 MINIMUM PARTICULARS TO APPEAR
156 MINIMUM PARTICULARS
156
157 MINIMUM PARTICULARS TO
157 MINIMUM
16736
17 , Km 22 ,
17 , Km 22
17 , Km
17 ,
4.2 Posology
4.2
signs and symptoms of
17 and 33 IU/ kg
17 and 33
17 and
17
Incidence of individual
16/ 20 PACKAGE LEAFLET Yarvitan
16/ 20 PACKAGE LEAFLET
16/ 20
160 MINIMUM PARTICULARS TO APPEAR
160 MINIMUM PARTICULARS
160
E171 ) , macrogol
E171 ) ,
E171 )
161 MINIMUM PARTICULARS TO
161
E171
172 breast , 64
172 breast ,
172 breast
1736
164 MINIMUM PARTICULARS TO APPEAR
164 MINIMUM PARTICULARS
174 gynaecological
164
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS
Ireland BRISTOL-MYERS SQUIBB
Ireland BRISTOL-MYERS
Ireland
165 MINIMUM PARTICULARS TO
175 mg/ m2
175
If you
If
168 MINIMUM PARTICULARS TO APPEAR
168 MINIMUM PARTICULARS
168
169 MINIMUM PARTICULARS TO
169 MINIMUM
18 %
4.7 Effects on
4.7 Effects
4.7
18 84 00
18 84 16
18 84
18 86 68
18 86
Dosage adjustment Concomitant illness
18 years of age .
age 18 years due
18 years of age due
18 years of age
18 years of age
age 18 years
18 months Use product
18 months Use
18 months
18 , or 13
18 , or
18 ,
18
18.3 ] ( n =
18.3 ] (
18.3 ]
18.3
18.7
18.93
, 34.05 ] (
34.05 ] (
, 34.05 ]
34.05 ]
180 mg
180
180-minute infusions of Abraxane
180-minute infusions of
180-minute infusions
180-minute
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS
Ireland BRISTOL-MYERS SQUIBB
Ireland BRISTOL-MYERS
Ireland
172 MINIMUM PARTICULARS TO APPEAR
172 MINIMUM PARTICULARS
172
173 MINIMUM PARTICULARS TO
If you
173 MINIMUM
185 patients
185 patients
185
176 MINIMUM PARTICULARS TO APPEAR
176 MINIMUM PARTICULARS
176
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS
Ireland BRISTOL-MYERS SQUIBB
Ireland BRISTOL-MYERS
Ireland
177 MINIMUM PARTICULARS TO
177 MINIMUM
19 %
19 %
19
Usual warning symptoms may
19
19.3 ] ( n =
19.3 ] (
19.3 ]
19.3
% , 10.4 % ,
Treatment should be
Treatment
180 MINIMUM PARTICULARS TO APPEAR
180 MINIMUM PARTICULARS
Important information about some
180
181 MINIMUM PARTICULARS TO
181 MINIMUM
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS
Ireland BRISTOL-MYERS SQUIBB
Ireland BRISTOL-MYERS
Ireland
184 MINIMUM PARTICULARS TO APPEAR
184 MINIMUM PARTICULARS
184
185 MINIMUM PARTICULARS TO
185
Pregnancy and breast-feeding You
196 ± 28.1 ng/ ml
196 ± 28.1
France BRISTOL-MYERS SQUIBB SARL
France BRISTOL-MYERS SQUIBB
France BRISTOL-MYERS
France
1HU - United Kingdom
1HU - United
1HU -
1HU
2 (
2 ) at
2 )
2 ) .
1.4 , 4.0 )
2 ) at
2 )
2 , 4 , 8
2 , 4 ,
2 , France
2 ,
2,127 men
involved 2,127 men
2,127
involved 2,127
2 3-week
2 352 74 60
2 352 74
2 352
Dosage adjustment Concomitant illness
2 diabetes mellitus and
2 diabetes mellitus
2 diabetes
2 units .
2 units
two years ,
two years
two years
two years
2 years
two years
2 months
Patients with
Patients
2 studies in healthy subjects
2 studies in healthy
2 studies
achieved 2 hours after administration
2 hours after administration
2 hours after
2 hours
Patients
2 weeks
2 g/ dl ( 1.25
2 g/ dl (
2 g/ dl
2 mg aspartame ( E951
2 mg aspartame (
2 mg aspartame
dose 2 mg )
dose 2 mg
2 mg
2 mg/ ml
2 ml calibrated dropper
2 ml calibrated dropper
2 ml
2-78 units
2-78
1.4 , 4.0
2
to 2
2.1 % )
2.1 %
2.1
2.3 % of
2.3 %
2.3
2.47 in favour of controls
2.47 in favour of
2.47 in favour
2.47 in
2.49
2.5 % ( 96
2.5 % (
2.5 % ) of
2.5 % )
2.5 % ; 0.5
2.5 % ;
2.5 %
1.5-2.5 hours after
1.5-2.5 hours
2.5 mm
1.5-2.5
2.5
2.7 % ] ) .
2.7 % ] )
2.7 % ]
2.7 %
2.7
2 5 % .
2 5 %
2 5
2-hour endpoint was 5.8 for
2-hour endpoint was 5.8
2-hour endpoint was
2-hour endpoint
2-hour
Before you
Before you
Before you
Before you
Before
What benefit has Abilify
What benefit has
What benefit
What
20 % dissolved insulin and
20 % dissolved insulin
20 % dissolved
20 % and isophane insulin
20 % and
20 %
20 00
20 501 76 03
20 501 76
20 501
20 : soluble insulin 20
20 : soluble insulin
20 : soluble
20 :
20 ACTRAPHANE 30 ACTRAPHANE 40
20 ACTRAPHANE 30 ACTRAPHANE
20 ACTRAPHANE 30
20 ACTRAPHANE
18 PARTICULARS
The recommended dosing regimen is
The recommended dosing regimen
20 NovoLet 100
20 NovoLet
20 Penfill 100
20 Penfill
20 on one side .
20 on one side
20 on
20 consists of 20 %
20 consists of 20
20 consists of
20 mg ( baseline 7.3
20 mg ( baseline
20 mg (
20 mg .
20 mg
20 mg and
20 mg reduced the risk
20 mg reduced
20 mg
, 20
20
200 - 300 mg
200 - 300
200 -
Your doctor will check
200 kg
200 mg fructose per ml
200 mg fructose per
200 mg of fructose and
200 mg fructose
200 mg of fructose
200 mg of
200 mg
of 200 mg
200
not exceed 200
of 200
2000 IU ) of solution
2000 IU ) of
2000 IU of epoetin alfa*
2000 IU
2000 IU/ 1 ml
2000 IU/ 1 ml
2000 IU/ 1
2000 IU/
2000 international units ( IU
2000 international units (
2000 international units
2000 international
2000
Chi-squared
,
refer to the relevant modules
refer to the
refer to
refer
2007
July 2007
The amount
The amount
eská republika OncoEurope Tel
eská republika OncoEurope
eská republika
eská
21 % of
21 %
21 230
21 412 6600
21 412
Interaction with receptors other than
Interaction with receptors other
21
21 days of treatment ,
21 days
210 ml : 40 kg
210 ml : 40
210 ml :
210 ml
210
211 patients in the
211 patients in
211
22 , 67019 Scoppito (
22 , 67019 Scoppito
22 , 67019
22 ,
22 11
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
22 prostate
22 to 143
22 to
22 kg BW 210 ml
22 kg BW 210
22 kg BW
22 kg
22 out of 3,852 )
22 out of 3,852
,
22
22.5 8.1 41.7 11.9 47.3
22.5 8.1 41.7 11.9
22.5 8.1 41.7
22.5 8.1
22.5
221 multiple
225 ) , or as
225 ) , or
225 ) , or
225 ) ,
225 )
225
229 ) .
229 )
229
9 229
23 05 20 00
23 05 20
23 05
In patients with
In patients
In
23 lung , 22 prostate
23 lung , 22
23 lung ,
23 lung
23 hours .
23 hours
23 mg ) per
23 mg )
23
230
24 % of
24 %
22 PARTICULARS TO APPEAR
22 PARTICULARS
24 months
24 hours .
24 hours may
in 24 hours may
24 hours may
in 24 hours may
24 hours after the
24 hours after
24 hours
24-hour
24 hours
24 and 36 months )
24 and 36 months
24 and 36
24 and 36 months
24 and
, the
22
24
24-hour period
24-hour
any 24-hour period
any 24-hour
over 24
the
24.9
241 941-0
241
25 % of the patients
25 %
25 16 16
25 16
25 800
25 D-90429 Nuremberg Germany
25 D-90429 Nuremberg
25 D-90429
25 and 50
25 and
25
at 25
25°C
above 25°C
25.2 9.5 22.5 8.1 41.7
25.2 9.5 22.5 8.1
25.2 9.5 22.5
25.2 9.5
25.2 micrograms epoetin alfa
25.2 micrograms epoetin
corresponding to 25.2 micrograms epoetin
25.2 micrograms
corresponding to 25.2 micrograms
25.2
to 25.2
251 21 230
251 21
251
25°C ) .
25ºC ) .
25°C )
25ºC )
25°C
25ºC
Dosage adjustment Concomitant illness
Patients with
Patients
26-week
26.7
260 12 55
260 12
260 lung ,
260 lung
260 mg
260 mg/ m2 , paclitaxel
260
2649600
2653 to 16736
2653 to
2653
268
27 % of the
; 27 % had
27 %
; 27 %
Phlebotomy may be performed
Phlebotomy may be
Usual warning symptoms may
Tardive Dyskinesia : in clinical
Tardive Dyskinesia : in
Tardive Dyskinesia :
Tardive Dyskinesia
27
27166 , F-37071 Tours Cedex
27166 , F-37071 Tours
27166 , F-37071
27166 ,
27166
272 16 00
272 16
272
273 0
273
28 %
28 , 56 , 84
28 , 56 ,
28 , 56
28 ,
Weight gain : weight gain
Weight gain :
28 tablets 30 tablets 50
28 tablets 30 tablets
28 tablets 30
28 tablets
28 x 1 orodispersible tablets
28 x 1 tablets 49
28 x 1 tablets in
28 x 1 tablets
28 x 1
28 x
28
28 % reduction in
29 % of the
29 % of
29 %
29 5193
In animal studies , epoetin
29 [ 2.7 % ]
29 [ 2.7 %
29 [ 2.7
29 [
,
29
rat
291 patients
291
2AQ United Kingdom
2AQ United
2AQ
2C19 ( omeprazole )
2C19 ( omeprazole
2C19 (
2C19
2C8 although
2C8/ 9 , and 3A4
2C8/ 9 , and 3A4
2C8/ 9 and 3A4 .
2C8/ 9 and 3A4
2C8/ 9 and
2C8/ 9
2C9 ( warfarin )
2C9 ( warfarin
2C9 (
2C9
2°C - 8°C ) .
2°C - 8°C )
2°C - 8°C
2°C -
2°C - 8°C ) .
2°C - 8°C )
2°C - 8°C
2°C -
2°C
3 -p-hydroxypaclitaxel ,
, 3 -p-hydroxypaclitaxel and 6
3 -p-hydroxypaclitaxel and 6
3 -p-hydroxypaclitaxel
pharmacokinetics and safety of
pharmacokinetics and
Usual warning symptoms may
An increased 3H-thymidine incorporation
3 years Shelf-life after
3 years Shelf-life
3 years
3 sites of metastases .
3 sites of metastases
can significantly impact renal function
significantly impact renal function
renal function
3 patients with
3 patients
Tardive Dyskinesia : in clinical
Tardive Dyskinesia : in
Tardive Dyskinesia :
Tardive Dyskinesia
3 days
3 weeks .
3 weeks
3 weeks
3-week
3 consecutive
3
3
3 mg aspartame ( E951
3 mg aspartame (
3 mg aspartame
3 mg
3 ml ( 3.5
3 ml (
3 ml ) .
3 ml )
3 ml .
3 ml glass cartridge
3 ml equivalent to 300
3 ml equivalent to 300
3 ml equivalent to
3 ml equivalent to
3 ml
3 and
3 x
3x/ week or 450
3x/ week or
3x/ week
, 3
3 consecutive
3 sites of
3 sites
3
over 3 years
3.0 % with placebo .
3.0 % with placebo
3.0 % with
3.0 %
3.0
3.1 kg over 2 years
3.1 kg over 2
2.3 , 8.3
3.1
3.2 % ] ) and
3.2 % ] )
3.2 % ]
3.2 % with placebo .
3.2 % with placebo
3.2 % with
3.2 %
3.2
3.3-fold higher than those
3.3-fold higher
3.3-fold
3.5 % of
3.5 %
3.5 years
3.5 hours
3.5
3 or 5 times
three-year
3 X
4.8 Interaction with
4.8 Interaction
4.8
30 " on one side
30 " on
30 "
30 % )
30 % )
30 % ) .
30 % )
30 % of patients )
30 % of patients
30 % of
30 % dissolved insulin and
30 % dissolved insulin
30 % dissolved
30 % and isophane insulin
30 % and
30 %
30 % .
30 ) .
30 )
, 30 , 50 ,
, 30 , 50
, 30 , 50
30 , 56 , 84
30 , 56 ,
30 , 56
, 30 ,
, 30
30 ,
30 - 100
30 -
30 100
4.7 Effects on
4.7 Effects
4.7
30 40
6.6 Special
6.6
30 60 25 800
30 60 25
30 60
30 : soluble insulin 30
30 : soluble insulin
30 : soluble
30 :
30 ACTRAPHANE 40 ACTRAPHANE 50
30 ACTRAPHANE 40 ACTRAPHANE
30 ACTRAPHANE 40
30 ACTRAPHANE
30 minutes , every three
30 minutes , every
30 minutes every 3 weeks
30 minutes
30 minutes ,
30 minutes
30
30 months when stored between
30 months
30 NovoLet 100
30 NovoLet
30 Penfill 100
30 Penfill
30 tablets 50 tablets 56
30 tablets 50 tablets
30 tablets 50
30 tablets
30 on one side .
30 on one side
30 on
30 consists of 30 %
30 consists of 30
30 consists of
30 kg require higher
30 kg and adults .
30 kg and adults
30 kg and
30 kg
30 mg ( i. e.
30 mg (
of 30 mg (
30 mg )
30 mg of aripiprazole .
30 mg aripiprazole as the
30 mg aripiprazole as
30 mg aripiprazole
30 mg of aripiprazole
30 mg pioglitazone ( as
30mg of pioglitazone ( as
30 mg pioglitazone (
30mg of pioglitazone (
30 mg of pioglitazone as
30 mg of pioglitazone
30 mg pioglitazone
30mg of pioglitazone
30 mg orodispersible tablets (
30 mg orodispersible tablets are
30 mg orodispersible tablets
30 mg tablets , as
30 mg tablets ,
30mg tablets :
30mg tablets
30mg tablets
30mg tablets is pioglitazone
30mg tablets is
30 mg tablets may
30mg tablets can be
30mg tablets with
30 mg tablets are round
30 mg tablets are
30mg tablets are
30 mg tablets
30mg tablets
30 mg once daily .
30 mg once daily
30 mg once
30 mg .
30 mg
not exceed 30 mg .
not exceed 30 mg
30 mg should be
, 30 mg
30 mg ,
30 mg of
30 mg
30mg of
30mg
of 30 mg
30 mg/ day (
30 mg/ day .
30 mg/ day
30 to a similar
30 to a
30 to a similar mix
30 or 45 mg of
30 or 45 mg
30 or 45
30 or
, 30
30 to
30
30mg
of 30
to 30
30-36 Avenue Gustave Eiffel ,
30-36 Avenue Gustave Eiffel
30-36 Avenue Gustave
30-36 Avenue
30-36
260 mg/ m2 over 30
300 IU per kilogram .
300 IU per kilogram
300 IU per
300 IU .
300 IU
300 IU/ kg
300 IU/ kg 3
300 IU/ kg given by
300 IU/ kg given
300 gastro-intestinal
300 mg Fe2+/ day is
300 mg Fe2+/ day
300 mg
300 mg/ m2 ; 95
300 mg/ m2 ;
300 mg/ m2
300
300-360 mOsm/ kg .
300-360 mOsm/ kg
3000
3000 IU ) of solution
3000 IU ) of
3000 IU/ 0.3 ml
3000 IU/ 0.3 ml
3000 IU/ 0.3
3000 IU/ 0.3
3000 international units ( IU
3000 international units (
3000 international units
3000 international
3000 IU/
3000
301
31 % )
31 %
31 %
31 ( 0 ) 30
31 ( 0 )
31 ( 0
31 (
31 34 857 42 22
31 34 857 42
31 34 857
31 34
31
31.0 65.1 26.7
31.0 65.1
31.0
3116 8000
3116 8950
3116 8951
3116 8952
3116 8953
3116 8954
3116
32 % of
32 % and 47
32 % and
32 %
32 00
32 2 352 74 60
32 2 352 74
32 2 352
32 2
4.2 Posology
4.2
Deutschland Novartis Pharma GmbH
Deutschland Novartis Pharma
Deutschland Novartis
Deutschland
32
33 %
33 ( 0)1 47 56
33 ( 0)1 47
33 ( 0)1
33 ( 0)810 410 500
33 ( 0)810 410
33 ( 0)810
33 (
33 - 39 % )
33 - 39 %
of 33 - 39 %
33 - 39
of 33 - 39
33 -
of 33 -
33 22 11
33 22
33 IU/ kg 3 times
33 IU/ kg ,
33 IU/ kg
Interaction with receptors other than
Interaction with receptors other
33
of 33
33.6 micrograms epoetin alfa
33.6 micrograms epoetin
corresponding to 33.6 micrograms epoetin
33.6 micrograms
corresponding to 33.6 micrograms
33.6
to 33.6
34 % )
34 % ,
34 %
34 %
34 ( 91 ) 663
34 ( 91 )
34 ( 91
34 (
34 857 42 22
34 857 42
34 857
Dosage adjustment Concomitant illness
31 In a
31 In
34 [ 3.2 % ]
34 [ 3.2 %
34 [ 3.2
34 [
31
34
( 28 %
347 patients
347
35 %
Usual warning symptoms may
The recommended dosing regimen is
The recommended dosing regimen
35 trials and
35 trials
35
when pioglitazone was
when
35
351 21 412 6600
351 21 412
351 21
351
352 74 60
352 74
352
353 ( 1 800 )
353 ( 1 800
353 ( 1
353 (
353
354 535 7000
354 535
354
357 patients
357
358 ( 0)9 8545250
358 ( 0)9
358 (
358 9 251 21 230
358 9 251 21
358 9 251
358 9
358
36 %
34 The recommended
34 The
36 months ) .
36 months )
36 months
34
36
36(0 ) 20 501 76
36(0 ) 20 501
36(0 ) 20
36(0 )
36(0
360 dogs
360 dogs over the
360 dogs over
360
37 ( 16 % )
37 ( 16 %
37 ( 16
37 (
37 , D-58638 Iserlohn ,
37 , D-58638 Iserlohn
37 , D-58638
37 ,
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
37 D-58638 Iserlohn Germany
37 D-58638 Iserlohn
37 D-58638 Iserlohn
37 D-58638
37 D-58638
37
However , the
However ,
375
In patients with
Patients with
Patients
3800
384 patients .
384 patients
384
39 % )
39 %
39 06 5026 01
39 06 5026
39 06
39 16 84 00
39 16 84
39 16
Tardive Dyskinesia : in clinical
Tardive Dyskinesia : in
Tardive Dyskinesia :
Tardive Dyskinesia
39
39 ± 16 %
39 ± 16
39 ±
39.0 , 55.3 ] (
39.0 , 55.3 ]
39.0
3A4 ( dextromethorphan ) .
3A4 ( dextromethorphan )
3A4 ( dextromethorphan
3A4 (
3A4 .
3A4
3XX United Kingdom
3XX United
3XX
repeated
Weight gain : weight gain
Weight gain :
shown reproductive toxicity ( see
shown reproductive toxicity (
shown reproductive toxicity
reproductive toxicity
4 hours in
4 hours
for four days
4 weeks
4 to 6 weeks )
4 to 6 weeks )
4 to 6 weeks
4 to 6 weeks
4 to 6
4 to
4 or more units of
4 or more units
4 or more
4 or
4
four
4.6 6.2 months )
4.6 6.2 months
4.6 6.2
4.6
4.8
European
Possible side effects 5 How
4.
4.10
4.10 Overdose ( symptoms ,
4.10 Overdose ( symptoms
4.10 Overdose (
4.10 Overdose
4.2 ) .
4.2 )
4.2 ) The
4.2 )
4.2 Method of administration
4.2 Method
4.2 Indications for
4.2 Treatment of patients
4.2 Treatment of
4.2 Treatment
4.2 Posology and
4.2 Posology
4.2
4.3 ) .
4.3 )
4.3 and 4.4
.
patient .
4.3 and
4.3
4.3
4.4 ) .
4.4 ) .
4.4 )
4.4 -
4.4 and 5.2
4.4 and
4.4
. and 5.2 ) .
and 5.2 )
and 5.2
4.5 ) .
4.5 )
4.5 .
4.5 Interaction with other
15 4.5 Interaction with
26 4.5 Interaction with
37 4.5 Interaction with
4 4.5 Interaction with
4.5 Interaction with
4.5 Interactions with
15 4.5 Interaction
26 4.5 Interaction
37 4.5 Interaction
4 4.5 Interaction
4.5 Interaction
4.5 Interactions
15 4.5
26 4.5
37 4.5
4 4.5
4.5
nefazodone)(see
4.6 ) .
4.6 )
4.6
4.7 Use during pregnancy
4.7 Use during
4.7 Use
17 4.7 Effects
29 4.7 Effects
4.7 Effects on
53 4.7 Effects
4.7
.
4.8 ) .
patient .
4.8 )
4.8 - General )
4.8 - General
4.8 -
4.8 and 4.9 ) .
4.8 and 4.9 )
4.8 and 4.9
4.8 and
4.8
4.9 ) .
4.9 )
4.9
It is assumed
40 % of the patients
40 % of the
40 % dissolved insulin and
40 % dissolved insulin
40 % dissolved
40 % and isophane insulin
40 % and
40 % in the
40 % in
40 %
40 ( 0)21 272 16
40 ( 0)21 272
40 ( 0)21
40 (
40 64
40 : soluble insulin 40
40 : soluble insulin
40 : soluble
40 :
40 ACTRAPHANE 50
40 ACTRAPHANE
Weight gain : weight gain
Weight gain :
40 IU of insulin human
40 IU of insulin
40 IU of
40 NovoLet 100
40 NovoLet
40 Penfill 100
40 Penfill
40 consists of 40 %
40 consists of 40
40 consists of
40 kg BW
40 kg
40
old
40,000 dalton .
40,000 dalton
40,000
increase 40,000/ µl or
increase 40,000/ µl
400 IU .
400 mg of sucrose .
400 mg sucrose per ml
400 mg sucrose per
400 mg of sucrose
400 mg sucrose
400 mg of
400 mg
400
4000 IU ) of solution
4000 IU ) of
4000 IU/ 0.4 ml
4000 IU/ 0.4
4000 international units ( IU
4000 international units (
4000 international units
4000 international
4000 IU/
4000
41 % )
41 %
41
41.7 11.9 47.3 11.6 63.8
41.7 11.9 47.3 11.6
41.7 11.9 47.3
41.7 11.9
41.7
410 500
410
412 6600
412
Approximately 42 % of patients
Approximately 42 % of
42 %
Approximately 42 %
42 22
4.7 Effects on
4.7 Effects
4.7
Dosage adjustment Concomitant illness
Phlebotomy may be performed
Phlebotomy may be
42 trials and 8167 patients
42 trials and 8167
42 trials and
42 trials
42
Approximately 42
42.0 micrograms epoetin alfa
42.0 micrograms epoetin
corresponding to 42.0 micrograms epoetin
42.0 micrograms
corresponding to 42.0 micrograms
42.0
to 42.0
425 mg sodium per dose
425 mg sodium per
425 mg sodium
425 mg
425
43 ( 1 ) 524
43 ( 1 )
43 ( 1
43 (
43 1 60 14 30
43 1 60 14
43 1 60
43 1
Usual warning symptoms may
43
to 43
43-(0)800 29 5193
43-(0)800 29
43-(0)800
44 ( 0)1628 537 900
44 ( 0)1628 537
44 ( 0)1628
44 ( 0)20 3116 8950
44 ( 0)20 3116 8951
44 ( 0)20 3116 8952
44 ( 0)20 3116 8953
44 ( 0)20 3116 8954
44 ( 0)20 3116
44 ( 0)20
44 ( 0800 ) 731
44 ( 0800 )
44 ( 0800
44 (
In animal studies , epoetin
In
44
44-20 ) 74 18 84
44-20 ) 74 18
44-20 ) 74
44-20 )
44-20
45 % ) .
45 % )
45 % of the patients
45 % of the patients
45 % of the
45 %
45 45 93 05 06
45 45 93 05
45 45 93
45 45
6.6 Special
6.6
45 93 05 06
45 93 05
45 93
45 mg ( once daily
45 mg ( once
45 mg (
45 mg pioglitazone ( as
45mg of pioglitazone ( as
45 mg pioglitazone (
45mg of pioglitazone (
45 mg of pioglitazone .
45 mg of pioglitazone as
45 mg of pioglitazone
45 mg pioglitazone
45mg of pioglitazone
45mg tablets :
45mg tablets
45mg tablets
45mg tablets
45mg tablets is pioglitazone
45mg tablets is
45 mg tablets may
45mg tablets can be
45mg tablets with
45mg tablets are
45 mg tablets
45mg tablets
45 mg once daily
45 mg daily
45 mg of
45 mg
45mg of
45mg
Interaction with receptors other than
Interaction with receptors other
45
45mg
, 76.9 ] (
76.9 ] (
, 76.9 ]
76.9 ]
450 IU/ kg once weekly
450 IU/ kg
450
457 65 00
457 65
457
46 25 16 16
46 25 16
46 25
46 8 704 71 00
46 8 704 71
46 8 704
46 8
42 In a
42 In
42
46
46.7 [ 39.0
46.7 [
46.7
460 women with
460 women
460
povidone
4.2 Posology
4.2
47 56 69 00
47 56 69
47 56
47 67 55 53 50
47 67 55 53
47 67 55
47 67
47
47.3 11.6 63.8 31.0 65.1
47.3 11.6 63.8 31.0
47.3 11.6 63.8
47.3 11.6
47.3
48 kg for the
48 kg for
48 kg
48
480 ml oral solution
480 ml per
480 ml
480
core :
core
49 ( 0 ) 241
49 ( 0 )
49 ( 0
49 (
49 orodispersible tablets .
49 orodispersible tablets
49 x 1 , 56
49 x 1 ,
49 x 1 orodispersible tablets
49 x 1 tablets 56
49 x 1 tablets in
49 x 1 tablets
49 x 1
49 x
49
4AE , United Kingdom .
4AE , United Kingdom
4AE , United
4AE ,
4AE United Kingdom
4AE United
4AE
5 " on one side
5 " on
5 "
5 % ansteigt . Die
5 % ansteigt .
5 % ansteigt
5 % und 10
5 % und
5 %
5 ) 2649600
5 )
5 The valid Summary of
5 The valid Summary
The recommended dosing regimen is
The recommended dosing regimen
The
5 vials x 10
5 vials x
5 vials
5 bottles , each bottle
5 hours
5 on one side .
5 on one side
5 on
5 of the
5 l/ kg .
5 l/ kg
5 mg , 10 mg
5 mg , 10
5 mg ,
5 mg Aclasta .
5 mg Aclasta
5 mg solution for infusion
5 mg of paclitaxel .
5 mg of paclitaxel
5 mg tablets are rectangular
5 mg tablets are
5 mg tablets
5 mg zoledronic acid anhydrous
5 mg zoledronic acid (
5 mg zoledronic acid
5 mg zoledronic acid .
5 mg zoledronic acid
5 mg once a year
5 mg once a
5 mg in 100
5 mg in
5 mg
5 mg of
5 mg
5 mg/
5 mg/ ml ) .
5 mg/ ml )
5 mg/ ml Butylated hydroxyanisole
5 mg/ ml oral solution
5 mg/ ml
or 5 or more units
or 5 or more
or 5 or
5 and 10 cartridges
5 and 10
5 and
5 and
5 x ULN or ASL/
5 x ULN or
5 x ULN
5 x
5 The
5
The
5 %
5.1 % ) .
5.1 % )
5.1 %
5.1
5.25 mg ( 0.7 ml
5.25 mg ( 0.7
5.25 mg (
5.25 mg
5.25
5.3 months ( 175
5.330 mg zoledronic acid monohydrate
5.330 mg
5.330
5.4
5.8 for placebo
5.8 for
5.8
5.9 - 6.8 mmol/ l
5.9 - 6.8
5.9 -
, 5.9
5.9
5-hydroxytryptamine ( also called serotonin
5-hydroxytryptamine ( also
5-hydroxytryptamine (
5-hydroxytryptamine and dopamine
5-hydroxytryptamine and
5-hydroxytryptamine are involved
5-hydroxytryptamine are
5-hydroxytryptamine
5.1 ) . no
5.1 ) .
5.1 ) :
5.1 ) ,
5.1 )
5.1
5.2 ) . dic
5.2 ) .
and 5.2 ) .
5.2 )
and 5.2 )
5.2
and 5.2
5.3 ) .
5.3 )
5.3
50 % isophane insulin .
50 % isophane insulin
50 % dissolved insulin and
50 % dissolved insulin
50 % dissolved
50 % and isophane insulin
50 % and
50 %
50 , 150 or 480
50 , 150 or
50 , 150
50 , 56 , 84
, 50 , 56
50 , 56 ,
50 , 56
, 50
50 ,
50 00
50 80
50 : soluble insulin 50
50 : soluble insulin
50 : soluble
50 :
Dosage adjustment Concomitant illness
The orodispersible tablet
The recommended dosing regimen is
The recommended dosing regimen
The
50 IU/ kg 3 times
50 IU/ kg 3
of 50 IU/ kg 3
50 IU/ kg 2 times
50 IU/ kg 2
50 IU/ kg 2
50 IU/ kg
50 International Units ( IU
50 International Units (
50 International Units
50 International
47 MINIMUM PARTICULARS TO APPEAR
47 MINIMUM PARTICULARS
50 NovoLet 100
50 NovoLet
50 Penfill 100
50 Penfill
50 tablets 56 tablets 84
50 tablets 56 tablets
50 tablets 56
50 tablets
50 consists of 50 %
50 consists of 50
50 consists of
50 ml bottle
50 ml oral solution
50 ml
47
50
of 50
50.4 micrograms epoetin alfa
50.4 micrograms epoetin
corresponding to 50.4 micrograms epoetin
50.4 micrograms
corresponding to 50.4 micrograms
50.4
to 50.4
aged
500 film-coated tablets .
and 500 film-coated tablets .
500 film-coated tablets
and 500 film-coated tablets
500 mg calcium
500 mg elemental
500 mg
500
and 500
5000 IU ) of solution
5000 IU ) of
5000 IU/ 0.5 ml
5000 IU/ 0.5
5000 international units ( IU
5000 international units (
5000 international units
5000 international
5000 IU/
5000
501 76 03
501 76
501
5026 01
5026
508 men
508
about 51 %
Usual warning symptoms may
48 The recommended
48 The
48 MINIMUM PARTICULARS TO APPEAR
48 MINIMUM PARTICULARS
51 out of 3,862 )
51 out of 3,862
48
51
517 to
517
5193
52 %
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
49 MINIMUM PARTICULARS TO APPEAR
49 MINIMUM PARTICULARS
52 weeks
52
5238 patients with type 2
5238 patients with type
5238 patients with
5238 patients
5238
524 40 64
524 40
524
53 % ) .
53 % )
53 %
53 50
In patients with
In patients
53
53.3 % for
53.3 %
535 7000
535
537 900
537
Due to
55 % ) and
55 % ) and
55 % )
55 %
55 53 50
55 53
In placebo-controlled trials ,
In placebo-controlled trials
In placebo-controlled
In
55 ml : 10 kg
55 ml : 10
55 ml :
55 ml
55 to
55
55.3
55 ,
55
up to 36
56 , 84 , 90
, 56 , 84 ,
56 , 84 ,
56 , 84 AND 98
56 , 84 AND
56 , 84
, 56
56 ,
56-99 years ) of
56-99 years )
56-99 years
56-99
56 69 00
56 69
56 tablets 84 tablets 90
56 tablets 84 tablets
56 tablets 84
56 tablets
56 x 1 , 98
56 x 1 ,
56 x 1 tablets 98
56 x 1 tablets
56 x 1
56 x
56
Phlebotomy may be performed
Phlebotomy may be
Dosage adjustment Concomitant illness
In
58
58.8 micrograms epoetin alfa
58.8 micrograms epoetin
corresponding to 58.8 micrograms epoetin
58.8 micrograms
corresponding to 58.8 micrograms
58.8
to 58.8
580 00 10
580 00
580
Fifty-nine percent received study
In animal studies , epoetin
Patients
Fifty-nine
5AB United Kingdom
5AB United
5AB
5HT1a and 5HT2a receptors and
5HT1a
5HT2a receptors
, alpha-1 adrenergic and histamine
, alpha-1
alpha-1
6 % )
6 % of
6 %
6 , 12 , 24
6 , 12 ,
6 , 12
6 ,
6 -hydroxypaclitaxel and 3 -p-hydroxypaclitaxel
6 -hydroxypaclitaxel and 3
6 -hydroxypaclitaxel ; and
6 -hydroxypaclitaxel and
6 -hydroxypaclitaxel ;
6 -hydroxypaclitaxel
4.7 Effects on
4.7 Effects
4.7
6 courses
six months of therapy )
six months of therapy
6 The recommended
6 The
6 pre-filled syringes of 0.3
6 pre-filled syringes of 0.4
6 pre-filled syringes of 0.5
6 pre-filled syringes of 0.6
6 pre-filled syringes of 0.7
6 pre-filled syringes of 0.8
6 pre-filled syringes of 0.9
6 pre-filled syringes of 1
6 pre-filled syringes of
a PSUR at 6 monthly
a PSUR at 6
provide a PSUR at 6
6 months after treatment
6 months after
6 months
at 6
6 months ago
6 months
over 6 months
6 hours has been
6 hours
6 weeks )
6 weeks when used or
6 weeks when used
6 weeks
six weeks after
6 weeks
six weeks
6 mg aspartame ( E951
6 mg aspartame (
6 mg aspartame
6 mg
6
over 6
six
6.1 months ( 300
6.1 months (
6.1 months
6.1
6.2 % with aripiprazole and
6.2 % with aripiprazole
6.2 % with
6.2 %
6.2 - 7.5 mmol/ l
6.2 - 7.5
6.2 -
6.2 mmol/ l ) to
6.2 mmol/ l )
6.2 mmol/ l
6.2
6.7
6.8 mmol/ l ) .
6.8 mmol/ l )
6.8 mmol/ l
6.8
6-7.5 and an osmolality of
6-7.5 and an osmolality
6-7.5 and an
6-7.5 and
6-7.5
( for a cumulative dose
( for a cumulative
( for a
( for
(
6.1 ) .
6.1 )
6.1 .
6.1
6.1
6.6 .
28 6.6 Special precautions
35 6.6 Special precautions
56 6.6 Special precautions
6.6 Special precautions
63 6.6 Special precautions
70 6.6 Special precautions
77 6.6 Special precautions
21 6.6 Special
6.6
5/ 20 6.6
6.6
60 % Actraphane 50 :
60 % Actraphane 50
60 % Actraphane
60 % isophane insulin .
60 % isophane insulin
60 % in
60 %
60 - 150 30 -
60 - 150 30
60 - 150
60 -
60 14 30
60 14
60 25 800
60 25
6.6 Special
6.6
Within 60 days
Within 60 days
60 days
60 days
60
600 IU/ kg body weight
600 IU/ kg
600 International Units ( IU
600 International Units (
600 International Units
600 International
600
6000 IU ) of solution
6000 IU ) of
6000 IU/ 0.6 ml
6000 IU/ 0.6
6000 international units ( IU
6000 international units (
6000 international units
6000 international
6000 IU/
6000
61 % below baseline levels
61 % below
61 %
61 33 22 11
61 33 22
61 33
61 Aldwych , London ,
61 Aldwych , London
61 Aldwych ,
61 Aldwych London WC2B 4AE
61 Aldwych London WC2B
61 Aldwych London
61 Aldwych
Uncommon - Diabetic retinopathy
Uncommon - Diabetic
Uncommon -
Uncommon
61
4.2 Posology
4.2
Danmark Takeda Global R
Danmark Takeda Global
Danmark Takeda
Danmark
The orodispersible tablet
63 patients with metastatic
63 patients with
63 patients
63 , 86)** 25
63
63 % reduction
63.8 31.0 65.1 26.7
63.8 31.0 65.1
63.8 31.0
63.8
632
64 gynaecological , 23
64 gynaecological ,
64 gynaecological
64
"
"
"
65 00
The recommended dosing regimen is
The recommended dosing regimen
The
65 years )
age 65 and over
65 years
65 years
65 to 200 kg
65 to 200
65 to
65
65.1 26.7
65.1
6570
Dosage adjustment Concomitant illness
62 The recommended
62 The
62
6600
663 50 00
663 50
663
67 %
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
67 55 53 50
67 55 53
67 55
Patients
If
Due to
67
67.2 micrograms epoetin alfa
67.2 micrograms epoetin
corresponding to 67.2 micrograms epoetin
67.2 micrograms
corresponding to 67.2 micrograms
67.2
to 67.2
67019 Scoppito ( AQ )
67019 Scoppito ( AQ
67019 Scoppito (
67019 Scoppito
67019
68 % of
68 %
In patients with
In patients
In
Danmark Takeda Global R
Danmark Takeda Global
Danmark Takeda
Danmark
In placebo-controlled trials ,
In placebo-controlled trials
In placebo-controlled
In
68
683 breast
69 % ,
to 69 % ,
69 %
to 69 %
69 00
Uncommon - Diabetic retinopathy
Uncommon - Diabetic
Uncommon -
Uncommon
69
to 69
fold
therapeutic
7 %
7 ) prior to
7 )
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
In clinical studies for
In clinical studies
In clinical
In
7 patients
In a large clinical trial
7
7.2 % ) .
7.2 % )
7.2 %
7.2
7.3 % ) and +0.1
7.3 % ) and
7.3 % )
7.3 %
7.3
7.5 %
7.5 kg over 2
7.5 kg over 2
7.5 mg/ ml )
7.5 mg/ ml
7.5 mmol/ l ) .
7.5 mmol/ l )
7.5 mmol/ l )
7.5 mmol/ l ) should
7.5 mmol/ l ) should
7.5 mmol/ l ) .
7.5 mmol/ l )
7.5 mmol/ l )
7.5 mmol/ l ) in
7.5 mmol/ l )
7.5 mmol/ l
7.5 mmol/
7.5
7.54 , 18.93 ] (
7.54 , 18.93 ]
7.54
34.9 %
7.9 % for both groups
7.9 % for both
7.9 % for
7.9 %
7.9
7400
7,736 patients ,
7,736 patients
7,736
70 % Actraphane 40 :
70 % Actraphane 40
70 % Actraphane
70 % isophane insulin .
70 % isophane insulin
70 %
70 x 1 film-coated tablets
70
7000 IU ) of solution
7000 IU ) of
7000 IU/ 0.7 ml
7000 IU/ 0.7 ml
7000 IU/ 0.7
7000 IU/ 0.7
7000 international units ( IU
7000 international units (
7000 international units
7000 international
7000 IU/
7000
704 71 00
704 71
704
71 % of patients
71 % of
71 %
71 00
,
71
72 ( 31 % )
, 72 ( 31 %
72 ( 31 %
, 72 ( 31
72 ( 31
, 72 (
72 (
Phlebotomy may be performed
Phlebotomy may be
, 72
72
73 % ) .
73 % )
73 %
73
731 1736
731
732 32 00
732 32
732
7364000
74 18 84 00
74 18 84 16
74 18 84
74 18 86 68
74 18 86
74 18
74 60
Dosage adjustment Concomitant illness
In animal studies , epoetin
In
74
749 749
749
75 % and 73 %
75 - 150 60 -
75 - 150 60
75 - 150
75 -
6.6 Special
6.6
75 years of age
75 years and
75 years and
75 and 300 IU per
75 and 300 IU
75 and 300
75 and
75 out of 3,852 )
75 out of 3,852
75
75 ± 33 %
75 ± 33
75 ±
75.6 micrograms epoetin alfa
75.6 micrograms epoetin
75.6 micrograms
75.6
to 75.6
old
76 % had >
76 % had >
76 % had >
76 03
The orodispersible tablet
76
77 %
4.2 Posology
4.2
Uncommon - Diabetic retinopathy
Uncommon - Diabetic
Uncommon -
Uncommon
77
Seventy-seven
789 patients
79 % of
79 %
79
8 704 71 00
8 704 71
8 704
8 732 32 00
8 732 32
8 732
In patients with
In patients
In
8 hours
8 kg
8 and 16 mg
8 and 16
8 and
8
8.1 41.7 11.9 47.3 11.6
8.1 41.7 11.9 47.3
8.1 41.7 11.9
8.1 41.7
8.1 mmol/ l )
8.1 mmol/ l
8.1
8.4 micrograms epoetin alfa
8.4 micrograms epoetin
8.4 micrograms
8.4
to 8.4
8.7 % for
8.7 %
8.7 for aripiprazole .
8.7 for aripiprazole
8.7 for
8.7 mmol/ l ) ,
8.7
80 % Actraphane 30 :
80 % Actraphane 30
80 % Actraphane
80 % isophane insulin .
80 % isophane insulin
80 % of the population
80 % of the
80 %
80 ,
The recommended dosing regimen is
The recommended dosing regimen
Polysorbate 80 Water for injections
Polysorbate 80 Water for
Polysorbate 80 Water
80 to 300 mg/ m2
80 to 300
80 to 375
80 to
Due to
80
Polysorbate 80
800 ) 749 749
800 ) 749
800 )
800
8000 IU ) of solution
8000 IU ) of
8000 IU/ 0.8 ml
8000 IU/ 0.8 ml
8000 IU/ 0.8
8000 IU/ 0.8
8000 international units ( IU
8000 international units (
8000 international units
8000 international
8000 IU/
8000
802 with haematological malignancies .
802 with haematological malignancies
802 with
802
76 The recommended
76 The
In placebo-controlled trials ,
In placebo-controlled trials
In placebo-controlled
In
- 81
76
81
the maximum recommended
8167 patients ) .
8167 patients )
8167 patients
8167
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
Dosage adjustment Concomitant illness
82 Biopsien gefunden . Microcomputed
In patients with
In patients
In
It has been
84 , 90 and 98
, 84 , 90 or
84 , 90 and
84 , 90
84 , 90 and 98
84 , 90 and
, 84 , 90
84 , 90 and
84 , 90
, 84 ,
84 ,
84 00
84 16
In
84 tablets 90 tablets 98
84 tablets 90 tablets
84 tablets 90
017 84 tablets EU/ 1/
020 84 tablets EU/ 1/
023 84 tablets EU/ 1/
84 tablets
84 AND 98 TABLETS ONLY
84 AND 98
84 AND
84
dummy treatment
dummy
of 84
84.0 micrograms epoetin alfa
84.0 micrograms epoetin
84.0 micrograms
84.0
to 84.0
Uncommon - Diabetic retinopathy
Uncommon - Diabetic
Uncommon -
Uncommon
8545250
857 42 22
857 42
857
86 %
86 6570
86 68
86
87 % .
87 % Caucasian and 9
87 %
Phlebotomy may be performed
Phlebotomy may be
87
In animal studies , epoetin
In
Recurrence prevention of manic
Recurrence prevention of
Recurrence prevention
89
8950
8951
8952
8953
8954
8°C ) .
8°C )
8°C .
8ºC .
8°C
8ºC
9 % of the patients
, 9 % of the
9 % of the
, 9 %
9 %
9 251 21 230
9 251 21
9 251
9 61 33 22 11
9 61 33 22
9 61 33
9 61
conclusions can be drawn with
conclusions can be drawn
conclusions can be drawn
conclusions can be drawn
9 weeks )
9 weeks
Interaction with receptors other than
Interaction with receptors other
, 9
9
chloride 9
sodium chloride 9
9.5 22.5 8.1 41.7 11.9
9.5 22.5 8.1 41.7
9.5 22.5 8.1
9.5 22.5
9.5 years .
9.5 years
9.5 and 11 g/ dl
9.5 and 11
9.5 and
9.5
9.6 for lorazepam
9.6 for
9.6
9.75 mg ( 1.3 ml
9.75 mg ( 1.3
9.75 mg (
9.75 mg in 1.3
9.75 mg in
9.75 mg
9.75
sulphone metabolite
the sulphone metabolite
90 % Actraphane 20 :
90 % Actraphane 20
90 % Actraphane
90 % isophane insulin .
90 % isophane insulin
90 % of the
90 %
was 90 %
6.6 Special
6.6
Dosage adjustment Concomitant illness
90 tablets 98 tablets
90 tablets 98
90 tablets
90 days ) low- trauma
90 days ) low-
90 days )
90 days
90 and 98 film-coated tablets
90 and 98
90 and
90 or
90
90 and 98 tablets .
90 and 98 tablets
90 and 98
90 and
90 and
90
1,900 patients .
of 1,900 patients .
1,900 patients
of 1,900 patients
900
9000 IU ) of solution
9000 IU ) of
9000 IU/ 0.9 ml
9000 IU/ 0.9
9000 international units ( IU
9000 international units (
9000 international units
9000 international
9000
91 ) 663 50 00
91 ) 663 50
91 ) 663
91 )
Patients
91
91.6 ± 14.1 ng/ ml
91.6 ± 14.1
911 273 0
911 273
911
4.2 Posology
4.2
In a clinical trial
In a clinical
In a
92
93 05 06
93 05
Uncommon - Diabetic retinopathy
Uncommon - Diabetic
Uncommon -
Uncommon
93
938 ; mean age :
938 ; mean age
938 ;
938 ;
941-0
95 % ) were receiving
95 % )
47.6 %
95 % CI :
95 % CI ] (
95 % CI ]
95 % CI
95 %
Ninety-five percent
The recommended dosing regimen is
The recommended dosing regimen
The
95
Ninety-five
95 % CI :
95 % CI
90 The recommended
90 The
90
96
4.4 Special warnings and
4.4 Special warnings
4.4 Special
4.4
98 film-coated tablets .
and 98 film-coated tablets .
98 film-coated tablets
and 98 film-coated tablets
98 TABLETS ONLY )
98 TABLETS ONLY
98 tablets .
or 98 tablets .
or 98 tablets
98 tablets .
98 tablets
150/ 003 98 tablets
150/ 006 98 tablets
150/ 015 98 tablets
98 tablets
98 and 500 film-coated tablets
98 and 500
98 and
98
98 x 1 tablets .
98 x 1 tablets
98 x 1
98 x
,
015 98
98 and
98
and 98
99 % ) .
99 % )
99 %
99
of
99.9 % ) and
99.9 % )
99.9 %
99.9
: + 31 ( 0
: + 31 (
: + 31 34 857
: + 31 34
: + 31
: + 32 2 352
: + 32 2
: + 32
: + 33 ( 0)1
: + 33 ( 0)810
: + 33 (
: + 33
: + 34 ( 91
: + 34 (
: + 34
: + 351 21 412
: + 351 21
: + 351
: + 353 ( 1
: + 353 (
: + 353
: + 354 535 7000
: + 354 535
: + 354
: + 358 ( 0)9
: + 358 (
: + 358 9 251
: + 358 9
: + 358
: + 36(0 ) 20
: + 36(0 )
: + 36(0
: + 39 06 5026
: + 39 06
: + 39
: + 40 ( 0)21
: + 40 (
: + 40
: + 43 ( 1
: + 43 (
: + 43 1 60
: + 43 1
: + 43
: + 43-(0)800 29 5193
: + 43-(0)800 29
: + 43-(0)800
: + 44 ( 0)1628
: + 44 ( 0)20
: + 44 ( 0800
: + 44 (
: + 44
: + 45 45 93
: + 45 45
: + 45
: + 46 8 704
: + 46 8
: + 46
: + 47 67 55
: + 47 67
: + 47
: +
: +33 ( 0)1 46
: +33 ( 0)1
: +33 (
: +33
: +353 1 260 12
: +353 1 260
: +353 1
: +353
: +358 9 61 33
: +358 9 61
: +358 9
: +358
: +36 1 457 65
: +36 1 457
: +36 1
: +36
: +371 7364000
: +371
: +3726441100
: +386 ( 0)1 580
: +386 ( 0)1
: +386 (
: +386
: +43 1 86 6570
: +43 1 86
: +43 1
: +43
: +44 ( 0)20 3116
: +44 ( 0)20
: +44 (
: +44
: +45 39 16 84
: +45 39 16
: +45 39
: +45
: +46 8 732 32
: +46 8 732
: +46 8
: +46
: +47 23 05 20
: +47 23 05
: +47 23
: +47
: +49 911 273 0
: +49 911 273
: +49 911
: +49
: 10 kg BW 120
: 10 kg BW
: 10 kg
: 10
: 22 kg BW 210
: 22 kg BW
: 22 kg
: 22
: 40 kg BW
: 40 kg
: 40
: fatigue Psychiatric disorders Common
: fatigue Psychiatric disorders
: fatigue Psychiatric
: fatigue*
: anaemia in
: anaemia
: rash .
: rash
: treatment of
: treatment
: calcitonin , raloxifene
: calcitonin ,
: calcitonin
: dehydrogenation , hydroxylation ,
: dehydrogenation
: dysgeusia ,
: dysgeusia , oesophagitis ,
: dysgeusia , oesophagitis
: dysgeusia
: dyspepsia , vomiting ,
: dyspepsia , vomiting
: dyspepsia ,
: dyspepsia
sulfobutylether -cyclodextrin (
contains sulfobutylether b-cyclodextrin ,
sulfobutylether -cyclodextrin
sulfobutylether b-cyclodextrin ,
contains sulfobutylether
sulfobutylether
: myocardial infarction or stroke
: hyperglycaemia , in some
: hyperglycaemia , in
: hyperglycaemia ,
: hyperglycaemia
: store in a refrigerator
: store
: in clinical trials
: in clinical
lactose monohydrate , maize starch
lactose monohydrate ,
lactose monohydrate
: after
: osteoporosis ( a disease
: osteoporosis ( a
diseases : osteoporosis ( a
: osteoporosis (
diseases : osteoporosis (
: osteoporosis
diseases : osteoporosis
: patients with
: patients
Psychiatric disorder : psychotic disorders
: schizophrenia
stroke
: somnolence , dizziness ,
: somnolence , dizziness
: somnolence ,
: somnolence
: Educational leaflet
: tachycardia*
new information is received
new information is
new
: up to 36
: up to
: the levels remain the
: the levels
: the
: a maximum volume of
: a maximum volume
: a
: extrapyramidal disorder , akathisia
: extrapyramidal disorder ,
: extrapyramidal disorder
: extrapyramidal
: in clinical trials
: in clinical trials
: in clinical
: in
: in line with the
: in line with
: in line
: soluble insulin 10 %
: soluble insulin 10
: soluble insulin 20 %
: soluble insulin 20
: soluble insulin 30 %
: soluble insulin 30
: soluble insulin 40 %
: soluble insulin 40
: soluble insulin 50 %
: soluble insulin 50
: soluble insulin
: soluble
: oral
: orthostatic hypotension* ,
: orthostatic hypotension*
: orthostatic
: blurred vision
: blurred
: if your dog has
: if your dog
: if your
: if
.
: rapid biphasic
: rapid
:
commonly
diseases :
process : rapid biphasic
process : rapid
process :
stearate .
: nausea
; 0.5
; 1.0
, 18.93 ] (
, 18.93 ]
; 19
, 25.9 ] (
25.9 ] (
, 25.9 ]
25.9 ]
, 25.9
25.9
; 34 % )
; 34 %
; 34
; 41 % )
; 41 %
; 41
, 55.3 ] (
, 55.3 ]
13 , 36)*
; 95 % CI :
; 95 % CI
; 95 %
; 95
% CI :
% CI
; ATC code :
; ATC code
; Ctrough =
; Ctrough
; leukopenia
dependent ; leukopenia
dose dependent ; leukopenia
; suicide attempt ,
; suicide attempt
; but excluded other bisphosphonates
dogs
in dogs
dogs
in dogs
; therefore ,
; therefore
; the large
; the
, therefore weight
, therefore
; the average duration of
; the average duration
; the average
; systemic exposure was generally
; systemic exposure was
; systemic exposure
; systemic
; the
;
; this is especially important
; this is especially
; this is
; this
, especially in patients
, especially in
, especially
; none
, and
,
;
and
dependent ;
dose dependent ;
yellowing of
yellowing
common
in patients
patients
=
= 196 ± 28.1
= 225 ) , or
= 225 ) , or
= 225 ) ,
= 225 )
= 225
= 229 ) .
= 229 )
= 229
= 30 ) .
= 30 )
= 30
= 50 80
Clcr = 50 80
= 50
Clcr = 50
= 91.6 ± 14.1
=
Clcr =
> 0.5 % ) of
> 0.5 % )
> 0.5 %
> 0.5
> 1.5 x
> 1.5
ALT > 10 x ULN
ALT > 10 x
ALT > 10
> 100 x
> 100
> 13 g/ dl ;
haemoglobin > 13 g/ dl
> 13 g/ dl ;
> 27
> 5 x ULN or
> 5 x ULN
> 5 x
> 5
> 99 % ) .
> 99 % )
> 99 %
> 99
20.6 [ 15.6 ,
20.6 [ 15.6
20.9 [ 15.7 ,
20.9 [ 15.7
20.9 [
26.5 [ 18.98 ,
26.5 [ 18.98
56.4 [ 45.1 ,
56.4 [ 45.1
> 1st-line
>
ALT >
3.
? er Die
? er
?
for 2.
A "
A " over
A
A-007 " and " 5
A-007 " and "
A-007 " and
A-007 "
A-007 and 5 on
A-007 and 5
A-007 and
A-007
A-008 " and " 10
A-008 " and "
A-008 " and
A-008 "
A-008 and 10 on
A-008 and 10
A-008 and
A-008
A-009 " and " 15
A-009 " and "
A-009 " and
A-009 "
A-009 and 15 on
A-009 and 15
A-009 and
A-009
A-011 " and " 30
A-011 " and "
A-011 " and
A-011 "
A-011 and 30 on
A-011 and 30
A-011 and
A-011
A MANUFACTURING AUTHORISATION
A MANUFACTURING
A
A/ S Novo Allé DK-2880
A/ S Novo Allé
A/ S Novo
A/ S Tlf : +45
A/ S Tlf :
A/ S Tlf
A/ S
AB Puh/ Tel : +
AB Puh/ Tel :
AB Puh/ Tel
AB Tel : + 46
AB Tel : +
AB Tel : +46 8
AB Tel : +46
AB Tel :
AB Tel
AB
, IF ANY
APPROPRIATE
ABILIFY ( all formulations )
ABILIFY ( all formulations
of ABILIFY ( all formulations
ABILIFY (
of ABILIFY (
ABILIFY , must be discontinued
ABILIFY ,
ABILIFY 1 mg/ ml
ABILIFY 1
ABILIFY 10 mg tablets are
ABILIFY 10 mg tablets
ABILIFY 10 mg
ABILIFY 10
ABILIFY 15 mg tablets are
ABILIFY 15 mg tablets
ABILIFY 15 mg
ABILIFY 15
ABILIFY 30 mg tablets are
ABILIFY 30 mg tablets
ABILIFY 30 mg
ABILIFY 30
ABILIFY 5 mg tablets are
ABILIFY 5 mg tablets
ABILIFY 5 mg
ABILIFY 5
ABILIFY 7.5 mg/ ml
ABILIFY 7.5
ABILIFY :
oral formulations of ABILIFY
formulations of ABILIFY
aripiprazole solution for injection is
ABILIFY solution for injection than
ABILIFY solution for injection
ABILIFY solution for injection is
ABILIFY solution for injection
ABILIFY solution for injection should
ABILIFY solution for injection is
182 ABILIFY solution for injection
ABILIFY solution for injection
solution for injection
ABILIFY Each ml of ABILIFY
ABILIFY Each ml of
ABILIFY oral solution .
ABILIFY oral solution contains
ABILIFY oral solution must be
ABILIFY oral solution
the ABILIFY oral solution
ABILIFY orodispersible tablets contain
ABILIFY orodispersible tablet at the
orodispersible tablets or ABILIFY
ABILIFY orodispersible tablets
ABILIFY orodispersible
ABILIFY tablet at the
ABILIFY tablets , ABILIFY
ABILIFY tablets ( see also
ABILIFY tablets ( see
ABILIFY tablets (
ABILIFY tablets
ABILIFY tablets
ABILIFY 3.
ABILIFY affects you .
ABILIFY affects you
ABILIFY is 10 or 15
ABILIFY is 10 or 15
ABILIFY is 10 or
ABILIFY is 10
ABILIFY is 15 mg
ABILIFY is 15
ABILIFY is
Do not use ABILIFY
Do not take ABILIFY
Do not use ABILIFY
ABILIFY contains The active substance
ABILIFY contains The
ABILIFY contains
ABILIFY .
ABILIFY
ABILIFY exactly as your doctor
ABILIFY in
ABILIFY
ABILIFY is indicated for
ABILIFY is not
ABILIFY is effective in
ABILIFY is effective
ABILIFY is
ABILIFY may increase the effect
ABILIFY may increase the
ABILIFY can be
ABILIFY may increase
ABILIFY occurs with carbamazepine
not use ABILIFY if
not use ABILIFY
not take ABILIFY if
not take ABILIFY
ABILIFY and
ABILIFY is used
ABILIFY is
ABILIFY .
ABILIFY
concomitant administration of ABILIFY with
concomitant administration of ABILIFY
182 ABILIFY
ABILIFY
of ABILIFY
on ABILIFY
ABBREVIATIONS FOR DAYS OF
ABBREVIATIONS FOR
ABBREVIATIONS
ABSEAMED
ABSEAMED
enzyme
carprofen
ACLASTA
, ACOMPLIA 20 mg
ACOMPLIA 20 mg
, ACOMPLIA 20
ACOMPLIA 20
ACOMPLIA darf bei Patienten mit
ACOMPLIA darf bei Patienten
ACOMPLIA darf bei
ACOMPLIA darf
ACOMPLIA should not be
For
ACOMPLIA can be found here
ACOMPLIA can be found
or
ACOMPLIA with some medicines ,
ACOMPLIA with some medicines
ACOMPLIA with
ACOMPLIA and placebo
ACOMPLIA and
ACOMPLIA is not recommended
ACOMPLIA is not
ACOMPLIA is
ACOMPLIA were
, ACOMPLIA
ACOMPLIA in
ACOMPLIA
or
weight
ACTOS on the other face.
ACTOS on the other
ACTOS on the
ACTOS on
ACTOS
ACTRAPHANE 10 ACTRAPHANE 20 ACTRAPHANE
ACTRAPHANE 10 ACTRAPHANE 20
ACTRAPHANE 10 ACTRAPHANE
ACTRAPHANE 10
ACTRAPHANE 20 ACTRAPHANE 30 ACTRAPHANE
ACTRAPHANE 20 ACTRAPHANE 30
ACTRAPHANE 20 ACTRAPHANE
ACTRAPHANE 20
ACTRAPHANE 30 ACTRAPHANE 40 ACTRAPHANE
ACTRAPHANE 30 ACTRAPHANE 40
ACTRAPHANE 30 ACTRAPHANE
ACTRAPHANE 30
ACTRAPHANE 40 ACTRAPHANE 50
ACTRAPHANE 40 ACTRAPHANE
ACTRAPHANE 40
ACTRAPHANE 50
ACTRAPHANE
ALT ) ,
ALT )
ALT
PARTICULARS TO APPEAR ON THE
PARTICULARS TO APPEAR ON
PARTICULARS TO
PARTICULARS TO APPEAR ON
PARTICULARS TO APPEAR
PARTICULARS TO APPEAR ON
PARTICULARS TO APPEAR
PARTICULARS TO
PARTICULARS
USED FOR
valid Summary of Product Characteristics
valid Summary of
valid Summary
USE ,
EFFECTIVE USE
USE
USE ABILIFY
USE ABSEAMED
USE
ADMINISTRATION
USE
AQ ) , Italy
AQ ) ,
AQ )
AQ
ROUTE(S ) OF ADMINISTRATION
OF
ROUTE(S ) OF
ROUTE(S ) AND METHOD OF
ROUTE(S ) AND METHOD
ROUTE(S ) AND
ROUTE(S )
AND ROUTE(S ) OF ADMINISTRATION
AND ROUTE(S ) OF
AND ROUTE(S )
AND ROUTE(S
STATEMENT OF THE ACTIVE SUBSTANCE(S
QUANTITY OF
STATEMENT OF THE
MUST BE STORED OUT OF
MUST BE STORED
PRODUCT OR
MUST
PRODUCT
MEDICINAL PRODUCT
MEDICINAL PRODUCT ,
MEDICINAL PRODUCT AND ROUTE(S )
MEDICINAL PRODUCT AND ROUTE(S )
MEDICINAL PRODUCT AND ROUTE(S
MEDICINAL PRODUCT AND
MEDICINAL PRODUCT
MEDICINAL PRODUCT
MEDICINAL
AS Tlf : +47 23
AS Tlf : +47
AS Tlf :
AS Tlf
AS
ASL/ ALT > 10 x
ASL/ ALT > 10
ASL/ ALT >
ASL/
AST ) , increased Gamma
AST ) , increased
AST ) ,
AST )
AST
ATC code :
ATC code
AUC ) increased linearly
AUC ) increased
AUC ) increased
AUC )
AUC than a 40 year
AUC in the first
AUC after the same
AUC after the
AUC after
AUC after
in AUC
AUC and Cmax of dehydro-aripiprazole
AUC and Cmax of
AUC and Cmax
AUC and
AUC
SUPPLY OR USE
SUPPLY OR
APPEAR ON SMALL IMMEDIATE PACKAGING
TO APPEAR ON BLISTERS OR
TO APPEAR ON BLISTERS
OUTER PACKAGING
OUTER
TO APPEAR ON THE OUTER
APPEAR ON THE IMMEDIATE PACKAGE
APPEAR ON THE
TO APPEAR ON THE
TO APPEAR ON
TO
TO APPEAR ON THE
TO APPEAR ON THE OUTER
TO APPEAR ON
TO APPEAR
APPEAR ON SMALL IMMEDIATE PACKAGING
APPEAR ON SMALL IMMEDIATE
APPEAR ON BLISTERS OR STRIPS
APPEAR ON BLISTERS OR
APPEAR ON
ON
TO APPEAR
AUTHORISATION HOLDER
KEEP OUT OF THE REACH
KEEP OUT OF THE
KEEP OUT OF
Ab Puh/ Tel : +
Ab Puh/ Tel :
Ab Puh/ Tel
Ab
break down their internal
break down
decrease of
decrease
decrease of
decrease
such veterinary medicinal products
such veterinary medicinal
products
fatigue Psychiatric disorders Common :
fatigue Psychiatric disorders Common
fatigue Psychiatric disorders
fatigue Psychiatric
fatigue*
Depending on your individual situation
Depending on your
Depending on
Abilify , aripiprazole , is
Abilify , aripiprazole ,
Abilify , aripiprazole
Abilify ,
Abilify
Abilify should not
Abilify can be found here
Abilify can be found
Abilify also had a
Abilify also had a similar
Abilify also had
Abilify shown during the studies
Abilify shown during the
Abilify shown during
Abilify is a medicine
Abilify is a
Abilify is
Abilify and placebo
Abilify and placebo over three
Abilify and placebo over
Abilify and
Abilify
Abilify is
Abilify has not been
, Abilify
Abilify at
Abilify
of Abilify
Injections of Abilify at doses
Abilify experience
Abilify
of Abilify experience
of Abilify
resolution
reduction in red blood cell
height loss compared
height loss
height
decrease in
reduction in
decrease in
Decreased circulating levels of sex
Decreased circulating levels of
Decreased circulating levels
Decreased circulating
Abraxane (
Abraxane 260
Abraxane 5 mg/ ml
Abraxane 5
Abraxane as first-line
Abraxane as
Abraxane
patients on Abraxane
Abraxane
on Abraxane
Abraxane at any dose in
Abraxane at
Abraxane is 260
Abraxane is
Abraxane should not be
Abraxane contains human
Abraxane contains
Abraxane has minor or moderate
Abraxane has minor or
Abraxane has minor
Abraxane has
Abraxane shown during the studies
Abraxane shown during the
Abraxane shown during
Abraxane into
Abraxane is
Abraxane may cause side effects
Abraxane may
Abraxane at dose levels of
Abraxane at dose levels
Abraxane at dose
Abraxane after
Abraxane should not be administered
Abraxane should not be
Abraxane should not
Abraxane should only be administered
Abraxane should only be given
Abraxane should only be
Abraxane should
Abraxane was more effective than
Abraxane was more effective
Abraxane was
Abraxane is
Abraxane is not recommended
Abraxane is not
Abraxane is
Abraxane also affects
Abraxane has not been
Abraxane has been
Abraxane were
, Abraxane
Abraxane should
Abraxane
Abraxane
Abraxis BioScience Limited West Forest
Abraxis BioScience Limited West
Abraxis BioScience Limited
Abraxis BioScience
Abraxis
In conclusion
In conclusion
section 5.2 ) .
Section 4.2 ) .
section 4.2 ) .
section 4.2 )
section 4.2 ) The
Section 4.2 )
section 4.2 )
section 4.2 Method
section 4.2 Treatment of patients
section 4.2 Treatment of
section 4.2 Treatment
section dic
Section 4.2
section 4.2
section dic
section 4.3 ) .
section 4.3 )
section 4.3
section 4.4 ) .
section 4.4 ) .
section 4.4 )
section 4.4 -
4.4 und 5.2 )
4.4 und 5.2
section 4.4 and 5.2
section 4.4 and section 4.8
section 4.4 and section
4.4 und
section 4.4 and
4.4
section 4.4
section 4.5 ) .
section 4.5 )
section 4.5 .
section 4.5
section 4.6 ) .
section 4.6 )
section 4.6
section 4.8 ) .
section 4.8 )
section 4.8
section 5.1 ) . no
section 5.1 ) .
section 5.1 ) :
section 5.1 ) ,
section 5.1 )
section 5.1
4.4 and 5.2 ) .
section 5.2 ) .
4.4 and 5.2 )
section 5.2 )
4.4 and 5.2
5.2
section 5.2
section 5.3 ) .
section 5.3 )
section 5.3
section 6.1 ) .
section 6.1 )
, see section 6.1
section 6.1 .
see section 6.1
section 6.1
section 6.6 .
in section 6.6
mentioned in section 6.6
section 6.6
in section 6.6
mentioned in section 6.6
section 6.6
, see section
4.4 and
4.4
Section
in section
mentioned in section
section 4.4 )
section
see section
sections 4.3 and 4.4
sections 4.3 and
sections 4.3
sections 4.8 and 4.9 )
sections 4.8 and 4.9
sections 4.8 and
sections 4.8
sections
Abseamed 10 000 IU/ 1
Abseamed 10 000 IU/
Abseamed 10 000
Abseamed 10
Abseamed 1000 IU/ 0.5 ml
Abseamed 1000 IU/ 0.5
Abseamed 1000 IU/
Abseamed 1000
Abseamed 2000 IU/ 1 ml
Abseamed 2000 IU/ 1 ml
Abseamed 2000 IU/ 1
Abseamed 2000 IU/
Abseamed 2000
Abseamed 3000 IU/ 0.3 ml
Abseamed 3000 IU/ 0.3 ml
Abseamed 3000 IU/ 0.3
Abseamed 3000 IU/ 0.3
Abseamed 3000 IU/
Abseamed 3000
Abseamed 4000 IU/ 0.4 ml
Abseamed 4000 IU/ 0.4
Abseamed 4000 IU/
Abseamed 5000 IU/ 0.5 ml
Abseamed 5000 IU/ 0.5
Abseamed 5000 IU/
Abseamed 6000 IU/ 0.6 ml
Abseamed 6000 IU/ 0.6
Abseamed 6000 IU/
Abseamed 7000 IU/ 0.7 ml
Abseamed 7000 IU/ 0.7 ml
Abseamed 7000 IU/ 0.7
Abseamed 7000 IU/ 0.7
Abseamed 7000 IU/
Abseamed 7000
Abseamed 8000 IU/ 0.8 ml
Abseamed 8000 IU/ 0.8 ml
Abseamed 8000 IU/ 0.8
Abseamed 8000 IU/ 0.8
Abseamed 8000 IU/
Abseamed 8000
Abseamed 9000 IU/ 0.9 ml
Abseamed 9000 IU/ 0.9
Abseamed 9000
dose of Abseamed accordingly
dose of Abseamed
Abseamed
Abseamed pre-filled syringe is
The Abseamed pre-filled syringe is
Abseamed pre-filled syringe
The Abseamed pre-filled syringe
Abseamed than
Abseamed
a kidney patient Abseamed
Abseamed 3.
Abseamed in adult patients
Abseamed in patients at
Abseamed .
Abseamed
Abseamed
Abseamed contains
Abseamed has no influence
Abseamed has no
Abseamed has
Abseamed has been injected .
Abseamed has been injected
Abseamed is a sterile
Abseamed is a
Abseamed is presented as a
Abseamed is presented
Abseamed is
Abseamed may be associated with
Abseamed can be
Abseamed may be
not receive Abseamed , since
not receive Abseamed ,
not receive Abseamed
Abseamed or
Abseamed should be administered intravenously
Abseamed should be given
Take special care with Abseamed
Abseamed should be
blood , Abseamed should
Abseamed .
Abseamed
Abseamed may be injected by
, Abseamed may be
Abseamed may be
You will receive Abseamed
You will receive Abseamed
Abseamed is given by injection
Abseamed is used :
Abseamed is used
Abseamed is
to Abseamed adequate
to Abseamed
Abseamed between 17 and 33
Abseamed between 17 and
Abseamed between 17
Abseamed between 25 and 50
Abseamed between 25 and
Abseamed between 25
Abseamed between
, Abseamed
Abseamed accordingly
Abseamed has
Abseamed out
Abseamed
The Abseamed
blood , Abseamed
of Abseamed
discontinuation
fracture event
3
four weeks .
four weeks
cell-killing
Acesulfame potassium Vanilla
Acesulfame potassium
Aclasta ( 5 mg in
Aclasta ( 5 mg
Aclasta ( 5
Placebo Absolute reduction ( N=3,861
Aclasta (
Aclasta , zoledronic acid ,
Aclasta , zoledronic acid
Aclasta ,
Aclasta .
Aclasta 5 mg once a
Aclasta 5 mg
Aclasta 5
Aclasta can be
Aclasta can be
Aclasta ( see section
Aclasta ( see
Aclasta (
Aclasta .
Aclasta
Aclasta-treated
Aclasta in children and
Aclasta in children
Aclasta in
Aclasta must not be
Aclasta should not be
administer Aclasta
Aclasta administered once a year
Aclasta contains the
Aclasta contains
Aclasta ?
Aclasta is available here .
Aclasta is available here
Aclasta has no known effects
Aclasta has
assessing Aclasta .
assessing Aclasta
in Aclasta
Aclasta shown during the studies
Aclasta shown during the
Aclasta shown during
Aclasta is a clear and
Aclasta is a clear
Aclasta is a
Aclasta is contraindicated for patients
Aclasta is contraindicated for
Aclasta is contraindicated
Aclasta is
Aclasta after
Aclasta or they received risedronate
Aclasta or they received
Aclasta or they
Aclasta or
store Aclasta properly
to store Aclasta properly
Aclasta significantly decreased
Aclasta , see section 6.6
Aclasta , see section
Aclasta , see
Aclasta
Aclasta tend to
Aclasta tend
Aclasta and 0.8 % for
Aclasta and 0.8 %
Aclasta and 0.8
Aclasta and risedronate
Aclasta and
are given Aclasta .
are given Aclasta
Aclasta .
Aclasta
Aclasta demonstrated a
Aclasta demonstrated
Aclasta is given as a
Aclasta is not recommended for
Aclasta is not recommended
Aclasta is not
Aclasta is given
Aclasta is
Aclasta works by
Aclasta works
Aclasta works
Aclasta was
, Aclasta
Aclasta ,
Aclasta Placebo Absolute
Aclasta as
Aclasta
Placebo Absolute
substances Aclasta
Aclasta
are treated with Aclasta .
are treated with Aclasta
Aclasta infusion
Aclasta
doses of Aclasta .
of Aclasta .
doses of Aclasta
of Aclasta
Aclasta-treated
Aclasta-treated
men treated
Actos .
Actos 15
taking Actos 15mg tablets
Actos 15mg tablets
Actos 15mg tablets is
Actos 15 mg tablets may
Actos 15mg tablets can be
Actos 15mg tablets with
Actos 15 mg tablets are
Actos 15 mg Tabletten werden
Actos 15mg tablets are
Actos 15 mg Tabletten
Actos 15 mg tablets
Actos 15mg tablets
Actos 15 mg
Actos 15mg
Actos 15mg
taking Actos 15mg
Actos 15
Actos 30
taking Actos 30mg tablets
Actos 30mg tablets
Actos 30mg tablets is
Actos 30 mg tablets may
Actos 30mg tablets can be
Actos 30mg tablets with
Actos 30 mg tablets are
Actos 30 mg Tabletten werden
Actos 30mg tablets are
Actos 30 mg Tabletten
Actos 30 mg tablets
Actos 30mg tablets
Actos 30 mg
Actos 30mg
Actos 30mg
taking Actos 30mg
Actos 30
Actos 45
taking Actos 45mg tablets
Actos 45mg tablets
Actos 45mg tablets is
Actos 45 mg tablets may
Actos 45mg tablets can be
Actos 45mg tablets with
Actos 45 mg Tabletten werden
Actos 45mg tablets are
Actos 45 mg Tabletten
Actos 45 mg tablets
Actos 45mg tablets
Actos 45 mg
Actos 45mg
Actos 45mg
taking Actos 45mg
Actos 45
Actos tablets contain lactose monohydrate
Actos tablets contain
Actos tablets
Actos should not
Actos contains The active
Actos contains The
Actos contains
Actos is a medicine
Actos is a
Actos is
Actos or placebo
Actos or
Actos and insulin
Actos and
Actos are visual disturbance ,
Actos are visual disturbance
Actos are
Actos is taken once daily
Actos is
Actos has been studied
Actos to the existing treatment
Actos to the existing
Actos to the
Actos to
Actos 15mg
Actos 30mg
Actos 45mg
Actos are
Actos to
Actos
taking Actos
when starting Actos
Actraphane 10 : soluble insulin
Actraphane 10 : soluble
Actraphane 10 :
Actraphane 10 NovoLet 100
Actraphane 10 NovoLet
Actraphane 10 Penfill 100
Actraphane 10 Penfill
Actraphane 10 consists of 10
Actraphane 10 consists of
Actraphane 10
Actraphane 20 : soluble insulin
Actraphane 20 : soluble
Actraphane 20 :
Actraphane 20 NovoLet 100
Actraphane 20 NovoLet
Actraphane 20 Penfill 100
Actraphane 20 Penfill
Actraphane 20 consists of 20
Actraphane 20 consists of
Actraphane 20
Actraphane 30 100
Actraphane 30 40
Actraphane 30 : soluble insulin
Actraphane 30 : soluble
Actraphane 30 :
Actraphane 30 NovoLet 100
Actraphane 30 NovoLet
Actraphane 30 Penfill 100
Actraphane 30 Penfill
Actraphane 30 consists of 30
Actraphane 30 consists of
Actraphane 30
Actraphane 40 : soluble insulin
Actraphane 40 : soluble
Actraphane 40 :
Actraphane 40 NovoLet 100
Actraphane 40 NovoLet
Actraphane 40 Penfill 100
Actraphane 40 Penfill
Actraphane 40 consists of 40
Actraphane 40 consists of
Actraphane 40
Actraphane 50 : soluble insulin
Actraphane 50 : soluble
Actraphane 50 :
Actraphane 50 NovoLet 100
Actraphane 50 NovoLet
Actraphane 50 Penfill 100
Actraphane 50 Penfill
Actraphane 50 consists of 50
Actraphane 50 consists of
Actraphane 50
Actraphane NovoLet is
Actraphane NovoLet is
Actraphane NovoLet
Actraphane Penfill is
Actraphane contains metacresol , which
Actraphane contains the active ingredient
Actraphane contains both fast-acting
Actraphane contains both
Actraphane contains
Actraphane .
Actraphane
Actraphane can be found here
Actraphane can be found
Actraphane shown during the studies
Actraphane shown during the
Actraphane shown during
Actraphane is a mixture
Actraphane is a range of
Actraphane is a range
Actraphane is a
Actraphane is
Actraphane may
Actraphane should not be
Actraphane is usually
Actraphane is given subcutaneously (
Actraphane is given subcutaneously
Actraphane is
Actraphane has been studied in
Actraphane
Adipositas ( ca . Me
Adipositas (
obesity ) and
obesity )
Adipositas infolge des höheren
Adipositas infolge des höheren
Adipositas ist die Eliminationshalbwertszeit wegen
Adipositas ist die Eliminationshalbwertszeit wegen
Adipositas ist die
( See section
( See
( See section
( See
Adipositas ist
obese or overweight
in
Adipositas
obese
monkeys ,
monkeys after repeated oral
monkeys after repeated
monkeys after
monkeys
or monkeys
affinity for muscarinic receptors .
affinity for muscarinic receptors
affinity for
affinity
agitation , nervousness
agitation ,
agitation and disturbed behaviours ,
agitation and disturbed behaviours
agitation and
agitation
agitation and disturbed behaviours
agitation and disturbed behaviours
agitation and
agitation
agitation/ behavioural
in agitation/ behavioural
akathisia , tremor , dizziness
akathisia , tremor ,
akathisia , tremor
akathisia ,
akathisia , nausea and vomiting
akathisia , nausea and
akathisia , nausea
akathisia was 6.2 % with
akathisia was 6.2 %
akathisia was 6.2
akathisia Gastrointestinal disorders Common
akathisia Gastrointestinal disorders
akathisia in bipolar patients
akathisia in bipolar patients
akathisia in bipolar
akathisia in bipolar
akathisia in
Akathisia is
Akathisia
akathisia was
akathisia
activity , concentrations and
activity , concentrations
activity ,
activity and
activity of rimonabant was
activity of rimonabant
activity of
to increase their physical activity
activity
physical activity
physical
Activated charcoal ( 50
Activated charcoal (
52 Activated
76 Activated
88 Activated
Activated charcoal
Activated
Actual scores
Acute toxicity The highest
Acute toxicity The
Acute toxicity
Acute
albumin-bound nanoparticle
albumin-bound
Human albumin solution ( containing
Human albumin
28108 Alcobendas
Aldwych , London , WC2B
Aldwych , London ,
Aldwych , London
Aldwych ,
Aldwych London WC2B 4AE United
Aldwych London WC2B 4AE
Aldwych London WC2B
Aldwych London
Aldwych
Alcohol may
alcohol or other CNS
alcohol or other
alcohol or
Alcohol
alcohol
alcohol or
alcohol wipe .
alcohol wipe
All women received
All women
All patients being
Alle Patienten unter Abseamed
Alle Patienten unter
All participants received
All participants
All other causes of anaemia
All other
All special warnings and
All special warnings
All
However
allergic reaction (
allergic reaction
General )
General
General disorders and administration
somewhat higher but the systemic
somewhat higher but the systemic
performance status , chest pain
performance
Allé DK-2880 Bagsværd Denmark
Allé DK-2880 Bagsværd
Allé DK-2880
Allé
Alopecia was observed in 90
Alopecia was observed in
Alopecia was observed
Alopecia
As a consequence of
As a consequence
Attention should be paid
Particular attention should be paid
Attention should
Particular attention should
At equivalent doses ,
At equivalent doses
Particular
age , gender , and
age , race or
age , race
age ,
of age
aged over 65 years
age
age group
age where
age
Aluminium/ aluminium blisters , packs
At the end of a
American post
amidohydrolase ( predominantly
aminoglycosides or diuretics that
aminoglycosides or diuretics
aminoglycosides or
aminoglycosides
amino acids .
amino acids
Anagni-Frosinone Italy
Anagni-Frosinone
analogues for injection ,
analogues for injection
analogues for
Analogue Scale ( CLAS )
Analogue Scale ( CLAS
Analogue Scale (
Analogue Scale
analysis
pharmacokinetic analysis (
population pharmacokinetic analysis (
subpopulation analyses
subpopulation
analysis indicated that
analysis
subpopulation
Anaphylactic reactions Symptoms of generalised
Anaphylactic reactions Symptoms of
Anaphylactic reactions Symptoms
superfluous
within 6
when used or stored at
when used or
when used
Other disturbances of mineral metabolism
Other disturbances of
Other disturbances
Other potent inhibitors of CYP3A4
Other potent inhibitors of
Other potent inhibitors
Other potent
Other
androgen suppression is
androgen suppression
aneurysms
starting
Starting dose of 50
starting dose is 15 mg
starting dose is 15
initial dose is 150
initial dose is
starting dose is
starting dose for ABILIFY is
starting dose for ABILIFY
starting dose for ABILIFY
initial dose for
starting dose for
starting dose is 150 International
starting dose is 150
starting dose is 50 International
starting dose is 50
starting dose is 600 International
starting dose is 600
starting dose is
Starting dose of 50
Starting dose of
Starting dose of
Starting dose
dose
initial dose
starting dose
request
applies to you
other relevant persons
other relevant persons
Haemoglobin variability
angina pectoris , increased risk
angina pectoris , increased
angina pectoris ,
angina pectoris
angina
unstable angina pectoris
angiotensin II antagonists , calcium
angiotensin converting enzyme (
angiotensin converting
angioedema
angioedema including swollen tongue
angioedema and anaphylactic reaction .
angioedema and anaphylactic reaction
angioedema and
angioedema
and dizziness .
and dizziness
dizziness .
dizziness
feeling anxious ,
feeling anxious
clinical trials .
Persistent pain and/ or non-healing
Persistent pain and/ or
Persistent pain and/ or
Persistent pain
Persistent
Annex I )
Annex I
Annex
Approximately one third of patients
Approximately one third of
Approximately one third
Approximately one
anorexia , hyponatremia
anorexia , severe weight
anorexia , severe
anorexia ,
anorexia
Dosage adjustment Concomitant illness ,
Dosage adjustment Concomitant illness
Anpassung der Dosis notwendig
Anpassung der Dosis
Anpassung der Dosis
dosage of medicinal
Thereafter , your dog should
Thereafter bone markers stabilised
Thereafter ,
Thereafter
address of
address of
address of the manufacturer
address of the manufacturer
address of the manufacturer
address of the
address
address
swelling of hands ,
swelling of hands
swelling of
swelling
response
was defined as the patient
was defined as the
was defined as
was defined
was
response
rate ,
Response rate [ 95
Response rate [
Response rate
rate
response rates in all patients
response rates in all
response rates in
response rates
increase in AUC
increase
increases
the rise in packed
rise in haemoglobin of greater
rise in haemoglobin of
the rise in
increase of
increase
increase of
increase
increases
antagonist .
antagonist
Anteil der Patienten , der
Anteil der Patienten ,
Anteil der Patienten
proportion of patients
Anteil der
proportion of
, dehydro-aripiprazole ,
dehydro-aripiprazole
Anteil
proportion
anthracycline (
anthracycline
anthracyclines or
anthracyclines
antibiotics
hypoglycaemic agents ( OHA )
hypoglycaemic agents ( OHA
antimicrotubule agent
medicines called antipsychotics .
medicines called antipsychotics
antipsychotic medicinal products
antipsychotic
antipsychotics , aripiprazole should
antipsychotics ,
antipsychotics
antipsychotic medicine ) in 384
antipsychotic medicine ) in
antipsychotic medicine ) and
antipsychotic medicine )
antipsychotic medicine
antipsychotic
application for the use of
application for the use
application for the
application for
application
instructions given to you by
instructions given to
instructions given to
instructions given
surgeon
of administration ) .
of administration )
use in children and
use in children below
use in children
use in animals The safety
use in animals The
use in animals
use in
on the use of
use
this
use
use in this
use in
the perisurgical setting
recombinant erythropoietins should be based
subcutaneous route of administration should
administration
use ABILIFY
as type 2 diabetes or
use of Abraxane as first-line
use of Abraxane as
use of Abraxane
use Abseamed
use of Abseamed
are given Aclasta :
are given Aclasta
use of Aclasta in children
use of Aclasta in
use of Aclasta ?
Aclasta administration
are given Aclasta
use of Aclasta
use of Aclasta
Actos with other
use of pioglitazone in patients
use of pioglitazone in
use of pioglitazone
administration of zoledronic acid
the administration of zoledronic acid
administration of recombinant human erythropoietin
administration of recombinant human
2 diabetes
2
Using
administration of
administration
concomitant
from
the administration of
type 2 diabetes
type 2
use of
use of
use
Use during pregnancy ,
Use during pregnancy
Use during
Rimonabant is
Use
Using
administration
are
concomitant
of administration
the administration
use ,
use
solution
difficult
Indications for
gait
patients and doctors , and
patients and doctors , and
number of patients who
number of patients
number of
red blood cell count
red blood cell
number of
counts
number
signs of local infection including
signs of local infection
signs of local
signs of
signs and symptoms reported
signs and symptoms
signs and symptoms of hyperglycaemia
for signs and symptoms of
signs and symptoms of
for signs and symptoms
signs and symptoms
for signs and
signs and
for signs
signs of
signs
symptoms
To
anaemia ( e. g.
anaemia ( e.
anaemia (
anaemia , are not sufficient
anaemia in adult and paediatric
anaemia associated with chronic
anaemia associated with
anaemia in
anaemia with epoetin alfa
anaemia with epoetin
anaemia with
anaemia the medicinal product has
anaemia the medicinal product
anaemia
anaemia and reduction
anaemia and
anaemia ,
anaemia associated
anaemia
of anaemia
Anaemia symptoms and sequelae may
Anaemia symptoms and sequelae
Anaemia symptoms and sequelae may
Anaemia symptoms and sequelae
causes of anaemia (
causes of anaemia
pharmacist if you are
nurse if you
pharmacist if you are
nurse if
pharmacist how
pharmacist how
pharmacist
pharmacist This
pharmacist .
pharmacist
pharmacist
pharmacist or nurse .
pharmacist or nurse
pharmacist or nurse .
pharmacist or nurse
pharmacist or
pharmacist for advice before
pharmacist for advice
pharmacist how
nurse
pharmacist
, anorexia
anorexia
appetite
decreased appetite .
decreased appetite
. They include thirst
They include thirst
route ,
administration .
route .
administration of epoetin alfa
administration of epoetin
administration of
administration
route
areflexia , dyskinesia , hyporeflexia
areflexia , dyskinesia ,
areflexia , dyskinesia
areflexia ,
areflexia
aripiprazole ( dose 15 mg
aripiprazole ( 30 mg )
aripiprazole ( 30 mg
aripiprazole ( 30
, oral aripiprazole
oral aripiprazole
, oral aripiprazole
oral aripiprazole
aripiprazole ( see section 4.8
aripiprazole ( see section
aripiprazole ( see
aripiprazole (
aripiprazole
aripiprazole ) .
aripiprazole ) once a day
aripiprazole ) once a
aripiprazole )
aripiprazole , there were no
aripiprazole , there were
aripiprazole , is an
aripiprazole , is
aripiprazole ,
aripiprazole .
of aripiprazole .
aripiprazole 77 %
aripiprazole 77
aripiprazole :
aripiprazole AUC
lorazepam solution for injection
Aripiprazole solution for injection
aripiprazole solution for injection
lorazepam solution for injection
Aripiprazole orodispersible tablets may
Aripiprazole orodispersible tablet is bioequivalent
Aripiprazole orodispersible tablets
Aripiprazole orodispersible
aripiprazole tablets , with
aripiprazole tablets ,
aripiprazole tablets
aripiprazole Intramuscular use
aripiprazole Intramuscular
, aripiprazole was considered non-genotoxic
aripiprazole was considered non-genotoxic
aripiprazole as the
aripiprazole as
Aripiprazole did not
aripiprazole should be initiated .
aripiprazole should be initiated
aripiprazole treated patients
aripiprazole treated
aripiprazole in pregnant women
aripiprazole in pregnant
aripiprazole in
of aripiprazole in
have been receiving aripiprazole ,
have been receiving aripiprazole
been receiving aripiprazole
aripiprazole .
aripiprazole
aripiprazole was administered concomitantly with
aripiprazole was administered concomitantly
aripiprazole in the bile
aripiprazole in the
aripiprazole in
aripiprazole , close medical
ABILIFY is indicated for
ABILIFY is effective in
ABILIFY is effective
ABILIFY is
Aripiprazole is the predominant medicinal
been reported while taking aripiprazole
while taking aripiprazole
aripiprazole or any of the
aripiprazole or any
aripiprazole or
Aripiprazol sollte
Aripiprazole should be
aripiprazole
aripiprazole and 3.0 % with
aripiprazole and 3.0 %
aripiprazole and 3.0
aripiprazole and 3.2 % with
aripiprazole and 3.2 %
aripiprazole and 3.2
aripiprazole and dehydro-aripiprazole , but
aripiprazole and dehydro-aripiprazole ,
aripiprazole and dehydro-aripiprazole did
, aripiprazole and dehydro-aripiprazole are
aripiprazole and dehydro-aripiprazole are
aripiprazole and dehydro-aripiprazole
Aripiprazole and other antipsychotic drugs
Aripiprazole and other
, aripiprazole and
Aripiprazole and
aripiprazole and
aripiprazole
Aripiprazole also demonstrated
Aripiprazole is well
Aripiprazole is
Aripiprazole is metabolised
Aripiprazole is extensively metabolised
Aripiprazole is thought to
Aripiprazole is thought
of unchanged aripiprazole was
unchanged aripiprazole was
Aripiprazole was
aripiprazole during
Aripiprazole exhibited antagonist properties in
Aripiprazole exhibited
, aripiprazole
ABILIFY
Aripiprazol
Aripiprazole
aripiprazole ( Cmax )
aripiprazole ( Cmax
aripiprazole ,
aripiprazole .
aripiprazole
lorazepam
of aripiprazole ( Cmax )
of aripiprazole ( Cmax
of aripiprazole
for aripiprazole-treated
for aripiprazole-treated
aripiprazole dose
aripiprazole concentrations .
aripiprazole concentrations
arrhythmias , sudden unexplained
arrhythmias , sudden
arrhythmias ,
arrhythmias .
arrhythmias
type of white
type of white
Amounts to be
type of
type of
type
and method of administration
and method of
and method
Amounts
on the type
the type
type of
type
drug types were not
drug types were
drug types
types of paclitaxel contain
types of paclitaxel
types of
types
Arthralgia occurred in 32 %
Arthralgia occurred in 32
Arthralgia occurred in
Arthralgia occurred
Arthralgia
.
and lp
kg .
lp
medicine containing the active
medicine containing
medicinal products :
Arzneimittel Pütter GmbH & Co
Arzneimittel Pütter GmbH &
Arzneimittel Pütter GmbH
Arzneimittel Pütter
Medicinal product subject to restricted
Arzneimittel auf eingeschränkte ärztliche Verschreibung
Keep out of the
medicine can only be
product must not be
medicinal product must
taking or
taking or
taking
medicinal product contains approximately 425
medicinal product contains approximately
medicinal product contains
Keep out of the reach
Keep out of the reach
Keep out of the
Keep out of
anticancer medicine since 1993.
anticancer medicine
anti-fungal medicines ) ,
anti-fungal medicines )
anti-fungal medicines
medicines
medicinal products .
medicinal products
medicine can only be obtained
medicine can only be
medicine can only be
product immediately
product
intravenous route has to
after the expiry
this medicine after
product should be used immediately
Medicines should not be
medicinal product and , as
medicinal product and ,
medicinal product and
medicine has been
to dispose of
to dispose of
to dispose
to dispose of
to dispose
to dispose
medicinal product to prevent
Arzneimittel
Medicines
medicinal product
medicinal products
medicinal
medicine can
medicine
medicines
of medicines
product
the product
this medicine
to the product
drug-drug interaction
product involvement should be considered
products to affect ABILIFY :
products to affect ABILIFY
products to affect
be treated with medicinal products
medicinal products with
medicinal products and
products and
medicines used to
medicines used
some medicines , such as
medicines to reduce side effects
medicines to reduce
medicines to
drug
medicinal products
medicines
products
some medicines ,
some medicines
medicine (
Characterisitics , Section 4.2 )
Characterisitics , Section 4.2
Characterisitics , Section
Characterisitics ,
product moiety in systemic circulation
medicinal product must
medicine .
medicine
Characterisitics
medicine
product
drug reactions from clinical
drug reactions from
doctor , pharmacist or
doctor , pharmacist
doctor ,
doctor .
Patient information pack
physician if they become
physicians
doctor can recommend a mild
doctor can recommend a
doctor can recommend
doctor
medicine :
medicine
physician must therefore take possible
physician must therefore
doctor or pharmacist .
doctor or pharmacist
doctor or pharmacist
doctor or pharmacist
doctor or
your doctor immediately if you
your doctor immediately if
your doctor immediately
doctor immediately if you
doctor immediately if
doctor immediately
doctor will ask you
doctor will take this
doctor will decide when
doctor will
can
disorders can
doctor
medical
medicine
the medicine
use the medicine
your doctor
doctor carefully before
doctor
appointment and discuss
appointment
aspart ) .
aspart )
aspartame ( E951 ) per
Aspartame ( E951 )
aspartame ( E951 )
Aspartame ( E951
aspartame ( E951
Aspartame (
aspartame (
, aspartame
Aspartame
aspartame
aspiration have been associated with
aspiration have been
, aspirin , statins ,
, aspirin , statins
, aspirin ,
aspirin
Assessment of Cancer Therapy- Anaemia
Assessment of Cancer
Assessment of
Asthenia/ Fatigue was reported in
ataxia , sensory
ataxia ,
ataxia
in breathing
respiratory
breathlessness .
or breathlessness .
breathlessness
or breathlessness
, abnormal blood pressure
, abnormal
Other disturbances of
Other disturbances
138 Even if you
143 Even if you
148 Even if you
153 Even if you
Even if you
138 Even if
143 Even if
148 Even if
153 Even if
Even if
138 Even
143 Even
148 Even
153 Even
Even
the request of the EMEA
the request of the EMEA
the request of the
On this basis
On this
On
The printed
the immune-system
the immune-system
immune-system
Because of potential serious
Because of potential
Because
Due to
No other erythropoietic therapy
Due to its 1-adrenergic receptor
Because
Due to
No
Physician educational material
educational
attention
in attention
muscle
of
occurrence of
occurrence
eyes
in the eyes
the eyes
Eye disorders :
Eye disorders Common : blurred
Eye disorders Common :
Eye disorders Common
Eye disorders Very rare -
Eye disorders Very rare
Eye disorders Very
Eye disorders
Eye
the first
Eye irritation , eye
Eye irritation ,
Eye irritation
eye pain Uveitis , episcleritis
eye pain Uveitis ,
eye pain Uveitis
eye
eye pain , abnormal vision
eye pain , abnormal
eye
Therefore
No evidence exists
12 From
From
precipitates or settling are visible
161 Detailed information on
167 Detailed information on
173 Detailed information on
179 Detailed information on
Detailed information on
ge Detailed information on
outcome has been reported ,
outcome has been reported
outcome has
seines Ausgangsgewichtes reduzierte
baseline 7.2 % ) .
baseline 7.2 % )
baseline 7.2 %
baseline 7.2
baseline 7.3 % ) and
baseline 7.3 % )
baseline 7.3 %
baseline 7.3
baseline on the PANSS Excitement
baseline on the PANSS
baseline on the
baseline on
above baseline
baseline
baseline .
baseline
gluconate
extent
excretion .
and is excreted unchanged
and is
and
excretion
expulsions , cellulitis , flare
expulsions , cellulitis
rash )
rash .
rash
Committee for Medicinal products for
Ausschuss für
Committee
prevent dehydration .
prevent dehydration
impact on overall survival
effect on the
effect on
impact on
effect of
effect
impact
meal on the pharmacokinetics of
meal on the pharmacokinetics
Effects on ability
Effects on ability
Effects on
meal on the
on the
Effects on
meal on
on
Effects
meal
You will also take
will also
Moreover , monitoring of
In addition , cases of
In addition , cases
In addition ,
Aripiprazole also exhibited
Additionally , aripiprazole and dehydro-aripiprazole
Additionally , aripiprazole and
Additionally , aripiprazole
Additionally ,
Moreover ,
also
Avda . de
Avda
Avenue Gustave Eiffel , BP
Avenue Gustave Eiffel ,
Avenue Gustave Eiffel
Avenue Gustave
Avenue
B-CTx was significantly
B-CTx was
B-CTx
to patients when indicated .
to patients when indicated
e. g. rifampicin
g. diminished parathyroid reserve ,
g. diminished parathyroid reserve
g. diminished
g. diminished
g.
e. g. during
e. g.
g.
GIVEN
CONDITIONS OR RESTRICTIONS
CONDITIONS OR RESTRICTIONS
CONDITIONS OR RESTRICTIONS
CONDITIONS OR RESTRICTIONS WITH
CONDITIONS OR
CONDITIONS
PACKAGING
PACKAGING UNITS
S. A. / N. V.
S. A.
RESTRICTIONS OF
RESTRICTIONS
PRODUCTS OR WASTE MATERIALS
PRODUCTS OR WASTE
PRODUCTS
SPECIAL PRECAUTIONS
SPECIAL PRECAUTIONS
Enthält Lactosemonohydrat
EVALUATION
NAME OF THE MEDICINAL PRODUCT
NAME OF THE MEDICINAL
NAME OF THE
NAME
REGARDING SUPPLY OR USE
REGARDING SUPPLY OR
REGARDING
BL5 3XX United Kingdom
BL5 3XX United
BL5 3XX
BL5
ON BLISTERS OR STRIPS
ON BLISTERS OR
ON
ON BLISTERS
BLUE BOX ) AND BOTTLE
BLUE BOX ) AND
BLUE BOX )
BLUE BOX
BLUE
BMD ) In
BMD )
BMD assessed at 24 months
BMD
BMI
BOX ) AND BOTTLE
BOX ) AND
BOX )
BOX
BP 27166 , F-37071 Tours
BP 27166 , F-37071
BP 27166 ,
BP 27166
BP
BRISTOL-MYERS SQUIBB ( FINLAND )
BRISTOL-MYERS SQUIBB ( FINLAND
BRISTOL-MYERS SQUIBB (
BRISTOL-MYERS SQUIBB AB Tel :
BRISTOL-MYERS SQUIBB AB Tel
BRISTOL-MYERS SQUIBB AB
BRISTOL-MYERS SQUIBB BELGIUM S. A.
BRISTOL-MYERS SQUIBB BELGIUM S. A.
BRISTOL-MYERS SQUIBB BV Tel :
BRISTOL-MYERS SQUIBB BV Tel
BRISTOL-MYERS SQUIBB BV
BRISTOL-MYERS SQUIBB GESMBH Tel :
BRISTOL-MYERS SQUIBB GESMBH Tel
BRISTOL-MYERS SQUIBB GESMBH
BRISTOL-MYERS SQUIBB NORWAY LTD Tlf
BRISTOL-MYERS SQUIBB NORWAY LTD
BRISTOL-MYERS SQUIBB NORWAY
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD
BRISTOL-MYERS SQUIBB PHARMACEUTICALS
BRISTOL-MYERS SQUIBB SARL Tél :
BRISTOL-MYERS SQUIBB SARL Tél
BRISTOL-MYERS SQUIBB SARL
BRISTOL-MYERS SQUIBB Tlf : +
BRISTOL-MYERS SQUIBB Tlf :
BRISTOL-MYERS SQUIBB Tlf
BRISTOL-MYERS SQUIBB BELGIUM
BRISTOL-MYERS SQUIBB
BRISTOL-MYERS
BSAP ) ,
BSAP ) ,
BSAP )
BSAP
BV Tel : + 31
BV Tel : +
BV Tel :
BV Tel
BV
Bagsværd Denmark
Bagsværd
Based on results of
Based on results
Non-clinical data reveal no
Non-clinical safety data revealed no
Non-clinical
Based on laboratory assessment
Based on laboratory assessment
Based on in vitro studies
Based on in
Based on
Non-clinical
Based
basis
, abdominal and stomach discomfort
abdominal and stomach discomfort ,
abdominal and stomach discomfort
abdominal discomfort
of the pancreas
pancreas
the pancreas
of the pancreas
pancreas
the pancreas
( N=70
N=70
relevance of such a mechanism
precautions to avoid
precautions to avoid
use machines .
use machines .
use machines have been performed
use machines have
use machines
use machines
precautions to
use
precautions
be followed .
be followed
There may be an increased
of the
the
hepatic impairment ( see sections
hepatic impairment (
hepatic impairment
renal impairment ( see
renal impairment (
renal impairment
however , should
however ,
however
pharmacokinetics and safety of
pharmacokinetics and
stopping Aclasta treatment
stopping
Follow carefully all instructions given
Follow carefully all
Follow carefully
Follow
finding
findings is unknown .
findings is unknown
findings is
findings from
findings
findings
the start of your therapy
continued when starting Actos
initiation of therapy with pioglitazone
initiation of therapy with
the initiation of therapy with
initiation of therapy
the initiation of therapy
initiation of
the initiation of
occur upon initiation of insulin
initiation
start of
start
starting
treatment ( see
treatment (
treatment ,
treatment .
when treating your diabetes
when treating your
initial treatment response .
initial treatment response
treatment to
Treatment of anaemia associated with
Treatment of anaemia and reduction
Treatment of anaemia and
Treatment of anaemia associated
Treatment of anaemia
Treatment of osteoporosis in post-menopausal
Treatment of osteoporosis in
Treatment of osteoporosis
the treatment of schizophrenia .
the treatment of schizophrenia
treatment of bipolar disorder
treatment of bipolar
the treatment of the following
treatment of post-menopausal osteoporosis (
treatment of post-menopausal osteoporosis
the treatment of post-menopausal
treatment of post-menopausal
Treatment of symptomatic anaemia in
Treatment of symptomatic anaemia
Treatment of symptomatic
Treatment of
the treatment of
the treatment of
treatment of
treatment of diabetes is
treatment of diabetes
treatment of Paget s disease
treatment of
6 months of treatment
treatment in this patient group
treatment in this
treatment of
treatment should be initiated
treatment is part of
treatment is
of treatment , the
of treatment ,
may
Abseamed treatment should be discontinued
Abseamed treatment begins .
Abseamed treatment begins
Abseamed treatment
Aclasta treatment
aripiprazole treatment
treatment with aripiprazole .
treatment with aripiprazole
treatment with epoetin alfa
treatment with epoetin alfa is
treatment with epoetin alfa
treatment with epoetin
treatment with lithium
treatment with metformin and
treatment with metformin
with treatment with pioglitazone .
with treatment with pioglitazone
treatment with the product
treatment with the
of subcutaneous erythropoietin treatment
treatment with two other
treatment with two
treatment ,
treatment with
treatment
with treatment with
treatment
of treatment of post-menopausal osteoporosis
treatment of post-menopausal osteoporosis
of continued therapy .
of continued therapy
treatment , these patients should
treatment should be
and
treatment of diabetes
treatment of diabetes
Treatment of adult patients
Treatment of adult
Treatment of adult
Treatment of Paget s disease
Treatment of patients
treatment of advanced prostate cancer
Treatment of
than its
than
the treatment of
treatment of
management of overweight and obesity
management of overweight and
management of overweight
course of continued therapy
treatment for the prevention of
, treatment
Treatment
be treated
be
experienced
of treatment of
of treatment
palliative treatment
the treatment
treatment ,
treatment of
treatment
start of
start
the start of
the start
being achieved and to ensure
being achieved and to
with
courses
plan of each patient
plan
regimens including bisphosphonates
regimens including
regimens
treatment schedule
schedule .
treatment schedule .
schedule
treatment schedule
Using ABILIFY
Using Aclasta
Using
In CYP2D6
Taking ABILIFY
Taking
Taking
There was
There
2 In combination with insulin
In combination with insulin ,
In combination with insulin
2 In combination with
In combination with
2 In combination
In combination
For Paget s disease ,
For Paget s disease
For Paget s disease
In Paget s disease ,
In Paget s disease
In osteoporosis , Aclasta was
For osteoporosis
In osteoporosis ,
In osteoporosis
For patients who
In patients with diabetes mellitus
In patients with diabetes
Patients with hepatic impairment
In chronic renal failure patients
Serum electrolytes
Bei Patienten mit einer Adipositas
Bei Patienten mit einer
In patients with a
Bei Patienten mit
In patients with
No dosage adjustment
Patients with
Patients receiving pioglitazone had
Bei Patienten
If patients
In patients
No dosage
Patients
In chronic renal failure patients
For schizophrenia ,
For schizophrenia
In animals ,
In cancer patients receiving chemotherapy
In cancer patients
In type 1
In type
Following recurrence of severe neutropenia
Following recurrence of severe
Following recurrence of
Following recurrence
In all patients receiving
In all patients
All of
In all
The
The
Bei bipolarer Störung
Bei bipolarer
In the pooled results ,
In the pooled results
In most of these patients
In most of these
In most
When used to treat
Taking ABILIFY
Taking
with
Bei diesen Patienten sollte
In these patients
These patients may be at
These patients may
In these
These
If it contacts
If it
With an efficacy of 98-100
an efficacy of
an efficacy
In
an
Some patients with long-standing
If an elevated ( or
If an elevated (
In fed dogs ,
In fed dogs
In fed
90
In patients treated with Aclasta
Hypertension
In paediatric patients
In paediatric
In schizophrenia patients
In schizophrenia
Usual warning symptoms may
In pregnant or
Discard
At therapeutic concentrations , aripiprazole
At therapeutic concentrations ,
At therapeutic concentrations
At therapeutic
If accidental eye contact
In case of accidental
In case of accidental
In case of accidental
In case of accidental
In case of accidental overdosing
Many of these patients
Many of these
Many of
As weight increases from 65
As weight increases from
As weight increases
2 In
A
Bei
For
If
In the
In
Pioglitazone
Serum
The
There
When
dosage
of
with
Bei älteren Patienten ist keine
Bei älteren Patienten ist
In elderly patients with
Bei älteren Patienten
In elderly patients
Bei älteren
In elderly
in maintaining
In Paget s disease
contribution
exertional dyspnoea ,
exertional dyspnoea
Belgique/ België/ Belgien BRISTOL-MYERS
Belgique/ België/ Belgien
België/ Belgique/ Belgien Takeda Global
België/ Belgique/ Belgien Takeda
België/ Belgique/ Belgien
enalapril
light-headedness , trouble sleeping ,
light-headedness , trouble sleeping
drowsiness
Beobachtung wurde klinisch durch
Beobachtung wurde klinisch durch
Beobachtung wurde klinisch
Beobachtung wurde klinisch
from 2 60 mg
from 2 60
the desired range .
the desired range
the desired range .
at the desired level :
at the desired level
the desired range
had sections of your
had sections of
had sections
given area may
to
to
reports refer to cancer patients
reports are based on in
reports are based on
reports are based
reports
reports of
reports of
reports
reports
reports
Berkshire RG40 2AQ United Kingdom
Berkshire RG40 2AQ United
Berkshire RG40 2AQ
Berkshire RG40
Berkshire
conducted according to standard medical
conducted according to standard
conducted
disposal and
for disposal and
Take special care with Abseamed
Special precautions for use
Special precautions for
Special precautions for
Special precautions
Special warnings and precautions
Special warnings and
Special warnings
Special
who have no obvious
Patients , especially those
greater improvements in
improvement from baseline on the
improvement from baseline on
improvement from baseline
improvement from
greater improvements
improvement in
improvement
substance in Actos 15mg
substance in Actos 30mg
substance in Actos 45mg
substance in Actos
substance in
substance
ACOMPLIA , see
ACOMPLIA , see
ingredients .
ingredients
PARTICULARS
see
Ongoing major depressive illness
Ongoing major
agents Certain medicines
Beta-blocking agents may
beta-sympathomimetics , growth hormone and
beta-sympathomimetics , growth hormone
beta-sympathomimetics ,
beta-sympathomimetics
pathways involving the CYP2D6 and
pathways involving the CYP2D6
pathways involving the
When looking only at the
When looking only
When looking
looking
Tell your doctor
Tell
be used in patients
be used in
be used
exercise
used in patients
used in
used
unconsciousness and/ or
unconsciousness
status and evidence of autonomic
level of consciousness should
level of consciousness
comparison
efficacy and
efficacy
with
For hypocalcaemia , see
For hypocalcaemia ,
For hypocalcaemia
formation of these hydroxylated metabolites
formation of these hydroxylated
formation of these
formation of erythrocytes from precursors
formation of erythrocytes from
formation of erythrocytes
abnormal arrays or bundles of
formation of
was abnormal
abnormal
formation of
formation
and subcutaneous tissue disorders :
subcutaneous tissue disorders :
binding is
binding
BioScience Limited West Forest Gate
BioScience Limited West Forest
BioScience Limited West
BioScience Limited
BioScience
bioavailability of the
bioavailability of mitratapide ( parent
bioavailability of mitratapide (
bioavailability of mitratapide
bioavailability of rimonabant has not
bioavailability of rimonabant has
bioavailability of
bioavailability of
bioavailability
Bipolar I Disorder -
Bipolar I Disorder , when
Bipolar I Disorder ,
Bipolar I Disorder
Bipolar I Disorder , aripiprazole
Bipolar I Disorder ,
Bipolar I Disorder
I
of Bipolar I Disorder
bisphosphonate .
bisphosphonate
bisphosphonate-naïve patients and 42 %
bisphosphonate-naïve patients and 42
bisphosphonate-naïve patients and
bisphosphonate-naïve patients
bisphosphonate-naïve
Bisphosphonates ( the
Bisphosphonates (
bisphosphonates .
bisphosphonates or any of the
bisphosphonates or
bisphosphonates and acts
bisphosphonates and
Bisphosphonates
bisphosphonates
bisphosphonates , including zoledronic acid
bisphosphonates , patients taking
bisphosphonates in
bisphosphonates
You should check with your
181 Tell the doctor
Please inform your doctor
Please tell your doctor
Please inform your
Please tell your
181 Tell the
181 Tell
Please inform
Please tell
Tell your doctor
Tell your
Tell
If
Please
Blister ( PVC/ aluminium )
Blister ( PVC/ aluminium
Blister (
blister .
Blister
blister
blocking
blockage of the uptake
blockage of the
blockage
blood in urine
blood
anaemia
anaemia
anaemia may
anaemia
blood pressure , somnolence ,
blood pressure , tachycardia ,
blood pressure , tachycardia ,
blood pressure , tachycardia
Blood pressure ,
blood pressure ,
blood pressure
blood pressure or if
blood pressure regularly
blood pressure
blood pressure should
blood pressure and
blood
Blood pressure
blood pressure
blood
in blood pressure
pressure
pressure*
raised blood pressure which may
raised blood pressure which
raised blood pressure which
sudden rise in blood
sudden rise
require
blood pressure or
blood pressure or
blood pressure
pigment ( haemoglobin ) regularly
pigment ( haemoglobin )
pigment ( haemoglobin
pigment ( haemoglobin )
pigment ( haemoglobin
blood vessels
, eating disorder , redness
, eating disorder
initiate
cell
count
Thrombotic events ( blood clotting
blood clotting ( thrombotic vascular
blood clotting ( thrombotic
clotting ( thrombotic events )
clotting ( thrombotic events
blood clotting (
of blood clotting after the
blood clotting after
blood clotting
blood clots/ blood
was shown
predonation
levels of sex
levels of
levels
blood tests ,
the operation
operation
blood tests to
blood tests
tests
blood loss and haemolysis )
blood loss and haemolysis
do
of some blood
some blood
blood glucose ) ,
blood glucose )
blood glucose is controlled .
blood glucose is controlled
glycaemic control despite
blood glucose
glycaemic control may be
glycaemic control is associated with
glycaemic control is associated
glucose control may
glycaemic control should be considered
glycaemic control should
glucose control
glycaemic control
glucose fluctuation ,
blood sugar ( hypoglycaemia )
blood sugar ( hypoglycaemia
blood sugar (
glycaemia
patient 's blood sugar should
patient 's blood sugar
's blood sugar
blood sugar
blood
glycaemia
blood sugar .
blood sugar
glucose
flatulence , glossodynia , dry
flatulence , glossodynia
flatulence ,
flatulence
bolus
bradycardia
Bray Business Park , Kilruddery
Bray Business Park ,
Bray Business Park
Bray Business
Bray
margin of epoetin alfa is
margin of epoetin alfa
margin of epoetin
margin of
margin
Bristol-Myers Squibb Srl Contrada Fontana
Bristol-Myers Squibb Srl Contrada
Bristol-Myers Squibb Srl
Bristol-Myers Squibb
Bristol-Myers
aluminium/
lung , 174 gynaecological
lung , 22 prostate
lung , 22
lung ,
lung
bronchoconstriction
abnormaler Gang
and mediastinal disorders :
and mediastinal disorders
chest pain )
chest pain , peripheral
chest pain , peripheral oedema
chest pain ,
chest pain
Brytania Tel : +44 (
Brytania Tel : +44
Brytania Tel :
Brytania Tel
Brytania
Business Park , Kilruddery ,
Business Park , Kilruddery
Business Park , Oxford Road
Business Park , Oxford
Business Park ,
Business Park
Business
Butylated hydroxyanisole ( E 320
Butylated hydroxyanisole (
Butylated hydroxyanisole
Multi-pack comprising 5
multi-pack comprising 5
Multi-pack comprising
multi-pack comprising
multipack with
Multi-pack
multipack
CA012-0 Addendum dated Final
CA012-0 Addendum
CA012-0 Addendum
pharmakologischen
CB1
CB1 antagonist is unknown .
CB1 antagonist is unknown
CB1 antagonist
endocannabinoid signalling via CB1 receptors
endocannabinoid signalling via CB1
CHMP )
CHMP .
CHMP Guideline
CHMP has
CHMP requests the inclusion ,
CHMP requests the inclusion
CHMP recommendations , read
CHMP recommendations ,
CHMP recommendations
CHMP
CI )
CI , 17
CI ,
CI :
CI ] ( weeks )
CI ] ( weeks
CI ] (
CI ]
CI
CLAS ) .
CLAS )
CLAS
CPK ( Creatine
CPK (
CPK
CYP enzymes or
CYP2C8 .
CYP2C8
CYP2C8 in vivo appears
CYP2C8 in vivo
CYP2C8 in
CYP2C8 and
CYP2C8
CYP2D6 ( dextromethorphan/ 3-methoxymorphinan ratio
CYP2D6 (
CYP2D6 and CYP3A4
CYP2D6 and CYP3A4
CYP2D6 and
CYP2D6
CYP2D6 or 3A4 inhibitor ,
CYP2D6 or 3A4 inhibitor
CYP2D6 inhibitor
CYP3A4 ( ketoconazole )
CYP3A4 ( ketoconazole
CYP3A4 ( e. g. ,
CYP3A4 ( e. g.
CYP3A4 ( e.
CYP3A4 (
CYP3A4 ,
CYP3A4
CYP3A4 and CYP2D6
CYP3A4 and
CYP3A4
CYP3A4 or CYP2D6 inhibitor
CYP3A4 or
CYP3A4
CYP3A4 inducer
CYP3A4 inducers is expected to
CYP3A4 inducers is expected
CYP3A4 inducers
CYP3A4 inducers
CYP3A4-Substrat )
CYP3A4-Substrat
CZOL446M2308 )
CZOL446M2308
medication
calcitonin , raloxifene
calcitonin ,
calcitonin
Calcium silicate Croscarmellose sodium Crospovidone
Calcium silicate Croscarmellose
Calcium silicate
UK Tel.
Cancer Linear Analogue Scale (
Cancer Linear Analogue Scale
Cancer Linear
Cancer Therapy- Anaemia ( FACT-An
Cancer Therapy- Anaemia (
Cancer Therapy- Anaemia
Cancer
-Antagonist
cannabinoid receptor antagonist .
cannabinoid receptor antagonist
cannabinoid receptor
cannabinoid type 1
cannabinoid type
part of
part
carbamazepine
and contents of the pack
and contents of the pack
and contents of the
and contents of
and contents
contents of the
contents of
contents
NSAIDs
Cedex 2 , France
Cedex 2 ,
Cedex 2
Cedex
cellulose , hydroxypropyl cellulose ,
cellulose , hydroxypropyl cellulose
cellulose Aspartame ( E951 )
cellulose Aspartame ( E951
cellulose Aspartame (
cellulose Aspartame
Magnesium stearate
cellulose
Centre ( Europe ) ,
Centre ( Europe ) Ltd
Centre ( Europe )
Centre ( Europe
Centre (
Centre Limited
Centre
Ceraso I-03012 Anagni-Frosinone Italy
Ceraso I-03012 Anagni-Frosinone
Ceraso I-03012
Ceraso
characteristics
chemotherapy )
chemotherapy
quinidine )
quinidine occurs .
quinidine occurs
quinidine
cyclosporin ( medicine to suppress
cyclosporin ( medicine to
cyclosporin (
cyclosporin ,
cyclosporin
cyclosporin
since cyclosporin
Wharf ,
E14 4HB
telithromycin
of
clearance is therefore
clearance is
clearance
Cmax =
Cmax = 196 ± 28.1
Cmax =
Cmax corrected for dose
Cmax corrected for dose
Cmax corrected for
Cmax corrected
Cmax corrected for
Cmax corrected
Cmax and AUC after
Cmax and AUC
Cmax and a
Cmax and
Cmax of dehydro-aripiprazole ,
Cmax of dehydro-aripiprazole
Cmax of
Cmax
Cmax
Cmax values
Cmax
Cmax of paclitaxel , which
Cmax of paclitaxel ,
Cmax of paclitaxel
Cmax of paclitaxel , which
Cmax of paclitaxel ,
Cmax of paclitaxel
Co KG , Kuhloweg 37
Co KG , Kuhloweg
Co KG ,
Co KG Kuhloweg 37 D-58638
Co KG Kuhloweg 37
Co KG Kuhloweg
Co KG
Co
Component score at the primary
Component score at the
Component score at
Component score
Contrada Fontana Del Ceraso I-03012
Contrada Fontana Del Ceraso
Contrada Fontana Del
Contrada Fontana
Contrada
and controls
controls
County Wicklow .
County Wicklow
County
Croscarmellose sodium Crospovidone
Croscarmellose
sodium Crospovidone Silicon dioxide Xylitol
sodium Crospovidone
Ctrough = 91.6 ± 14.1
Ctrough =
Ctrough
polymer )
polymer )
polymer
cytochrome P450 2C8 although
cytochrome P450
cytochrome
of cytochrome
of substances
substances
cytochrome P450 , 1A ,
D (
D (
D supplementation ,
D Centre ( Europe )
D Centre ( Europe
D Centre (
D Centre Limited
D Centre
D supplementation per day .
D supplementation per day
D supplementation per
D and
D prior to
D supplementation
D
D-58638 Iserlohn , Germany
D-58638 Iserlohn ,
D-58638 Iserlohn Germany
D-58638 Iserlohn
D-58638 Iserlohn
D-58638
D-58638
D-90429 Nuremberg Germany
D-90429 Nuremberg
D-90429
D2 and D3 ,
D2 and D3
caudate
NAMES
MEDICINAL PRODUCT MUST BE STORED
MEDICINAL PRODUCT MUST
MEDICINAL PRODUCT
DATE OF FIRST
DATE OF
DATE
METHOD OF ADMINISTRATION
METHOD OF
METHOD
PRODUCTS , IF APPROPRIATE
PRODUCTS , IF
PRODUCTS
ON THE OUTER CARTON OF
ON THE OUTER
SUPPLY AND/ OR USE
SUPPLY AND/ OR
OF ADMINISTRATION
OF THE NAMES ,
OF THE
OF FIRST
LABEL FOR UNIT PACK
LABEL FOR INTERMEDIATE PACK
LABEL FOR
OF THE MARKETING AUTHORISATION
ra
THE IMMEDIATE PACKAGE
leaflet are the final versions
leaflet are the final versions
OF THE SCIENTIFIC EVALUATION OF
THE AUTHORISATION
HOLDER
OF
THE
OF THE MEDICINAL PRODUCT AND
OF THE MEDICINAL PRODUCT
OF THE MEDICINAL
PRODUCT
THE MEDICINAL PRODUCT
OF SALE ,
OF SALE
obsolete
OF THE PRODUCT
OF THE
OF
THE
REGARDING SUPPLY AND USE
REGARDING
IMPOSED ON
MEMBER STATES
MEMBER STATES
DAYS OF THE WEEK (
DAYS OF
FOR
DK-2880 Bagsværd Denmark
DK-2880 Bagsværd
DK-2880
cell line by
DNA versus animal source insulin
DNA
DOSAGE FOR EACH SPECIES ,
DOSAGE FOR EACH SPECIES
DOSAGE FOR EACH
DOSAGE FOR
DOSAGE
COMBINATION THERAPY WITH METFORMIN AND
COMBINATION THERAPY WITH METFORMIN
COMBINATION THERAPY WITH
COMBINATION THERAPY
BE IMPLEMENTED BY
As ABILIFY 7.5 mg/ ml
As ABILIFY 7.5
As ABILIFY
Since dopamine and 5-hydroxytryptamine are
Since dopamine and 5-hydroxytryptamine
Since dopamine and
Since dopamine
Since insulin and pioglitazone
Since insulin and
Since insulin
As
Since the orodispersible tablet
Since the
Because these events
Because these
However , since cyclosporin
However ,
As
Because
Since
contrast
Therefore , pioglitazone should not
Therefore , no
Therefore ,
Therefore , aripiprazole should be
Intensified control in the
Intensified control in
Intensified control in
Consequently , haemoglobin and
Consequently , haemoglobin
Therefore your haemoglobin-levels and
Therefore your haemoglobin-levels
Consequently ,
Close blood glucose monitoring
Close
Therefore ,
Therefore ,
Therefore
dalton .
dalton
danazol .
danazol
Danmark BRISTOL-MYERS SQUIBB Tlf :
160 Danmark BRISTOL-MYERS SQUIBB Tlf
166 Danmark BRISTOL-MYERS SQUIBB Tlf
172 Danmark BRISTOL-MYERS SQUIBB Tlf
178 Danmark BRISTOL-MYERS SQUIBB Tlf
Danmark BRISTOL-MYERS SQUIBB Tlf
160 Danmark BRISTOL-MYERS SQUIBB
166 Danmark BRISTOL-MYERS SQUIBB
172 Danmark BRISTOL-MYERS SQUIBB
178 Danmark BRISTOL-MYERS SQUIBB
Danmark BRISTOL-MYERS SQUIBB
160 Danmark BRISTOL-MYERS
166 Danmark BRISTOL-MYERS
172 Danmark BRISTOL-MYERS
178 Danmark BRISTOL-MYERS
Danmark BRISTOL-MYERS
Danmark Novartis Healthcare A/ S
Danmark Novartis Healthcare
Danmark Novartis
Danmark Takeda Global R &
Danmark Takeda Global R
Danmark Takeda Global
Danmark Takeda
160 Danmark
166 Danmark
172 Danmark
178 Danmark
Danmark
Then , the vial should
Then ,
Then
The observed excess risk
The observed excess
intestine removed .
intestine removed
oral formulations of ABILIFY
oral formulations of
oral formulations
formulations of
formulations
Moreover , in patients
In addition ,
The medicine can only be
Medicines should not be
Do not
The medicine can only be
The medicine can only be
Use product immediately
Use product
The intravenous route has to
Medicines
The medicine can
The medicine
This medicinal product
The occurrence of
The occurrence
Omission of a meal or
Omission of a meal
Omission of a
Omission of
Overall survival
The peak is always well
The peak is always
The peak
The apparent molecular weight of
The educational programme contains the
The educational programme contains
The educational programme
Breastfeeding must be discontinued
Breastfeeding must be discontinued
Treatment should be
Treatment
The company decided
The company also carried out
The company
The company also presented data
The company also presented
Therefore , the company withdrew
, the company
The company
the company
The procedure for reconstitution is
The procedure for reconstitution
The procedure for
The procedure
The expiry date refers to
The expiry date refers
The expiry date
102 avoided ; guidance
116 avoided ; guidance
130 avoided ; guidance
18 avoided ; guidance
32 avoided ; guidance
4 avoided ; guidance
46 avoided ; guidance
74 avoided ; guidance
88 avoided ; guidance
avoided ; guidance
Epoetin alfa obtained by gene
The estimated volume of distribution
The estimated volume
The potential for inhibition of
The potential for inhibition
66
Continuous rotation of the
31
38
59
Continuous rotation
The mean volume of distribution
The mean
ra plateau in exposures
ra plateau
The potential risk for
The potential risk
The potential
The reconstituted medicinal product contains
The reconstituted medicinal product
The reconstituted
The
Use
volume
human data to
data from the
data from
data is based on
data in severe
data in
data from the Long Term
data from the
data of the
data on the use of
data on the use
data on the
data from 360 dogs
data from 360 dogs over
data from 360
data from
data ,
data available
data from
data on
data
of data
Datum der letzten Verlängerung
method of administration
method of
duration of diabetes was 9.5
duration of diabetes was
duration of diabetes
duration of
average
duration
method
time
thumb and forefinger .
thumb and forefinger
thumb and
thumb
dehydration )
dehydration )
dehydration and pale mucosae .
dehydration and pale mucosae
dehydration and pale
dehydration and
dehydration
dehydrogenation , hydroxylation , and
dehydrogenation , hydroxylation ,
dehydrogenation
dehydro-aripiprazole , but
dehydro-aripiprazole , the active metabolite
dehydro-aripiprazole ,
dehydro-aripiprazole the geometric means of
dehydro-aripiprazole the geometric means
dehydro-aripiprazole the
dehydro-aripiprazole did
dehydro-aripiprazole increased by 77
dehydro-aripiprazole are
dehydro-aripiprazole
Del Ceraso I-03012 Anagni-Frosinone Italy
Del Ceraso I-03012 Anagni-Frosinone
Del Ceraso I-03012
Del Ceraso
Del
bottom
dementia ( loss of
dementia ( loss of
Patients should be advised
Patients should
Patients
2/ 3 The full EPAR
The full EPAR for Abraxane
The full EPAR for
The full EPAR
The full
2/
Patients
However ,
Dennoch ist
However , in
However ,
However
Dennoch
However ,
However
procedures
dental surgeries .
dental surgeries
preventing depolymerisation .
preventing depolymerisation
Abraxane at any dose in
Abraxane at any dose
Depressive disorders
Depressive
Der Anteil der Patienten ,
Der Anteil der Patienten
Der Anteil der
Der Anteil
The physician must therefore
Physicians should consider clinical
Physicians should
Physicians
Der Ausschuss für
The Committee
Justification for
These increases in blood pressure
The patient 's blood sugar
The CHMP requests the inclusion
The CHMP
of rimonabant
A gastric
Paclitaxel is principally eliminated
The main measure of effectiveness
The main measure of
The main measure
The Committee
The company
The Committee
The company
The Marketing Authorisation Holder commits
The Marketing Authorisation Holder
The protein fraction of the
Patients should have their
The metabolism of paclitaxel is
The metabolism of paclitaxel
The metabolism of
The metabolism
The proposal
The active substance in Abilify
The active substance in Aclasta
The active substance in
The active substance is aripiprazole
The active substance is
The active substance is aripiprazole
The active substance is
The active substance
The active substance in
The active substance in
The active substance
The active substance
The active
The active
The most frequent
The individual insulin requirement is
The individual
The mean Cmax of paclitaxel
The mean
The natural course of
The natural course
The natural
The primary efficacy variable was
The primary efficacy variable
The primary
The percentage
The daily insulin requirement
The daily
Der
The Marketing
The in
The
Therefore
Thus
Consequently ,
Detailed information
Deutschland Takeda Pharma GmbH
Deutschland Takeda Pharma
Deutschland Takeda
Deutschland
Germany
Iserlohn
Development Centre ( Europe )
Development Centre ( Europe
Development Centre (
Development Centre
Development
ranitidine
dextromethorphan ) .
dextromethorphan )
dextromethorphan
dextromethorphan/ 3-methoxymorphinan ratio ) ,
dextromethorphan/ 3-methoxymorphinan ratio )
dextromethorphan/ 3-methoxymorphinan ratio
diabetes , ketoacidosis (
diabetes , ketoacidosis
in Asian/ Oriental
in Asian/
diabetes ,
diabetes ,
diabetes
diabetes mellitus ( see section
diabetes mellitus ( see
diabetes mellitus (
Diabetes Mellitus : hyperglycaemia ,
diabetes mellitus : hyperglycaemia ,
Diabetes Mellitus : hyperglycaemia
diabetes mellitus : hyperglycaemia
diabetes mellitus :
diabetes mellitus
diabetes was 9.5 years .
diabetes was 9.5 years
diabetes was 9.5
diabetes was
diabetes
family history of diabetes .
family history of diabetes
diabetes is dietary control
diabetes is dietary
diabetes is
Diabetes is a disease
Diabetes is a
Diabetes is
diabetes mellitus ( see section
diabetes mellitus ( see
diabetes mellitus (
diabetes mellitus , diabetic ketoacidosis
diabetes mellitus , diabetic
diabetes mellitus ,
Diabetes Mellitus : hyperglycaemia ,
Diabetes Mellitus : hyperglycaemia
diabetes mellitus and heart disease
diabetes mellitus and
diabetes mellitus
Diabetes
diabetes ,
diabetes
type 2
antidiabetic medicine (
antidiabetic medicine ) in patients
antidiabetic medicine ) in
antidiabetic medicine )
antidiabetic medicine
antidiabetic medicines ( metformin ,
antidiabetic medicines ( metformin
antidiabetic medicines (
antidiabetic medicines
Diabetic retinopathy Long-term improved glycaemic
Diabetic retinopathy Long-term improved glycaemic
Diabetic retinopathy Long-term improved
Diabetic retinopathy
Diabetic
a diagnosis
diagnosis
dialysis
information is
diarrhoea
dropper .
dropper
overseal ( aluminium ) .
overseal ( aluminium )
overseal ( aluminium
ABILIFY 10 mg orodispersible tablets
ABILIFY 10 mg
ABILIFY 10
ABILIFY 15 mg orodispersible tablets
ABILIFY 15 mg
ABILIFY 15
ABILIFY 30 mg orodispersible tablets
ABILIFY 30 mg
ABILIFY 30
The ABILIFY solution for injection
ABILIFY
The ABILIFY
ABILIFY dose should be reduced
ABILIFY dose should be
ABILIFY dose
The AUC and Cmax of
The AUC and Cmax
The AUC and
The AUC
The Aclasta
( See section
( See
Androgen ablation is considered to
Androgen ablation is considered
Androgen ablation is
Androgen ablation
The starting
The initial dose is 150
The initial dose is
The initial dose
The response rates in all
The response rates in
The response rates
The use in
The use of Abraxane
The use of Aclasta in
The use of Aclasta
The use of
from
Caution
The use
The aripiprazole AUC
The aripiprazole
Excretion is rapid and
Excretion is rapid
Excretion
The effect of
The effect
The treatment is part of
The treatment is
Treatment with Abseamed may be
Treatment with Abseamed
Pioglitazone may be
Treatment with a 5
Treatment with a
Treatment with
Treatment should only be
The treatment should be
Treatment should be directed
Treatment should consist of
The treatment
Treatment
The formation of these hydroxylated
The formation of these
The formation of
The blood glucose
The clearance
The data from the
The data of the
Immunogenicity data for
The data from
The data
Dialysis prescriptions may
Differences in Cmax and
Differences in
The dosing pipette has a
The dosing pipette has
The dosing pipette
The dosage should
The dosage
The dose you
The dose of ABILIFY
The dose of
The dose may be
The dose of 5 mg
The dose of 5
The dose of
The dose is adjusted
The dose is
The dose is
The dose
It is given
The vials are for use
The vials are for
The vials are
The vials
Introducing appropriate
Introducing
Introducing
Pioglitazone was associated
Zoledronic acid is eliminated
Zoledronic acid
The decision whether to
The decision whether
The decision to administer
The decision
Experience in patients
Experience in patients over
Experience in
Experience
Experience
The maintenance dose is 15
The maintenance dose
Keep the pre-filled syringe in
The pre-filled syringes are
The pre-filled syringes
Women
The marketing authorisation was
The marketing authorisation
The total dose of ABILIFY
The total dose of
The total dose
Total plasma concentration of pioglitazone
cause mortality was 10
mortality was 10
cause mortality was
mortality was
cause mortality
mortality
HOMA analysis
Haemoglobin levels should be
Haemoglobin levels
The frequency
The incidence of
The frequency of these events
The incidence of these symptoms
The frequency of these
The incidence of these
The frequency of hypocalcaemia was
The frequency of hypocalcaemia
The hip fracture event rate
The incidence of clinical
The incidence of
The frequency
The incidence
The rate
5 The frequency of undesirable
The frequency of undesirable
Frequencies of adverse
Frequencies of
The oedema rates for
Frequencies
The infusion must be conducted
The infusion must be
The infusion must be
The infusion will
The infusion
The infusion time
The injections are given in
The injections are given preferably
The injections are given
The needle should be
Insulin treatment of the nursing
Insulin treatment of the
Insulin treatment
Interaction with receptors other
Interaction with receptors
Bone biopsy results showed
Bone biopsy results
Bone histology was evaluated in
Bone histology was evaluated
Bone histology
The correction of your anaemia
The correction of your
Correction for anaemia may
Correction for anaemia
Correction for
The correction
Liver enzymes should be checked
Liver enzymes
The solution should be
The oral solution contains
The oral solution
The solution
13 maximum daily dose of
2 maximum daily dose of
35 maximum daily dose of
maximum daily dose of
35 maximum daily dose
maximum daily dose
The majority of reported cases
The majority of reported
The majority of the
The majority of
The majority of these symptoms
The majority of these symptoms
The majority of these
The majority
Meta-analysis of overall
The Member States shall
The possibility of multiple medicinal
The possibility of
The possibility
21 Fasting and postprandial
33 Fasting and postprandial
21 Fasting and
33 Fasting and
Fasting and
21 Fasting
33 Fasting
Fasting
The patients received
ge Patients should be instructed
Patients should be
patients should be
Patients should be
Patients should
Patients were treated without steroid
Patients were treated without
3 trials
Patients were treated
trials
Patients
The patients
The cartridge contains a
The cartridge contains
The cartridge is made
The cartridge
The cartridges are designed to
The cartridges are designed
The pharmacokinetics of total
Pharmacokinetics of paclitaxel
The pharmacokinetics of rimonabant
or The pharmacokinetics of rimonabant
Pharmacokinetics of
The pharmacokinetics of
or The pharmacokinetics of
Pharmacokinetics
The pharmacokinetics
or The pharmacokinetics
The pipette
The protein binding
Reactions usually resolve in
The absorption of
The absorption
also found in
also
Steady state rimonabant lon exposures
The risk reduction was 51
The risk
The orodispersible tablet can be
The orodispersible tablet
Die Schmelztabletten werden auf die
Die Schmelztabletten werden auf
Die Schmelztabletten werden
Die Schmelztabletten
The safety of androgen suppression
The safety of
The safety
The syringes contain 0.3 ml
The syringes contain 0.3
The syringes contain 0.4 ml
The syringes contain 0.4
The syringes contain 0.5 ml
The syringes contain 0.5
The syringes contain 0.6 ml
The syringes contain 0.6
The syringes contain 0.7 ml
The syringes contain 0.7
The syringes contain 0.8 ml
The syringes contain 0.8
The syringes contain 0.9 ml
The syringes contain 0.9
The syringes contain 1 ml
The syringes contain 1
The syringes contain
Syringes are
Syringes
The syringes
Die Steady-State-Pharmakokinetik eines oralen Kontrazeptivums
Die Steady-State-Pharmakokinetik eines oralen
Die Steady-State-Pharmakokinetik eines oralen
The study was not
The study was
The study
The study population had an
The study population had
The study population
The symptoms are
The symptoms are usually
The symptoms
The tablets are white
The tablets are
The tablets
The daily dose of Abilify
The daily dose of
The daily dose
Mitratapide therapy should be restricted
The safety and efficacy of
The safety and efficacy
The safety and
The safety
of mitratapide
of
Changes in HDL-C and
Changes in HDL-C
Changes in
D levels
Aseptic techniques
The efficacy and safety of
The efficacy and safety
The efficacy and
The effectiveness of Abraxane
The effectiveness of
The effectiveness
The efficacy
The drug exposure ( AUC
The drug exposure (
The drug exposure
Onset of action is within
The effect of the infusion
The effect of the
The effects of Abraxane (
The effects of Abraxane
The effect of pioglitazone (
The effect of pioglitazone
The effect of
The effects of
The effect
The effects
The effects of ACOMPLIA were
The effects of ACOMPLIA
The effects of Abraxane were
The effects of Abraxane
9 Pioglitazone effects may be
Pioglitazone effects may be
9 Pioglitazone effects may
Pioglitazone effects may
The effects of
The effects
Die
Die
Aseptic techniques
Cycles were
Cycles
The absolute bioavailability of
The absolute bioavailability
The absolute oral bioavailability of
The absolute oral
The absolute
The observed mean improvement from
The observed mean improvement
The observed mean
The observed
The biological efficacy of epoetin
The biological efficacy of
The biological efficacy
The biological
However , chemical and physical
However chemical and physical
Detailed instruction accompanying the
The recommended starting dose is
The recommended initial dose for
The recommended starting dose for
The recommended initial dose
The recommended starting dose
The recommended dose is 600
The recommended dose of Abraxane
The recommended dose of
The recommended dose is a
The recommended dose is
The recommended dose of
The recommended dose
The recommended weekly dose
The recommended total weekly dose
The recommended weekly
The recommended
The increased
The following information is
The following undesirable effects occurred
The following undesirable effects occurred
The following reactions
The following adverse events
The following adverse
The following
The early disposition phases (
The early disposition phases
The early
The appropriate doses for patients
The appropriate dose regimen
The appropriate doses for
The appropriate dose regimen
The appropriate doses
The usual dose is between
The usual dose is
The usual dose
The usual
Simultaneous administration of injectable
Simultaneous administration of
Co- administration
Co-administration
Concomitant administration
Simultaneous administration
Concomitant administration of CYP3A4 inducers
Concomitant administration of
Concomitant administration of
Concomitant administration
Concomitant administration
Concomitant
The rate of
Histomorphometric analysis showed a
Histomorphometric analysis showed
The most frequent adverse reaction
The most common side effects
The most common side effects
The most common side effects
The most common
The highest nontumorigenic exposure in
The highest
The inter- and intra-subject variation
The inter- and
The inter-
Intrinsic clearance is therefore
Intrinsic clearance is
Intrinsic clearance
Intrinsic
The clinical relevance of these
The clinical relevance
The clinical
The local safety of Vantas
The local safety of
The local safety
The local
The maximum dose should
The maximum dose
The maximum daily dose should
The maximum daily dose
Die maximale Tagesdosis
The maximum
The median time to
Most side effects with Aclasta
Most side effects with
Most side effects
Most
The mean total clearance was
The mean total clearance
The mean plasma elimination half-life
The mean
The pharmacokinetic characteristics of aripiprazole
The pharmacokinetics of insulin products
The pharmacokinetic characteristics of
The pharmacokinetics of
The pharmacokinetic characteristics
The pharmacokinetic parameters
The pharmacokinetic
The potentially medically serious signs
The potentially medically serious
The potentially
The reconstituted suspension has a
The reconstituted suspension has
The reconstituted suspension
The reconstituted
The correct amount
The correct
The other ingredients are disodium
The other ingredients are lactose
The other ingredients are mannitol
The other ingredients are
The other ingredients
The other ingredients
Subcutaneous injection into
The terminal half-life ( t½
The terminal half-life (
The terminal half-life is determined
The terminal half-life is determined
The terminal half-life
The terminal
The therapeutic margin of epoetin
The therapeutic margin of
The therapeutic margin
The therapeutic
The four carbohydrate chains are
The four carbohydrate chains
The four
For a full list
For the full list of
The white , round tablets
The white , round
The white ,
The white
The most
5 The
Die
Elderly
For
In
The dosing
The
Treatment with
Treatment
is
or The
recovery in all cases
recovery in all
recovery in
recovery
The reports of oedema were
The usual starting dose is
The usual starting dose
The usual dose is 9.75
The usual dose is
The usual dose is 15
The usual dose is 5
The usual dose is
The usual dose
The usual
This means that aripiprazole
This means that
This means
This is to check that
This corresponds to
This results in blockage
This results in
However , this did not
However , this did
This is predominantly via
This is especially important for
This is especially important in
This is especially important
This is especially
This is similar to
This is similar
This is similar
To be taken into
To be taken
This is
This may constitute
These may be the warning
may be the
may be
This represents a
This represents
This will help
You will receive appropriate training
You will receive appropriate training
You will
46
This can be
This
Diese Beobachtung wurde klinisch durch
Diese Beobachtung wurde klinisch
Diese Beobachtung wurde klinisch
These reports are based on
These reports are based
This data is based on
This data
This is the diabetes
but this dose should be
this dose should be
This is given 3
This is given 2
This is given twice
This is given
This is
This
this dose
These results were
These results
Pens should only be
as measured
as measured
This leaflet was last
This leaflet
197 This leaflet was
This leaflet was
197 This leaflet
This leaflet
These measures will help to
These measures will help
These measures will help
These measures
These measures should help to
These measures should
These may be more common
and such patients
such patients
Most reactions are transitory
Most reactions are
Most reactions
This stability results in
This stability
These trials included patients with
These trials included patients
These trials included
Diese Studien
These trials
This effect was maintained
This effect
These effects were
These effects
This is
This multi-centre trial was
This multi-centre trial
This multi-centre
The improved
197 This
Diese
Most
These may be
These may
These
This
and such
such
this
This regresses during the course
This regresses
The rate of
The rate
This was defined as the
This was defined as
This was defined
This was
This medicinal product must
This medicinal product contains
This medicine has been
This medicinal product
This medicinal product
This medicinal
This medicine
This risk should be
This risk
This medicinal
This
difference in
difference to placebo -2.9 kg
difference to placebo -2.9
difference to placebo
difference to
Difference
difference
differentiating hormone , the formation
differentiating hormone , the
differentiating hormone
digoxin , warfarin ,
digoxin , warfarin
digoxin ,
digoxin
edetate , fructose ,
dexamethasone
( ebenfalls
ebenfalls
disposition of paclitaxel
disposition of
disposition
diuretics that
nitrates , diuretics
diuretics
diet and
diet
dopamine and 5-hydroxytryptamine are involved
dopamine and 5-hydroxytryptamine are
dopamine and 5-hydroxytryptamine
dopamine and
dopamine
double-blind
at doses of 5.25
doses of 5.25
doses of Abseamed between 17
doses of Abseamed between 25
doses of Abseamed between
doses of Abseamed
at doses of
doses of
doses
at doses
doses
dosing pipette .
dosing pipette has a gradation
dosing pipette has a
dosing pipette has
dosing pipette
show graduations corresponding to the
show graduations corresponding to
show graduations
show graduations
Posology and method
Posology and method
Posology and
Posology
Posology
Dosage Dosage
dose is 600 IU/ kg
dose is 600
dosage may also
dosage may
dosage or discontinuation of treatment
dosage or
dosage should
dosage of ABILIFY
dosage of
of the
of
dosage
dosing
at doses
doses
Doses below 15 mg were
Doses below 15 mg
Doses below 15
Doses below
Doses
at doses
doses
doses above 45 mg (
doses above 45 mg
doses above 45
doses above
dose , i. e.
dose you receive
dose you
dose reflected differences in
for dose reflected differences in
dose reflected differences
for dose reflected differences
dose ,
dose
for dose
assay .
dose .
smaller dose of your medicines
dose of ABILIFY
dose of
dose is 9.75 mg (
dose is 9.75 mg
dose is 9.75
dose is between
dose is
dose to
insulin dose
dose of the sulphonylurea
dose of the
.
dose of
dose of
dose of Abraxane is 260
dose of Abraxane is
dose of Abraxane
dose of
dose
dose is injected .
dose is injected
dose is 15 mg
dose is 15
dose is 5 mg ,
dose is 5 mg
dose is 5
dose is a single intravenous
dose is a
dose is
dose may be
dose is between 75 and
dose is between 75
dose is between
( see section
( see
(
notwendig
dose should not exceed 200
in dose should
dose should be
dose should
dose of 300 mg/ m2
dose of 300
dose of 5 mg
dose of 5
dose of 5.25 mg (
dose of 5.25 mg
dose of 5.25
dose of 600 IU/ kg
dose of 600
dose of ABILIFY
dose of ABILIFY
dose of
dose
same
dose is adjusted
dose is
dose is
dose .
lowest effective dose .
lowest effective dose
dose
dose
administered dose
assay
dose ,
dose in
dose of
dose
for dose
same
Dose adjustment in order to
Dose adjustment in order
Dose adjustment
impairment .
impairment
Dosage adjustment to
dose adjustment is necessary ,
dose adjustment is necessary
Dosisanpassung sollte so gewählt werden
adjustment
dose adjustment
modifications in patients with
modifications in patients with
modifications in patients
modifications in patients
modifications in
modifications
increases
, with consideration for the
with consideration for the
, with consideration for
with consideration for
with consideration for
dose reduction
dose reduction .
dose reduction
Three of the six identified
Three of the six
Three of the
Three
third of patients were receiving
third of patients
third of
third
Do not push the tablet
blood perfusion of the
blood perfusion
blood
diarrhoea , vomiting , constipation
diarrhoea , vomiting ,
diarrhoea , vomiting
diarrhoea ,
diarrhoea .
diarrhoea softened stools
diarrhoea softened
, diarrhoea
diarrhoea
mean age :
average age of 62 years
average age of 62
mean age
Vial 50ml
vial .
vial contains 10
vial contains 9.75 mg (
vial contains 9.75 mg
vial contains 9.75
vial contains
Keep the vial in
vial of 100 mg paclitaxel
vial of 100 mg
vial of 100
vial of
the vial
vial
vial provides 9.75 mg in
vial provides 9.75 mg
vial provides 9.75
vial provides
vials , cartridges (
vials , cartridges
vials ,
vials are for use with
vials are for use
vials are for
vials are
vials x 10 ml
vials x 10
vials x
vials
dysfunction
dysgeusia , dizziness , peripheral
dysgeusia , dizziness ,
dysgeusia , dizziness
dysgeusia ,
dysgeusia , oesophagitis ,
dysgeusia , oesophagitis
dysgeusia
dyskinesia , hyporeflexia , neuralgia
dyskinesia , hyporeflexia ,
dyskinesia , hyporeflexia
dyskinesia ,
dyskinesia
dyslipidaemia ( abnormal
at inclusion .
inclusion .
Dyslipidämie eingeschlossen waren , wurde
Dyslipidämie eingeschlossen waren ,
Dyslipidämie eingeschlossen
at inclusion
dyslipidaemia
inclusion
dyspepsia ( heartburn ) ,
dyspepsia ( heartburn )
dyspepsia ( heartburn
dyspepsia (
night sweats , hyperhydrosis
dyspepsia , vomiting ,
dyspepsia , vomiting , nausea
dyspepsia , vomiting
dyspepsia ,
Gastrointestinal dyspepsia
dyspepsia
night
dysphagia , abdominal discomfort ,
48 Dysphagia : oesophageal dysmotility
60 Dysphagia : oesophageal dysmotility
72 Dysphagia : oesophageal dysmotility
84 Dysphagia : oesophageal dysmotility
Dysphagia : oesophageal dysmotility
48 Dysphagia : oesophageal
60 Dysphagia : oesophageal
72 Dysphagia : oesophageal
84 Dysphagia : oesophageal
Dysphagia : oesophageal
dysphagia
dystonia and dyskinesia
Dysuria , pollakiuria , haematuria
Dysuria ,
Dysuria
Denmark
E 320 ) 2
E 320 ) Yarvitan is
E 320 ) Yarvitan
E 320 )
E 320
Tablet core :
Tablet core
Tablet
E14 4HB ,
E14 4HB
E216 ) , sodium hydroxide
E216 ) ,
E216 ) Sodium hydroxide Sucrose
E216 ) Sodium hydroxide
E216 ) per ml
E216 ) per
E216 )
E216 .
E216
E218 ) Propylene glycol
E218 ) per ml 0.2
E218 ) per ml
E218 ) per
E218 )
E218
E951 ) Acesulfame potassium Vanilla
E951 ) Acesulfame potassium
E951 ) per orodispersible tablet
E951 ) per
E951 )
E951
REGARD TO SAFE AND
REGARD
THERAPY WITH SULPHONYLUREA
WITH INSULIN Metabolism
WITH METFORMIN Blood
TRIPLE ORAL COMBINATION THERAPY WITH
TRIPLE ORAL COMBINATION THERAPY
TRIPLE ORAL
THERAPY WITH
WITH METFORMIN
WITH
BY UNIT
RESTRICTIONS REGARDING
RESTRICTIONS
RESTRICTIONS WITH REGARD TO THE
RESTRICTIONS WITH REGARD TO
RESTRICTIONS WITH
EMEA
EMEA
THE DISPOSAL OF
THE DISPOSAL
EPAR für die
EPS was 19 %
EPS including parkinsonism , akathisia
EPS including parkinsonism ,
EPS including parkinsonism
EPS including
EPS was
EPS
AUTHORISATION/ RENEWAL OF THE AUTHORISATION
AUTHORISATION/ RENEWAL OF THE
AUTHORISATION/ RENEWAL OF
FIRST AUTHORISATION/ RENEWAL OF
FIRST
IS USED FOR
IS
ESAs ) have shown :
ESAs ) have shown
ESAs are not indicated for
ESAs are not indicated
BOTTLE LABEL FOR UNIT PACK
BOTTLE LABEL FOR INTERMEDIATE PACK
BOTTLE LABEL FOR
BOTTLE
EU/ 1/ 06/ 344/
55 ml 120
55 ml
55
120 ml 210
120 ml
120
210 ml
210
EU/ 1/ 00/ 150/ 001-003
EU/ 1/ 00/
EU/ 1/ 00/
EU/ 1/ 00/ 150/ 004-006
EU/ 1/ 00/
EU/ 1/ 00/
04/ 276/ 015 98 x
1/ 04/ 276/
05/ 308/ 002
06/ 344/ 004
06/ 344/ 007
06/ 344/ 011
07/ 412/ 002
07/ 412/ 004
07/ 412/ 006
07/ 412/ 008
07/ 412/ 010
07/ 412/ 012
07/ 412/ 014
07/ 412/ 016
07/ 412/ 018
07/ 412/ 020
Similarly , for dehydro-aripiprazole the
Similarly , for dehydro-aripiprazole
Similarly , for
Similarly ,
Similarly
is there any detectable
Eesti Eli Lilly Holdings Limited
Eesti Eli Lilly Holdings
Eesti Eli Lilly
Eesti Eli
Eesti filiaal Tel : +3726441100
Eesti filiaal Tel :
Eesti filiaal Tel
Eesti filiaal
Eesti
sollten ähnliche Dosiserhöhungen vorgenommen werden
sollten ähnliche Dosiserhöhungen
effect , which
effect , which
inhibitory effect on CYP2C8 has
Effect on bone
effect on
of clinical signs suggestive of
of clinical signs suggestive of
effect of rimonabant
of clinical signs suggestive of
effect of
Effect
effect
Effect on morphometric vertebral fractures
Effect on morphometric
Effect on
effects of aripiprazole .
effects of aripiprazole
effects of
effects were
Effect
Effekte
effects
similar
Effect on height
Effect on
Effect
Eiffel , BP 27166 ,
Eiffel , BP 27166
Eiffel , BP
Eiffel ,
Eiffel
blood donation procedure .
blood donation procedure
autologous
with autologous
predonation programme
models of dopaminergic hypoactivity .
models of dopaminergic hypoactivity
models of dopaminergic
characteristics of aripiprazole and
characteristics of aripiprazole
characteristics of
characteristics
A rise in haemoglobin of
Part of the treatment of
Part of the treatment
Part of the
Part of
a trend
trend
a trend
trend
Occlusion in the connection between
Occlusion in the connection
Occlusion of
efficacy or other symptoms of
efficacy or other symptoms
of efficacy or other symptoms
efficacy or other
loss of efficacy or other
of efficacy or other
efficacy or
loss of efficacy or
of efficacy or
efficacy
loss of efficacy
of efficacy
A sustained haemoglobin level
A direct effect of rimonabant
A direct effect of
A direct effect
A direct
Increased incidence and/ or severity
A calibrated measuring cup and
A calibrated measuring cup
A calibrated
Dystocia
Some settling of the reconstituted
Some settling of the
Some settling
One ml solution contains
One ml solution
One ml solution contains
One ml solution
One ml
One ml
1 pre-filled pen contains 3
1 pre-filled pen contains
1 pre-filled pen
A
One
impression
16 Adjustment of dosage may
2 Adjustment of dosage may
23 Adjustment of dosage may
30 Adjustment of dosage may
37 Adjustment of dosage may
44 Adjustment of dosage may
51 Adjustment of dosage may
58 Adjustment of dosage may
65 Adjustment of dosage may
72 Adjustment of dosage may
79 Adjustment of dosage may
9 Adjustment of dosage may
Adjustment of dosage may
16 Adjustment of dosage
2 Adjustment of dosage
23 Adjustment of dosage
30 Adjustment of dosage
37 Adjustment of dosage
44 Adjustment of dosage
51 Adjustment of dosage
58 Adjustment of dosage
65 Adjustment of dosage
72 Adjustment of dosage
79 Adjustment of dosage
9 Adjustment of dosage
Adjustment of dosage
Adjustments of daily dosage
16 Adjustment of
2 Adjustment of
23 Adjustment of
30 Adjustment of
37 Adjustment of
44 Adjustment of
51 Adjustment of
58 Adjustment of
65 Adjustment of
72 Adjustment of
79 Adjustment of
9 Adjustment of
Adjustment of
2 Adjustment
23 Adjustment
30 Adjustment
37 Adjustment
44 Adjustment
51 Adjustment
58 Adjustment
65 Adjustment
72 Adjustment
79 Adjustment
9 Adjustment
Adjustment
Patients
Patients
No dose adjustment is required
No dose adjustment is necessary
No dose adjustment is
Dosage adjustment may be necessary
Dosage adjustment may
Dosage adjustment
No dose adjustment
A vial contains 9.75 mg
A vial contains 9.75
A vial contains
A vial
A vial provides 9.75 mg
A vial provides 9.75
A vial provides
A single-dose study in subjects
A single-dose study in
A single-dose study
The pioglitazone dose may need
Each bottle with 100 ml
Each bottle with 100
Each bottle with
Each bottle
Weight gain has
Weight gain
Hypoglycaemia may occur in combination
Hypoglycaemia may occur in
Hypoglycaemia may occur
Hypoglycaemia may
Hypoglycaemia
The patient s ability
One IU ( International Unit
One IU ( International
One IU (
One IU
There is
8 tomography ( CT )
8 tomography ( CT
Renal or hepatic impairment may
Renal or hepatic impairment
Renal or
Renal
1 cartridge contains 3
1 cartridge contains
1 cartridge
Population pharmacokinetic evaluation has
A number of cleavage (
A number of cleavage
A number of
A number
observed
Each tablet contains 15 mg
Each tablet contains 15mg of
Each tablet contains 15mg
Each tablet contains 15
Each tablet contains 30 mg
Each tablet contains 30mg of
Each tablet contains 30mg
Each tablet contains 30
Each tablet contains 45 mg
Each tablet contains 45mg of
Each tablet contains 45mg
Each tablet contains 45
Each tablet contains
Each tablet
The use of specialized DEHP-free
The use of specialized
The use of
Close supervision
Close monitoring of glycaemic control
Close monitoring of
Early shunt revision and thrombosis
Elevated bone turnover is a
Elevated bone turnover
Enhanced efficacy at doses higher
Co-administration of pioglitazone
Co-administration of
Co-administration
Concomitant osteoporosis therapy
Concomitant
Hypertensive crisis with encephalopathy-like
Hypertensive crisis with
Hypertensive crisis
A cardiovascular outcome study of
A cardiovascular outcome study
A cardiovascular
A clinical trial of pioglitazone
A clinical trial of
A clinical trial
A clinical
Long-term improved glycaemic
Long-term improved glycaemic
Long-term improved
Mild hepatic impairment does
A lower dose of 5.25
A lower dose of
A lower dose
A lower
A proconvulsant activity of rimonabant
A proconvulsant activity of
A proconvulsant activity
A proconvulsant
Fast improvement in blood
Inadequate dosage or
Inadequate dosage
Inadequate
Pre-existing hypocalcaemia must be
Pre-existing hypocalcaemia
Pre-existing
Repeated dosing does
Eine zusätzliche oder verstärkte antihypertensive
A
Each
Mild
One
The
There
A similar increase
A similar
influence on the ability
alters the metabolism of other
alters the metabolism of
influence on the
alters
impact on
may impact on
Effects of rimonabant on
of rimonabant
influence
effects on ability to
Introducing appropriate
Introducing
Introducing
surgery and
orthopaedic surgery :
orthopaedic surgery
orthopaedic surgery and :
orthopaedic surgery and
orthopaedic surgery
surgery
Unit ) corresponds to 0.035
Unit ) corresponds to
units ( IU )
Units ( IU ) per
Units ( IU )
units ( IU )
Units ( IU
units ( IU
Units (
units (
units .
units
units in increments of 2
units in increments of
units in increments
Units
units of
units
unit scale .
unit scale
Some patients may
Some patients
10 A few
3 A few
A few
Some
consistent with biochemical marker
consistent with biochemical
consistent with
single-dose to healthy subjects
and repeat-dose
,
Single and multiple 5 and
Single and multiple 5
Single and multiple
administer .
taking this
dosing .
dosing
of
Taking Actos 15mg
taking Actos 15mg tablets
taking Actos 15mg
Taking Actos 30mg
taking Actos 30mg tablets
taking Actos 30mg
Taking Actos 45mg
taking Actos 45mg tablets
taking Actos 45mg
Taking Actos
in association with
allowed to take other medicines
Taking
to take
administer
intake
take
taking
you
Clear , colourless
Clear ,
Clear
oral
still
are
renal impairment .
renal impairment
renal impairment
smoking cessation
pH adjustment )
pH adjustment
control
diabetic patients
diabetic
the control
pad .
pad
single
case
isolated cases of angioedema and
isolated cases of angioedema
isolated cases of
isolated cases
There
oral doses of iron ,
oral doses of iron
doses of iron
iron
of iron
iron oxide ( E172 )
iron oxide ( E172
yellow iron oxide ( E172
yellow
red iron oxide ( E172
iron deficiency ,
iron deficiency
substitution of
substitution
Eli Lilly Finland Ab
Eli Lilly Finland
Eli Lilly Holdings Limited Eesti
Eli Lilly Holdings Limited p
Eli Lilly Holdings Limited
Eli Lilly Holdings
Eli Lilly farmacevtska dru ba
Eli Lilly farmacevtska dru
Eli Lilly farmacevtska dru
Eli Lilly
Eli
13 Elimination The
20 Elimination The
27 Elimination The
34 Elimination The
55 Elimination The
62 Elimination The
69 Elimination The
76 Elimination The
Elimination The
elimination per se of insulin
elimination per se
13 Elimination
20 Elimination
27 Elimination
34 Elimination
55 Elimination
62 Elimination
69 Elimination
76 Elimination
Elimination
elimination were
elimination
Eliminationshalbwertszeit wegen des
Eliminationshalbwertszeit wegen des
Eliminationshalbwertszeit wegen
Eliminationshalbwertszeit wegen
recommend dose modifications in patients
recommend dose modifications in
recommend dose modifications
recommend dose
recommend
, syncope , postural
, syncope ,
, syncope
,
sensitivity to a stimulus )
sensitivity to a stimulus
sensitivity to a
sensitivity
contraception
the end of treatment .
the end of treatment
the end of treatment .
the end of treatment
the end
endothelial
endpoint was 5.8 for placebo
endpoint was 5.8 for
endpoint was 5.8
endpoint was
endpoint
having excessive
enterocytes .
enterocytes may be followed by
enterocytes may be followed
enterocytes may be
enterocytes may be followed
enterocytes may be
enterocytes
Contains fructose , sucrose ,
Contains fructose
. Contains lactose monohydrate .
Contains lactose monohydrate
Also contains sulfobutylether
Also contains
Also
Contains
single tablet removal ,
single tablet removal
Immediately upon
Remove
decision whether to
decision whether
the CHMP .
the CHMP
the
decision to administer
decision
unused
developmental toxicity .
developmental toxicity
development
) shortly
)
inflammation of
inflammation
inflammation .
may help to
inflammation
breakdown of
breakdown
CYP3A4 and CYP2D6 enzymes
enzymes and
enzymes
episcleritis , iritis
episcleritis ,
episcleritis
episode in patients
episodes (
episodes in Bipolar I Disorder
episodes in patients
episodes in Bipolar I Disorder
episodes in
episodes in Bipolar I Disorder
episodes
episodes or
tongue ,
episodes and
episodes in
episodes
tongue
epoetin alfa ,
epoetin alfa ,
epoetin alfa Abseamed 3000
epoetin alfa Abseamed 4000 IU/
epoetin alfa Abseamed 5000 IU/
epoetin alfa Abseamed 6000 IU/
epoetin alfa Abseamed 7000
epoetin alfa Abseamed 8000
epoetin alfa Abseamed 9000
epoetin alfa Abseamed
epoetin alfa
epoetin alfa alters
epoetin alfa on
epoetin alfa in adult patients
reported with epoetin alfa including
epoetin alfa .
epoetin alfa
reported with epoetin alfa
epoetin alfa in cancer patients
epoetin alfa is a
epoetin alfa is very wide
epoetin alfa is very
epoetin alfa is
epoetin alfa may
epoetin alfa is not recommended
epoetin alfa or
Epoetin alfa should be
Epoetin alfa and other erythropoiesis-stimulating
Epoetin alfa and other
Epoetin alfa and
epoetin alfa and
Epoetin alfa is
epoetin alfa has been
to epoetin alfa , adequate
to epoetin alfa
epoetin alfa is given concomitantly
Epoetin alfa
alfa
epoetin alfa in
epoetin alfa
epoetin alfa
epoetin alfa
with epoetin alfa
of epoetin alfa*
Epoetin
epoetin
They recommended
It stops the
It stops
Your doctor will
will use
It acts by blocking
It acts by
It acts
It
Your
He/ she will work
vomiting , diarrhoea ,
vomiting , salivation , anorexia
vomiting , salivation ,
vomiting , constipation , stomatitis
vomiting , constipation ,
vomiting , constipation
vomiting , an
vomiting , salivation
vomiting ,
vomiting , nausea , constipation
vomiting , nausea ,
vomiting , nausea
vomiting .
vomiting diarrhoea softened stools
vomiting diarrhoea softened
vomiting diarrhoea
vomiting Uncommon
vomiting .
vomiting
vomiting and diarrhoea .
vomiting and diarrhoea
vomiting and
vomiting
events ( see
events (
events ) .
events )
events which
events :
events in patients
events in
events cannot be excluded .
events cannot be excluded
events compared
events .
events
events is
events have been
events
events
the events
to the events
event onset .
event onset
experience with
experience with
6 Post-Marketing In addition the
6 Post-Marketing
experience
has experience
experience in children and
experience in children
experience in
experience in this patient group
experience in this patient
experience in
experience
Results of
Results for overall response rate
Results for overall response
results were
results
new information is received
new information is
new
maintenance doses than children
maintenance doses than children over
maintenance doses than
maintenance doses
Usual maintenance dose 75 -
Usual maintenance dose 75
maintenance dose is 15 mg
maintenance dose is 15
Maintenance dose between 17 and
Maintenance dose between 17
Maintenance dose between 25 and
Maintenance dose between 25
Maintenance dose between
Maintenance dose
Usual maintenance dose
maintenance dose
permitted recovery from the
permitted recovery from
permitted
Increased mortality : in
Increased lacrimation , blurred vision
Increased lacrimation ,
Increased lacrimation
Increased
Blood pressure
Blood
pioglitazone dose may need to
pioglitazone dose may need
pioglitazone dose may need to
pioglitazone dose may need
pioglitazone dose may need to
pioglitazone dose may need
increase
increase
increased
Elevations of CPK ( Creatine
Elevations of CPK (
Elevations of CPK
Elevations of
Elevations
date , correction
date ,
date
, influenza-like illness , malaise
, bei der die Bauchspeicheldrüse
, influenza-like illness
Nervous disorders :
Nervous disorders
disease is
disease
illness
conditions
conditions
disorders Common :
disorders Common
Respiratory , thoracic
gastrointestinal disorders : abdominal pain
Gastrointestinal disorders Common :
Gastrointestinal disorders Common
Gastrointestinal disorders
Immune system disorders Uncommon
Immune system disorders
Nervous system disorders Uncommon -
Nervous system disorders Uncommon
Nervous system disorders
disorders
illnesses and mood disorders and
illnesses and mood disorders and
illnesses and mood disorders
disorders and
conditions
disorders
illnesses
colds )
colds
Bewegung steigern
diet
restrictive
be adjusted .
be adjusted
nutrition programme
dry mouth .
Vascular disorders General disorders
dry mouth
replacement insulin which
replacement insulin which
replacement insulin
,
first-line treatment during the assessment
first-line
granting
192 Adult
adults .
Use in adult patients in
Adult cancer
Adult surgery patients in
Adult surgery patients
Adult surgery
Adult and paediatric haemodialysis patients
Adult and
Adult
adults
adult patients scheduled
adult patients
adult
adult patients
adult patients on
to treat adults
adult patients
adult
adults ,
adults
have been proposed ; none
have been proposed ;
have been proposed
on ABILIFY
Pure Red Cell Aplasia (
PRCA means the
PRCA means
PRCA means the
PRCA means
PRCA can result in sudden
PRCA can result in
PRCA can result
PRCA
Pure Red Cell Aplasia
erythropoiesis stimulating agents (
erythropoiesis stimulating agents
erythropoiesis-stimulating agents (
erythropoiesis-stimulating agents
erythropoiesis-stimulating
erythropoietin .
erythropoietin treatment .
erythropoietin treatment
erythropoietin is 32,000 to 40,000
erythropoietin is 32,000 to
Erythropoietin is a
Erythropoietin is
Erythropoietin
erythropoietin
Erythropoietin receptors may
Erythropoietin receptors
Erythropoietins are growth factors
Erythropoietins are
Erythropoietins
erythropoietins
tumour proliferators .
tumour proliferators
Erythropoietin receptors may
Erythropoietin receptors
erythrocytes from precursors
erythrocytes from
erythrocytes
There is an increased risk
There is an increased
There is an
There is
It should also not be
It contains the active substance
It contains
However , in one of
However , in
However ,
and no cases
and no
no cases
no
Patients have taken
There is no specific antidote
There is no accumulation :
There is no accumulation
There are
There is not
There is
There
It is available as 5
It is available as
It is especially
It is available as
It is available as
It is available
It is not known
It does not matter
It is not
It is important that
It is important
It is available
It is available
It is
It
is
May be harmful for
It can be added to
It can be
It may
It could be
Another LHRH agonist could
could
could
could
There are no data
There is no experience of
Data are insufficient
There are no adequate and
There are no adequate
There are no adequate and
There are no adequate
Es liegen keine
There are no
Es liegen
There are
There
Use should be restricted
Use should be
It also prevents
Es werden möglicherweise nicht alle
Es werden möglicherweise nicht
Not all pack
Es werden möglicherweise
Not all the
Not all the
Not all
Not all
Es werden
Not
These changes are interpreted
It is recommended , therefore
It is
The use of
The use
No
No
No studies
No
A
ACOMPLIA
An
Es
It
No
The
Use
no
taken
food prior to administration .
food prior to administration .
food prior to administration
food prior
food
or lorazepam had
or lorazepam
Ethinylestradiol/Levonorgestrel-Kombination wurde durch die
Ethinylestradiol/Levonorgestrel-Kombination wurde durch
Ethinylestradiol/Levonorgestrel-Kombination wurde
Ethinylestradiol/Levonorgestrel-Kombination
vanillin ) Tartaric acid Magnesium
label
and
Approximately 80 % of the
Approximately 80 %
Approximately 80
Approximately half of the
Approximately half
About one third of the
About one third
About
Approximately
Europe ) , Royaume-Uni
Europe ) , Storbritannia Tlf
Europe ) , Storbritannia
Europe ) , Storbritannien Tel
Europe ) , Storbritannien Tlf
Europe ) , Storbritannien
Europe ) , Te .
Europe ) , Te
Europe ) , Wielka Brytania
Europe ) , Wielka
Europe ) ,
Europe ) , µ :
Europe ) , µ
Europe ) Ltd , 61
Europe ) Ltd ,
Europe ) Ltd 61 Aldwych
Europe ) Ltd 61
Europe ) Ltd
Europe )
Europe Ltd commits to provide
Europe Ltd commits to
Europe Ltd
Europe R & D Centre
Europe R & D
Europe R &
Europe R
Europe
Europharm Limited Wimblehurst Road Horsham
Europharm Limited Wimblehurst Road
Europharm Limited Wimblehurst
Europharm Limited
Europharm
marketing
EMEA
Excitement Component score at the
Excitement Component score at
Excitement Component score
Excitement
exposure of rimonabant
the exposure of rimonabant
exposure of
exposure
the exposure of
the exposure
exposure
widened brain ventricles and
widened brain ventricles
exposure was generally
exposure was
, exposure
exposure
exposures
in exposures
reached at 180 mg
F-37071 Tours Cedex 2 ,
F-37071 Tours Cedex 2
F-37071 Tours Cedex
F-37071 Tours
F-37071
FACT-An ) general scale
FACT-An )
FACT-An fatigue scale
FACT-An
FOLDING BOX ( WITH BLUE
FOLDING BOX ( WITH
FOLDING BOX (
FOLDING BOX
FINLAND ) AB Puh/ Tel
FINLAND ) AB
FINLAND )
FINLAND
STRIPS
UNITS
SPC )
medical staff .
medical staff
faeces .
faeces
the warning signs of
have frequent episodes of hypoglycaemia
the warning
have frequent
factor and differentiating hormone
factor and
factor
factors
event of an overdose
event
working
case of insulin resistance .
case of insulin resistance
case of
case
If you are considering stopping
If you are considering
If you develop PRCA
If you are
If you
You should
If patients experience
If patients
If ALT levels remain
If the disease is
If the disease
If the
If jaundice is observed ,
If jaundice is observed
When a dose adjustment
If
When a
If necessary
If necessary
Appropriate therapy such
In cases where there
In cases where there
Where appropriate you will receive
Where
For any information
For any
For
If any
If
When
Carton of 14 x 1
Carton of 14 x
Carton of 14
Carton of 28 x 1
Carton of 28 x
Carton of 28
Carton of 49 x 1
Carton of 49 x
Carton of 49
Carton of
14 , 28 ,
14 , 28 ,
acid blocker ,
powder is white
Farma - Produtos Farmacêuticos ,
Farma - Produtos Farmacêuticos
Farma - Produtos
Farma -
Farma
Farmaceutici SpA Tel : +
Farmaceutici SpA Tel :
Farmaceutici SpA Tel
Farmaceutici SpA
Farmaceutici
Farmacêuticos , Lda Tel :
Farmacêuticos , Lda Tel
Farmacêuticos , Lda
Farmacêuticos , S. A.
Farmacêuticos ,
Farmacêuticos
Almost all subjects ( 95
Almost all subjects (
Almost all subjects
Almost all subjects
Almost half of the patients
Almost half of the
Almost half
fatigue scale
Fe2+/ day for paediatric
Fe2+/ day is
Fe2+/ day
Febrile neutropenia occurred in four
Febrile neutropenia occurred in
Febrile neutropenia occurred
Febrile neutropenia
Febrile
a lack
lack
Furthermore ,
Furthermore
ready-to-infuse
Pre-filled pen (
pre-filled pen .
Pre-filled pen
pre-filled pen
pre-filled syringe ( injection )
pre-filled syringe ( injection
pre-filled syringe (
pre-filled syringe .
pre-filled syringe The syringes contain
pre-filled syringe The syringes
pre-filled syringe The
pre-filled syringe Epoetin alfa
pre-filled syringe Epoetin
pre-filled syringe is
pre-filled syringe of 0.3 ml
pre-filled syringe of 0.3
pre-filled syringe of 0.4 ml
pre-filled syringe of 0.4 ml
pre-filled syringe of 0.4
pre-filled syringe of 0.4
pre-filled syringe of 0.5 ml
pre-filled syringe of 0.5
pre-filled syringe of 0.6 ml
pre-filled syringe of 0.6 ml
pre-filled syringe of 0.6
pre-filled syringe of 0.6
pre-filled syringe of 0.7 ml
pre-filled syringe of 0.7
pre-filled syringe of 0.8 ml
pre-filled syringe of 0.8 ml
pre-filled syringe of 0.8
pre-filled syringe of 0.8
pre-filled syringe of 0.9 ml
pre-filled syringe of 0.9
pre-filled syringe of 1 ml
pre-filled syringe of 1
pre-filled syringe of
pre-filled syringe
pre-filled syringe
pre-filled syringe
Pre-filled syringes ( glass type
Pre-filled syringes ( glass
pre-filled syringes of 0.3 ml
pre-filled syringes of 0.3
pre-filled syringes of 0.4 ml
pre-filled syringes of 0.4
pre-filled syringes of 0.5 ml
pre-filled syringes of 0.5
pre-filled syringes of 0.6 ml
pre-filled syringes of 0.6
pre-filled syringes of 0.7 ml
pre-filled syringes of 0.7
pre-filled syringes of 0.8 ml
pre-filled syringes of 0.8
pre-filled syringes of 0.9 ml
pre-filled syringes of 0.9
pre-filled syringes of 1 ml
pre-filled syringes of 1
pre-filled syringes of
pre-filled syringes are
pre-filled syringes
or oestrous
corpora
fat mass .
fat mass
fat
obesity in adult dogs .
obesity in adult dogs
obesity in adult
obesity in
obesity is caused by a
obesity is caused by
obesity and
obesity
compared with placebo ,
compared with placebo
receptors on muscle
receptors on
fat tissue )
fibrates ) .
fibrates )
fibrates
fever ) .
fever )
, muscle rigidity ,
fever .
Fever and chills , headache
fever and chills , pain
fever
film-coated
film-coated tablets .
film-coated tablets
Finland Ab Puh/ Tel :
Finland Ab Puh/ Tel
Finland Ab
Finland
1st-line
exhibit complications ( e. g.
exhibit complications (
complications .
has complications .
complications
exhibit complications
has complications
bottle
bottle - 100 ml Component
bottle - 100 ml
bottle - 100
bottle contains 5 mg
bottle contains 5
bottle contains
bottle with 100 ml of
bottle with 100 ml
bottle with 100
bottle with
bottle
bottle ,
bottle
bottles , each bottle of
bottles , each bottle of
bottles , each bottle
bottles
FlexPen or InnoLet )
coated
fluoxetine
flushes ,
flushes
( at least one or
at least one or
least one or
one or
or
liquids or mixed with any
fluid retention , hypoalbuminaemia ,
fluid retention , hypoalbuminaemia
fluid retention ,
fluid retention
fluids before and
fluids before
fluids before and
fluids before
fluids
of
The following side effects have
The following adverse reactions were
The following adverse reactions
The following side effects
The following
reactions
are
following are
tract infection , folliculitis ,
tract infection , folliculitis ,
tract
Fontana Del Ceraso I-03012 Anagni-Frosinone
Fontana Del Ceraso I-03012
Fontana Del Ceraso
Fontana Del
Fontana
Forest Gate Wellington Road Wokingham
Forest Gate Wellington Road
Forest Gate Wellington
Forest Gate
Forest
ready for use .
ready for use
as white ,
as white
as
as
Form a
Form
formulations .
formulations
disease progression was
disease progression
progression ,
progression
progression ,
progression
progression of diabetic retinopathy .
progression of diabetic retinopathy
progression of diabetic
progression of
Fracture Trial [ PFT ]
Fracture Trial [ PFT
Fracture Trial [ RFT ]
Fracture Trial [ RFT
Fracture Trial [
Fracture Trial [
Fracture Trial
Fracture Trial
Fracture
Ask your pharmacist
Ask your pharmacist
Ask your doctor or
Ask your doctor
Ask your veterinary surgeon
Ask your
Ask your
Ask your
Ask your
Ask
Ask
fracture ( 92
fracture (
fracture
fracture , including those
of fracture , including those
fracture , including
of fracture , including
fracture ,
of fracture ,
fractures The incidence
fractures was 7.5 %
fractures was 7.5
fractures was
fractures following a recent
fractures following a
fractures after
fractures following
fractures per 100 patient years
Frakturen
fracture
fractures
of fracture
fractures over the duration
fractures over the
of fractures over
fractures over
fractures over
fracture variables are
fracture variables
observed in
France BRISTOL-MYERS SQUIBB SARL Tél
France BRISTOL-MYERS SQUIBB SARL
France BRISTOL-MYERS SQUIBB
France BRISTOL-MYERS
France Laboratoires Takeda Tél :
France Laboratoires Takeda Tél
France Laboratoires Takeda
France Laboratoires
France Therabel Lucien Pharma Tél
France Therabel Lucien Pharma
France Therabel Lucien
France Therabel
France
France
women , 87 %
women , 87
women , osteoporosis in
of women
women ,
women
women in men
women in
women received
and women .
women .
and women
women
women in the HORIZON-PFT
women in the
women in
women with osteoporosis
women with metastatic breast cancer
women with
women and
women .
women
Women
in women
more
of women
women ,
women
function
Good blood management
death in utero .
death in utero
fructose , sucrose ,
fructose per ml 400 mg
fructose per ml 400
fructose per ml
fructose per
fructose and 400 mg of
fructose and 400 mg
of fructose and 400 mg
fructose and 400
of fructose and 400
fructose and
of fructose and
fructose
of fructose
Early
Functional Assessment of Cancer
Functional Assessment of
Functional
monitoring
malfunction of the
malfunction of
malfunction
food your dog will need
food your dog will
food
food .
food
OF UNUSED MEDICINAL PRODUCTS
RESPONSIBLE FOR BATCH RELEASE
RESPONSIBLE FOR BATCH RELEASE
RESPONSIBLE FOR BATCH RELEASE
RESPONSIBLE FOR BATCH RELEASE
RESPONSIBLE FOR BATCH RELEASE
RESPONSIBLE FOR BATCH
RESPONSIBLE FOR BATCH
FOR THE DISPOSAL OF UNUSED
FOR DAYS OF
OF UNUSED MEDICINAL
FOR EACH SPECIES ,
FOR EACH SPECIES
FOR EACH
BE STORED OUT OF THE
BE STORED OUT OF
BE STORED
UNIT PACK
PACK SIZES OF 14 ,
PACK SIZES OF 14
PACK SIZES OF
FOR ANIMAL TREATMENT ONLY AND
INTERMEDIATE PACK
FOR
OF
to drive and use machines
ability to drive or
to drive and
cases of elevated liver enzymes
cases of bronchoconstriction
cases of seizure
cases of NMS
cases of stroke or
cases of stroke
cases of anaphylactic reaction/ shock
symptomatic cases of hypocalcaemia
symptomatic cases of
cases of
cases have been associated with
cases have been
cases of
cases
cases fatal outcome has
cases fatal
cases extreme and associated with
cases extreme and associated
it resolved .
of whom it resolved .
whom it resolved .
it resolved
of whom it resolved
whom it resolved
cases , these effects are
cases ,
cases
it
of whom it
whom it
faeces .
faeces
pioglitazone .
with pioglitazone .
pioglitazone
with pioglitazone
pioglitazone
Fill the
Fill
No information is
A specific overdose of
Osteonecrosis of the jaw
Osteonecrosis of
For the treatment of bipolar
For the treatment of
For the treatment
The unopened bottle does not
The unopened bottle does
For the
There are no
This medicinal product
This veterinary medicinal product
This medicinal
3 Elevated
For
No
This
G-CSF or GM-CSF (
G-CSF or GM-CSF
G-CSF or GM-CSF
G-CSF and GM-CSF
SPECIAL PRECAUTIONS FOR DISPOSAL
SPECIAL PRECAUTIONS FOR
THE MARKETING AUTHORISATION
THE MARKETING AUTHORISATION
THE MARKETING
GESMBH Tel : + 43
GESMBH Tel : +
GESMBH Tel :
GESMBH Tel
GESMBH
, BY VOLUME OR BY
, BY
GGT ) , increased alkaline
GGT ) , increased
GGT ) ,
GGT )
GGT
proliferation of
proliferation
conventional studies of
conventional studies
Abraxane administration and
Abraxane administration
administration of Abraxane
Aclasta administration
alendronate
alendronate
administration of ketoconazole or other
administration of ketoconazole or
administration of ketoconazole
placebo
administration of
administration
of
administration
when
bile
Gamma Glutamyl Transferase ( GGT
Gamma Glutamyl Transferase (
Gamma Glutamyl Transferase
Gamma
Reaktion am Anwendungsort
tablet from the mouth is
tablet from
tablet
gastrointestinal
subcutaneous tissue disorders
Gastrointestinal
Gate Wellington Road Wokingham Berkshire
Gate Wellington Road Wokingham
Gate Wellington Road
Gate Wellington
Gate
Therefore , administer the product
Geben Sie es nicht
Therefore , administer
and you
you
Therefore ,
Therefore
with
leaflet was last approved on
leaflet was last approved
leaflet was last
leaflet
leaflet was
leaflet
delivery ,
delivery
Introducing appropriate lifestyle changes
of
Vascular
feeling
If convenient it may
If convenient
There
antidotes ) , if necessary
antidotes ) , if
antidotes ) ,
antidotes )
antidotes
brain .
brain
Uncommon - Diabetic retinopathy
Uncommon - Diabetic
Uncommon - Peripheral neuropathy
Uncommon - Peripheral
Uncommon -
Uncommon - Oedema Oedema may
Uncommon : fatigue*
anxiety Uncommon : depression*
Uncommon : dysgeusia ,
Uncommon : dysgeusia , oesophagitis
Uncommon : dysgeusia
Uncommon : tachycardia*
Uncommon : orthostatic hypotension* ,
Uncommon : orthostatic hypotension*
Uncommon : orthostatic
Uncommon :
6
Uncommon
Uncommon side effects (
Uncommon side effects
Uncommon
joint
joints
,
gemfibrozil ( an
gemfibrozil ( an
gemfibrozil (
gemfibrozil
Union , for
Union , for
marketing authorisation was
marketing authorisation
general scale
In general
any origin .
any origin
delay recovery from hypoglycaemia
delay recovery
genotoxicity tests , aripiprazole
genotoxicity tests ,
genotoxicity tests
Purified water
Purified
a small reduction in
a small
total clearance was 15
total clearance was
total clearance
following 30- and 180-minute
following 30- and
following 30-
total dose of ABILIFY (
total dose of ABILIFY
total dose and rate
total dose and
total dose of
total dose
five minutes , depending
atrial fibrillation
atrial
pooled atrial fibrillation incidences
pooled atrial fibrillation
pooled atrial
atrial
cause mortality was 10 %
mortality was 10 %
cause mortality was 10
mortality was 10
cause mortality was
mortality was
cause mortality
mortality
all cause mortality ( p=0.01
all cause
overall survival and increased
overall survival and
overall survival between
overall survival
survival
gender
sex
, tremor
face
the face
, redness
face oedema , pruritus ,
face oedema
gluteal
weight gain , weight decreased
weight gain ,
weight gain
weight increases ,
weight increases
weight
weight decreased , anorexia ,
weight decreased , anorexia
weight loss , emaciated
weight decreased ,
weight loss ,
weight decreased
weight
category for mitratapide versus
loss category for mitratapide versus
category for mitratapide
loss category for mitratapide
category for mitratapide
loss category for mitratapide
category for
loss category for
category
loss category
weight loss
weight reduction
overall weight management programme
weight
ACOMPLIA
that seen in
that seen
Weight gain : weight gain
Weight gain :
Weight gain : in clinical
Weight gain :
weight gain and oedema
weight gain is
Weight gain
weight gain
weight increase
weight
obese patients and overweight patients
obese patients and overweight patients
taken
glass of water
glass of
glass
glass ball to facilitate the
glass ball to
glibenclamide
gliclazide ) .
gliclazide )
gliclazide .
gliclazide as monotherapy was
gliclazide as monotherapy
gliclazide as
gliclazide
Global R & D Centre
Global R & D
Global R &
Global R
Global Research and Development Centre
Global Research and Development
Global Research and
Global
glucocorticoids , thyroid hormones and
glucocorticoids , thyroid hormones
glucocorticoids ,
glucocorticoids
glucose output from the liver
glucose
glucose-galactose
glucose-galactose malabsorption or sucrase-isomaltase insufficiency
glucose-galactose malabsorption or
glucose-galactose malabsorption
Glutamyl Transferase ( GGT )
Glutamyl Transferase ( GGT
Glutamyl Transferase (
Glutamyl Transferase
, avoiding
avoiding
, avoiding
avoiding
chloride Glycerol Metacresol Phenol
chloride Glycerol
glycine ,
Glycine Polysorbate 80 Water for
Glycine Polysorbate 80 Water
Glycine Polysorbate 80
Glycine
glycine
P-glycoprotein ( P-gp ) in
P-glycoprotein ( P-gp )
P-glycoprotein ( P-gp
GmbH & Co KG ,
GmbH & Co KG Kuhloweg
GmbH & Co KG
GmbH & Co
GmbH &
GmbH Roonstraße 25 D-90429 Nuremberg
GmbH Roonstraße 25 D-90429
GmbH Roonstraße 25
GmbH Roonstraße
GmbH Tel : +43 1
GmbH Tel : +43
GmbH Tel : +49 911
GmbH Tel : +49
GmbH Tel :
GmbH Tel
GmbH Tel . + 49
GmbH Tel . +
GmbH Tel .
GmbH Tél/ Tel : +49
GmbH Tél/ Tel :
GmbH Tél/ Tel
GmbH
Grade 1 or 2
Grade 1 or
Grade 1
experiencing grade 3
grade 3
grade for patients experiencing
grade for patients
Grade
experiencing grade
grade
Flu , sleeplessness ,
Flu , sleeplessness
flu-like symptoms , such as
flu-like symptoms ,
flu-like symptoms
flu-like
a lack of data
lack of data
a lack of
lack of
treatment , read the Package
group compared to
group : oral blood
years
group .
group
group
groups ) at six months
groups )
groups
Guideline
Gustave Eiffel , BP 27166
Gustave Eiffel , BP
Gustave Eiffel ,
Gustave Eiffel
Gustave
HDL-C and TG in
HDL-C and
HDL-C
gliclazide .
gliclazide
HDPE bottles containing 28 ,
HDPE bottles containing 28
HDPE bottles
MANUFACTURER OF
MANUFACTURER
AUTHORISATION HOLDER
AUTHORISATION HOLDER(S )
AUTHORISATION HOLDERS
AUTHORISATION
HF Sími : + 354
HF Sími : +
HF Sími :
HF Sími
HF
REGARD TO THE SAFE AND
REGARD TO THE SAFE AND
REGARD TO THE SAFE
REGARD TO THE
REGARD TO
HIV ) .
of HIV ) .
HIV )
of HIV )
HIV
of HIV
reductase inhibitors are not
reductase inhibitors are
reductase inhibitors
HORIZON Pivotal Fracture Trial [
HORIZON Pivotal Fracture Trial
HORIZON Pivotal Fracture
HORIZON Pivotal
HORIZON
HORIZON-PFT
HORIZON-RFT study
half-life ( t½ ) is
half-life ( t½ )
half-life ( t½
half-life (
half-life of
half-life was
half-life is
half-life
terminal
of t½ 0.24 and t½
t½ 0.24 and t½
of t½ 0.24 and
t½ 0.24 and
of t½ 0.24
t½ 0.24
hallucinations
haloperidol 73 % ) .
haloperidol 73 % )
haloperidol 73 %
haloperidol 73
haloperidol at week 12.
haloperidol ,
haloperidol
haloperidol-controlled trial
Shelf-life of the
Shelf-life after first opening the
Shelf-life after first opening
Shelf-life after
Shelf-life
urine ,
urine
urinary
main measure of effectiveness was
main measure of effectiveness
main measure of
The main measure
main measure
main study , 72 (
main study , 72
main study ,
main study
main studies looking at
main studies
main
shrunk in size by
shrunk in size
skin ( subcutaneously )
skin ( subcutaneously )
skin (
chest pain ,
skin at the injection site
skin
skin at
skin
rash and
rash
fold by pinching the
fold by pinching
fold
fold
, hypoglyceamia can occur (
hypoglyceamia can occur ( see
hypoglyceamia can occur (
, hypoglyceamia can
, hypoglyceamia
hypoglyceamia can
hypoglyceamia
, hypoglyceamia can
, hypoglyceamia
hypoglyceamia can
hypoglyceamia
Skin reactions such as redness
Skin reactions such as
Skin reactions
Flushing , hot flushes
Flushing , hot
Flushing , hot
Flushing ,
Hb 10 - 13
Hb between 10 and 12
Hb between 10 and
Hb between 10
Hb between
Hb
Hb increase 1 g/ dl
Hb increase 1
Hb increase
level
HbA1c ( with a baseline
HbA1c ( with
HbA1c (
HbA1c
in HbA1c
Healthcare A/ S Tlf :
Healthcare A/ S Tlf
Healthcare A/ S
Healthcare
hoarseness ,
hoarseness
inhibition of any subtype of
inhibition
heparin ( heparinisation ) may
heparin ( heparinisation )
heparin ( heparinisation
heparin (
heparin )
heparin
heparinisation ) may
heparinisation )
heparinisation
hepatitis , increased Alanine Aminotransferase
hepatitis ,
hepatitis
Sulfobutylether -cyclodextrin ( SBECD
Sulfobutylether -cyclodextrin (
Sulfobutylether -cyclodextrin
Sulfobutylether
b-cyclodextrin
Manufacturer Novartis Pharma GmbH Roonstraße
Manufacturer Novartis Pharma GmbH
Manufacturer Novartis Pharma
Manufacturer Novartis
Manufacturer Marketing authorisation holder :
Manufacturer Marketing authorisation holder
Manufacturer Marketing authorisation
company
Manufacturer
company
batch release
manufacturer
manufacturer of the
manufacturer
manufacture ( recombinant DNA
of manufacture ( recombinant DNA
manufacture ( recombinant
of manufacture ( recombinant
heart or the blood vessels
heart or the
heart or
heart
heart , heart
Cardiac disorders :
62 Cardiac
Cardiac disorders
Cardiac
monkeys .
monkeys
monkeys
myocardial infarction or stroke in
myocardial infarction or stroke
myocardial infarction or
myocardial infarction
heart failure , however
heart failure ,
history of cardiac failure (
history of cardiac failure
heart failure or diabetic ketoacidosis
cardiac failure or
heart failure or
cardiac failure , therefore
cardiac failure ,
cardiac failure
cardiac failure
heart failure
heart disease or previous stroke
heart disease or previous
heart disease or
heart disease
heart rhythm ( atrial fibrillation
heart rhythm (
heart beat .
heart beat
heart rhythm
e. g. heart
heart failure
Hierunter waren Kopfschmerzen
Highbridge Business Park , Oxford
Highbridge Business Park ,
Highbridge Business Park
Highbridge Business
Highbridge
a
Regarding reproductive
Regarding reproductive
evidence of clinically significant
evidence of clinically
evidence of
evidence
evidence
For information on the infusion
For information on the
other handling
For
hot flushes ,
hot flushes
hot
hot
take for high
surgical castration )
surgical castration
Holdings Limited Eesti filiaal Tel
Holdings Limited Eesti filiaal
Holdings Limited Eesti
Holdings Limited atstovyb Tel .
Holdings Limited p rst vniec
Holdings Limited p rst
Holdings Limited p
Holdings Limited
Holdings
hormone erythropoietin .
hormone erythropoietin
hormone
replacement
Horsham West Sussex , RH12
Horsham West Sussex ,
Horsham West Sussex
Horsham West
Horsham
House Highbridge Business Park ,
House Highbridge Business Park
House Highbridge Business
House Highbridge
House
Medicinal Products
Medicinal products
insulin human ( rDNA )
insulin human ( rDNA
insulin human (
human insulin
insulin human
dog has impaired liver function
your dog
dog has
dog
dogs per weight loss
dogs per weight
dogs
, for dogs
dogs Mitratapide
to dogs results in reduced
to dogs results in
dogs rapidly absorb orally administered
dogs rapidly
dogs
for dogs
dogs in which
dogs in which overweight
dogs .
dogs with impaired liver function
dogs with
dogs and rats ,
dogs and rats
dogs and
dogs
in dogs
dogs ,
dogs
in dogs
dogs over the
dogs over
Hunton House Highbridge Business Park
Hunton House Highbridge Business
Hunton House Highbridge
Hunton House
Hunton
cough , exertional dyspnoea ,
cough , exertional dyspnoea
cough ,
cough
hydrochloride ) .
hydrochloride )
hydrochloride
hydrochloride ) .
hydrochloride )
tablets
hydrochloride .
hydrochloride
hydrolysis ) sites on
hydrolysis ) sites
conjugates of hydroxy metabolites of
hydroxylation of aliphatic
hydroxylation of aripiprazole ,
hydroxylation of aripiprazole
hydroxylation
hyperglycaemia ( such as
hyperglycaemia (
hyperglycaemia , diabetes mellitus ,
hyperglycaemia , diabetes mellitus
hyperglycaemia , diabetes
hyperglycaemia , hypocalcaemia , hypoglycaemia
hyperglycaemia , hypocalcaemia ,
hyperglycaemia , hypocalcaemia
hyperglycaemia , in some cases
hyperglycaemia , in some
hyperglycaemia , in
hyperglycaemia ,
hyperglycaemia and diabetes mellitus (
Hyperglycaemia and diabetes mellitus :
Hyperglycaemia and diabetes mellitus
hyperglycaemia and diabetes mellitus
hyperglycaemia and diabetes mellitus (
hyperglycaemia and diabetes mellitus
Hyperglycaemia and Diabetes
Hyperglycaemia and diabetes
hyperglycaemia and diabetes
Hyperglycaemia and
hyperglycaemia and
Hyperglycaemia
hyperglycaemia
hypertension .
hypertension and/ or
hypertension ,
hypertension
hypoactivity .
hypoactivity
hypoalbuminaemia , polydipsia , hyperglycaemia
hypoalbuminaemia , polydipsia ,
hypoalbuminaemia , polydipsia
hypoalbuminaemia ,
hypoalbuminaemia
hypocalcaemia ( low blood calcium
hypocalcaemia ( low blood
hypocalcaemia ( low
hypocalcaemia (
hypocalcaemia
hypoglycaemia ) , sugar
hypoglycaemia ) ,
hypoglycaemia )
hypoglycaemia , hyponatraemia Common :
hypoglycaemia , hyponatraemia Common
hypoglycaemia , hyponatraemia
hypoglycaemia ,
hypoglycaemia may
from hypoglycaemia .
from hypoglycaemia
hypoglycaemia
of hypoglycaemia
hypoglycaemia .
hypoglycaemia
change in their usual
change in their usual
episodes of
hypoglycaemia ( low blood
hypoglycaemia (
hypoglycaemia
hypocalcaemia ( see section 4.4
hypocalcaemia ( see section
hypocalcaemia ( see
hypocalcaemia (
hypocalcaemia , hypoglycaemia , hyponatraemia
hypocalcaemia , hypoglycaemia ,
hypocalcaemia , hypoglycaemia
hypocalcaemia ,
Hypocalcaemia In clinical trials
Hypocalcaemia In
hypocalcaemia were observed .
hypocalcaemia were observed
hypocalcaemia , reversal may be
hypocalcaemia , reversal
hypocalcaemia must be
Hypocalcaemia
hypocalcaemia
hyponatremia
hyponatraemia Common :
hyponatraemia Common
hyponatraemia
Hypophosphataemia , fluid retention ,
Hypophosphataemia , fluid retention
Hypophosphataemia ,
Hypophosphataemia
hyporeflexia , neuralgia , sensory
hyporeflexia , neuralgia
hyporeflexia ,
hyporeflexia
Hypotension , peripheral coldness ,
Hypotension , peripheral coldness
Hypotension , peripheral
Hypotension ,
hypotension Rare :
hypotension Rare
Hypotension
hypotension
to hypotension
hypotension* ,
hypotension*
hypoaesthesia ( decreased sensitivity
hypoaesthesia ( decreased
hypoaesthesia (
hypoaesthesia
hydroxypropyl
hypoaesthesia , paraesthesia .
hypoaesthesia , paraesthesia
hypoaesthesia ,
hypoaesthesia
one-half of
one-half
haematocrit of 33 - 39
haematocrit of 33 -
haematocrit of 33
haematocrit of
haematocrit
packed cell volume .
packed cell volume
packed
haematological malignancies ( 221 multiple
haematological malignancies (
haematological malignancies .
haematological malignancies
haemodialysis and adult patients
haemodialysis and
haemodialysis
desired haemoglobin level may
is achieved and periodically thereafter
haemoglobin level may be observed
haemoglobin concentration aimed for is
haemoglobin target range of 10
haemoglobin target range of
haemoglobin level
haemoglobin target range
target haemoglobin concentration
haemoglobin concentration should be between
haemoglobin concentration should be
haemoglobin
levels
haemoglobin is rising by more
haemoglobin is rising by more
haemoglobin is rising by
haemoglobin
haemoglobin and blood pressure
haemoglobin and
haemoglobin is
haemoglobin level
haemoglobin
haemoglobin ( 1 to
haemoglobin ( 1
in haemoglobin ( 1 to
in haemoglobin ( 1
haemoglobin (
in haemoglobin (
maintain haemoglobin values
maintain haemoglobin
haemoglobin
in haemoglobin
haemoglobin values exceeding 12
haemoglobin values exceeding
haemolysis , blood loss ,
haemolysis , blood loss
haemolysis
hands ,
hands
hands
Common : fatigue Psychiatric disorders
Common : fatigue Psychiatric
Common : dyspepsia , vomiting
Common : dyspepsia ,
Common : dyspepsia
Common : somnolence , dizziness
Common : somnolence ,
Common : somnolence
Common : extrapyramidal disorder ,
Common : extrapyramidal disorder
Common : extrapyramidal
Common : blurred vision
Common : blurred
Common :
disorders :
Common : nausea
Common
disorders
Common side effects (
Common side effects
Common
incidence of post-dose symptoms
frequency listed below
frequency
incidence of
frequency of these events is
frequency of these events
incidence of these symptoms decreased
incidence of these symptoms
frequency of these
incidence of these
frequency of hypocalcaemia was
frequency of hypocalcaemia
frequency and severity
frequency and
incidence of vertebral fractures did
incidence of vertebral fractures
incidence of clinical fractures was
incidence of clinical fractures
incidence of clinical fractures over
incidence of clinical
incidence of
incidence
frequency
incidence
frequency of these events is
rates of key clinical
rates of key
frequency of undesirable
key
oedema rates for
frequency grouping , undesirable effects
frequency grouping , undesirable effects
frequency grouping , undesirable
of
hip
hip fracture .
broken their hip should receive
hip
broken their hip ,
broken their hip
hip fracture ,
hip fracture
hip
hip fractures Aclasta demonstrated a
hip fractures Aclasta demonstrated
hip fractures Aclasta
hip fracture ,
hip fracture
hip fractures
of hip fractures
I-03012 Anagni-Frosinone Italy
I-03012 Anagni-Frosinone
I-03012
IU per kilogram ,
IU per kilogram
IU per
IU
IU ( International Unit )
IU ( International Unit
IU ( International
IU (
IU ) corresponding to 16.8
IU ) corresponding to 25.2
IU ) corresponding to 33.6
IU ) corresponding to 42.0
IU ) corresponding to 50.4
IU ) corresponding to 58.8
IU ) corresponding to 67.2
IU ) corresponding to 75.6
IU ) corresponding to 8.4
IU ) corresponding to 84.0
IU ) corresponding to
IU )
IU ) of solution .
IU ) of solution
IU ) per kilogram bodyweight
IU ) per
IU ) of
IU )
IU of epoetin alfa*
IU of insulin human .
IU of insulin human
IU of insulin
IU of vitamin D supplementation
IU of vitamin
IU per kilogram .
IU per kilogram
IU per
IU .
IU of
IU of
IU
0.3 ml solution for injection
0.3 ml
IU/ 0.3 ml
0.3
IU/ 0.3
0.4 ml solution for injection
0.4 ml
0.4
0.5 ml solution for injection
0.5 ml
0.5
0.6 ml solution for injection
0.6 ml
0.6
0.7 ml solution for injection
0.7 ml
IU/ 0.7 ml
0.7
IU/ 0.7
0.8 ml solution for injection
0.8 ml
IU/ 0.8 ml
0.8
IU/ 0.8
IU/ 0.9 ml
IU/ 0.9
IU/ 1 ml
IU/ kg once weekly
IU/ kg 3x/ week or
IU/ kg 3x/ week
IU/ kg epoetin alfa ,
IU/ kg epoetin alfa ,
IU/ kg epoetin alfa
IU/ kg epoetin
IU/ kg body weight
IU/ kg
IU/ kg 3 times per
IU/ kg , three times
IU/ kg 3 times
IU/ kg 3
IU/ kg 3
IU/ kg given subcutaneously 3
IU/ kg given subcutaneously
IU/ kg 2 times
IU/ kg 2 times
IU/ kg 2 times per
IU/ kg 2
IU/ kg 2
IU/ kg ,
IU/ kg
IU/ ml suspension for injection
lon ANNEX II
II
III ) with a
III ) with
III )
III
Product Characteristics ,
Product Characteristics
of Product Characteristics ,
of Product Characteristics
COMBINATION THERAPY WITH INSULIN Metabolism
COMBINATION THERAPY WITH METFORMIN Blood
COMBINATION THERAPY WITH SULPHONYLUREA
IN TRIPLE ORAL COMBINATION THERAPY
IN TRIPLE ORAL
COMBINATION THERAPY WITH METFORMIN
COMBINATION THERAPY WITH
COMBINATION THERAPY WITH
COMBINATION THERAPY
COMBINATION
IN
MANUFACTURING AUTHORISATION HOLDER
MANUFACTURING AUTHORISATION HOLDER(S )
MANUFACTURING AUTHORISATION HOLDERS
MANUFACTURING AUTHORISATION
MANUFACTURING
INHABER DER HERSTELLUNGSERLAUBNIS
APPLICANT
CONTENTS BY WEIGHT , BY
CONTENTS BY WEIGHT , BY
CONTENTS BY WEIGHT
CONTENTS
ABILIFY IS AND WHAT IT
ABILIFY IS AND WHAT
ABSEAMED IS AND WHAT IT
ABSEAMED IS AND WHAT
ACLASTA IS AND WHAT IT
ACLASTA IS AND WHAT
ACTOS IS AND WHAT IT
ACTOS IS AND WHAT
CHILDREN
RELEASE
IV )
IV
ibuprofen ( anti-inflammation medicines
ibuprofen ( anti-inflammation medicines
ibuprofen ( anti-inflammation
ibuprofen shortly following
ibuprofen shortly
ibuprofen or paracetamol
ibuprofen or
ibuprofen
ideas and sometimes severe irritability
ideas and sometimes
ideas and
ideas
you by your doctor or
you by your doctor
you are due to have
you cannot receive
you have been told by
prescribed for you .
prescribed for you
advise you on the
advise you on
advise you
advise you on the
advise you on
advise you
for you to
for you
of your
you by
you to
you
your
you to do this .
for you to do this
you to do this
Your doctor , pharmacist or
Your doctor , pharmacist
Your doctor ,
Your doctor can recommend a
Your doctor can recommend
The doctor may also want
doctor may also want
The doctor may
doctor may
your doctor may
your doctor or
Your doctor will advise you
Your doctor will conduct investigations
Your doctor will take this
Your doctor may check your
Your doctor may check
Your doctor may
Your doctor will check
Your doctor will consider
Your doctor will
Your doctor will
The doctor
Your doctor
doctor
your doctor
your
your blood pressure
your blood pressure should
your weight increases ,
your weight increases
your weight
your dog will need .
your dog will need
your dog has
your dog will
your dog
your dog
your haemoglobin
Your veterinary surgeon should
Your veterinary surgeon will
Your veterinary surgeon
your condition is controlled
your condition is controlled
your condition
your condition
Your
your
adjust your dose of Abseamed
your anaemia
your anaemia
your anaemia
your dose of
your dose
Serum electrolytes should
Serum electrolytes
your levels of the
your levels
your
this medicine :
this medicine
doctor
your doctor
your blood
this
your
your pharmacist how
your pharmacist
your pharmacist how
your pharmacist
your doctor , pharmacist or
your doctor , pharmacist
your doctor ,
your doctor ,
your doctor .
your doctor or pharmacist .
your doctor or pharmacist .
doctor or nurse
the doctor or nurse
your doctor or pharmacist
your doctor or pharmacist
your doctor or your pharmacist
doctor or
the doctor or
your doctor or your
your doctor or
your doctor or
to tell your doctor immediately
tell your doctor immediately if
tell your doctor immediately
, tell your doctor
doctor
for your doctor
tell your doctor
tell your doctor
the doctor
to tell your doctor
your doctor
your doctor
your blood pressure regularly
your blood pressure
your shunt and
your shunt
doctor
for your
tell your
to tell
your
of your ABILIFY tablets
your ABILIFY tablets
of your ABILIFY
your ABILIFY
of your
of your anaemia may
of your anaemia
your surgery .
your surgery
your individual situation
of your
of your
your immune
your
your doctor carefully before
your doctor
of your intestine removed .
your intestine removed .
of your intestine removed
your intestine removed
of your
your
jaundice , hepatitis ,
jaundice , hepatitis
jaundice ,
jaundice
Generally , children under
Generally , children
Generally ,
In the event
The following are the
Store in a refrigerator (
store in a refrigerator (
Store in a refrigerator
store in a refrigerator
In
In
At steady state
There was a
was a
Insulin requirements usually fall in
At steady
In the
In
Store
a
store
In 2 studies in healthy
In 2 studies
In 2
In subpopulation analyses
In subpopulation
In subpopulation
Studies in man suggest
Interaction studies have
In combination with a sulphonylurea
In combination with
In combination
In combination trials
Longer-term repeat
In placebo-controlled trials ,
In placebo-controlled trials
In placebo-controlled
In standard
In vitro studies
In the intravenous bolus studies
Animal studies could
Foetal growth restriction
Animal studies
In both studies ,
In both studies
In both
In the long-term studies ,
In the long-term studies
adipocytes ) that affects energy
When seen , it
Over the first 24 hours
Over the first
In the clinical studies ,
In the clinical studies
In the clinical
In most cases ,
In most clinical trials
In most clinical
In most of the
In most
In the four placebo-controlled studies
In the four placebo-controlled
In the four
If psychiatric illness
In the long-term
In the osteoporosis trials
In the
In
Over the
In the HORIZON Pivotal Fracture
In the HORIZON Pivotal
In the HORIZON
In the indication increasing
In the indication
Osteoporosis Osteoporosis
In PROactive , a
In PROactive ,
In PROactive
In the study of
In the study of elderly
The study
In the study of
The study
In the past ,
In the past
In the limited number of
In the limited number
In the limited
The second trial utilised
28 In the
In the
The
The advisability of driving should
These studies have shown
three placebo-controlled trials (
three placebo-controlled trials
three placebo-controlled trials ( n=
three placebo-controlled
In three
In an
In a haloperidol-controlled trial
In controlled clinical trials the
In controlled clinical trials
In a study
In another
In a small study
In a small study
In a small
In clinical trials in
In a clinical trial
In a clinical
In clinical trials
In a prospective ,
In a prospective
102 In a
20 In a
9 In a
In a
In one
In the
In
In some , but
In some ,
In some cases
In some
There were five short-term studies
In clinical trials
The following maintenance doses were
In clinical trials
The following maintenance doses
In clinical trials aripiprazole has
In clinical trials of aripiprazole
In clinical trials with aripiprazole
In clinical trials with pioglitazone
In clinical trials with
In clinical trials and
In clinical trials and
In clinical trials , an
In clinical trials , rare
In clinical trials ,
53 In clinical trials
58 In clinical trials
63 In clinical trials
In clinical studies ,
In clinical studies
In clinical trials of
In clinical trials
clinical trials
in clinical trials
53 In clinical
58 In clinical
63 In clinical
In clinical
clinical
in clinical
In active comparator controlled trials
In controlled clinical studies ,
In controlled clinical studies
In controlled clinical
In controlled
In several controlled studies
In several controlled
In several
In placebo-controlled studies ,
In placebo-controlled studies
In placebo-controlled
Foetal growth restriction
In animal studies , epoetin
In vitro studies have shown
In vitro studies have
In two large
In two
20 In
28 In
32 In
53 In
58 In
63 In
9 In
In the
In
Over
The
There
d In
studies
battery
indigo carmine
indication increasing
indication
indications .
other indications .
indications , and a
indications , and
indications ,
indications
other indications
main
Industrial Park Westhoughton BL5 3XX
Industrial Park Westhoughton BL5
Industrial Park Westhoughton
Industrial Park
Industrial
Industrie , 30-36 Avenue Gustave
Industrie , 30-36 Avenue
Industrie , 30-36
Industrie ,
Industrie
Infection , urinary tract
Infection , urinary
Infection
infection
upper respiratory tract infection (
upper respiratory tract infection
infection
infection including osteomyelitis , and
infection including osteomyelitis ,
infection including osteomyelitis
infection including
infection or
infections and
infection
infections
infiltration were observed .
infiltration were observed
infiltration were
Accumulation of triglycerides inside
Accumulation of triglycerides
information is
more information
more information
information is received
information is
information on
information
more information
information about some
information on the
information about
information about
information on
information
more information about
Be sure to tell your
Be sure to tell
Be sure to tell
If any of the
If any of
If any
137 Tell your doctor immediately
142 Tell your doctor immediately
147 Tell your doctor immediately
152 Tell your doctor immediately
157 Tell your doctor immediately
163 Tell your doctor immediately
169 Tell your doctor immediately
175 Tell your doctor immediately
Tell your doctor immediately
Tell your doctor immediately
Tell your doctor immediately
137 Tell
142 Tell
147 Tell
152 Tell
157 Tell
163 Tell
169 Tell
175 Tell
Be sure to
Be sure to
Be sure
Tell
If
Tell
infusion )
infusion
infusion .
infusion , becoming
infusion ,
infusion , becoming
infusion ,
infusion
infusion , or
infusion ,
infusion
infusion lasts for a year
infusion lasts for a
infusion lasts
infusion was approximately six
infusion was approximately
infusion was
infusion must be conducted
infusion must be
infusion must be
after
infusion of 5 mg Aclasta
infusion of 5 mg
infusion of 5
infusion of Aclasta (
infusion of Aclasta .
infusion of Aclasta
infusion of Aclasta , see
dose of Aclasta for
infusion of Aclasta ,
infusion of Aclasta
infusion of
infusion will
infusion two or more weeks
infusion two or more
infusion two or
infusion two
infusion , or
infusion ,
infusion
single infusion
the infusion
infusions of Abraxane
infusions of
infusions
infusion bag :
infusion bag
infusion bag
infusion time must not be
infusion time
solution for infusion ( drip
solution for infusion (
solution for infusion is
solution for infusion is
solution for infusion
infusion .
infusion
contents of the pack ABILIFY
contents of the pack Aclasta
contents of the pack Actos
contents of the pack ABILIFY
contents of the pack
contents of the pack
contents of the
contents
inhibitor of osteoclast-mediated bone resorption
inhibitor of osteoclast-mediated
inhibitor of
inhibitor
inhibitors of CYP3A4 (
inhibitors of CYP3A4 ,
inhibitors of CYP3A4
inhibitors of
inhibitors
dose
injection , intermediate-acting combined
injection , intermediate-acting
injection ,
injection .
injection : a maximum volume
injection : a
injection :
injection of the necessary amount
injection of the
before injection so
injection under the skin (
injection under the skin
injection under the
injection under
injection ,
injection
injections .
If convenient ,
If convenient
injections are given in
injections are given preferably
injections are given
injections in
injections
for injection ( 7.5
for injection (
solution for injection aripiprazole Intramuscular
solution for injection aripiprazole
Solution for injection Clear ,
Solution for injection Clear
solution for injection contains 10
solution for injection contains 1000
solution for injection contains 2000
solution for injection contains 3000
solution for injection contains 4000
solution for injection contains 5000
solution for injection contains 6000
solution for injection contains 7000
solution for injection contains 8000
solution for injection contains 9000
solution for injection contains
solution for injection than
solution for injection
Solution for injection in a
for injection in a
solution for injection in a
Solution for injection in
for injection in
solution for injection in
solution for injection is a
solution for injection is ready
solution for injection is
solution for injection
solution for injection
solution for injection should not
solution for injection should
solution for injection is given
solution for injection is
solution for injection
solution for injection
Solution for injection
for injection
solution for injection
solution for injection
solution for
needle .
needle top .
needle top
needle should be
needle
injection site within a
injection site
injection )
injection
injections .
injections Hydrochloric acid (
injections Hydrochloric acid
injections
5 Within each
Within each
Within each
Within 60 days of
An
Up to
5 Within
Up
Within
In particular , no
In particular ,
Overall , in the
Overall , in
Overall ,
instability ( irregular pulse or
instability ( irregular pulse
instability ( irregular
insulin ( human ) .
insulin ( human )
insulin ( human
insulin (
insulin , metformin )
insulin , metformin
insulin ,
insulin .
insulin
insulin 10 % and
insulin 10 %
insulin 10
insulin 20 % and
insulin 20 %
insulin 20
insulin 30 % and
insulin 30 %
insulin 30
insulin 40 % and
insulin 40 %
insulin 40
insulin 50 % and
insulin 50 %
insulin 50
insulin .
insulin
insulin in
insulin effectively
Insulin human , rDNA (
Insulin human , rDNA
Insulin human ,
human insulin .
insulin human .
Insulin human
human insulin
insulin human
insulin in combination with metformin
insulin in combination with
insulin in combination
insulin in
insulin or
insulin
insulin and 50 %
insulin and 50
insulin and 60 %
insulin and 60
insulin and 70 %
insulin and 70
insulin and 80 %
insulin and 80
insulin and 90 %
insulin and 90
insulin and isophane ( NPH
insulin and isophane (
insulin and isophane
insulin and pioglitazone
insulin and
insulin
insulin to control the
insulin to control
Insulin zur
insulin to
Insulin
included insulin .
included insulin
insulin ,
insulin
on insulin
insulin suspensions for injection .
insulin suspensions for injection
insulin suspensions for
insulin suspensions
method of
method
( if present ) has
first trimester
insulin requirement may be
insulin requirement is
both decrease and increase
insulin requirement
Insulins and analogues for injection
Insulins and analogues for
Insulins and
Insulins
insulin products with fast
insulin products are therefore affected
insulin products ,
insulin products
insulin resistance
insulin resistance .
insulin resistance
insulin resistance .
insulin resistance
insulin sensitivity .
insulin sensitivity
increasing insulin sensitivity .
increasing insulin sensitivity
insulin sensitivity
insulin syringes with a corresponding
insulin syringes with a
insulin syringes with
insulin syringes
Insulin suspensions are not to
Insulin suspensions should not
Insulin suspensions are never to
Insulin suspensions are
Insulin suspensions should
Insulin suspensions
insulin therapy
type or brand of
receptors
interactions resulting from displacement of
spezifische Interaktionsstudien bestätigt , in
spezifische Interaktionsstudien bestätigt , in
spezifische Interaktionsstudien bestätigt ,
spezifische Interaktionsstudien bestätigt
International Unit ) corresponds to
International Units ( IU )
international units ( IU )
International Units ( IU
international units ( IU
International Units (
international units (
International Units
international units
International Unit ) corresponds to
International Unit )
International Unit
International
international
vital
intoxication with Aclasta .
intoxication with Aclasta
intoxication with
intoxication
Intravenously administered zoledronic acid
Intravenously administered
Intravenously
Intravenous injection : over
incidence (
incidence of EPS was
incidence of EPS
incidence of
event rate event rate
incidence of
incidence
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS
Ireland BRISTOL-MYERS SQUIBB
Ireland BRISTOL-MYERS
Ireland Limited Tel : +353
Ireland Limited Tel :
Ireland Limited Tel
Ireland Limited
Ireland Novartis Ireland Limited Tel
Ireland Novartis Ireland Limited
Ireland Novartis Ireland
Ireland Novartis
Ireland Takeda UK Ltd Tel
Ireland Takeda UK Ltd
Ireland Takeda UK
Ireland Takeda
Ireland
iritis
Iserlohn , Germany
Iserlohn ,
Iserlohn Germany
Iserlohn
isophane ( NPH ) insulin
isophane ( NPH )
isophane ( NPH
isophane (
isophane
isophane insulin .
isophane insulin 50 %
isophane insulin 50
isophane insulin 60 % Actraphane
isophane insulin 60 %
isophane insulin 60
isophane insulin 70 % Actraphane
isophane insulin 70 %
isophane insulin 70
isophane insulin 80 % Actraphane
isophane insulin 80 %
isophane insulin 80
isophane insulin 90 % Actraphane
isophane insulin 90 %
isophane insulin 90
isophane insulin
If blood pressure
If
Italia Farmaceutici SpA Tel :
Italia Farmaceutici SpA Tel
Italia Farmaceutici SpA
Italia Farmaceutici
Italia Takeda Italia Farmaceutici SpA
Italia Takeda Italia Farmaceutici
Italia Takeda Italia
Italia Takeda
Italia
Italy
EACH SPECIES , ROUTE(S )
EACH SPECIES ,
EACH SPECIES
EACH
Jahr ) beobachtet
Jahr )
0 1 year )
0 1 year
0 2 year )
0 2 year
Jahr 5 % und 10
Jahr 5 % und
Jahr 5 %
Jahr 5
year after
year after
year or more .
year or more
year or longer .
year or longer
year or
treatment
Jahr
year
years ) No dose adjustment
years ) of
years )
years .
years Shelf-life after first opening
years Shelf-life after
years Shelf-life
have shown maintenance of this
years of age
years and
years and
years and over ) Aclasta
years and over )
years and over
years and over
years of
years
years ; the average duration
years ; the average
years ; the
years ;
years .
years
age
aged
years of age due
years of age
years
year
information or procedural aspects please
Japanese subjects .
Depending on how your
Depending on how
Depending on
Depending on
Each bottle with 100 ml
Each bottle with 100
Each bottle with
Each bottle
Each carton contains 1 bottle
Each carton contains 1
Each carton contains one single-use
Each carton contains
Each carton
Each orodispersible tablet contains 10
Each orodispersible tablet contains 15
Each orodispersible tablet contains 30
Each orodispersible tablet contains
Each orodispersible tablet
At
Each
Changes in strength ,
Changes in strength
Changes
Each ml of ABILIFY
Each ml of solution contains
Each ml of solution
Each ml of
However , elevated creatine
However
itching
itching , hives , swelling
itching , hives ,
itching , hives
itching ,
pruritus
pruritus
itching
pruritus
adolescents has not been studied
adolescents has not
adolescents has
adolescents under
2007
July 2007
European
achieved during the Coordination group
KG , Kuhloweg 37 ,
KG , Kuhloweg 37
KG , Kuhloweg
KG ,
KG Kuhloweg 37 D-58638 Iserlohn
KG Kuhloweg 37 D-58638
KG Kuhloweg 37 D-58638
KG Kuhloweg 37
KG Kuhloweg
KG
AND SIGHT
THE WORDS KEEP OUT OF
THE WORDS
SMALL IMMEDIATE PACKAGING UNITS
SMALL IMMEDIATE PACKAGING UNITS
SMALL IMMEDIATE PACKAGING
SMALL IMMEDIATE
SULPHONYLUREA Ear and labyrinth disorders
INSULIN Metabolism and nutrition disorders
Blood and lymphatic system disorders
Blood
INSULIN Metabolism
SULPHONYLUREA
OVERALL SUMMARY
potassium in
( hyperkalaemia
hyperkalaemia
potassium level
potassium
until hyperkalaemia has been corrected
until hyperkalaemia has been
calcium and
calcium twice a day for
calcium twice a day
calcium
hypocalcaemia
with hypocalcaemia
supplements
malabsorption ) .
malabsorption )
malabsorption
calcium
of calcium
take daily calcium supplements .
take daily calcium supplements
come into
( anencephaly
anencephaly
exposures
and carcinogenicity
carcinogenicity
testing did not
testing
Caucasian and 9 %
Caucasian and 9
This medicinal product
sugar lumps
keratoconjunctivitis sicca , madarosis
keratoconjunctivitis sicca ,
keratoconjunctivitis sicca
keratoconjunctivitis
, ketoacidosis (
ketoacidosis (
ketoacidosis , diabetic hyperosmolar coma
ketoacidosis , diabetic hyperosmolar
ketoacidosis ,
ketoacidosis or hyperosmolar coma or
ketoacidosis or hyperosmolar coma
ketoacidosis or hyperosmolar
ketoacidosis or
, ketoacidosis
ketoacidosis
ketoconazole )
ketoconazole or other
ketoconazole or
ketoconazole
acids
jaw have
kilogram .
kilograms .
kilogram bodyweight .
kilogram bodyweight
kilogram , three times a
kilogram ,
kilogram
kilograms
Irland.Lilly S.A. ,
Irland.Lilly S.A.
Kilruddery , County Wicklow .
Kilruddery , County Wicklow
Kilruddery , County
Kilruddery ,
Kilruddery
to the baby .
to the baby
child
Children and adolescents Aclasta is
Children and adolescents Aclasta
Children and adolescents
children under 30 kg
children under 30
children under
reach and sight of children
reach and sight
the reach and sight
anyone
children
reach
the reach
children over 30 kg and
children over 30 kg
children over 30
children over
children
children
children .
children
adult and paediatric patients :
paediatric and adult patients on
adult and paediatric
paediatric and adult patients
children and adolescents has not
children and adolescents has
children and adolescents under
children and
paediatric and
children below age 18 years
children below
children
in children
paediatric
Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD
Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS
Kingdom BRISTOL-MYERS SQUIBB
Kingdom BRISTOL-MYERS
Kingdom Takeda UK Ltd Tel
Kingdom Takeda UK Ltd
Kingdom Takeda UK
Kingdom Takeda
Kingdom
Clear , colourless , aqueous
Clear , colourless ,
Clear , colourless
Clear ,
Clear
class differs
liver cirrhosis
of liver cirrhosis
Clinical manifestations
Two-year clinical studies
Clinical efficacy in men In
Clinical efficacy in men
Clinical efficacy in the treatment
Clinical efficacy in the
Clinical efficacy in
Clinical efficacy
3.0 , 5.8
Clinical
Km 22 , 67019 Scoppito
Km 22 , 67019
Km 22 ,
Km 22
Km
bone .
has made their bones weaker
made their bones weaker
makes bones fragile )
makes bones fragile
makes bones fragile
bone and therefore makes it
bone and therefore makes
bone and
bone
bones
break .
break
bone tissue )
bone tissue
bone .
bone
are bone
bone
bone marrow fibrosis of
bone marrow
or woven bone formation
Bone marrow suppression (
bone marrow cells
mineral density ( BMD )
mineral density ( BMD
mineral density (
density
bone resorption .
bone resorption
bone .
bone Aclasta was
bone Aclasta
bone
bone .
bone
bone
mineral metabolism must also
mineral metabolism must
mineral metabolism
bone
of bone
bone remodelling process
bone remodelling
turnover markers .
turnover markers
repeated annual dosing .
repeated annual dosing
repeated annual dosing
bone turnover
of bone turnover
changed
carbohydrate chains are
carbohydrate chains
plunger
coma or death
coma or
coma ,
coma
a combination of
a combination
combination with insulin ,
combination with insulin
combination with metformin and/ or
combination with metformin
combination with sulphonylureas or
combination with sulphonylureas
combination with a sulphonylurea
combination with
combination of Actos and insulin
combination of Actos and
combination of Actos
combination of metformin and
combination of metformin
combination of
, combination of
, combination
combination of
combination
combination
combination therapy ( see section
combination therapy ( see
combination therapy (
combination therapy
authorisation valid throughout the European
complications
Conjunctivitis , eye pain Uveitis
Conjunctivitis , eye
Conjunctivitis ,
Conjunctivitis
contacts
contraeptives , thiazides , glucocorticoids
contraeptives , thiazides ,
contraeptives , thiazides
contraeptives ,
contraeptives
Kontrazeptivums mit einer ng Ethinylestradiol/Levonorgestrel-Kombination
Kontrazeptivums mit einer ng
Kontrazeptivums mit einer
Kontrazeptivums mit
Kontrazeptivums
control .
your liver is working normally
is controlled .
is controlled
control of agitation and
control of agitation
control of
control
controlled
controls ( 95 % CI
controls (
controls .
controls
Your
Controlled clinical trials have not
Conventional types of paclitaxel contain
Conventional types of paclitaxel
Conventional types of
Conventional types
Conventional
observed in
observed
convulsions
(
.
level of a substance
level of a
concentrations and protein binding
concentrations and
concentration
concentrations
level
concentrations , aripiprazole and
concentrations , aripiprazole
concentrations ,
concentrations
headache
headache ( 5.1 % )
headache ( 5.1 %
headache ( 5.1
headache (
headache , akathisia ,
headache , akathisia , nausea
headache , akathisia
headache , dysgeusia , dizziness
headache , dysgeusia ,
headache , dysgeusia
headache , tiredness ,
headache , tiredness , nausea
headache , tiredness
headache ,
headache in the
headache in
headache
headache Eye disorders Common :
headache Eye disorders Common
headache Eye disorders
headache Eye
headache in the
headache in
headache
correction of your anaemia may
correction of your anaemia
correction of your
correction
corticosteroids .
corticosteroids
dentistry
Seizure : in clinical trials
Seizure : in clinical
Seizure : in
Seizure :
Seizure
Therapy
stopped . du
stopped
seizure
stopped
hospital and take
hospital and
hospital
hospital as
hospital
disease in which the
disease in which
condition may also
condition may
Committee
Committee
condition
disease has
disease
disease progression [ 95 %
disease progression [ 95
disease progression [
disease progression
Creatine Phosphokinase ) , generally
Creatine Phosphokinase ,
Creatine Phosphokinase
creatinine and potassium in
creatinine and
creatinine
Phosphokinase ) , generally
) ,
anticancer agents .
anticancer agents
anticancer
treatments
dental examination
dental examination
dental
cancer cells to break down
cancer cells to
cancer cells
systemic circulation
should be commenced because of
shock-like
crisis with encephalopathy-like symptoms (
crisis with encephalopathy-like symptoms
crisis with
crisis
Kuhloweg 37 , D-58638 Iserlohn
Kuhloweg 37 , D-58638
Kuhloweg 37 ,
Kuhloweg 37 D-58638 Iserlohn Germany
Kuhloweg 37 D-58638 Iserlohn
Kuhloweg 37 D-58638 Iserlohn
Kuhloweg 37 D-58638
Kuhloweg 37 D-58638
Kuhloweg 37
Kuhloweg
( cycloolefinic polymer )
( cycloolefinic polymer )
( cycloolefinic polymer
( cycloolefinic
cycloolefinic
shortness of breath or rapid
( 24-hour )
( 24-hour
( 24-hour
( 24-hour
(
coldness , orthostatic hypotension Rare
coldness , orthostatic hypotension
coldness , orthostatic
coldness ,
coldness
Kingdom .
Kingdom
body does not produce enough
body does not
body
body fat distribution on pioglitazone
body fat distribution on
metre
bodyweight ( 1 ml
bodyweight ( 1
bodyweight (
body weight .
BW 120 ml : 22
BW 120 ml :
BW 120 ml
BW 120
BW 210 ml : 40
BW 210 ml :
BW 210 ml
BW 210
body weight in kilograms .
body weight in kilograms
range
body weight in
body weight 2 times
BW
body weight
bodyweight
kg bodyweight results
kg bodyweight
body weight of the
body weight
gradation in
gradation
height
Paget
body
Store and transport refrigerated (
Store and transport refrigerated
Store and transport refrigerated (
Store and transport refrigerated
Store
in a refrigerator ( 2°C
in a refrigerator (
refrigerate . This
refrigerate .
in a refrigerator
refrigerate
refrigerator
LHRH agonist and this
LHRH agonist and this
LHRH agonist and
LHRH agonist
Another LHRH agonist
LHRH agonist and
LHRH agonist
LTD Tel : + 353
LTD Tel : + 44
LTD Tel : +
LTD Tel :
LTD Tel
LTD Tlf : + 47
LTD Tlf : +
LTD Tlf :
LTD Tlf
LTD
Laboratoires Takeda Tél : +33
Laboratoires Takeda Tél :
Laboratoires Takeda Tél
Laboratoires Takeda
Laboratoires
laboratory parameters revealed no
laboratory parameters revealed
laboratory parameters
laboratory parameters
ACOMPLIA has not
Laboratory tests did not show
Laboratory tests did
Laboratory tests
test values .
test values
lapp lactase deficiency or glucose-galactose
lapp lactase deficiency or
lapp lactase deficiency
Lactose : patients with
Lactose : patients
Lactose :
Lactose
What Actos looks like
What Actos looks
What
lactose monohydrate and
Lactose monohydrate Maize
lactose monohydrate
lactose monohydrate
storage
storage conditions .
storage conditions
For storage conditions of the
lactation .
lactation or lay
lactation or
lactation or
lactation
Lancaster Way Wingates Industrial Park
Lancaster Way Wingates Industrial
Lancaster Way Wingates
Lancaster Way
Lancaster
74-week extension
long-term use of Actos .
long-term use of Actos
long-term use of
long-term use
Long-term carcinogenicity studies have not
Long-term carcinogenicity studies have
Longer-term repeat
studies ,
studies
Long Term
achieve androgen
to achieve androgen
Keep the
Keep
Latvij Tel : +371 7364000
Latvij Tel : +371
Latvij Tel :
Latvij Tel
Latvij
Latvija Eli Lilly Holdings Limited
Latvija Eli Lilly Holdings
Latvija Eli Lilly
Latvija Eli
Latvija
Lda Tel : + 351
Lda Tel : +
Lda Tel :
Lda Tel
Lda
lifestyle
liver ,
liver
a problem with
with
hepatic impairment on the pharmacokinetics
hepatic impairment on the
hepatic impairment on
hepatic impairment
with
liver disease .
liver disease
liver
hepatic impairment No dose adjustment
hepatic impairment may
hepatic impairment should not
hepatic impairment should
hepatic impairment
( bilirubin > 5
( bilirubin >
( bilirubin
impaired liver function .
has impaired liver function .
has impaired liver function
impaired liver function .
impaired liver function
hepatic impairment : no dosage
hepatic impairment : no
hepatic impairment :
hepatic impairment
liver microsomes and tissue
microsomes and tissue
liver problems
lay
Read all of
, lethargy , hyperpyrexia
leukopenia
does not affect leucopoiesis .
does not affect leucopoiesis
Lietuva Eli Lilly Holdings Limited
Lietuva Eli Lilly Holdings
Lietuva Eli Lilly
Lietuva Eli
Lietuva
Lilly Finland Ab Puh/ Tel
Lilly Finland Ab
Lilly Finland
Lilly Holdings Limited Eesti filiaal
Lilly Holdings Limited Eesti
Lilly Holdings Limited p rst
Lilly Holdings Limited p
Lilly Holdings Limited
Lilly Holdings
Lilly Portugal - Produtos Farmacêuticos
Lilly Portugal - Produtos
Lilly Portugal -
Lilly Portugal
Lilly farmacevtska dru ba
Lilly farmacevtska dru
Lilly farmacevtska dru
Lilly
Limited Eesti filiaal Tel :
Limited Eesti filiaal Tel
Limited Eesti filiaal
Limited Eesti
Limited Tel : +353 1
Limited Tel : +353
Limited Tel :
Limited Tel
Limited West Forest Gate Wellington
Limited West Forest Gate
Limited West Forest
Limited West
Limited Wimblehurst Road Horsham West
Limited Wimblehurst Road Horsham
Limited Wimblehurst Road
Limited Wimblehurst
Limited atstovyb Tel . +370
Limited atstovyb Tel .
Limited p rst vniec ba
Limited p rst vniec
Limited p rst
Limited p
Limited
Linear Analogue Scale ( CLAS
Linear Analogue Scale (
Linear Analogue Scale
Linear
stimulate red blood cell
stimulate red
stimulate
uptake of dietary lipids .
uptake of dietary lipids
uptake
literature
lithium (
lithium or valproate
lithium or
lithium
with lithium .
with lithium
lithium concentrations .
lithium concentrations
tooth .
tooth
London , WC2B 4AE ,
London , WC2B 4AE
London , WC2B
London ,
London WC2B 4AE United Kingdom
London WC2B 4AE United
London WC2B 4AE
London WC2B
London
lorazepam (
of lorazepam (
lorazepam
of lorazepam
arm
reference arm
solution for injection
solution for injection
solution for injection
Ltd , 61 Aldwych ,
Ltd , 61 Aldwych
Ltd , 61
Ltd ,
Ltd 61 Aldwych London WC2B
Ltd 61 Aldwych London
Ltd 61 Aldwych
Ltd 61
Ltd Tel : + 44
Ltd Tel : +
Ltd Tel :
Ltd Tel
Ltd commits to provide
Ltd commits to
Ltd
Lucien Pharma Tél : +
Lucien Pharma Tél :
Lucien Pharma Tél
Lucien Pharma
Lucien
pulmonary embolism ) .
pulmonary embolism )
pulmonary embolism
pulmonary
pneumonia ,
pneumonia
pneumonia ,
pneumonia
agonists ( LH-RHas )
agonists ( LH-RHas
Luxembourg/ Luxemburg BRISTOL-MYERS SQUIBB BELGIUM
Luxembourg/ Luxemburg BRISTOL-MYERS
Luxembourg/ Luxemburg Novartis Pharma GmbH
Luxembourg/ Luxemburg Novartis Pharma
Luxembourg/ Luxemburg Novartis
Luxembourg/ Luxemburg Takeda Global R
Luxembourg/ Luxemburg Takeda Global
Luxembourg/ Luxemburg Takeda
Luxembourg/ Luxemburg
Lymphopenia was observed in 45
Lymphopenia was observed in
Lymphopenia was observed
Lymphopenia
chromosome aberrations
lymphoedema
solution (
solution .
solution contains 0.05 mg
solution contains 0.05
solution contains 10 000 IU
solution contains 10 000
solution contains 10
solution contains 2000 IU
solution contains 2000
of solution contains 5 mg
of solution contains 5 mg
solution contains 5 mg
of solution contains 5
of solution contains 5
solution contains 5
of solution contains
of solution contains
solution contains
solution should be
solution
solution has been accidentally frozen
solution has been accidently frozen
unused amount .
unused amount
oral solution for dogs
oral solution for
oral solution
oral solution .
oral solution 150 ml
oral solution 150
oral solution 480 ml
oral solution 480
Oral solution Clear ,
Oral solution Clear
oral solution contains 200
oral solution contains methyl parahydroxybenzoate
oral solution contains
oral solution is a
oral solution is
oral solution must be
oral solution
oral solution
, the oral solution
oral solution
oral solution
the oral solution
Oral solution
of solution
of solution
solution
DEHP-free
M-II , M-III , and
M-II , M-III ,
M-II is minimal .
M-II is minimal
M-II
M-III
M-IV ) .
M-IV )
M-IV
gluteus
MAOI ) ,
MAOI )
MAOI
METFORMIN AND SULPHONYLUREA
METFORMIN AND
METFORMIN
MINIMUM PARTICULARS TO APPEAR ON
MINIMUM PARTICULARS TO APPEAR
PARTICULARS TO APPEAR ON
MINIMUM PARTICULARS TO
MINIMUM PARTICULARS
PARTICULARS TO
WITH BLUE BOX ) AND
WITH BLUE BOX )
WITH BLUE BOX
WITH BLUE
Ear and labyrinth disorders
and nutrition disorders
WITH METFORMIN AND SULPHONYLUREA
WITH METFORMIN AND
WITH METFORMIN
and lymphatic system disorders
WITH
MEMBER STATES
MEMBER
NMS is a
NMS is
NMS are
NMS
MTP ) .
MTP )
MTP
macrogol 3000
macrogol
madarosis Eye disorders :
madarosis Eye disorders
madarosis
Madrid ) Spain
Madrid )
Madrid
food .
food
magnesium stearate , yellow
magnesium stearate ,
magnesium stearate .
of the pack
pack
the pack
magnesium stearate
of the pack
pack
stearate
the pack
Magyarország OncoEurope Tel . :
Magyarország OncoEurope Tel .
Magyarország OncoEurope Tel
Magyarország OncoEurope
Magyarország
meal or unplanned ,
meal or unplanned
meal or
fat meal
meal
maize starch , microcrystalline
maize starch ,
starch Microcrystalline cellulose Hydroxypropyl cellulose
maize starch
starch Microcrystalline cellulose
Neuroleptic Malignant Syndrome ( NMS
Neuroleptic Malignant Syndrome (
Neuroleptic Malignant Syndrome
Neuroleptic
Malta Takeda Italia Farmaceutici SpA
Malta Takeda Italia Farmaceutici
Malta Takeda Italia
Malta Takeda
Malta
breast cancer
droplets
Management
deficiency or
deficiency
mania
Manic episodes
Manic
Mannitol , sodium citrate and
mannitol , sodium citrate and
Mannitol , sodium citrate
mannitol , sodium citrate
Mannitol ,
mannitol ,
Mannitol
mannitol
brand ( manufacturer ) ,
brand ( manufacturer )
brand ( manufacturer
, recovered label
recovered label
marker
marker
avoid
avoid
machines .
machinery
machines , until you
machines until you
machines , until
machines until
machines if you
machines if
machines
use machines have been observed
use machines have
use machines have
machines
pharmacies
Maternal toxicity
maximum volume of 1 ml
maximum volume of 1
maximum volume of
maximum volume
peak is always well below
peak is always well
peak is always
peak
a lesser degree .
a lesser degree
measures will help to
measures will help
measures will help
measures
measures should help to
measures are being taken to
, to treat
,
measures are being
case of overdose .
in case of overdose .
case of overdose
in case of overdose
weight management programme ,
weight management programme ,
weight management programme
weight management programme
pharmacovigilance activities
measures in order to
management
management
,
management
measures in order
measures in
measures should
measures
Medice Arzneimittel Pütter GmbH &
Medice Arzneimittel Pütter GmbH
Medice Arzneimittel Pütter
Medice Arzneimittel
Medice
your doctor :
your doctor
medications
nephrotoxic medications
majority of the side effects
majority of patients received a
majority of patients received
majority of reported cases
majority of reported
majority of the
majority of
majority of these symptoms
majority of these symptoms were
majority of these symptoms
majority of these
majority
mellitus ( see section 4.4
mellitus ( see section
mellitus ( see
mellitus (
Mellitus : hyperglycaemia , in
mellitus : hyperglycaemia , in
Mellitus : hyperglycaemia ,
mellitus : hyperglycaemia ,
Mellitus : hyperglycaemia
mellitus : hyperglycaemia
mellitus :
mellitus
NSAIDs
amount
menopause ,
menopause
to reproduction .
to reproduction
contraindicated during
in humans is unclear and
in humans is
People with this condition may
People with this condition
People with this
People with
humans . dic
People
ausgeschieden
human
humans .
in humans
Product Characterisitics , Section
Product Characteristics , section
Product Characterisitics ,
Product Characteristics ,
Product Characteristics
Product Characterisitics
Product Characteristics
Product
features and with or without
features and with or
features and with
features and
features
measuring cup and a
measuring cup and
measuring cup
in rating scales
Aclasta
, orchidectomy
orchidectomy
result
Metabolism Human
metabolite M-III contribute equally to
metabolite M-III
metabolite
metabolites , 3
minor metabolites , 3
metabolites ,
metabolites
minor metabolites ,
minor metabolites
metabolites .
metabolites 6 -hydroxypaclitaxel and 3
metabolites 6 -hydroxypaclitaxel and
metabolites 6 -hydroxypaclitaxel
metabolites 6
metabolites bind very extensively
metabolites is catalysed
metabolites is catalysed by CYP2C8
metabolites is catalysed by
metabolites is catalysed
metabolites .
metabolites
metabolites are extensively
metabolites are active ( M-II
metabolites are active (
metabolites are active
metabolites are
metabolites ,
metabolites
minor metabolites ,
minor metabolites
metacresol , which
Metacresol Phenol
metastases
metastases .
of metastases .
sites of metastases .
metastases
of metastases
sites of metastases
metformin ) were 2 5
metformin ) were
metformin ) .
metformin )
metformin , gliclazide )
metformin , gliclazide
metformin ,
metformin in patients ( particularly
metformin , in patients (
metformin in patients (
metformin , in patients
metformin in patients
metformin , in
metformin in
metformin and a sulphonylurea
metformin or
metformin and /
metformin and gliclazide .
metformin and gliclazide
metformin and a sulphonylurea ,
metformin and a sulphonylurea
metformin and
metformin and/ or a sulphonylurea
metformin and/ or
monotherapy with metformin
metformin ,
metformin and
metformin
Methyl parahydroxybenzoate ( E218 )
methyl parahydroxybenzoate ( E218 )
Methyl parahydroxybenzoate ( E218
methyl parahydroxybenzoate ( E218
Methyl parahydroxybenzoate (
methyl parahydroxybenzoate (
methyl parahydroxybenzoate and
Methyl parahydroxybenzoate
methyl parahydroxybenzoate
denen Midazolam ( CYP3A4-Substrat )
denen Midazolam ( CYP3A4-Substrat
denen Midazolam (
denen Midazolam
Middlesex UB8 1HU - United
Middlesex UB8 1HU -
Middlesex UB8 1HU
Middlesex UB8 1HU - United
Middlesex UB8 1HU -
Middlesex UB8
Middlesex
8 tomography ( CT )
8 tomography ( CT
micrograms epoetin alfa
micrograms epoetin
micrograms
Microcrystalline cellulose Aspartame ( E951
Microcrystalline cellulose Aspartame (
Microcrystalline cellulose Aspartame
Hydroxypropyl cellulose Magnesium stearate
Microcrystalline cellulose
Hydroxypropyl cellulose
Microcrystalline
Glycerin Lactic acid Methyl parahydroxybenzoate
Glycerin Lactic acid
women who are breast
women
At least one new
At least one
mineral metabolism must also be
mineral metabolism must also
mineral metabolism must also
mineral metabolism must
minute
minutes ) .
minutes )
minutes .
minutes , every three weeks
minutes , every three
minutes , every
minutes .
minutes
15-minute infusions of 2
15-minute infusions of
minutes every 3 weeks .
minutes every 3 weeks
minutes
be followed
minutes .
minutes
minutes ,
minutes caused
minutes
mixture of dissolved insulin and
mixture of dissolved insulin
mixture of dissolved
mixture
malformations ( see section
malformations ( see
malformations (
malformations and death in utero
malformations and
malformations
Owing to the
Owing to
Iron supplementation should be
Iron supplementation
With their skeleton still
Member States shall
STATES
mitosis .
mitosis
mitratapide ( parent
mitratapide (
Mitratapide 5 mg/ ml
Mitratapide 5
Mitratapide also has a
Mitratapide also has
mitratapide versus placebo
mitratapide versus
mitratapide
Mitratapide is
mitratapide or
mitratapide .
mitratapide
Mitratapide and its
Mitratapide and
mitratapide has not been investigated
mitratapide has not been
, mitratapide
Mitratapide
mitratapide ,
mitratapide
mitratapide/ kg bodyweight results
mitratapide/ kg bodyweight
mitratapide/
kg
constipating
apparent molecular weight of erythropoietin
apparent molecular weight of
molecule contributes about 58 %
molecule contributes about 58
molecule
month ) with
month )
month , or if the
month , or if
month , or if the
month , or if
month , or
month ,
month
month and should not exceed
month after
month or the
month or
month
months ( 300 mg/ m2
months ( 300
5.3 months (
months (
months ) .
months ) and 6.1 months
months ) and 6.1
months ) and
months )
months Use product immediately
months Use product
months Use
months when stored between
a PSUR at
provide a PSUR at
months
months after treatment
months after
at
months
months ago
months
. if
if
that month .
month before your
the month before your
month before
the month before
month
that month
the month
monoamine oxidase inhibitors ( MAOI
monoamine oxidase inhibitors (
monoamine oxidase inhibitors
Actos looks like
Actos looks
45 mg monotherapy
treatment with aripiprazole alone .
treatment with aripiprazole alone
than lithium or valproate monotherapy
control despite maximal tolerated dose
monotherapy
monotherapy or combination therapy (
monotherapy or combination therapy
monotherapy or
monotherapy was
administered alone
monotherapy
type 2 diabetes mellitus :
Montgomery-Asberg
Paget s disease 6 months
Paget s disease 6
27 Paget s disease The
Paget des
Paget s disease of the
Paget s disease of the
Paget s disease of the
Paget s disease Aclasta may
27 Paget s disease
Paget s disease ,
Paget s disease
Paget s disease
Paget s disease
mortality : in three placebo-controlled
mortality : in
in mortality in this study
in mortality in this study
in mortality in this
in mortality in
mortality
of death when administered
risk of death and
of death and
of death
marrow suppression
mouth ,
mouth .
mouth
Vascular disorders Uncommon : orthostatic
Vascular disorders Uncommon :
Vascular disorders Uncommon
Vascular disorders
;
dry mouth
for muscarinic receptors .
nurse
spasms
, muscle pain
muscle pain
Mutagenicity and
Mutagenicity
bacterial and mammalian cell
bacterial
mother
parent substance
parent
myalgia (
Myalgia occurred in 24 %
Myalgia occurred in 24
Myalgia occurred in
Myalgia occurred
Myalgia
myalgia
from myelosuppression
myelosuppression
from myelosuppression
myelosuppression
profound myelosuppression
myoglobinuria ( rhabdomyolysis ) ,
myoglobinuria (
myoglobinuria
myocardial infarction and approximately 20
myocardial infarction and approximately
myocardial infarction and
myocardial infarction
of myocardial infarction
infarction , cerebrovascular accidents (
infarction , cerebrovascular accidents
men
men ( study CZOL446M2308 )
men ( study CZOL446M2308
men ( study
men (
men )
men )
men )
men .
men In the
men In
male patients ( see section
male patients ( see sections
male patients ( see
male patients (
male patients
men with
men and women
men and Paget s disease
men and
among men and women
among men and
among men
2,127 men
men ,
men
Male patients should seek
Male patients should
Male patients
Male
Male patients
Male patients
Male
mouse spleen cell
mice .
mice
Potential for ABILIFY to affect
Potential for other medicinal products
Potential for other medicinal
Potential for
Only a few
Only
Only
risk of pregnancy .
risk of pregnancy
risk of
possibility of multiple medicinal
possibility of
possibility of
possibility
risk
tiredness , feeling dizzy or
tiredness , feeling dizzy
tiredness , feeling dizzy or
tiredness , feeling dizzy
tiredness ,
tiredness , nausea , vomiting
tiredness , nausea ,
tiredness , nausea
at the start of treatment
tiredness
Package Leaflet .
Package
Package
Package
N = 225 ) ,
N = 225 )
N = 225
N = 229 ) .
N = 229 )
N = 229
N = 30 ) .
N = 30 )
N = 30
N =
N
N-dealkylation .
N-dealkylation is catalysed by CYP3A4
N-dealkylation is
N-dealkylation
N-terminal
152 post- menopausal
152 post-
152
in 152 post- menopausal
in 152 post-
in 152
iliac crest
iliac crest
BY WEIGHT , BY VOLUME
BY WEIGHT , BY
BY WEIGHT , BY
BY WEIGHT
NAME AND ADDRESS OF THE
AND ADDRESS
REACH AND SIGHT OF CHILDREN
REACH AND SIGHT OF
MATERIALS DERIVED FROM SUCH MEDICINAL
MATERIALS
REACH
NORWAY LTD Tlf : +
NORWAY LTD Tlf :
NORWAY LTD Tlf
NORWAY LTD
NORWAY
NPH ) insulin .
NPH ) insulin
NPH )
NPH
THE WEEK
NYHA stages I to IV
NYHA stages I to
NYHA stages I
At two years ,
At two years
At 24 months
At 24
These symptoms can temporally
These symptoms can temporally
Upon discontinuation of potent CYP3A4
Upon discontinuation of
97 Upon discontinuation of the
Upon discontinuation of the
97 Upon discontinuation
Upon discontinuation
After administration of epoetin alfa
After administration of epoetin
After administration of
After administration
Following initiation of therapy with
Following initiation of therapy
Following initiation of
Following initiation
After injection of the
After injection
There have been cases
There have been
When reconstituted , Abraxane contains
When reconstituted ,
When reconstituted
Once opened ,
Once opened ,
Once opened
At the menopause ,
At the menopause
After reconstitution ,
After reconstitution
administration
following the administration
the administration
administration
following the administration
the administration
After first reconstitution ,
After first reconstitution
After first
After
At the
After a single treatment
After a single
Following concomitant administration
Following concomitant
Following intravenous administration of Abraxane
Following intravenous administration of
Following intravenous administration
Following intravenous
After each dose ,
After each dose
Following any confirmed or suspected
After each
Following multiple
Following oral administration of
Following oral administration
Following oral administration ,
Following oral administration
Following oral
Following subcutaneous injection ,
Following subcutaneous injection
Following subcutaneous
Based on information available to
At two
After multiple
After
At
Following
after
After opening the bottle ,
After opening the bottle
After opening the
After opening
extended follow-up
observation study
observation
treated with gliclazide , compared
is presented in Table 3.
presented in Table 3.
is presented in
is presented
presented in
presented
needle quickly and apply pressure
needle quickly
needle
food .
food
food with
of food with
food
of food
food and drink :
food and drink
fatty foods . du
fatty foods
Name and address of
Name and address of
state the name and address
Name and address of the
Name and address
Name and address
and address
Name and
name and
Name
name
nanoparticle
in
sinus
sodium per dose .
sodium per dose
sodium per
sodium
sodium chloride , glycine ,
sodium chloride , glycine
sodium chloride ,
Sodium chloride Glycine Polysorbate 80
Sodium chloride Glycine
Sodium chloride
chloride
sodium chloride
sodium citrate and water for
sodium citrate and water
sodium citrate and
sodium citrate
dihydrogen phosphate
dihydrogen
ra Tablet core :
ra Tablet core
ra Tablet
ra
ra
Disodium edetate Fructose
Sodium hydroxide ( for pH-adjustment
sodium hydroxide ( for pH-adjustment
Sodium hydroxide (
sodium hydroxide (
sodium hydroxide , sucrose
sodium hydroxide ,
Sodium hydroxide Sucrose Purified water
Sodium hydroxide Sucrose Purified
Sodium hydroxide Sucrose
hydroxide Water for injection
Sodium hydroxide
hydroxide
sodium hydroxide
nausea ( feeling sick
sick
adrenal
adenomas/ carcinomas in female rats
parathyroid reserve , intestinal calcium
diminished parathyroid reserve ,
parathyroid reserve ,
diminished parathyroid reserve
parathyroid reserve
parathyroid
adverse reaction
adverse
an adverse reaction
effect
adverse reactions ( * )
side effects ( affecting 10
side effects ( affecting less
side effects ( affecting
side effects (
Adverse reactions
Nebenwirkungen , die aus
Adverse reactions
Nebenwirkungen , die
side effects , such as
Adverse reactions
Nebenwirkungen ,
side effects ,
adverse reactions related to
adverse reactions
adverse reactions
adverse reactions in
please
notice
notice
cause side effects ,
side effects with Actos are
side effects with
side effects
effects related to the
effects related to
side effects have
undesirable effects occurred more often
undesirable effects occurred
undesirable effects occurred
undesirable effects occurred
more common at the start
be more common
may be more common
more common
can cause side effects .
can cause side effects
can cause side effects .
can cause side effects
cause side effects such as
cause side effects
side effects with Aclasta tend
side effects with Aclasta
side effects with
side effects
adverse reactions were
Nebenwirkungen
adverse reactions
adverse
effects
reduce side effects
side effects
Nederland BRISTOL-MYERS SQUIBB BV Tel
Nederland BRISTOL-MYERS SQUIBB BV
Nederland BRISTOL-MYERS SQUIBB
Nederland BRISTOL-MYERS
Nederland
Always take ABILIFY
Always take the tablet
Always take the
Do not take a
Do not take
Always take
Always take
touch ) ,
central nervous system (
nervous system (
Nervensystem zu finden
nervous system
nervous
Nervous
nerve cells in the brain
nerve cells in the
nerve cells
nervousness ; suicide attempt ,
nervousness ; suicide attempt
nervousness
hives , swelling and inflammation
hives , swelling and
site within a given area
hives , swelling
hives ,
site within a
hives
microtubule network
emergence of such
emergence of
and unspecified ( including cysts
and unspecified ( including
neuralgia , sensory loss
neuralgia , sensory
neuralgia
Malignant Syndrome ( NMS
Malignant Syndrome (
Malignant Syndrome
neuropathy , ataxia , sensory
neuropathy , ataxia ,
neuropathy , ataxia
neuropathy , hypoaesthesia , paraesthesia
neuropathy , hypoaesthesia ,
neuropathy , hypoaesthesia
neuropathy , headache , dysgeusia
neuropathy , headache ,
neuropathy , headache
neuropathy , neuropathy , hypoaesthesia
neuropathy , neuropathy ,
neuropathy , neuropathy
neuropathy ,
neuropathy Fast improvement in blood
neuropathy , additional
neuropathy ,
neuropathy
Neurotoxictiy to paclitaxel
Neurotoxictiy to
neurotoxicity
neurotransmitters ,
neurotransmitters
neutropenia (
primarily neutropenia )
neutropenia or severe sensory neuropathy
neutropenia or severe sensory
neutropenia or severe
neutropenia or
neutropenia occurred in four
neutropenia occurred in
neutropenia occurred
Neutropenia was the most
Neutropenia was
Neutropenia
neutropenia
, a type of
, a type
, a
,
neutrophils recover to > 1.5
neutrophils recover to >
neutrophils recover to
vorgenommen werden
Do not give by injection
Do not use in dogs
Do not use in dogs
Do not use in dogs
Do not use in dogs
Do not use in case
Do not use in
Do not use in
Do not use
Do not use
Do not give by injection
Do not refrigerate .
Do not refrigerate
Do not store them in
Do not
Any unused product
Any unused
Any
Do not
not including braille accepted
not including braille
non-cancer cells
and healthy diet Key
non-smoking
There
kidneys .
kidneys
kidney have
kidney have
kidney
renal or hepatic dysfunction on
renal or hepatic dysfunction
kidney disease
or additional risk factors (
compromise or additional risk factors
or additional risk factors
compromise or additional
or additional
compromise or
or
kidney
significantly impact renal function (
significantly impact renal function
can significantly impact renal function
significantly impact renal function
impaired renal function
renal function
Renal dysfunction
with renal insufficiency not yet
renal
with renal
renal impairment :
undergoing dialysis :
renal failure in paediatric and
renal failure in paediatric
renal failure in
renal insufficiency .
renal insufficiency
renal failure
renal impairment
renal
undergoing dialysis
with renal
kidney problems are not known
kidney
Adult patients with
Nordisk A/ S Novo Allé
Nordisk A/ S Novo
Nordisk A/ S
Nordisk
Norge AS Tlf : +47
Norge AS Tlf :
Norge AS Tlf
Norge AS
Norge BRISTOL-MYERS SQUIBB NORWAY LTD
Norge BRISTOL-MYERS SQUIBB NORWAY
Norge BRISTOL-MYERS SQUIBB
Norge BRISTOL-MYERS
Norge Novartis Norge AS Tlf
Norge Novartis Norge AS
Norge Novartis Norge
Norge Novartis
Norge Takeda Global R &
Norge Takeda Global R
Norge Takeda Global
Norge Takeda
Norge
normalisation
normal
normal
emergency procedures , antidotes )
emergency procedures , antidotes
emergency procedures ,
emergency procedures
Novartis Europharm Limited Wimblehurst Road
Novartis Europharm Limited Wimblehurst
Novartis Europharm Limited
Novartis Europharm
Novartis Farma - Produtos Farmacêuticos
Novartis Farma - Produtos
Novartis Farma -
Novartis Farma
Finland Novartis Finland Oy
Finland Novartis Finland
Novartis Healthcare A/ S Tlf
Novartis Healthcare A/ S
Novartis Healthcare
Novartis Ireland Limited Tel :
Novartis Ireland Limited Tel
Novartis Ireland Limited
Novartis Ireland
Novartis Norge AS Tlf :
Novartis Norge AS Tlf
Novartis Norge AS
Novartis Norge
Novartis Pharma GmbH Roonstraße 25
Novartis Pharma GmbH Roonstraße
Novartis Pharma GmbH Tel :
Novartis Pharma GmbH Tel
Novartis Pharma GmbH Tél/ Tel
Novartis Pharma GmbH
Novartis Pharma
Novartis Sverige AB Tel :
Novartis Sverige AB Tel
Novartis Sverige AB
Novartis Sverige
Novartis
Novo Allé DK-2880 Bagsværd Denmark
Novo Allé DK-2880 Bagsværd
Novo Allé DK-2880
Novo Allé
Novo Nordisk A/ S Novo
Novo Nordisk A/ S
Novo Nordisk
Novo
NovoFine needles .
NovoFine needles
NovoLet ,
NovoLet 100
NovoLet is
NovoLet delivers
NovoLet is designed to be
NovoLet is
NovoLet
an approximate 3
an approximate
For animal treatment
Only
benefit .
in the weight
the weight
benefit has Abilify shown during
benefit has Abilify
benefit has Abraxane shown during
benefit has Abraxane
benefit has Aclasta shown during
benefit has Aclasta
benefit has Actos
benefit has Actraphane shown during
benefit has Actraphane
benefit has
the
benefit
benefits
For more information
For
Nuremberg Germany
Nuremberg
one O-glycosidic bond to the
OR RESTRICTIONS OF
OR RESTRICTIONS
OR BY UNIT
OR RESTRICTIONS REGARDING
OR RESTRICTIONS
OR RESTRICTIONS WITH REGARD TO
OR RESTRICTIONS WITH
BLISTERS OR STRIPS
OR STRIPS
OR WASTE MATERIALS
BLISTERS OR
OR
Finland OY BRISTOL-MYERS SQUIBB (
Finland OY BRISTOL-MYERS SQUIBB
Finland OY BRISTOL-MYERS
Finland OY
surface of nerve cells
surface of
surface
upper limit of normal ,
upper limit of normal
thigh or
,
Although
Although
Although in very rare cases
Although in very rare
Although in very
Although in
,
Although
Octreotide/ lanreotide may
13-10-2000 Date of
13-10-2000 Date
13-10-2000
omeprazole )
omeprazole
OncoEurope Tel . : +
OncoEurope Tel . :
OncoEurope Tel .
OncoEurope Tel : + 36(0
OncoEurope Tel : +
OncoEurope Tel :
OncoEurope Tel
OncoEurope
qualified oncologist
Opaque white HDPE bottles
Opaque white
Opaque
surgery
surgery .
surgery
Oral hypoglycaemic agents ( OHA
Orale Eisensubstitution , beispielsweise 200
oral iron substitution of 200
oral iron substitution of
Oral contraeptives , thiazides ,
Oral contraeptives , thiazides
Oral contraeptives ,
Oral contraeptives
Oral
orlistat , ethanol or lorazepam
orlistat , ethanol
the infusion
the infusion
the
osmolality of 300-360 mOsm/ kg
osmolality of
osmolality
osteoclasts ,
osteoclasts
osteoclast-mediated bone resorption .
osteoclast-mediated bone resorption
osteoclast-mediated
osteomalacia , marrow fibrosis
osteomyelitis , and the majority
osteomyelitis , and the
osteomyelitis , and
osteomyelitis ,
osteomyelitis
osteonecrosis (
, osteonecrosis of
, osteonecrosis
osteonecrosis of
osteonecrosis
Osteonecrosis of
osteoporosis ( PFT ) The
osteoporosis ( PFT )
osteoporosis ( PFT
osteoporosis ( a disease
osteoporosis ( a
osteoporosis (
Osteoporosis The
Osteoporosis The usual dose is
Osteoporosis The usual dose
Osteoporosis The usual
osteoporosis in post-menopausal women in
osteoporosis in post-menopausal women
osteoporosis in post-menopausal
osteoporosis in
osteoporosis
osteoporosis and
osteoporosis , Aclasta was
osteoporosis ,
Osteoporose
Osteoporosis
osteoporosis ,
osteoporosis
( PFT , HORIZON
( PFT ,
( PFT
osteoporosis therapy
treatment of
treatment
Otsuka Pharmaceutical Europe Ltd
Otsuka Pharmaceutical Europe
Otsuka Pharmaceutical
Otsuka
outcome study , 5238 patients
outcome study , 5238
outcome study ,
outcome study of pioglitazone
outcome study of
outcome study
syndrome .
syndrome
syndrome
Oxford Road Uxbridge - Middlesex
Oxford Road Uxbridge -
Oxford Road Uxbridge
Oxford Road
Oxford
Finland Oy Eli Lilly Finland
Finland Oy Eli Lilly
Finland Oy Eli
Oy Puh/ Tel : +358
Oy Puh/ Tel :
Oy Puh/ Tel
Finland Oy
Oy
P-glycoprotein .
P-glycoprotein
P1NP )
P1NP was significantly
P1NP was
P1NP
P450 2C8 although
P450
systems .
systems
cytochrome P450 .
cytochrome P450
PACKAGE LEAFLET Yarvitan 5
PACKAGE LEAFLET Yarvitan
PACKAGE LEAFLET
procedure .
PANSS Excitement Component score at
PANSS Excitement Component score
PANSS Excitement
PANSS
PET-bottles with
PET-bottles
PFT ) The
PFT )
PFT ] ( see section
PFT ] ( see
PFT ] (
PFT ]
PFT
PHARMACEUTICALS LTD Tel : +
PHARMACEUTICALS LTD Tel :
PHARMACEUTICALS LTD Tel
PHARMACEUTICALS LTD
PHARMACEUTICALS
19 PIOGLITAZONE IN TRIPLE ORAL
31 PIOGLITAZONE IN TRIPLE ORAL
PIOGLITAZONE IN TRIPLE ORAL
PIOGLITAZONE IN COMBINATION THERAPY WITH
PIOGLITAZONE IN COMBINATION THERAPY WITH
19 PIOGLITAZONE IN
31 PIOGLITAZONE IN
PIOGLITAZONE IN COMBINATION THERAPY
PIOGLITAZONE IN COMBINATION
PIOGLITAZONE IN
19 PIOGLITAZONE
31 PIOGLITAZONE
PIOGLITAZONE IN
PIOGLITAZONE
PRCA ,
PRCA
IMMEDIATE PACKAGE
UNITS
leaflet are the final versions
leaflet are the final versions
PSUR
thereafter yearly PSURs unless
thereafter yearly PSURs unless
yearly PSURs unless
yearly PSURs
PSURs
PVC-aluminium perforated
PVC-aluminium blister
PVC/ aluminium ) Blister (
PVC/ aluminium ) Blister
PVC/ aluminium )
PVC/ aluminium
mating ( 9 weeks )
mating ( 9 weeks
mating ( 9
mating (
mating
pack The ABILIFY
pack The
carton .
carton
carton contains 1 bottle
carton contains 1 bottle
carton contains 1
carton contains one single-use
carton contains one single-use
carton contains
pack with
pack and
carton
pack
Package Leaflet (
Package Leaflet
leaflet .
leaflet
package leaflet before use .
package leaflet before use
package leaflet or
this leaflet carefully before
this leaflet carefully
Package Leaflet ) .
Package Leaflet )
Package Leaflet
Package Leaflet
Package leaflet
Package
leaflet
package leaflet are
package leaflet
Pack size one vial of
Pack size one vial
Pack size one
Pack size
Packungsgrößen bernsteinfarbene Glasflaschen mit 55
Packungsgrößen bernsteinfarbene Glasflaschen mit
Packungsgrößen in
Packungsgrößen
paclitaxel ( 5 mg/ ml
paclitaxel ( 5
paclitaxel (
paclitaxel , which
paclitaxel , which
paclitaxel ,
of paclitaxel .
paclitaxel .
paclitaxel in patients
Paclitaxel blocks the ability of
Paclitaxel blocks the ability
Paclitaxel blocks
, paclitaxel
paclitaxel
paclitaxel contain substances ( solvents
paclitaxel contain
Paclitaxel has been shown to
paclitaxel .
paclitaxel
Paclitaxel in
Paclitaxel is an antimicrotubule agent
Paclitaxel is a cytotoxic anticancer
Paclitaxel is a cytotoxic
Paclitaxel is a
Paclitaxel is an
Paclitaxel has been available
Paclitaxel has
Paclitaxel is
paclitaxel following
paclitaxel or
Paclitaxel
Paclitaxel has been
paclitaxel is
paclitaxel has not been formally
paclitaxel has not been
administering paclitaxel concomitantly with
paclitaxel concomitantly with
administering paclitaxel concomitantly
paclitaxel concomitantly
, paclitaxel
Paclitaxel
administering paclitaxel
of paclitaxel
paclitaxel
single-agent paclitaxel
declined in a multiphasic manner
declined in
declined
declined in
declined
pancreatitis , dysphagia
pancreatitis ,
pancreatitis
paracetamol or ibuprofen ( anti-inflammation
paracetamol or ibuprofen shortly following
paracetamol or ibuprofen shortly
paracetamol or ibuprofen
paracetamol or
paracetamol
Parahydroxybenzoates may cause allergic reactions
Parahydroxybenzoates may
Parahydroxybenzoates
parameters
paranoia .
paranoia
behaviour
Park , Kilruddery , County
Park , Kilruddery ,
Park , Kilruddery
Park , Oxford Road Uxbridge
Park , Oxford Road
Park , Oxford
Park ,
Park Westhoughton BL5 3XX United
Park Westhoughton BL5 3XX
Park Westhoughton BL5
Park Westhoughton
Park
parkinsonism , akathisia
parkinsonism ,
parkinsonism
expected to
free from particles and
free from particles
free
paraesthesia .
Paresthesia
paraesthesia
patient should not
patient
patients ( 65 years )
patients ( 65 years
patients ( 65
( 95 % )
( 95 %
( 95
patients ( mean age :
patients ( mean age
patients ( particularly
patients ( particularly overweight patients
patients ( particularly overweight patients
patients ( particularly overweight
patients ( particularly overweight
(
patients (
patients
patients )
patients ) .
patients )
Patients scheduled
patients who have experienced hypoglycaemic
107 Patients scheduled
121 Patients scheduled
135 Patients scheduled
23 Patients scheduled
37 Patients scheduled
51 Patients scheduled
65 Patients scheduled
79 Patients scheduled
9 Patients scheduled
93 Patients scheduled
Patients scheduled for
Patients scheduled
Patienten , der nach einem
Patienten , der
patients receiving Aclasta
, patients receiving pioglitazone
patients receiving placebo
patients who
, patients receiving
, that patients
10 Patients who
46 The
58 The
70 The
Patients who
Patients who
The
patients who have
patients who
patients who
patients
, patients continuing
, patients receiving
, patients
107 Patients
121 Patients
135 Patients
160 patients
23 Patients
37 Patients
46
51 Patients
65 Patients
79 Patients
9 Patients
93 Patients
Patienten ,
Patients
in patients
patients , receiving
patients ,
patients experiencing
patients
patients .
patients was 12.1 % with
patients was 12.1 %
patients was 12.1
patients of other races .
patients of other races
patients of other
usual
patient
patients in the study population
patients in the
patients .
patients .
patients
patients the incidence of
patients the incidence
patients were 39.5 %
patients were 39.5
patients were
patients received a
patients were receiving insulin in
patients were receiving insulin
patients were receiving
patients were also receiving chemotherapy
patients received
received
patients .
patients
patients had a previous
patients had
patients had signs of local
patients had signs of
patients had signs
patients had a
patients had
result of hypoglycaemia .
result of hypoglycaemia
patients
in patients
patients in
patient above and
anaemic patients .
of anaemic patients .
anaemic patients
of anaemic patients
Patienten ist keine
Patienten ist
patients are not iron deficient
patients may
patients with agitation and
patients with agitation
patients with renal impairment
patients with diabetes mellitus
patients with diabetes
patients with hypocalcaemia (
patients with hypocalcaemia
patients with hypocalcaemia ( see
patients with hypocalcaemia (
patients with hypocalcaemia
patients with haematological malignancies (
patients with haematological malignancies
Patients with hepatic impairment
Patients with hepatic impairment :
Patients with hepatic impairment
patients with liver problems
patients with Paget s disease
Patients with renal impairment :
Patients with renal impairment
people with phenylketonuria .
people with phenylketonuria
patients with type 2 diabetes
patients with type 2
patients with type
bipolar mania patients due to
bipolar mania patients due
bipolar mania patients
patients with bipolar disorder
patients with bipolar
chronic renal failure patients )
chronic renal failure patients
patients with chronic renal failure
patients with chronic renal failure
electrolytes
patients with chronic
patients with the
patients with these characteristics
patients with these
patients with baseline
Patienten mit einer Adipositas ist
Patienten mit einer Adipositas
patients with a manic or
patients with a manic
patients with a recent low-trauma
Patienten mit einer
patients with a
patients with reported estimated doses
patients with reported estimated
Mildly anaemic patients (
Mildly anaemic patients
patients with metastatic breast cancer
patients with metastatic breast cancer
patients with metastatic
to patients with moderate anaemia
to patients with moderate
patients with residual
patients with normal or
patients with normal
patients with or without psychotic
patients with or without
patients with or
patients with renal anaemia ,
patients with renal anaemia
patients with renal
Black patients may
Black patients
Patients with severe hepatic impairment
patients with severe agitation ,
patients with severe agitation
Patients with severe hepatic impairment
available are insufficient to establish
patients with severe renal
Patients with severe
patients with severe
Patients with rare hereditary problems
Patienten mit stark eingeschränkter
patients with severe
, in patients with
, patients with
Patienten mit
Patients who have
Patients who
Patients with
and patients who have
and patients who
in patients with less
in patients with
in patients with
patients .
patients who have
patients who
patients who
patients with
patients
with
Patienten ohne Adipositas (
Patienten ohne Adipositas
Patienten ohne
be performed in such patients
be performed in
treatment .
treatment
patients dosing should
patients should seek
patients should
that examined the metabolic and
patients reported concurrent peripheral
patients and 42 %
patients and 42
in patients who
patients ,
patients and
patients
in patients less than 65
for aripiprazole-treated patients and
for aripiprazole-treated patients
haloperidol-treated patients .
haloperidol-treated patients
olanzapine-treated patients .
olanzapine-treated patients
patients who received risedronate .
patients who received risedronate
in patients less than
patients who received
that in patients less than
patients .
patients
prior to the initiation of
prior to
patients
patients , antibodies
3 trials
trials
, and a patient
, in patients
, patients
10 Patients
160 patients
46
Patienten
Patients who
Patients
The patients
a patient
and a patient
available
evaluated in patients
in patients who
in patients
in patients
of patients
of
patient has
patient in
patient
patients ,
patients :
patients and
patients experiencing
patients had
patients in
patients of
patients on
patients received
patients receiving
patients studied
patients treated
patients who
patients
receiving
that examined the metabolic
that examined the
that examined
that in patients
the patients
to that in patients
usual
weight
patients over 75
patients over
population ,
population
populations ( see section 4.2
Special populations ( see section
populations ( see section
Special populations ( see
populations ( see
Special populations (
populations (
information pack should
information pack
population
this patient population .
this patient population
sample size
sample size
patient
patients who
fatal
of fatal
patients may be at risk
patients may be at
chronic renal failure patients ,
chronic renal failure patients
patients with mild or moderate
patients with
ise their
in male and female patients
fractures , when
fractures ,
fractures
ise
patients may
patients
cartridge ( 3 ml )
cartridge ( 3 ml
cartridge ( 3
cartridge (
cartridge .
glass cartridge ( type
glass cartridge (
glass cartridge
cartridge
cartridge contains a
cartridge contains
cartridge is made of glass
cartridge is made
cartridge
cartridges (
Cartridges should only
cartridges are designed to
cartridges are designed
cartridges x 3 ml
cartridges x 3
cartridges x
cartridges
cartridges
Penfill 100
Penfill is
Penfill
Aluminium perforated unit dose
Aluminium perforated
Peripheral neuropathy , neuropathy ,
Peripheral neuropathy , neuropathy
Peripheral neuropathy ,
Peripheral neuropathy
Peripheral sensory neuropathy , headache
Peripheral sensory neuropathy ,
Peripheral sensory neuropathy
Peripheral sensory
Peripheral
Peripheral oedema , mucosal
Peripheral oedema ,
Peripheral oedema
in vitro permeability and
in vitro permeability
permeability
of specific nuclear receptors
specific nuclear receptors
prepared and administered by personnel
) should be alerted about
)
nurse
nurse .
nurse
nurse
of your concern .
your concern .
of your concern
your concern
of your
your
N-acetyl DL tryptophanate ) .
sodium hydroxide , and
sodium hydroxide ,
Sodium hydroxide
Sodium
sodium
Pharma GmbH Roonstraße 25 D-90429
Pharma GmbH Roonstraße 25
Pharma GmbH Roonstraße
Pharma GmbH Tel : +43
Pharma GmbH Tel : +49
Pharma GmbH Tel :
Pharma GmbH Tel
Pharma GmbH Tel . +
Pharma GmbH Tel .
Pharma GmbH Tél/ Tel :
Pharma GmbH Tél/ Tel
Pharma GmbH
Pharma Tel . : +36
Pharma Tel . :
Pharma Tel .
Pharma Tel
Pharma Tél : + 33
Pharma Tél : +
Pharma Tél :
Pharma Tél
Pharma
Pharmaceutical Europe Ltd
Pharmaceutical Europe
Pharmaceutical
Pharmacodynamic effects
Pharmacodynamic
pharmacokinetics of the sulphonylurea
pharmacokinetics of
revealed no evidence of
revealed no evidence
revealed no
revealed
pharmacokinetics or
pharmacokinetics of aripiprazole .
pharmacokinetics of aripiprazole
rimonabant pharmacokinetics are
pharmacokinetics of rimonabant
rimonabant pharmacokinetics are
pharmacokinetics are
pharmacokinetics of
pharmacokinetics
pharmacology
Pharmacotherapeutic group : oral blood
Pharmacotherapeutic
Pharmacovigilance system The
Pharmacovigilance system
performing
Pharmacovigilance Plan or
Pharmacovigilance Plan
Marketing Authorisation Holder commits
Marketing Authorisation Holder
Marketing authorisation holder :
29 Marketing Authorisation Holder Novartis
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder and
29 Marketing Authorisation Holder
Marketing Authorisation Holder
Marketing authorisation holder
Marketing authorisation
Marketing
included
triphasic process
triphasic
ähnliche Wirkungen haben und deshalb
ähnliche Wirkungen
phenprocoumon and metformin .
phenprocoumon and metformin
Nevirapin und Johanniskraut
phosphatase ( BSAP ) ,
phosphatase ( BSAP )
phosphatase ( BSAP
phosphatase (
alkaline phosphatase
phosphatase
anti-fungal
pioglitazone ( as hydrochloride )
of pioglitazone ( as hydrochloride
pioglitazone ( as hydrochloride
pioglitazone ( as hydrochloride )
of pioglitazone ( as hydrochloride
pioglitazone ( as hydrochloride
of pioglitazone ( as
pioglitazone ( as
pioglitazone ( see section 4.5
pioglitazone ( see section
pioglitazone ( see
of pioglitazone (
pioglitazone (
,
pioglitazone , whilst the relative
pioglitazone , whilst the
pioglitazone , whilst
pioglitazone ,
of pioglitazone .
pioglitazone .
Pioglitazone tablets are
Pioglitazone tablets
pioglitazone .
pioglitazone
in cardiac status occurs .
in cardiac status occurs
of pioglitazone as hydrochloride .
pioglitazone as hydrochloride .
of pioglitazone as hydrochloride
pioglitazone as hydrochloride
of pioglitazone as
pioglitazone as
pioglitazone treated group
pioglitazone treated
pioglitazone-treated
pioglitazone in patients
pioglitazone in
pioglitazone in man is 5
pioglitazone concentration is unchanged .
pioglitazone concentration is unchanged
combination therapy with insulin .
Pioglitazone should not be
taking pioglitazone compared to
taking pioglitazone
taking pioglitazone
pioglitazone have been accompanied
pioglitazone was used in combination
Pioglitazone is also indicated
Pioglitazone is also
Pioglitazone is
Pioglitazone can
pioglitazone with gemfibrozil ( an
pioglitazone with gemfibrozil ( an
pioglitazone with gemfibrozil (
pioglitazone with gemfibrozil
pioglitazone was
pioglitazone with
pioglitazone or placebo
pioglitazone or any of the
pioglitazone or any
pioglitazone or
pioglitazone
Pioglitazone appears to act via
was apparent in
Pioglitazone and all active metabolites
Pioglitazone and all active
Pioglitazone and all
pioglitazone and
pioglitazone and its metabolites are
pioglitazone and its metabolites
pioglitazone and its
Pioglitazone and
pioglitazone and
pioglitazone
pioglitazone vs. gliclazide as monotherapy
pioglitazone vs. gliclazide as
pioglitazone vs. gliclazide
pioglitazone vs.
Pioglitazone will
pioglitazone , it is recommended
Pioglitazone undergoes extensive hepatic metabolism
pioglitazone there was
pioglitazone during
pioglitazone in all
pioglitazone in all
pioglitazone in all
pioglitazone in
pioglitazone in
, pioglitazone
Pioglitazone was
Pioglitazone
combination therapy with
in combination therapy with
of pioglitazone
pioglitazone and
pioglitazone in
pioglitazone was
pioglitazone
pipette
Pivotal Fracture Trial [ PFT
Pivotal Fracture Trial [
Pivotal Fracture Trial
Pivotal Fracture
Pivotal
placebo ( 139 out of
placebo ( 139 out of
placebo ( 139
placebo ( 2.1 % )
placebo ( 2.1 %
placebo ( 2.1
placebo ( 29 [ 2.7
placebo ( 29 [
placebo ( 29
placebo (
placebo -2.9 kg ) .
placebo -2.9 kg )
placebo -2.9 kg
placebo -2.9
placebo .
in fracture event
placebo-treated
placebo-treated patients .
placebo-treated patients
placebo-treated
placebo to existing treatment
placebo to existing
placebo to
Aclasta Placebo
in patients being
placebo (
placebo ,
placebo
placebo over three weeks in
placebo over three
placebo over
placebo group .
placebo group
placebo
placebo-controlled trial , the incidence
placebo-controlled trial , the
placebo-controlled trial ,
placebo-controlled trial
26-week , placebo-controlled trial ,
26-week , placebo-controlled trial
26-week , placebo-controlled trial
6-week , placebo-controlled trial involving
placebo-controlled trials , the incidence
placebo-controlled trials , the incidence
placebo-controlled trials ,
placebo-controlled trials
, placebo-controlled
placebo-controlled
placebo group .
placebo .
placebo group
placebo
placebo group
is unchanged , but with
is unchanged , but
is unchanged ,
is unchanged
plasma elimination half-life of unchanged
plasma elimination half-life of
plasma elimination half-life
transcytosis
plasma concentration
plasma concentration of pioglitazone (
plasma concentration of pioglitazone
plasma concentration of
plasma concentration
plasma concentrations
plasma
plasma proteins
serum proteins
peak plasma concentrations were 1
plasma concentrations were 1
peak plasma concentrations were
plasma concentrations were
pleural effusion , allergic rhinitis
pleural effusion , allergic
pleural effusion ,
pollakiuria , haematuria
Polska Takeda Global R &
Polska Takeda Global R
Polska Takeda Global
Polska Takeda
Polska
polydipsia , hyperglycaemia , hypocalcaemia
polydipsia , hyperglycaemia ,
polydipsia , hyperglycaemia
polydipsia ,
polydipsia
Polyneuropathy , areflexia , dyskinesia
Polyneuropathy , areflexia ,
Polyneuropathy , areflexia
Polyneuropathy ,
Polyneuropathy
polyps ) :
polyps )
polyps
adenomatous polyposis ( FAP )
low-density polyethylene dropper .
low-density polyethylene dropper
low-density polyethylene
polysorbate 80 , hydrochloric acid
population of 789 patients
number of patients .
number of patients
number of
population of
population
non-diabetic
pharmacokinetic analysis
pharmacokinetic
population pharmacokinetic
Portugal - Produtos Farmacêuticos ,
Portugal - Produtos Farmacêuticos
Portugal - Produtos
Portugal -
Portugal Lilly Portugal - Produtos
Portugal Lilly Portugal -
Portugal Lilly Portugal
Portugal Lilly
Portugal Novartis Farma - Produtos
Portugal Novartis Farma -
Portugal Novartis Farma
Portugal Novartis
Portugal
Häufigkeit
Häufigkeit
The potentially medically important signs
The potentially medically
The potentially
practice .
practice
haben und deshalb
immediate packaging :
immediate packaging
healthy subjects
of
subjects the
31.1
subjects with
subjects , a potent inhibitor
subjects , a potent inhibitor
subjects ,
healthy subjects
subjects ,
subjects
problem of the heart or
problem of the heart
problem of the
problem of
problem ,
problem
product and is
product and
product
members within
members
Productive cough , exertional dyspnoea
Productive cough ,
Productive cough
Productive
Produtos Farmacêuticos , Lda Tel
Produtos Farmacêuticos , Lda
Produtos Farmacêuticos , S. A.
Produtos Farmacêuticos ,
Produtos Farmacêuticos
Produtos
Proportional increases of the
Proportional increases
Propyl parahydroxybenzoate ( E216 )
propyl parahydroxybenzoate ( E216 )
Propyl parahydroxybenzoate ( E216
propyl parahydroxybenzoate ( E216
Propyl parahydroxybenzoate (
propyl parahydroxybenzoate (
Propyl parahydroxybenzoate
propyl parahydroxybenzoate
Propylene glycol Propyl parahydroxybenzoate (
Propylene glycol Propyl parahydroxybenzoate
Propylene glycol
glycol
ago
androgen- independent prostate cancer (
androgen independent ,
androgen independent
androgen- independent prostate cancer
prostate cancer which
prostate cancer
prostate
Protamine sulphate Water for injections
Protamine sulphate Water for
Protamine sulphate Water
protein fraction of the molecule
protein fraction of the
protein intake .
protein intake
protein binding
Percentages of dogs
Percentages of dogs
Percentages of
Percentages
pruritus
marked
marked
Recurrence prevention of manic episodes
Recurrence prevention of manic
preventing recurrence of manic
Recurrence prevention of
preventing recurrence of
preventing
prevention of a new manic
prevention of a new
preventing recurrence
investigator
Psychiatric
including hallucinations , delusion
including hallucinations ,
including hallucinations
puberty or due to
Puh/ Tel : + 358
Puh/ Tel : +
Puh/ Tel : +358 9
Puh/ Tel : +358
Puh/ Tel :
Puh/ Tel
pulse , respiratory rate and
pulse , respiratory rate
pulse or blood pressure ,
pulse or blood pressure
pulse or
pulse
powder for suspension for infusion
powder
powder
powder
powder
pyrexia ( fever ) .
pyrexia ( fever )
pyrexia ( fever
pyrexia (
pyrexia ) , chest pain
pyrexia ) ,
pyrexia )
pyrexia
QT prolongation , ventricular arrhythmias
QT prolongation , ventricular
QT prolongation ,
QT prolongation
square metre
square
lips
R & D Centre (
R & D Centre Limited
R & D Centre
R & D
R &
R
RFT ) The incidence of
RFT ) The incidence
RFT ) The
RFT )
RFT ] )
RFT ]
RFT
RG40 2AQ United Kingdom
RG40 2AQ United
RG40 2AQ
RG40
RH12 5AB United Kingdom
RH12 5AB United
RH12 5AB
RH12
RMP should
RMP
during a 3
In
during
raloxifene , tamoxifen , hormone
raloxifene
a rapid-cycling course .
a rapid-cycling course
race or body weight .
race or body weight
race or
race
rat at doses
rat
rats , but not in
rats , but not
rats , polycythaemic mice )
rats , polycythaemic mice
rats ,
rats after
rats or
rats
du
Smoking status :
Smoking status
room temperature ( below 25°C
room temperature ( below 25ºC
room temperature ( below
room temperature (
room temperature before administration .
room temperature before administration
room temperature before
room temperature
reaction ( e. g.
reaction (
reaction ,
reaction
injection site reactions
reactions have also occurred in
reactions have also occurred
reactions after
reactions are transitory and
reactions are transitory
reactions are
reactions have
reactions
with
be impaired as a
Recurrent Fracture Trial [ RFT
Recurrent Fracture Trial [
Recurrent Fracture Trial
Recurrent
reduction of bone turnover markers
reduction of bone
reduction
reduction
reduction of transfusion requirements in
reduction of transfusion requirements
reduction in new
reduction in
reduction
reduction in
reduction of
reduction
reduction
Refraction disorders Refraction anomalies may
Refraction anomalies may
Refraction disorders
generally mild to moderate
generally mild to
control the blood sugar .
control the blood sugar
control the
control
range of insulin suspensions for
range of insulin suspensions
number of symptoms
number of other
number of
range of
number
range
Clean the skin at
Clean the
Aggressiveness
stimulus ) .
stimulus )
stimulus
reconstitution is
reconstitution , the suspension should
reconstitution ,
reconstitution
relevance of these findings is
relevance of these findings
relevance of these
relevance
also looked at how
also looked at
also looked
looked at how
looked at
looked
study also looked at how
study also looked at
study also looked
Reproduction is authorised provided the
Reproduction
shown reproduction toxicity ( see
shown reproductive toxicity ( see
shown reproduction toxicity (
shown reproductive toxicity (
shown reproduction toxicity
shown reproductive toxicity
reproductive toxicity
toxicity
Research and Development Centre (
Research and Development Centre
Research and Development
Research and
Absorption The absorption
absorption rather than of the
absorption rather than
absorption of lipid soluble drugs
absorption of
absorption
absorption
absorption .
absorption
nadir for
nadir
rate of absorption from the
rate and
rate and extent of absorption
rate and extent of
rate
resuspension of any powder
resuspension of any powder
resuspension of any powder
resuspension of any
resuspension
reticulocyte count has increased 40,000
well
Reticulocyte count increase 40,000/ µl
Reticulocyte count
retinopathy .
retinopathy Long-term improved glycaemic
retinopathy Long-term improved glycaemic
retinopathy Long-term improved
retinopathy .
retinopathy
retinopathy
antagonism , aripiprazole has
receptors .
receptors on
receptors
rhabdomyolysis ) , and
rhabdomyolysis ) ,
rhabdomyolysis ,
rhabdomyolysis
rhinitis , hoarseness ,
rhinitis , hoarseness
rhinitis ,
rhinitis
rifampicin ( an inducer
Glycaemic control should
rifampicin
rimonabant 20 mg ( baseline
rimonabant 20 mg (
Rimonabant 20 mg reduced
Rimonabant 20 mg
rimonabant 20 mg
Rimonabant 20
rimonabant 20
rimonabant :
rimonabant ; therefore ,
rimonabant ; therefore
rimonabant ;
rimonabant treatment in
rimonabant
Rimonabant ist ein
rimonabant has not been determined
rimonabant has not
Rimonabant ist
rimonabant has
side
rimonabant
Rimonabant wird hauptsächlich
Rimonabant is
Rimonabant wird
rimonabant was found in one
Rimonabant has been detected in
rimonabant was found in
Rimonabant has been detected
rimonabant is
rimonabant was
rimonabant
Rimonabant displays high
Rimonabant displays
ACOMPLIA
Rimonabant
Seizures Rimonabant has not
rimonabant and
rimonabant
dosing for a longer
for a longer
dosing for a
for a
dosing for
for
and suicide .
harm and suicide .
suicide .
and suicide
harm and suicide
suicide
of rimonabant . ct
rimonabant . ct
of rimonabant
rimonabant
risedronate (
risedronate .
risedronate-treated
risedronate once a day
risedronate once a
risedronate
evaluate the potential risks
potential risks
the potential risks
evaluate the potential risks
potential risks
risks
the potential risks
its risks
risks
at risk for aspiration pneumonia
risk to the baby
risk
risk for humans is
risk for humans
risk for thromboembolic events in
risk for thromboembolic events
risk for thromboembolic
risk of thrombotic vascular events
risk of thrombotic vascular
risk of thrombotic
risk for
risk of
risk of
risk
Risiko ist mit
Risiko ist
is the risk
risk should be
reported risk of thromboembolic events
risk of blood clots/ blood
risk of
risk
Risiko
risk of
risk
risk factors ( e.
risk factors (
such as type 2 diabetes
such as
risk factors for diabetes
risk factors for
risk factors such as
Risk factors
risk factors
risk
with
Risk Management
agreed
agreed
risk reduction was 51 %
risk reduction was 51
risk
adequate clinical monitoring
ritonavir (
ritonavir
Road Horsham West Sussex ,
Road Horsham West Sussex
Road Horsham West
Road Horsham
Road Uxbridge - Middlesex UB8
Road Uxbridge - Middlesex
Road Uxbridge -
Road Uxbridge
Road Wokingham Berkshire RG40 2AQ
Road Wokingham Berkshire RG40
Road Wokingham Berkshire
Road Wokingham
Road
play
Roonstraße 25 D-90429 Nuremberg Germany
Roonstraße 25 D-90429 Nuremberg
Roonstraße 25 D-90429
Roonstraße 25
Roonstraße
Royaume-Uni Tél/ Tel : +
Royaume-Uni Tél/ Tel :
Royaume-Uni Tél/ Tel
Royaume-Uni
restlessness , feeling anxious ,
restlessness , feeling anxious
restlessness , insomnia ,
restlessness ,
Restlessness 1 The
Restlessness 1
Restlessness
restlessness
redness , swelling and/ or
redness , swelling
redness ,
redness
of relapse
relapse
regarding pharmacokinetics in
regarding
residues of the cell line
S. A.
/ N. V.
S. p. A. ,
SARL Tél : + 33
SARL Tél : +
SARL Tél :
SARL Tél
SARL
SBECD ) Tartaric acid
SBECD )
SBECD
Serenade ) ,
Serenade )
Serenade
REGARDING SUPPLY AND
TO SAFE AND
REGARDING
SAFE
SAFE AND EFFECTIVE USE OF
THE SAFE AND EFFECTIVE USE
SAFE AND
THE SAFE AND
SAFE
AND SIGHT OF CHILDREN
AND SIGHT OF
REACH AND SIGHT OF CHILDREN
REACH
RELEASE
OTHER INGREDIENT(S )
SONSTIGE BESTANDTEILE Enthält Lactosemonohydrat
SONSTIGE BESTANDTEILE
PRODUCT AND ROUTE(S ) OF
PRODUCT AND ROUTE(S )
PRODUCT AND ROUTE(S ) OF
PRODUCT AND ROUTE(S )
PRODUCT AND ROUTE(S
PRODUCT AND
PRODUCT
SQUIBB ( FINLAND ) AB
SQUIBB ( FINLAND )
SQUIBB ( FINLAND
SQUIBB (
SQUIBB AB Tel : +
SQUIBB AB Tel :
SQUIBB AB Tel
SQUIBB AB
SQUIBB BELGIUM S. A.
SQUIBB BELGIUM S. A.
SQUIBB BV Tel : +
SQUIBB BV Tel :
SQUIBB BV Tel
SQUIBB BV
SQUIBB GESMBH Tel : +
SQUIBB GESMBH Tel :
SQUIBB GESMBH Tel
SQUIBB GESMBH
SQUIBB NORWAY LTD Tlf :
SQUIBB NORWAY LTD Tlf
SQUIBB NORWAY LTD
SQUIBB NORWAY
SQUIBB PHARMACEUTICALS LTD Tel :
SQUIBB PHARMACEUTICALS LTD Tel
SQUIBB PHARMACEUTICALS LTD
SQUIBB PHARMACEUTICALS
SQUIBB SARL Tél : +
SQUIBB SARL Tél :
SQUIBB SARL Tél
SQUIBB SARL
SQUIBB Tlf : + 45
SQUIBB Tlf : +
SQUIBB Tlf :
SQUIBB Tlf
SQUIBB BELGIUM
SQUIBB
, IF APPROPRIATE
, IF
OF THE
PHARMACEUTICAL FORM ,
PHARMACEUTICAL FORM
NUMBER OF DOSES
SULPHONYLUREA
Saccharomyces cerevisiae ) .
Saccharomyces cerevisiae )
Saccharomyces cerevisiae
Saccharomyces
Safety
Safety
Safety
Tell your doctor before you
Hydrochloric acid ( for pH-adjustment
Hydrochloric acid ( for
Hydrochloric acid (
Hydrochloric acid
Sanofi Winthrop Industrie , 30-36
Sanofi Winthrop Industrie ,
Sanofi Winthrop Industrie
Sanofi Winthrop
Sanofi
is excreted in human milk
is excreted in
is excreted
scale or
scale
foam subsides .
foam subsides
result in foaming .
result in foaming
femoral neck bone
femoral neck
femoral neck bone
femoral neck
thyroid hormones and beta-sympathomimetics ,
thyroid hormones and beta-sympathomimetics
thyroid hormones and
thyroid hormones
Schizophrenia -
schizophrenia .
schizophrenia .
schizophrenia
schizophrenia or
schizophrenia and Bipolar I Disorder
schizophrenia and manic
schizophrenia and
schizophrenia , Abilify was
of schizophrenia
schizophrenia ,
schizophrenia
554
,
Adverse reactions reported with
insomnia ,
Adverse reactions reported
insomnia
)
Aggressive behaviour
Aggressive
stroke who
a stroke or
stroke or
stroke in
stroke
stroke or
stroke
mucosal inflammation , pain
mucosal
mucosae .
mucosae
concluded
somnolence , dizziness , headache
somnolence , dizziness ,
somnolence , dizziness
somnolence , sedation , headache
, somnolence , sedation ,
somnolence , sedation ,
somnolence , sedation
somnolence , tremor , syncope
somnolence , tremor ,
somnolence , tremor
sleepiness , shaking and blurred
sleepiness , shaking and
sleepiness , shaking
, somnolence
somnolence ,
somnolence
That
orodispersible tablet
Orodispersible tablet Round and yellow
Orodispersible tablet Round and pink
Orodispersible tablet Round and
Orodispersible tablet Round
orodispersible tablet contains 10 mg
orodispersible tablet contains 10
orodispersible tablet contains 15 mg
orodispersible tablet contains 15
orodispersible tablet contains 30 mg
orodispersible tablet contains 30
orodispersible tablet contains
entire orodispersible tablet on the
entire orodispersible tablet on
entire orodispersible tablet
orodispersible
orodispersible tablet can be
orodispersible tablet is fragile ,
orodispersible tablet is fragile
orodispersible tablet
orodispersible
orodispersible tablets ( tablets
orodispersible tablets (
orodispersible tablets 28 x 1
orodispersible tablets 28 x
orodispersible tablets 28
orodispersible tablets 49 x 1
orodispersible tablets 49 x
orodispersible tablets 49
orodispersible tablets contain
orodispersible tablet at the same
orodispersible tablet at the
orodispersible tablets may
orodispersible tablets or
orodispersible tablet is bioequivalent to
orodispersible tablet is bioequivalent
orodispersible tablets are round and
orodispersible tablets are round
orodispersible tablets are
orodispersible tablets and
Schmelztabletten werden auf die
Schmelztabletten werden auf
Schmelztabletten werden
Schmelztabletten
orodispersible tablets
orodispersible
pain , itching , hives
Continuous rotation of the injection
pain , itching ,
Continuous rotation of the injection
pain , itching
pain , swelling
pain , tremor Common :
pain , tremor Common
pain , tremor
pain ,
pain at the infusion site
into less pain from
into less pain
into less pain from
into less pain
pain and itching
pain and
pain and/ or non-healing sores
pain and/ or non-healing
pain and/ or
pain and/ or
Nail disorder ,
less pain from
less pain
pain from
pain
pain reliever such as ibuprofen
pain reliever such as
reliever
a result of
as a result of
result of
a result
as a result
result
be of 25 IU/ kg
be of 25
done
intervals
Educational leaflet Summary of
Educational leaflet Summary
Educational leaflet
leaflet
educational programme contains the
educational programme contains
educational programme
goggles and protective clothing is
goggles and protective
clothing is
pregnant women .
pregnant women
pregnancy .
Pregnancy and breast-feeding You should
Pregnancy and breast-feeding You
Pregnancy and breast-feeding You
pregnancy and in
pregnancy and
should
pregnancy .
pregnancy
zu
pregnancy
pregnant
variation .
variation
range ( less than 2.10
swelling , redness , pain
swelling , redness ,
given area may help to
swelling and inflammation .
swelling and inflammation
given area
swelling and
swelling and/ or pain
swelling and/ or
swelling
Severe hypoglycaemia may
Severe hypoglycaemia
severity
difficulty
difficulty
be used as an alternative
be used as an alternative
difficulty
dizziness , headache , akathisia
dizziness , headache ,
dizziness , headache
dizziness , somnolence , sedation
, dizziness , somnolence
dizziness , somnolence ,
dizziness , somnolence
dizziness , neuropathic pain ,
dizziness , neuropathic pain
dizziness , neuropathic
dizziness , peripheral motor neuropathy
dizziness , peripheral motor
dizziness , peripheral
, dizziness
dizziness ,
dizziness
Dizziness
, sweating ,
diaphoresis and cardiac dysrhythmia )
diaphoresis and cardiac dysrhythmia
sweating
weakness )
weakness
tiredness may occur , especially
of weakness ,
weakness ,
of weakness
weakness
Fever and chills ,
chills , pain in the
chills , pain in
chills , pain
Fever and chills
chills
agitation before use .
agitation before use
agitation before
Scoppito ( AQ ) ,
Scoppito ( AQ )
Scoppito ( AQ
Scoppito (
Scoppito
, sedation , headache Eye
sedation , headache Eye disorders
, sedation , headache
sedation , headache
, sedation ,
sedation ,
sedation ( see
sedation (
sedation
sedation and cardiorespiratory depression
sedation and
excessive sedation and
excessive sedation
sedation
vision , reduced visual acuity
vision , reduced
vision ,
vision .
vision Gastrointestinal disorders Common
vision Gastrointestinal disorders
vision
Frequencies
Very common
Very rare - Refraction disorders
Very rare -
Very rare
Very
visual acuity ,
visual acuity
visual disturbance ,
visual disturbance
Its exact mechanism of action
Its exact
face. .
face.
Suicidal thoughts and
thoughts of
thoughts
Rare :
Hypersensitivity reactions have been rarely
Rare
Rare cases of
Rare side effects (
Rare side effects
Rare
Sensory neuropathy
Sensory
submit one additional 6
submit one additional
submit one
submit
a comprehensive battery of
a comprehensive
called serotonin ) .
called serotonin )
called serotonin
serotonin
the serotonin reuptake site and
the serotonin reuptake site
serum
serum calcium
serum calcium
creatinine
levels remain the
levels
Sexually active
Sexually
shunt and
shunt
occur especially
Shunt thromboses may occur ,
Shunt thromboses may occur
safety of androgen suppression is
safety of androgen suppression
safety of
reactions
safety of Aclasta 5 mg
safety of Aclasta 5
safety of Aclasta
safety of pioglitazone during
safety of pioglitazone
safety of Vantas is sufficiently
safety of Vantas is
safety of Vantas
safety of Vantas is
safety of Vantas
safety of
Schwangerschaft
safety
Applicant/
Safety
Safety
, dry eye , keratoconjunctivitis
, dry eye ,
, dry eye
,
taking ABILIFY .
taking ABILIFY
after you have received Aclasta
Actos 15mg tablets are
Actos 30mg tablets are
Actos 45mg tablets are
you are concerned that
your doctor
your doctor
your
your doctor , pharmacist
your dentist that
your doctor ,
your doctor or pharmacist
your doctor or dentist
your doctor or
your dentist
your doctor
your doctor
your veterinary surgeon how
your veterinary surgeon
your
you have a problem with
you have polycystic ovary
you have cardiovascular disorders
you have cardiovascular
you have severe
you have
tell you to take a
tell you to take
tell your
tell
tell
, administer the product with
administer the product with
, administer the product
administer the product
you are having any
the product orally during
the product orally
the product
you have the impression
you are considering stopping
the needle into the skin
the pack with you .
the pack with you
the syringe by pulling
the
you are considering
this with your doctor
this with your
Keep this leaflet .
Keep this leaflet
Keep this leaflet
Keep this
taking this medicine .
taking this medicine
Do not use Aclasta after
Do not use Aclasta
Do not use this medicine
Do not use ABILIFY
Do not use
Do not use
one syringe from the
you inject more
you
no longer required
you
you may not
you think
you think
here .
here
It is an inhibitor of
It is an inhibitor
It is an
It is
It can be
It may
Alternatively , disperse the tablet
you are given more ABILIFY
you are given more
to your doctor .
your doctor .
to your doctor
your doctor
to your
your
only inject the amount
you or
you are pregnant ,
you are pregnant
you are pregnant
that you
you feel better .
you feel better
Alcohol should be avoided
Alcohol should
However , you should not
However , you should
you should
You should receive
you should
you are breast-feeding .
you are breast-feeding
your doctor immediately
, see section 6.1
see section 6.1
, see section
see section
you develop PRCA
you have chronic kidney failure
you experience these symptoms
you experience these
you experience
you have
your doctor immediately
you accidentally
you attempt
you use
you
, you will
you will
you
you have any further
you have further
you need more information about
It explains
It
you have any
you need
you
You will probably need
You will
you will
you know how ABILIFY
you know how
, administer
Do
It explains
It
Keep
Sie
You will
You
administer
and you
if you
or no
please inform
the
you are on
you are
you have
you will
you
your doctor
your
, silicon dioxide ,
, silicon dioxide
, silicon
silicon
settling are
settling
situations
skeleton that allows
Slovenija Eli Lilly farmacevtska dru
Slovenija Eli Lilly farmacevtska dru
Slovenija Eli Lilly
Slovenija Eli
Slovenija
Slovenská republika Eli
Slovenská republika OncoEurope Tel :
Slovenská republika OncoEurope Tel
Slovenská republika OncoEurope
Slovenská republika
Slovenská
When your
Once the dog
Upon regaining
Once the
Once
When
heartburn ) , vomiting ,
heartburn ) , vomiting
heartburn ) ,
heartburn )
heartburn
Therefore ,
Therefore
experience somnolence
somnolence
Excipients :
Excipients The reconstituted medicinal product
Excipients The reconstituted
Excipients The
Excipients
In both women and
SpA Tel : + 39
SpA Tel : +
SpA Tel :
SpA Tel
SpA
cleavage ( hydrolysis ) sites
cleavage (
cleavage
Spain
, anorexia , severe
, anorexia ,
, anorexia
,
production of saliva ,
production of saliva
salivary hypersecretion Vascular
salivary hypersecretion
species , both via subcutaneous
species , both via
species , both
species ,
species , both via
species , both
species ,
species
Specific drug-drug interaction
Specific
spongiosa in the metaphyses of
speech disorder , Neuroleptic
speech disorder ,
speech disorder
syringe by pulling
syringe onto a portion of
syringe onto a
syringe onto
syringe from
syringe ,
syringe onto
syringe
syringes contain 0.3 ml (
syringes contain 0.3 ml
syringes contain 0.3
syringes contain 0.4 ml (
syringes contain 0.4 ml
syringes contain 0.4
syringes contain 0.5 ml (
syringes contain 0.5 ml
syringes contain 0.5
syringes contain 0.6 ml (
syringes contain 0.6 ml
syringes contain 0.6
syringes contain 0.7 ml (
syringes contain 0.7 ml
syringes contain 0.7
syringes contain 0.8 ml (
syringes contain 0.8 ml
syringes contain 0.8
syringes contain 0.9 ml (
syringes contain 0.9 ml
syringes contain 0.9
syringes contain 1 ml (
syringes contain 1 ml
syringes contain 1
syringes contain
syringes
Tardive Dyskinesia : in clinical
Tardive Dyskinesia : in clinical
47 Tardive Dyskinesia : in
59 Tardive Dyskinesia : in
71 Tardive Dyskinesia : in
Tardive Dyskinesia : in
Tardive Dyskinesia : in
Tardive Dyskinesia :
83 Tardive
Tardive Dyskinesia
Squibb Srl Contrada Fontana Del
Squibb Srl Contrada Fontana
Squibb Srl Contrada
Squibb Srl
Squibb
Srl Contrada Fontana Del Ceraso
Srl Contrada Fontana Del
Srl Contrada Fontana
Srl Contrada
Srl
stability results in
stability
stabilization phase prior to
stabilization phase
Stability of the reconstituted suspension
Stability of the reconstituted
Stability of the
Stability
standard
range of standard
range of
range
standard treatment
standard
standard scale for
standard scale
Strada Statale 17 , Km
Strada Statale 17 ,
Strada Statale 17
Strada Statale
statins , fibrates ) .
statins , fibrates )
statins , fibrates
statins ,
statins
Stattdessen ist Paclitaxel in
Stattdessen ist Paclitaxel
Stattdessen ist
Steady State ist bei Patienten
Steady State ist bei
Steady State ist
Steady State
Steady-State-Pharmakokinetik eines oralen Kontrazeptivums mit
Steady-State-Pharmakokinetik eines oralen Kontrazeptivums
Steady-State-Pharmakokinetik eines oralen
Steady-State-Pharmakokinetik eines oralen
Insert
measured annually using a stadiometer
annually using a
annually
stiffness
increasing
place
stenoses , aneurysms , etc.
stenoses
human
pup mortality
pup mortality
mortality
pre- treatment or
pre- treatment
flatness .
flatness
mood alterations with depressive symptoms
mood alterations with depressive
compounds ,
compounds
metabolism of paclitaxel is
metabolism of paclitaxel
metabolism of
metabolism
disorders : stomach discomfort ,
groups
groups
vitro .
vitro
important metabolic transformation is sulphoxidation
stomatitis ( inflammation of
stomatitis ( inflammation
stomatitis (
stomatitis
( butyl
Storbritannia Tlf : + 44
Storbritannia Tlf : +
Storbritannia Tlf :
Storbritannia Tlf
Storbritannia
Storbritannien Tel : + 44
Storbritannien Tel : +
Storbritannien Tel :
Storbritannien Tel
Storbritannien Tlf : + 44
Storbritannien Tlf : +
Storbritannien Tlf :
Storbritannien Tlf
Storbritannien
ability
study (
study ) in women with
study )
study ,
study
study .
study CZOL446M2308 )
study CZOL446M2308
study in men ( study
study in men (
study in men
in osteoporosis ,
in osteoporosis
in
study in
was
trial , the incidence of
trial , the incidence
trial , the
trial ,
trial
study in patients with advanced
study in patients with
trial of pioglitazone vs. gliclazide
trial of pioglitazone vs.
trial of pioglitazone
fixed-dose trial ,
fixed-dose trial
fixed-dose trial
trial in healthy subjects ,
trial in healthy
trial of
study included only 3 patients
study included only 3
study included only
study included
study was not powered
study was not
study was
trial was
at study
study
trial ,
trial
study of
trials ( n= 938 ;
trials ( n= 938 ;
trials (
trials of one year
trials of one year
trials of
trials , a
trials in which
trials ,
trials
studies also looked at
studies also looked
studies in pregnant women .
studies in pregnant women
studies for other indications
studies for other
Studien bei
studies for
studies in
trials included patients with or
trials included patients with
trials included patients
trials included
studies .
studies
trials that
trials , the incidence of
trials , the incidence of
trials , the incidence
trials , the incidence
studies ?
the studies ?
trials have
trials aripiprazole has not been
trials aripiprazole has
vitro studies
trials with aripiprazole ,
trials of aripiprazole in pregnant
trials of aripiprazole in
trials of aripiprazole ,
trials of aripiprazole
trials of aripiprazole
trials with aripiprazole
and repeat-dose studies , the
and repeat-dose studies ,
and repeat-dose studies
trials with pioglitazone there was
trials with pioglitazone
studies in healthy subjects
studies in healthy
intravenous bolus studies ,
intravenous bolus studies
the intravenous bolus studies ,
the intravenous bolus studies
trials with oral
excluded in the studies for
excluded in the studies
in the studies for
in the studies
studies , the
studies ,
studies
trials of
trials with
trials and
trials aripiprazole has not been
trials and 8167 patients )
trials and 8167 patients
trials and 8167
trials and post-marketing experience
studies and additional
studies and
trials and
studies , the patients were
studies , use of
studies , use
studies demonstrated that
studies demonstrated
studies ,
studies
studies ,
studies looked
studies
trials , an increased
trials , an
trials , uncommon cases of
trials , uncommon cases
trials , uncommon
trials , rare cases of
trials , rare cases
trials , rare
trials , cerebrovascular adverse events
trials , cerebrovascular adverse
trials ,
trials ,
trials
studies
Studien
Studies
The studies
studies , the
studies , where
studies ,
studies
the studies
trials ,
trials in
trials of
trials
as second or greater than
as second or greater than
study duration :
study duration
study population had an
study population had
population were women , 87
population were women ,
population were women
population were
study population had
population
study population
loose stools ,
loose stools , oesophagitis
stools
hour ,
hour
to 6 hours and
to 6 hours and
hours .
hours in
hours after administration
hours after the first
hours after the
hours after subcutaneous administration
hours after an
hours after
hours has been
6 hours
hours in
hours
injection route
strength
disorder , akathisia , tremor
disorder , akathisia ,
disorder , akathisia
disorder , akathisia
disturbance , somnolence .
disturbance , somnolence
disorder ,
disorder
temperature regulation disorder (
temperature regulation disorder
disorder
bipolar disorder or
disorder , there were eight
disorder , there were
Störung
bipolar disorder
disorder
oedema , difficulties in
.
exclude potential
disturbances in
disturbances of mineral metabolism must
disturbances of mineral metabolism
disturbances of
and
disturbances
Subchronic and
Subcutaneous injection : a
Subcutaneous injection :
Subcutaneous injection
Subcutaneous
antiresorptive
substances ( solvents )
substances ( solvents
of substances
substances
substrate of P-glycoprotein .
substrate of P-glycoprotein
substrate of
substrate
sucrase-isomaltase insufficiency should
sucrase-isomaltase insufficiency
sucrose , purified water ,
of sucrose .
sucrose .
Sucrose Purified water
Sucrose Purified
sucrose per ml 1.8 mg
sucrose per ml 1.8
sucrose per ml
sucrose per
Sucrose
of sucrose
sucrose
depressive disorders
suicidal ideation , and
suicidal ideation ,
and suicidal ideation in
suicidal ideation in
and suicidal ideation
suicidal ideation
sulphonamides .
sulphonamides
sulphonylurea
sulphonylureas , insulin , metformin
sulphonylureas , insulin ,
sulphonylureas , insulin
sulphonylureas ,
sulphonylureas
sulphonylureas or insulin .
sulphonylureas or insulin
sulphonylureas or
sulphonylureas
sulphonylurea
Suomi/ Finland Novartis Finland Oy
Suomi/ Finland Novartis Finland
Suomi/ Finland OY BRISTOL-MYERS SQUIBB
Suomi/ Finland OY BRISTOL-MYERS
Suomi/ Finland OY
Suomi/ Finland Oy Eli Lilly
Suomi/ Finland Oy Eli
Suomi/ Finland Oy
Suomi/
resulting suspension .
resulting suspension
suspension has a pH of
suspension has a pH
suspension has a
suspension has
suspension in the infusion bag
suspension in the
suspension may occur .
suspension may occur
suspension may
suspension
suspension contacts the
suspension contacts
resulting suspension .
resulting suspension
suspension
Sussex , RH12 5AB United
Sussex , RH12 5AB
Sussex , RH12
Sussex ,
Sussex
Sverige AB Tel : +46
Sverige AB Tel :
Sverige AB Tel
Sverige AB
Sverige BRISTOL-MYERS SQUIBB AB Tel
Sverige BRISTOL-MYERS SQUIBB AB
Sverige BRISTOL-MYERS SQUIBB
Sverige BRISTOL-MYERS
Sverige Novartis Sverige AB Tel
Sverige Novartis Sverige AB
Sverige Novartis Sverige
Sverige Novartis
Sverige Takeda Global R &
Sverige Takeda Global R
Sverige Takeda Global
Sverige Takeda
Sverige
symptoms , emergency procedures ,
symptoms , emergency procedures
post-dose symptoms occurring within the
post-dose symptoms occurring within
post-dose symptoms
symptoms ,
symptoms .
symptoms .
symptoms
symptoms
such symptoms
symptoms
symptoms reported
symptoms
symptoms of heart failure ,
symptoms of heart failure
symptoms of hyperglycaemia (
symptoms of hyperglycaemia
symptoms of
time
time
in symptoms of agitation than
symptoms of agitation than
symptoms of agitation , and
symptoms of agitation ,
symptoms of agitation
symptoms is less common .
symptoms is less common
symptoms is less
symptoms is
symptoms decreased
symptoms are
symptoms are usually mild to
symptoms are usually
symptoms were
symptoms , such as
not
such symptoms
symptoms ,
symptoms of
symptoms
symptoms over 3 weeks .
symptoms over 3 weeks
symptoms over 3
symptoms over
symptoms can occur .
symptoms can occur
symptoms can
symptoms have been
symptoms of
symptoms
syncope , postural dizziness ,
syncope , postural dizziness
syncope , postural
syncope ,
syncope
CNS metastases are
CNS metastases
culture mutagenicity tests and
Sími : + 354 535
Sími : + 354
Sími : +
Sími :
Sími
TABLETS ONLY )
TABLETS ONLY
SPECIES , ROUTE(S ) AND
SPECIES , ROUTE(S )
SPECIES ,
SPECIES
ANIMAL TREATMENT ONLY AND
prior history of TVEs (
prior history of TVEs
Table 1 lists
Table 1 lists
table 1
Table 2 ) .
Table 2 )
2
Table 2
Table
table
tablet ; systemic exposure
tablet ; systemic
tablet ;
tablet ;
Tablet Rectangular and blue ,
Tablet Rectangular and blue
Tablet Rectangular and pink ,
Tablet Rectangular and pink
Tablet Rectangular and
Tablet Rectangular
Tablet Round and yellow ,
Tablet Round and yellow
Tablet Round and pink ,
Tablet Round and pink
Tablet Round and
Tablet Round
tablet contains 15 mg pioglitazone
tablet contains 15mg of pioglitazone
tablet contains 15 mg of
tablet contains 15 mg
tablet contains 15mg of
tablet contains 15mg
tablet contains 15
tablet contains 30 mg pioglitazone
tablet contains 30mg of pioglitazone
tablet contains 30 mg of
tablet contains 30 mg
tablet contains 30mg of
tablet contains 30mg
tablet contains 30
tablet contains 45 mg pioglitazone
tablet contains 45mg of pioglitazone
tablet contains 45 mg of
tablet contains 45 mg
tablet contains 45mg of
tablet contains 45mg
tablet contains 45
tablet contains
tablet with water
tablet with
tablet
tablet at the same
tablet at the
blisters
tablet
tablets , as 10 mg
tablets , as 10
tablets , as
tablets ,
tablets .
tablets 28 tablets 30 tablets
tablets 28 tablets 30
tablets 28 tablets
tablets 28 x 1 tablets
tablets 28 x 1
tablets 28 x
tablets 28
tablets 30 tablets 50 tablets
tablets 30 tablets 50
tablets 30 tablets
tablets 30
tablets 49 x 1 tablets
tablets 49 x 1
tablets 49 x
tablets 49
tablets 50 tablets 56 tablets
tablets 50 tablets 56
tablets 50 tablets
tablets 50
tablets 56 tablets 84 tablets
tablets 56 tablets 84
tablets 56 tablets
tablets 56 x 1 tablets
tablets 56 x 1
tablets 56 x
tablets 56
tablets 84 tablets 90 tablets
tablets 84 tablets 90
tablets 84 tablets
tablets 84
tablets 90 tablets 98 tablets
tablets 90 tablets 98
tablets 90 tablets
tablets 90
tablets 98 tablets
tablets 98 x 1 tablets
tablets 98 x 1
tablets 98 x
tablets 98
tablets
tablets
tablets :
tablets
tablets
tablets
tablets contain 15 , 30
tablets contain 15 ,
tablets contain 15
tablets contain lactose monohydrate and
tablets contain lactose monohydrate
tablets contain
tablets in
tablets is pioglitazone .
tablets is pioglitazone
tablets is
tablets can be
tablets may
tablets with food and drink
tablets debossed with 20
tablets debossed with
tablets
tablets , with
tablets with
tablets
tablets , with a similar
tablets are rectangular and blue
tablets are rectangular and pink
tablets are rectangular and
tablets are rectangular
tablets are round and yellow
tablets are round and pink
tablets are round and
tablets are round
tablets are white to off-white
tablets are white
tablets are
tablets are supplied in blister
tablets are
tablets ,
tablets
tablet formulation is 87 %
tablet formulation is 87
tablet formulation is
tachycardia ,
tachycardia , nausea , vomiting
tachycardia , nausea ,
tachycardia , nausea
tachycardia
tachycardia*
day .
on day 1 and
on day 1
days 21 , 14 and
days 21 , 14
days 21 ,
days 21
day 35
day of that month .
day of that month
day of
day , before breakfast
same time each day
same time
same
day ,
day
on day
days ,
days after administration of Aclasta
days after administration of
days after administration
days after administration of
days after
days following the
days after
days following
days immediately
days
days ) low- trauma
days ) low-
days )
days.
days of the
days
days
days to a few weeks
days to
days prior to
days
daily dose should
daily dose of 15 mg
daily dose of 15
daily dose of Abilify
daily dose of
daily dose
daily
waist circumference ,
waist circumference
Takeda Europe R & D
Takeda Europe R &
Takeda Europe R
Takeda Europe
Takeda Global R & D
Norge Takeda Global R &
Takeda Global R &
Norge Takeda Global R
Takeda Global R
Takeda Global Research and Development
Takeda Global Research and
Norge Takeda Global
Takeda Global
Takeda Ireland Limited
Takeda Ireland
Takeda Italia Farmaceutici SpA Tel
Takeda Italia Farmaceutici SpA
Takeda Italia Farmaceutici
Takeda Italia
Takeda Pharma GmbH Tel .
Deutschland Takeda Pharma GmbH
Takeda Pharma GmbH
Deutschland Takeda Pharma
Takeda Pharma
Takeda Tél : +33 (
Takeda Tél : +33
Takeda Tél :
Takeda Tél
Takeda UK Ltd Tel :
Takeda UK Ltd Tel
Takeda UK Ltd
Takeda UK
Norge Takeda
Takeda
tamoxifen
anticancer
Te . : +44 (
Te . : +44
Te . :
Te .
Te
.
action .
portion of the food .
portion of the food
Teil des körpereigenen eim The
Teil des körpereigenen eim
portion of the
part , by
Component of a multi-pack comprising
Component of a
Component
Teil
of
part of
part
portion of
some of
parts of the body
participants received
participants
Tel . : + 36(0
Tel . : +
Tel . : +36 1
Tel . : +36
Tel . :
Tel .
Tel : + 31 (
Tel : + 31 34
Tel : + 31
Tel : + 34 (
Tel : + 34
Tel : + 351 21
Tel : + 351
Tel : + 353 (
Tel : + 353
Tel : + 36(0 )
Tel : + 36(0
Tel : + 39 06
Tel : + 39
Tel : + 40 (
Tel : + 40
Tel : + 43 (
Tel : + 43 1
Tel : + 43
Tel : + 43-(0)800 29
Tel : + 43-(0)800
Tel : + 44 (
Tel : + 44
Tel : + 46 8
Tel : + 46
Tel : +
Tel : +353 1 260
Tel : +353 1
Tel : +353
Tel : +371 7364000
Tel : +371
Tel : +3726441100
Tel : +386 ( 0)1
Tel : +386 (
Tel : +386
Tel : +43 1 86
Tel : +43 1
Tel : +43
Tel : +44 ( 0)20
Tel : +44 (
Tel : +44
Tel : +46 8 732
Tel : +46 8
Tel : +46
Tel : +49 911 273
Tel : +49 911
Tel : +49
Tel :
Tel
Tel . + 49 (
Tel . + 49
Tel . +
Tel .
or telithromycin or clarithromycin (
or telithromycin or clarithromycin
clarithromycin
, testosterone suppression
testosterone suppression
Tetrazyklin-Markierungen wurden bei allen außer
Tetrazyklin-Markierungen wurden bei allen
Tetrazyklin-Markierungen wurden bei
Tetrazyklin-Markierungen wurden
Therabel Lucien Pharma Tél :
Therabel Lucien Pharma Tél
Therabel Lucien Pharma
Therabel Lucien
Therabel
risk of cross-reaction .
the risk of cross-reaction .
risk of cross-reaction
the risk of cross-reaction
, especially
Abseamed
Aclasta therapy If you are
Aclasta therapy If
Aclasta therapy
therapy with pioglitazone in all
therapy with pioglitazone in
therapy with pioglitazone
therapy with
therapy
therapy is not appropriate .
therapy is not appropriate
therapy ,
therapy
discontinuation of treatment .
discontinuation of treatment
improvement during continuation therapy in
care .
of care .
care
of care
Therapy- Anaemia ( FACT-An )
Therapy- Anaemia ( FACT-An
Therapy- Anaemia (
Therapy- Anaemia
thiazides , glucocorticoids ,
thiazides , glucocorticoids
thiazides ,
thiazides
; Thiazolidinediones ; ATC code
; Thiazolidinediones ;
; Thiazolidinediones
prophylaxis by
receive adequate antithrombotic prophylaxis .
receive adequate antithrombotic prophylaxis
prophylaxis
Thrombotic events can be a
Thrombotic events can be
epoetin alfa .
epoetin alfa
Thrombocytosis has been observed
Thrombocytosis has been
Thrombocytosis
tibolone ;
tibolone
product
veterinary medicinal product
veterinary medicinal product as packaged
product
veterinary medicinal product
veterinary surgeon how
veterinary surgeon .
veterinary surgeon
veterinary surgeon or
veterinary surgeon should
veterinary surgeon will advise you
veterinary surgeon will advise you
veterinary surgeon will
veterinary surgeon
animals The safety
animals The
animals ,
animals
Studies in animals have
Studies in animals have
animal model of familial
animal models
Paclitaxel at
titanium dioxide ( E171 )
titanium dioxide ( E171
titanium dioxide (
Tlf : + 44 (
Tlf : + 44
Tlf : + 45 45
Tlf : + 45
Tlf : + 47 67
Tlf : + 47
Tlf : +
Tlf : +45 39 16
Tlf : +45 39
Tlf : +45
Tlf : +47 23 05
Tlf : +47 23
Tlf : +47
Tlf :
Tlf
or even death .
or even death
death
no fatalities .
no fatalities
tolbutamide )
tolbutamide
de pointes , bradycardia
de pointes ,
de pointes
Tours Cedex 2 , France
Tours Cedex 2 ,
Tours Cedex 2
Tours Cedex
Tours
toxicity ( reported in 79
toxicity ( reported in
toxicity (
toxicity The highest
toxicity The
toxicity In
toxicity
toxicity
humans
toxicity
transport of paclitaxel
correct
transport
tremor , dizziness , somnolence
, tremor , dizziness ,
tremor , dizziness ,
, tremor , dizziness
tremor , dizziness
tremor , syncope
, tremor ,
tremor ,
tremor Common :
tremor Common
tremor
Trial [ PFT ] (
Trial [ PFT ]
Trial [ PFT
Trial [
Trial
transfer protein ( MTP )
transfer protein ( MTP
transfer protein (
transfer protein
( zum Zeitpunkt ein
TG
inside the enterocytes
inside the
inside
prandial hypertriglyceridaemia
in
1,400
dry eye , keratoconjunctivitis sicca
dry eye , keratoconjunctivitis
dry eye ,
dry eye
drip
drip into a vein )
drip into a vein
drip
calibrated dropper
calibrated dropper
calibrated dropper
but no differences
pregnancy , lactation or
pregnancy , lactation or
pregnancy , lactation
pregnancy ,
pregnancy and lactation .
pregnancy and lactation
pregnancy and
pregnancy
lacrimation , blurred vision ,
lacrimation , blurred vision
lacrimation ,
lacrimation
was 7 times
negative impact
negative
tumours ( 172 breast ,
tumours ( 172 breast
tumours ( 683 breast
tumours (
tumours ,
either sex .
of either sex .
either sex
of either sex
and 478 other tumour types
tumours ,
tumours
that indicates an
Adult cancer
cancer
in cancer
191 Cancer patients or
191 Cancer patients or
cancer patients receiving chemotherapy ,
cancer patients receiving chemotherapy
191 Cancer
cancer patients
cancer
in cancer
tumour progression ,
tumour progression
a variety of tumour cells
type 1 )
type 1 )
type 1 ) ,
type 1 )
type 1
type
type 2 diabetes mellitus and
type 2 diabetes mellitus
type 2 diabetes
type 2
type III ) with a
type III ) with
type III )
type III
type
Typ-2-Diabetes ist eine Erkrankung
type 2 diabetes or
Typ-2-Diabetes
control type 2 diabetes
type 2 diabetes
type 2
butyl
propeptide
action of the osteoclasts ,
action of the osteoclasts
action of the
Tél : + 33 (
Tél : + 33
Tél : +
Tél : +33 ( 0)1
Tél : +33 (
Tél : +33
Tél :
Tél
Tél/ Tel : + 32
Tél/ Tel : + 44
Tél/ Tel : +
Tél/ Tel : +49 911
Tél/ Tel : +49
Tél/ Tel :
Tél/ Tel
UB8 1HU - United Kingdom
UB8 1HU - United
UB8 1HU -
UB8 1HU
UB8 1HU - United Kingdom
UB8 1HU - United
UB8 1HU -
UB8
UK Ltd Tel : +
UK Ltd Tel :
UK Ltd Tel
UK Ltd
UK Tel .
UK
ULN ) should not
ULN ) should
ULN )
ULN or ASL/ ALT >
ULN or ASL/
ULN or
ULN
ON THE OUTER PACKAGING
ON THE OUTER
ON THE
ON
CARTON OF MULTI-PACK ( INCLUDING
CARTON OF
AND 98 TABLETS ONLY )
AND 98 TABLETS ONLY
AND 98
THE OUTER PACKAGING
THE OUTER
AND ON THE
AND METHOD OF ADMINISTRATION
AND METHOD OF
AND METHOD
SUPPLY AND USE
SUPPLY AND USE
AND BOTTLE LABEL FOR
AND BOTTLE
THE REACH AND SIGHT OF
THE REACH
THE REACH
AND OTHER INGREDIENT(S )
AND SULPHONYLUREA
SUPPLY AND USE
SUPPLY AND
AND EFFECTIVE USE OF THE
AND EFFECTIVE USE OF
AND THE
AND
THE
OUT OF THE REACH
OUT OF THE
OUT OF
To enhance absorption
To enhance
In order
Injection sites
In order
Injection
Iron
To
order
adipose regions , is recommended
adipose regions ,
adipose regions
several
a small minority
small minority
protect the environment .
to protect the environment .
protect the environment
to protect the environment
protect the
to protect the
safety .
safety and efficacy of rimonabant
safety and efficacy of
safety and efficacy
safety and
safety of rimonabant
safety of
safety
Unbehagen
Adverse reactions
Adverse reactions
Adverse reactions
United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS
United Kingdom BRISTOL-MYERS SQUIBB
United Kingdom BRISTOL-MYERS
United Kingdom Takeda UK Ltd
United Kingdom Takeda UK
United Kingdom Takeda
United Kingdom
United
Irregular heart rhythm (
Irregular heart rhythm
Irregular
agitation
Non-specific skin
Using a sterile syringe ,
Using a sterile syringe
Using a sterile
Using a
Under no circumstances should you
Under no circumstances should
Under no circumstances
Using
suppress
diminished parathyroid reserve ,
diminished parathyroid reserve
diminished
diminished
subsets ranging from 517 to
subsets ranging from 517
subsets ranging from
analyses
subsets
tissue
company decided
company also carried out studies
company also carried out
company
company also presented data from
company also presented data
company also presented
company
holder :
Authorisation Holder and Manufacturer
Authorisation Holder and
Authorisation Holder
holder
Authorisation Holder .
Authorisation Holder :
Authorisation Holder :
Authorisation Holder
Authorisation
difference in overall survival between
difference in
differences .
differences in hip fracture ,
differences in hip fracture
differences in
differences
an aid in the
an aid
conduct investigations , for example
conduct investigations , for
conduct investigations ,
The carcinogenic potential
standard genotoxicity tests , aripiprazole
standard genotoxicity tests ,
standard genotoxicity tests
The safety and
The safety
standard
The
conduct investigations
low blood
, malaise
malaise
Inadequate thinning
urine
urticaria )
Urticaria , rash Very rare
Urticaria , rash Very
Urticaria , rash
urticaria and angioedema
urticaria and
urticaria
pain Uveitis , episcleritis ,
pain Uveitis , episcleritis
pain Uveitis ,
pain Uveitis
Uxbridge - Middlesex UB8 1HU
Uxbridge - Middlesex UB8
Uxbridge - Middlesex
Uxbridge -
Uxbridge
VANTAS ( see Annex I
VANTAS ( see
VANTAS (
VANTAS
PROHIBITION OF SALE ,
PROHIBITION OF SALE
PROHIBITION OF
PROHIBITION
SALE ,
SALE
THE WORDS FOR
THE WORDS
DERIVED FROM SUCH MEDICINAL PRODUCTS
PRODUCT OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL
PRODUCTS OR WASTE MATERIALS
PRODUCTS OR
PRODUCTS
LIST OF THE
LIST
VISTOR HF Sími : +
VISTOR HF Sími :
VISTOR HF Sími
VISTOR HF
VISTOR
VOLUME OR BY UNIT
VOLUME OR BY
VOLUME OR
VOLUME
WASTE MATERIALS , IF ANY
AND SIGHT OF CHILDREN
OF
OR WASTE MATERIALS
OR WASTE
WASTE MATERIALS
YOU USE
YOU
DISPOSAL OF UNUSED MEDICINAL PRODUCTS
DISPOSAL OF UNUSED MEDICINAL
DISPOSAL
valproate ( another antipsychotic medicine
valproate ( another
valproate (
valproate (
either valproate or lithium
valproate or lithium
valproate or
valproate
Vanilla flavour ( including
Vanilla
Vantas
unique Vantas
Vantas is a new
Vantas is a
Vantas is
Vantas is sufficiently investigated and
Vantas is sufficiently investigated
Vantas is sufficiently
Vantas is
Vantas
Vantas is
Vantas
unique Vantas
variability
vein (
vein
vein (
vein
( DVTs ) .
( DVTs )
Do not administer Yarvitan :
Do not administer Yarvitan
Always administer Yarvitan
Administer the product orally during
Administer the product orally
Administer the product
Always administer
Administer
administer
consistently apparent
consistently apparent
administration of a CB1 antagonist
administration of a
refrigerated solution to reach
refrigerated
Aclasta administration .
dose of Aclasta .
Aclasta administration
dose of Aclasta
administration of Aclasta
administration of CYP3A4 inducers
administration of CYP3A4 inducers
administration of
administration
following the administration
the administration
administration ,
administration
and
following the administration
the administration
dosing did not lead to
dosing did not
dosing did
dosing
markedly
multiple dosing
glycaemic control decreases
improvement in insulin sensitivity .
improvement in insulin sensitivity
improvement in
glycaemic
improvement in
improvement
as
Holder .
Holder :
Holder :
.
Holder
United Kingdom .
United Kingdom
United
procedure for reconstitution is
procedure for reconstitution
procedure for
procedure
expiry date refers to the
expiry date refers to
expiry date refers
expiry date
methods
reducing
procedures
past , testosterone suppression was
past ,
past
Ensure that you
Ensure
of
versus 8.7 % for
versus 8.7 %
versus 8.7
versus placebo :
versus placebo
versus risedronate-treated patients
versus risedronate-treated
compared to baseline .
compared to baseline
compared to
compared
versus
Between
There was
compared
significantly
versus
was
Similar changes in
Similar
a sulphonylurea active comparator group
comparative
and behaviour and
behaviour
disturbed behaviours ,
disturbed behaviours
disturbed
for sale :
for sale
Verkehr gebracht . Me
be marketed .
be marketed
ability to drive and
ability to drive and
on ability to drive and
ability
Driving and
ability
on ability
Driving
slowing of tumour progression ,
slowing of tumour progression
slowing of
slowing
observed during the clinical trials
during the
course of peripheral neuropathy to
course of peripheral neuropathy
course of
course
fall
; intercurrent infections ; inflammatory
loss of consciousness and extrapyramidal
loss of consciousness and
loss of consciousness
loss , syncope
loss ,
loss
loss
) .
)
renewal :
multiply .
multiply
decreased blood sugar ( hypoglycaemia
decreased blood sugar (
decreased blood sugar
decreased
Blister ( PVC/ aluminium )
Blister ( PVC/ aluminium
Blister (
Blister
reduction of insulin resistance .
reduction of insulin resistance
reduction in clinical fractures in
reduction in
reduction of
reduction
by decreased appetite .
followed by decreased appetite .
by decreased appetite
followed by decreased appetite
by
followed by
35 % reduction
reduction
by
followed by
reduction
worsening of
aggravation of existing hypertension .
aggravation of existing hypertension
aggravation of existing
worsening
occlusion of the dialysis system
pen cap on
obstructive
prescription ( See Annex I
prescription (
a prescription . du
with a prescription .
with a prescription
prescription
siehe Anhang
on veterinary prescription .
on veterinary prescription
version 3.0
version
metabolism
constipation , salivary hypersecretion Vascular
constipation , salivary hypersecretion
constipation , stomatitis
constipation ,
constipation
Try to take the ABILIFY
Try to take the
Try to take
Try to take
Laboratory animals and dogs rapidly
Laboratory animals and
Laboratory animals
Distribution No
Distribution
disposition phases ( and ,
disposition phases ( and
disposition phases (
disposition phases
of distribution in humans
of distribution
volume of distribution
well-tolerated
single-dose tolerability
EXP Use
EXP
EXP { month/ year }
EXP
Only use each syringe
Use
)
a sterile syringe ,
a sterile syringe
a sterile
a
use with insulin syringes with
use with insulin syringes
use with
use of zoledronic acid in
use of zoledronic acid
use of
use
using
change in aripiprazole concentrations .
change in aripiprazole concentrations
change in lumbar spine BMD
important change in valproate or
important change in valproate
change in
change in
in
changes in routine
changes in
changes
Changes in HDL-C and
Changes in HDL-C
Changes in
changes in bacterial
lifestyle changes (
lifestyle changes
changes
changes in
alter laboratory test values .
alter laboratory test values
alter laboratory
changes
Many had signs
Many had
Following the menopause bone loss
Following the menopause bone
Many
Many of these patients had
Many of these patients
Many of these
Following the menopause bone loss
Following the menopause bone
Many
You
vitamin D supplementation ,
vitamin D supplementation per day
of vitamin D supplementation per
vitamin D supplementation per
vitamin D and
vitamin D prior to
of vitamin D supplementation
vitamin D supplementation
vitamin D
of vitamin
vitamin
vitamin B12 or folate deficiency
vitamin B12 or
vitamin B12
have the following causes
Before use : store
Before use :
Before use
Complete
Patients must
Before stopping
Allow the refrigerated
Allow the
Iron status
Patients
Allow
Before
Patients
prepare and
prepare and
prevent manic episodes
prevent manic
prevent
prevention of
prevention
uncommon in the
uncommon in
Premixed insulin products are usually
Premixed insulin products
atrial fibrillation ) has
atrial fibrillation )
fibrillation serious
Atrial fibrillation Headache , dizziness
Atrial fibrillation Headache ,
Atrial fibrillation Headache
atrial fibrillation is unknown .
atrial fibrillation is unknown
atrial fibrillation is
atrial fibrillation
fibrillation incidences
fibrillation
precursors of the stem cell
precursors
proposal
in accordance
Vorsicht anzuwenden
used cautiously in patients
Vorsicht bei Patienten
Vorsicht bei
, caution should be exercised
caution should be exercised
Caution
Vorsicht
caution
precautions
precautions for use in
precautions for use
precautions for use
precautions for
precautions for
precautions for
precautions
SPECIAL WARNING THAT THE
SPECIAL WARNING
WHAT ABILIFY IS AND WHAT
WHAT ABSEAMED IS AND WHAT
WHAT ACLASTA IS AND WHAT
WHAT ACTOS IS AND WHAT
BEFORE YOU
BEFORE
BEFORE YOU
BEFORE
WHAT
WC2B 4AE , United Kingdom
WC2B 4AE , United
WC2B 4AE ,
WC2B 4AE United Kingdom
WC2B 4AE United
WC2B 4AE
WC2B
IT IS USED FOR
IT IS
IT
EFFECTIVE USE OF THE PRODUCT
SUPPLY
EFFECTIVE USE OF THE
EFFECTIVE USE OF
EFFECTIVE USE
SCIENTIFIC EVALUATION
SCIENTIFIC
growth
growth factor
growth
growth
growth factors that primarily
growth factors
growth factors
growth
growth hormone and danazol .
growth hormone and danazol
growth hormone and
growth hormone
delusion and paranoia .
delusion and paranoia
delusion and
delusion
beliefs , incoherent speech
beliefs
of
experiencing
of experiencing
experiencing
of experiencing
it less likely
less likely
likely
Warfarin ( CYP2C9-Substrat ) und
Warfarin ( CYP2C9-Substrat )
Warfarin ( CYP2C9-Substrat
warfarin )
warfarin ,
warfarin
warnings and precautions for
warnings and precautions
warnings and
warnings
be paid to sudden stabbing
be paid to sudden
be paid
What ABILIFY contains The
What ABILIFY contains
What ABILIFY
What Actos contains The
What Actos contains
What Actos
What ABILIFY is and
What ABILIFY is
What Abseamed is and
What Abseamed is
What Aclasta is and
What Aclasta is
What Actos is and
What Actos is
What
water and
water
water and swallow it
and water for injections .
water for injection .
water for injections .
Water for injections Hydrochloric acid
Water for injection
Water for injections
and water for injections
water for injection
water for injections
Water for
and water for
water for
of water .
water .
of water
water
Water
and water
of water
water
Way Wingates Industrial Park Westhoughton
Way Wingates Industrial Park
Way Wingates Industrial
Way Wingates
Way
menopause
an interaction between epoetin alfa
an interaction between epoetin
an interaction between
an interaction
interactions
interaction
Interactions with
Interaction with other medicinal products
Interactions with other
Interaction with
Interactions with
Interaction
Interactions
interaction
interactions
by multiple pathways involving the
by multiple
Due
Tartaric acid Sodium hydroxide
Tartaric acid Sodium
Tartaric acid
tartaric acid
manner
Further studies also looked
Further studies
Additional signs may include
further comparative studies are not
and further comparative studies are
further comparative studies are
and further comparative studies
further comparative studies
Further
exercise , to treat
Which measures are being
exercise ,
Which measures
exercise ,
Which
exercise
What benefit has Abraxane
What benefit has Aclasta
What benefit has Actos
What benefit has Actraphane
What benefit has
What benefit
What
Welches Risiko ist mit
Welches Risiko ist
Welches Risiko
2/ 3 What
Welches
Wellington Road Wokingham Berkshire RG40
Wellington Road Wokingham Berkshire
Wellington Road Wokingham
Wellington Road
Wellington
Less than 1 % of
Less than 1 %
Less than 1
Less than
Less
When activity , concentrations and
When activity , concentrations
When activity ,
When activity
When aripiprazole was administered concomitantly
When aripiprazole
If your levels of the
If your levels
If your
If you have polycystic ovary
If you have the impression
If you
If you
if you are
If you experience these symptoms
If you experience these
If you experience
If you accidentally
If you have any further
If you have further
If you have any
If you need
If you are
If you have
If you
You
if you are
if you have
if you
if you
you
if you have had sections
you have had some or
you have had some
if you have
you have had
When the CYP3A4 or
When the CYP3A4
When the CYP3A4 inducer
If the haemoglobin is
If the
When the
If ALT levels
If the suspension contacts the
If the suspension contacts
If the
If hypersensitivity occurs
If hypersensitivity
If any of these
Other psychiatric
If any
If
When either valproate or lithium
16 When either valproate or
27 When either valproate or
38 When either valproate or
5 When either valproate or
When either valproate or
16 When either valproate
27 When either valproate
38 When either valproate
5 When either valproate
When either valproate
16 When either
27 When either
38 When either
5 When either
When either
When concomitant
When considering concomitant administration
When considering concomitant
If after
Additional supportive
When performing haematologic assessments during
When weak inhibitors of CYP3A4
85 When weak inhibitors of
When weak inhibitors of
85 When weak inhibitors
When weak inhibitors
85 When weak
When weak
5 When
If
In case
When
mean
levels of the red blood
levels of the
levels of
levels
West Forest Gate Wellington Road
West Forest Gate Wellington
West Forest Gate
West Forest
West Sussex , RH12 5AB
West Sussex , RH12
West Sussex ,
West Sussex
West
Westhoughton BL5 3XX United Kingdom
Westhoughton BL5 3XX United
Westhoughton BL5 3XX
Westhoughton BL5
Westhoughton
Westferry Circus ,
Westferry Circus
Wharf
signs and symptoms of
Wichtige Informationen über
Important information about some
Important information about some
Important information about
Important
of
Wicklow .
Wicklow
What ABILIFY looks like and
What ABILIFY looks like and
What ABILIFY looks like
What ABILIFY looks like
195 What Abseamed looks like
What Aclasta looks like and
What Aclasta looks like
What Actos looks like and
What Actos looks like
Like all medicines
Like all
As with all growth factors
As with all
As with other antipsychotics ,
As with other antipsychotics
As for other insulin products
As for other
As with other
52 As with any
As with any
52 As with
As for
As with
However , as with
How to
How
Like
Following recurrence of severe neutropenia
Following recurrence of severe
Following recurrence of
Following recurrence
preventing
recurrence of manic episodes in
manic episodes
manic
recurrence of manic
recurrence of
Repeat dosing did not
Repeat dosing did
Repeat
Wielka Brytania Tel : +44
Wielka Brytania Tel :
Wielka Brytania Tel
Wielka Brytania
Wielka
Wimblehurst Road Horsham West Sussex
Wimblehurst Road Horsham West
Wimblehurst Road Horsham
Wimblehurst Road
Wimblehurst
Wingates Industrial Park Westhoughton BL5
Wingates Industrial Park Westhoughton
Wingates Industrial Park
Wingates Industrial
Wingates
Winthrop Industrie , 30-36 Avenue
Winthrop Industrie , 30-36
Winthrop Industrie ,
Winthrop Industrie
Winthrop
vertebral fracture (
vertebral fracture(s ) .
vertebral fracture(s )
vertebral fracture
vertebral fractures Aclasta significantly decreased
vertebral fractures Aclasta
vertebral fractures did
vertebral fractures
If epoetin alfa
If epoetin
If
Mechanism of action
efficacy .
efficacy .
efficacy in men In the
efficacy in men In
efficacy in men
efficacy in the treatment of
efficacy in the treatment
efficacy in the
efficacy in
efficacy
efficacy in the treatment
efficacy of one infusion of
efficacy .
efficacy
both long-term efficacy and safety
efficacy and safety
efficacy and safety of rimonabant
efficacy and safety of
efficacy and safety
efficacy and
effectiveness of Abraxane has been
effectiveness of Abraxane
effectiveness of Abseamed .
effectiveness of Abseamed
efficacy of Abseamed
aripiprazole s efficacy in schizophrenia
aripiprazole s efficacy in
aripiprazole s efficacy
efficacy of epoetin alfa
efficacy of epoetin
efficacy of M-II
efficacy of rimonabant
effectiveness of
effectiveness
efficacy of
s efficacy
effectiveness was whether
effectiveness was the number of
effectiveness was the number
effectiveness was the
effectiveness was
effectiveness
efficacy to
efficacy
of efficacy
s efficacy
terms of
terms
efficacy variable was the incidence
efficacy variable was the
efficacy variable was
efficacy variable
active substance in Abilify ,
active substance in Abilify
active substance in Aclasta ,
active substance in Aclasta
active substance in
active substance is aripiprazole .
active substance is aripiprazole
active substance is
active substance is aripiprazole .
active substance is aripiprazole
active substance is
active substance
of
multiple doses given
agents (
agents .
agents
agents
drug exposure ( AUC )
drug exposure ( AUC
drug exposure (
drug exposure
biological active substance
the compound or metabolites .
the compound or metabolites
the compound or
active substance
possibility of your becoming
antagonism of serotonin
effect .
effect
effect of the infusion lasts
effect of the infusion
effect of the
effect of adding
effect was maintained
desired effects should be
desired effects should be
effect of ACOMPLIA in
effect of ACOMPLIA
effects of Abraxane (
effects of Abraxane
effect of Actos 15mg
effect of Actos 30mg
effect of Actos 45mg
effect of Actos
effect of medicines used
effect of insulin
effect of pioglitazone (
effect of pioglitazone
of effect of zoledronic acid
effect of
effects of
of effect of
desired effects
effect
effects
effect over
effects of ACOMPLIA were
effects of ACOMPLIA
effects of Abraxane were
effects of Abraxane
effects may
effects may
effects of
effects were
effects
foetal effects
therapeutic
mechanism of action is unknown
mechanism of action is
mechanism of action
efficacy or other symptoms of
efficacy or other symptoms
of efficacy or other symptoms
efficacy or other
loss of efficacy or other
of efficacy or other
efficacy or
loss of efficacy or
of efficacy or
efficacy
loss of efficacy
of efficacy
present state of the art
present state
times per week
times
week .
week by the intravenous route
week by the intravenous
week by
times
week
weeks ( days 21 ,
weeks ( days 21
weeks (
weeks )
weeks .
weeks .
weeks in a total of
weeks in a total
weeks in
weeks
weeks the level of a
weeks the level
weeks the
weeks
weeks when used or
weeks when used
weeks after your
weeks after
weeks after
weeks after
weeks following
weeks
weeks prior to
a few weeks .
a few weeks
weeks ,
weeks
Wokingham Berkshire RG40 2AQ United
Wokingham Berkshire RG40 2AQ
Wokingham Berkshire RG40
Wokingham Berkshire
Wokingham
EPAR for ACOMPLIA
EPAR for Abilify
EPAR for Actraphane
EPAR for
EPAR for Abraxane
EPAR for
EPAR
sores of the mouth or
sores of
sores
Following dosing
Following
Following dosing for a longer
Following dosing for a
Following dosing for
Following dosing
Following
Frequent monitoring of blood cell
Loss of
While on treatment ,
While on treatment
There may be a moderate
18/ 20 During the first
During
While on
During
Loss
There
While
dioxide ,
Silicon dioxide Xylitol Microcrystalline cellulose
Silicon dioxide Xylitol Microcrystalline
Silicon dioxide Xylitol
dioxide
Yarvitan 5 mg/ ml
Yarvitan 5
Yarvitan is indicated as
Yarvitan is a colourless
Yarvitan is a
Yarvitan is
product .
product
Yarvitan
product
central
generally not well
generally not well
AUTHORISATION
TO BE IMPLEMENTED BY
, labelling and package
labelling and package
, labelling and package
labelling and package
blood
at the number of patients
number of
number
dentist .
dentist
, poor
poor
prudent
tooth extractions or other
tooth extractions or
tooth extractions
toothache
,
important signs and symptoms
important signs and
important signs
forefinger .
forefinger
time
time to
time to disease progression [
time to disease progression
time to
time until
time each day .
time each day
period
period
time
duration of the study .
duration of the study
duration of the
duration
failure in patients
the clinical course ,
the clinical course
timepoints ( 6 , 12
timepoints ( 6 ,
timepoints ( 6
timepoints (
timepoints .
timepoints
over
Abraxane over
duration ,
duration
it
not
over a period of
over a period
over
cells cannot divide and
cells cannot divide
cells cannot
cells
count has increased
mitotic cellular functions
, flare
microtubules throughout
Withdraw the needle quickly
Withdraw the needle
Withdraw the
Withdraw
maintain haemoglobin concentration between
maintain haemoglobin concentration
haemoglobin of
haemoglobin of greater than 12
haemoglobin of greater than
haemoglobin
after repeated dosing
after
Zinc chloride Glycerol Metacresol Phenol
Zinc chloride Glycerol
Zinc
zoledronic acid ( 5 mg/
zoledronic acid ( anhydrous )
zoledronic acid ( anhydrous
zoledronic acid anhydrous
zoledronic acid (
zoledronic acid
zoledronic acid ) ,
zoledronic acid ) ,
zoledronic acid )
zoledronic acid , is a
zoledronic acid , is
zoledronic acid ,
zoledronic acid anhydrous ,
zoledronic acid in pregnant women
zoledronic acid in
zoledronic acid .
Zoledronic acid belongs to
zoledronic acid must be
Zoledronic acid is not systemically
Zoledronic acid is not
Zoledronic acid is
Zoledronic acid has been
Zoledronic acid
zoledronic acid ,
zoledronic acid anhydrous
zoledronic acid in
zoledronic acid
zoledronic acid monohydrate .
zoledronic acid monohydrate
Zometa ( zoledronic acid )
Zometa ( zoledronic acid
Zometa (
Zometa , some
Zometa ,
Zometa
Undesirable effects known to
Undesirable effects known
Late in
dogs for breeding purposes has
sugar in urine , proteins
sugar
In addition , paclitaxel induces
In addition , paclitaxel induces
calcium and vitamin
calcium and
calcium
complete ,
complete
an increase
, tongue oedema ,
, tongue oedema
tongue .
tongue
glossodynia , dry mouth
glossodynia , dry
glossodynia
Only
Only
For the treatment of post-menopausal
For the treatment of
For single tablet removal ,
For single tablet removal
For preventing recurrence of manic
82 For preventing recurrence of
For preventing recurrence of
82 For preventing
For preventing
As an aid in the
As an aid
The orodispersible tablets are taken
Retreatment of Paget s disease
Retreatment
Intramuscular use Read the
Intramuscular use
Intramuscular
82 For
For
There is
There
Use
2 Adequate calcium and vitamin
Adequate calcium and vitamin
Adequate supplements of vitamin
Adequate calcium and vitamin
Summary of Product Characterisitics
Summary of Product Characteristics for
Summary of Product Characteristics
Summary of Product
Summary of
Summary
Summary of
conditions for the use of
Summary
conditions for the
conditions for
associated with antipsychotic
comparable with
linked to
with
rat .
rat
linked to
side
promotes
to reliably
to reliably
condition is controlled .
condition is controlled .
condition is controlled
condition is controlled
condition
condition
who have a
In addition
In addition ,
In addition
Therapeutic
Additional adverse events which
Additional adverse events
Additional adverse
Additional
Although there is no
Although there is
Two other smaller , randomised
snack containing carbohydrates .
snack containing carbohydrates
cysts and polyps ) :
cysts and polyps )
cysts and polyps
cysts and
cysts
cytotoxic agents .
of cytotoxic agents .
cytotoxic agents
of cytotoxic agents
Cytotoxic actions of epoetin alfa
Cytotoxic actions of epoetin
Cytotoxic actions of
Cytotoxic actions
[ 15.0 , 18.3 ]
[ 15.0 , 18.3
[ 15.0 , 19.3 ]
[ 15.0 , 19.3
[ 15.0 ,
[ 2.7 % ] )
[ 2.7 % ]
[ 2.7 %
[ 2.7
[ 3.2 % ] )
[ 3.2 % ]
[ 3.2 %
[ 3.2
[ 39.0 , 55.3 ]
[ 39.0
[ 7.54 , 18.93 ]
[ 7.54
[ 95 % CI ]
[ 95 % CI
[ 95 %
[ 95
[ PFT ] ( see
[ PFT ] (
[ PFT ]
[ PFT
[ RFT ] )
[ RFT ]
[ RFT
[
] ( weeks )
] ( weeks
] ( n = 131
] ( n = 135
] ( n =
] ( see section 5.1
] ( see section
] ( see
] (
] ) .
] ) and placebo (
] ) and placebo
] ) and
] )
]
a
in a
tissue .
tissue
but can cause side effects
but no
although not everybody gets
enzymes but not CYP1A
but not
but only 0.01
but only
, but a
, but
but a
but with
but
cell volume .
cell volume
are
emaciated appearance , dehydration and
emaciated appearance , dehydration
emaciated appearance ,
emaciated
sounds , pleural effusion ,
sounds ,
sounds
been observed .
been observed
.
must be discontinued .
be discontinued
must be discontinued
discontinued
patient group .
patient group
vary with age
vary with
abnormal
levels of fat in their
abrupt improvement in
intentional acute
intentional
absolute bioavailability of rimonabant has
absolute bioavailability of
absolute bioavailability
absolute change in
absolute oral bioavailability of the
absolute oral bioavailability of
absolute oral
absolute
absolute bioavailability of 100 %
absolute bioavailability of 100
absolute bioavailability of
absolute bioavailability
should be discontinued ( see
should be discontinued (
should be discontinued .
should be discontinued
eight main
eight
eighth
year .
acknowledged
year
properties in animal
active ( M-II
active (
active
active
active metabolites are extensively
active metabolites
active
active malignant disease
. dic Me
relevant modules .
the relevant modules .
to the relevant modules .
relevant modules
the relevant modules
to the relevant modules
current suicidal ideations and/
current Safety
current
current
current
acute intoxication with Aclasta
acute intoxication with
acute intoxication
acute
non-
acute renal failure .
acute renal failure
acute renal failure
acute
antihypertensive medications
SAWP .
SAWP
accumulation
alfa , given weekly
alfa ,
alfa ,
alfa Abseamed 3000 IU/ 0.3
alfa Abseamed 3000
alfa Abseamed 4000 IU/
alfa Abseamed 5000 IU/
alfa Abseamed 6000 IU/ 0.6
alfa Abseamed 6000 IU/
alfa Abseamed 7000
alfa Abseamed 8000 IU/ 0.8
alfa Abseamed 8000
alfa Abseamed 9000
alfa Abseamed
alfa
alfa alters the metabolism of
alfa alters
alfa on bone marrow cells
alfa on
may occur in epoetin alfa
alfa in adult patients with
alfa in adult patients
alfa .
alfa
alfa in cancer patients .
alfa in cancer patients
alfa is a
alfa is very wide .
alfa is very wide
alfa is very
alfa is
alfa may
alfa should be
alfa and G-CSF or GM-CSF
alfa and other erythropoiesis-stimulating agents
alfa and other erythropoiesis-stimulating
alfa and other
alfa and
alfa is
alfa has been
alfa did not show any
alfa is given concomitantly with
alfa is given concomitantly
alfa in
alfa
alkaline phosphatase ( BSAP )
alkaline phosphatase ( BSAP
specific alkaline phosphatase ( BSAP
alkaline phosphatase (
specific alkaline phosphatase (
alkaline phosphatase
specific alkaline phosphatase
alkaline
specific alkaline
alkaline phosphatase level 2.6
alkaline phosphatase level
alkaline phosphatase
detected following
detected
every 3 weeks
every 3 weeks
every 3
all instructions given to
all instructions given to
all instructions given
all medicines
sizes may be marketed
alle Packungsgrößen in
sizes may
alle Packungsgrößen
sizes may
all
all cancer patients
all active metabolites are extensively
all active metabolites
all active
, every three weeks .
every three weeks .
, every three weeks
every three weeks
, every three
every three
all clinical fractures The incidence
all clinical
every four weeks
every four
, every
all of
all
alle
every
alone
its own
on its own
own
act mainly by being a
act mainly
mainly
all bisphosphonates , patients taking
all of whom it resolved
all of whom it
all patients receiving
all patients were 39.5
all patients were
all patients receiving
all patients
all growth factors
all timepoints ( 6 ,
all timepoints ( 6
all timepoints (
all timepoints .
all timepoints
allen außer einer von
allen außer einer
allen außer
All
all of whom
all of
all
allen
all formulations ) should
all formulations )
all formulations of aripiprazole )
all formulations of aripiprazole
all formulations of
all formulations
all
of
of
allergic reaction ( e. g.
allergic reaction (
hypersensitivity occurs ,
hypersensitivity occurs
allergic reaction
hypersensitivity
reactions have been
reactions have
serious allergic reactions .
serious allergic reactions
serious allergic reactions
cause allergic reactions ( possibly
cause allergic reactions (
may cause allergic reactions .
may cause allergic reactions
cause allergic reactions
serious allergic reactions
allergic rhinitis , hoarseness ,
allergic rhinitis , hoarseness
allergic rhinitis ,
allergic rhinitis
allergic symptoms , may
allergic
hypersensitivity ( N =
prevent hypersensitivity ( N =
hypersensitivity ( N
prevent hypersensitivity ( N
hypersensitivity (
prevent hypersensitivity (
hypersensitivity
prevent hypersensitivity
contributing
than 1 % of
than 1 %
than 1 patient in 10
than 1
than 1
than 1 patient
than 1
as 10 mg , 15
as 10 mg ,
as 10 mg
than 10
as 10
than 15 minutes .
than 15 minutes
than 15
as
than 2 g/ dl (
than 2 g/ dl
than 2
3 sites of metastases .
3 sites of metastases
3 sites of
3 sites
3
as
than 30 % of patients
than 30 % of
than 30 %
than 30
as 5 mg , 10
as 5 mg ,
as 5 mg
as 5
than 6 months ago
than 6
as an anticancer medicine
as first-line
as hydrochloride ) .
as hydrochloride )
as hydrochloride
as hydrochloride ) )
as hydrochloride ) .
as hydrochloride )
as hydrochloride )
as hydrochloride .
as hydrochloride
as hydrochloride
give by injection under the
given by injection under the
give by injection under
given by injection under
give by injection
given by injection
than children
than children over 30 kg
than children over 30
than children over
as class
as monotherapy or combination therapy
as monotherapy or
as monotherapy was
administered as a
as monotherapy
than risedronate .
than risedronate
as triple
by a decrease in haemoglobin
by a decrease in
by a decrease
by a decrease in
by a decrease
may act as growth factor
act as growth factor
as growth
than in those with schizophrenia
than in those with
als bei Patienten ohne Adipositas
als bei Patienten ohne
als bei Patienten
than in those
than for haloperidol (
than for haloperidol
als bei
can occur
in
occur
than the
than those observed after the
than those observed after
than those
than
than three
than one year ,
than one year
than one year
rather than of the elimination
rather than of the
rather than
as a single
administered intramuscularly as
be administered by intravenous infusion
administered by intravenous infusion ,
administered by intravenous infusion ,
administered by intravenous infusion
administered by intravenous infusion
administered by intravenous
than conventional paclitaxel-containing medicines
identified as possibly medically relevant
considered not known (
considered not known
was considered non-genotoxic .
was considered non-genotoxic
as non
as
than normal .
than normal
than normal
is deemed necessary in
is deemed necessary
deemed necessary in
deemed necessary
by being a
in sudden and
in sudden
serious adverse events
used as secondary endpoints
used as secondary endpoints
than placebo , or were
than placebo , or
than placebo ,
than placebo
than
, than
a
als
as a
as a
as an
as non
as the patient
as the
as triple
as
be
conditions other than
considered to
considered
events
in
more than
other than
than
who have difficulty
in schizophrenic
at the end of the
at the end of the
at the end
or too near
human
at the infusion site
at the infusion site
emission tomography .
emission tomography
site conditions Uncommon -
site conditions Uncommon : fatigue*
site conditions Uncommon :
site conditions Uncommon
site conditions Common :
site conditions Common
site conditions
best to treat
most frequently occurring undesirable effect
most frequently
, rigors
of the
the
to
trials involving 1,228 schizophrenic patients
trials involving 1,228 schizophrenic
conducted in 375 anaemic patients
conducted in 375 anaemic
in 384 patients .
in 384 patients
in 384
patients participating in
in 63 patients with metastatic
in 63 patients with
in 63 patients
in 63
of ABILIFY oral solution
of ABILIFY
and mammalian cell
mammalian cell
disappear in patients with
serum albumin-paclitaxel nanoparticles .
serum albumin-paclitaxel nanoparticles
( anencephaly
anencephaly
studied in humans .
studied in humans
of patients who
of patients
bound to plasma proteins (
bound to plasma protein (
bound to plasma protein
bound to plasma proteins
in type 2 diabetics .
in type 2 diabetics
fibrillation
whose arteriovenous fistulae exhibit complications
whose arteriovenous fistulae
involving 460 women with
involving 460 women
involving 460
involved in the
the injection site using an
injection site
the injection site
in the rat
in the pharmacokinetic analysis
an
in the
involving
have polycystic ovary syndrome
have polycystic ovary
at one injection site should
at one injection site
an
since
in two species , both
in two species ,
in two species
in two
an
blood cells
dog infusion
dog
in
involving
of
since
to
women
hr/
anaphylactic reaction .
anaphylactic reaction
anaphylactic reaction/ shock
and t½ 1.87
and t½
and
antipsychotic
other medicinal products :
other medicinal products
bisphosphonates .
but excluded other bisphosphonates .
but excluded other bisphosphonates
bisphosphonates
other bisphosphonates
different dose .
different dose
non-cancer cells such as blood
non-cancer cells such as
other symptoms of
other symptoms
other parts of the body
other antipsychotic drugs should be
other antipsychotic drugs
Other
other
taken other
other .
other antipsychotics , aripiprazole should
other antipsychotics ,
other antipsychotics
other causes of anaemia (
other causes of anaemia
other drug types were
other drug types
medicines known to
medicines
medicines known
medicines known
medicines may
other medicinal products and other
other medicinal products and
other medicines to reduce
other medicines to
benefit from
from
may benefit from
medicines known
medicines
other medicinal products
other medicinal products
other medicines
with ACOMPLIA , see
other ingredients .
other ingredients
other bisphosphonates .
other bisphosphonates
other CYP enzymes or
other dental surgeries .
other dental surgeries
other antidiabetic medicine (
another antidiabetic medicine ) in
another antidiabetic medicine )
another antidiabetic medicine
other antidiabetic medicines ( metformin
other antidiabetic medicines (
to other antidiabetic medicines (
other antidiabetic medicines
to other antidiabetic medicines
other erythropoiesis-stimulating agents (
other erythropoiesis-stimulating agents
other erythropoiesis-stimulating
other human insulin
other indications
other insulin products ,
other insulin products
allowed to come into
other face. .
other face.
study
other atypical antipsychotic
other atypical
other three
other potent CYP3A4 inhibitors with
other potent CYP3A4 inhibitors
other clinical effects of
other clinical effects
other clinical
other oral
to other oral
other potentially toxic compounds ,
other potentially toxic compounds
other potentially toxic
other potentially
another ( see section
another ( see
another (
another
other CNS medicinal products with
other CNS medicinal products
other CNS
allowed to
another
benefit from
from
may benefit from
other
to other
with other
with
other medicinal products :
other medicinal products .
other medicinal products
other medicinal products
other medicinal
other illnesses
Another LHRH agonist
of other races .
other races .
of other races
other races
of other
other
another antipsychotic medicine ) in
another antipsychotic medicine )
another antipsychotic medicine
another
otherwise decided
decided
has
androgen dependent .
androgen dependent
androgen dependent
appropriate
is
it is
seriousness .
be presented .
be presented
seriousness
dietician and lp
dietician and
dietician
the concomitant
period of risk .
period of risk
includes appropriate dietary changes
appropriate lifestyle changes
appropriate
,
adequate
adjusted to
be adjusted until your
be adjusted until
be adjusted
adjusted
father
tense .
tense
tense .
tense
cells/ µl
cells/ µl
, when oral
, when
,
given when treatment
given when
.
used :
used for 2.
used to treat adults
used
( see section
( see
angewendet werden ( siehe Abschnitt
be used ( please see
angewendet werden (
be used (
be administered until
if you are
be administered
be used
.
Leaflet .
agents .
closely .
medicines .
agents
angewendet werden
be administered
be used
closely
liver
used
used
administered
is on
is
used
was used
administered
angewendet
combination
given
medicines
used on its
used on
used
indicated for combination
indicated for
indicated as an aid
indicated as
indicated
long-lasting effect is needed .
long-lasting effect is needed
long-lasting effect
using a standard scale for
using a standard scale
using a
using
approximately 20 %
approximately 20
approximately 6 hours has been
approximately 6 hours
approximately 6
approximately 60 % in
approximately 60 %
approximately 60
approximately
production .
production
production .
production
then 180 mg/ day for
and subsequently increase during the
anschließende biliäre
and biliary excretion .
biliary excretion .
and biliary excretion
biliary excretion
working ,
working
working ,
working
responds
ansteigt . Die
ansteigt . Die
ansteigt . Die
ansteigt .
ansteigt
strenuous physical exercise may
animal models of
ongoing antidepressive treatment ( see
ongoing antidepressive treatment (
ongoing antidepressive treatment
ongoing antidepressive
anticancer medicinal product and ,
anticancer medicinal product and
anticancer medicinal product
anticancer
antipsychotic drugs should be
antipsychotic drugs
antipsychotic drug
antipsychotic agents
antipsychotic
compound
.
use in dogs with
use in dogs
use in
use
anzuwenden
benzodiazepine may be
benzodiazepine
anaemic rats , polycythaemic mice
anaemic rats ,
anaemic rats
anaemic
ready to use ( see
ready to use (
ready to use
by the intravenous route .
by the intravenous route
arterial
arterial
active substance in ACOMPLIA
active substance in Actos
active substance in
active substance in
active substance
active substance
active
active substance or to
active substance or
active substance
active
followed during preparation of the
followed during preparation of
followed during preparation
4.8 ) .
atstovyb Tel . +370 (
atstovyb Tel . +370
atstovyb Tel .
atypical antipsychotic agents ,
atypical antipsychotic agents
atypical antipsychotic
atypical
also section 4.4 ) .
also section 4.4 )
also section 4.4
also section
and hyperglycaemia ,
hyperglycaemia ,
and hyperglycaemia
hyperglycaemia
also called serotonin ) .
also called serotonin )
also called serotonin
which also
also indicated for combination
also indicated for
also indicated
also be necessary
also
also known as non
also known as
also known as non
also known as
also known
insulin requirement .
insulin requirement
to learn how
to learn
learn
also be given in
also be used .
also be used
delayed ) .
delayed )
delayed
also be
also want
also
and
auch
both
including
which also
( less than
( less
(
of
to
to
.
conditions .
of treatment .
to 15 minutes caused
to 15 minutes
to 15
to 16736
18-week trial
to 200 kg
to 200
to affect ABILIFY :
to ABILIFY tablets , ABILIFY
to affect ABILIFY
the request of the EMEA
the request of the EMEA
the request of the
the use of Abraxane as
for the use of Abraxane
the use of Abraxane
for the use of
the use of
for the use
the use
on reports
on reports
and nerve cells ,
and nerve cells
on CYP2C8 .
on CYP2C8
of CYP2C8 in vivo
of CYP2C8 in
of CYP2C8
to insulin human ( rDNA
to insulin human (
to insulin human
on bone marrow cells
to zero and
to zero
to pioglitazone or any
to pioglitazone or
to pioglitazone
side effects
to you
efficacy and
efficacy
on all clinical
on all
to other
estimated at about 90 %
on overall survival
on body weight appeared to
of
on the human insulin molecule
on the PANSS Excitement
on the PANSS
on the
on results of a full
on results of
on results
on bone .
on bone
to the last day of
to the last day
to the last
on
to the
on laboratory assessment
on the other .
on the other face. .
on the other face.
on the other
on one side and
on one side
on laboratory assessment
on the
on
responded to treatment
on the disposition of paclitaxel
on the disposition of
on the disposition
increased to the level
pad .
pad
on fertility or oestrous
on bone mineral density (
on height
pharmacokinetics in moderate
pharmacokinetics in
on the pharmacokinetics of aripiprazole
on the pharmacokinetics of
on the pharmacokinetics
affect protein binding
of the
the
on the ability
on ability
on the ability
on the tongue .
on the tongue
at the major
specifically to the unique
specifically to the
specifically to the unique
specifically to the
affect
auf die
of the
on bone
on fertility
on the
on the
on
on
the
to the
on one
a portion of the food
a portion of the
a portion of
a
on a benefit-risk assessment with
on one side .
on one side
auf eingeschränkte ärztliche Verschreibung
estimated about 24 hours
to approximately one-half of its
to approximately
on in vitro
on in vitro studies
on in
source insulin
source
on mg/ m ) .
on mg/ m2 ) .
on mg/ m )
on mg/ m2 )
on mg/ m
on mg/ m2
on morphometric vertebral fractures Aclasta
on morphometric vertebral fractures
on morphometric
a multiphasic manner .
in a multiphasic manner .
a multiphasic manner
in a multiphasic manner
multiphasic manner
multiphasic
without food .
without food
without
, becoming
,
, becoming
,
affect
at
auf
be
for the
of treatment
of
on
the
to affect
to
obtained with a prescription .
obtained with a prescription
obtained with
obtained
the outer carton in order
the outer carton in order
outer
outer
of children .
and transport refrigerated ( 2°C
and transport refrigerated (
and transport refrigerated
of children
notable important
notable
reactions related to
reactions
reactions
1.8.1 .
1.8.1
effects listed
studies and additional
studies and
studies
listed
have
have
of rimonabant
rimonabant
heart failure was observed .
heart failure was observed
heart failure was
a kidney patient
assessed by
due to co- morbidities
due to
due to
due
of tumour due to
of tumour due
tumour due to
tumour due
dissolve
dosing
position , or may
position , or
can be
can be
occur .
occur during treatment .
therapy .
treatment .
may occur in
may occur
occur during treatment
occur in
occur
therapy
treatment
occurring undesirable effect .
occurring undesirable effect
stabbing migraine- like headaches as
stabbing migraine-like headaches as a
stabbing migraine-
stabbing migraine-like
stabbing
( see section 4.8
( see section
( see
(
occurs ,
.
occurs
.
of obese
children .
children
opening .
opening
in cartons
of glass ( type 1
of glass ( type
of glass (
of glass
from precursors
amber glass
( N=70
N=70
from the systemic circulation
from the
from the
from
removed from the bottle
output from the liver .
output from the liver
of dietary lipids .
of dietary lipids
the study population
from the published literature
from the
of
the
from a
of dissolved insulin and isophane
of dissolved insulin and
of dissolved insulin
of dissolved
from human tumour samples ,
from human tumour samples
clinical
recombinant DNA technology in Saccharomyces
recombinant DNA technology in
recombinant DNA technology
aus
from
made
rate
loss of appetite .
loss of appetite
increased tactile hyperesthesia were ro
tactile hyperesthesia were ro
increased tactile hyperesthesia were
tactile hyperesthesia were
excluded
of
of
exposure produced
exposure
adequate supplementation
adequate and well-controlled studies
adequate and well-controlled
adequate and
adequate
ausreichenden Daten am
insufficient
has to be administered intravenously
has
central
is authorised provided the source
is authorised provided the
autologous
except in paediatric patients
except in paediatric
except in
außer einer von
außer einer
außer
except
also carried out studies
also carried out
also
, d. o. o.
ba Latvij Tel : +371
ba Latvij Tel :
ba Latvij Tel
ba Latvij
ba
d.
is based on
based
based on one
based on mg/ m )
based on mg/ m2 )
based on mg/ m
based on mg/ m2
based on
based
is based only on reports
is based only on reports
is based only on
is based only
is based
before use .
3.
before use
possible warning signal .
possible warning signal
can only be
patient be aware
means that aripiprazole
means that aripiprazole
means the inability to
means that the
means that
means that
means the
means
means the
means
important differences .
important differences
important
vehicles , until they
vehicles , until
impact
may impact
concomitantly .
affect
concomitantly
disrupts signals transmitted between brain
not listed in this leaflet
serious
did not impair fertility in
did not
ECOG
hepatic impairment may be
hepatic impairment
should be discontinued .
should be discontinued
discontinued
also looked at long-term use
also looked at
also looked
be followed .
be followed
completed suicide ( see section
completed suicide ( see
completed suicide (
completed suicide
begins .
begins
groups
groups
iron stores .
should be initiated .
iron stores
should be initiated
ina
limited number
limited data ,
limited data
limited
( see section 4.3
( see section
( see
(
value
value
should be treated
be treated
been treated
were treated
been treated
cases reported
treated for
treated
were treated
% of patients treated with
being treated
treated ,
treated with
treated
behandelte ) Dyslipidämie eingeschlossen
behandelte )
behandelte
for
women treated
treated group .
treated group
patients treated
occur in
patients treated
treated patients
treated with
treated
vigilantly
a treatment related increase in
at 0.1 mg/ kg
at 0.1
141
at 180 mg
at 180
in 2.3 % of
in 2.3 %
in 2.3
229 patients
in 24 % of
in 24 %
in 24
in 29 % of the
in 29 % of
in 29 %
in 29
2°C - 8°C .
2ºC - 8ºC .
2°C - 8°C
2ºC - 8ºC
2°C -
2ºC -
in 3.5 % of
in 32 % of
in 32 %
in 32
in approximately 3800
in 45 % of the
in 45 %
in 45
in 64 patients yielded the
in 64 patients yielded
in 68 % of
in 68 %
in 68
in 7 %
in 7 patients
in 7
in 71 % of
in 71 %
in 71
reported in 79 % of
reported in 79 %
reported in 79
in 90 % of the
in 90 %
in 90
95 % in
in men treated with
in monkeys ,
in monkeys
at doses of
reduced at doses of
at doses
reduced at doses
, use of Epoetin alfa
use of Epoetin alfa
, use of Epoetin
use of Epoetin
, use of
use of
, use
use
stored at room temperature (
stored at room temperature
stored at
treatment with aripiprazole (
treatment with aripiprazole
treatment with
in Bipolar I Disorder with
in Bipolar I Disorder
in bisphosphonate-naïve patients and 42
in bisphosphonate-naïve patients and
in bisphosphonate-naïve patients
in bisphosphonate-naïve
new information is received
new information is
new
in adult patients with renal
in adult patients with renal
in adult patients with
in adult patients
adult patients
in adult patients
in women
in women who
in women
in case of HIV )
in case of HIV
haloperidol .
haloperidol
in dogs in which
in dogs
in dogs with
dogs
in dogs
dogs
in dogs
in dogs
in hip fracture ,
in hip fracture
in dogs during pregnancy
in dogs during
in dogs
you cannot receive
affects you .
affects you
reported in children .
reported in children
in adult and paediatric
in paediatric and adult patients
in children and adolescents has
in children and adolescents under
in children and
in paediatric and
in children below
in children
in children
in paediatric
receiving a chemotherapy for cancer
when stored between 2°C -
when stored between 2ºC -
when stored between
in Paget s disease
in men ( study CZOL446M2308
in men ( study
in men (
for males ) .
for males )
in men .
in men In the
in men In
observed in men
in men with
men , Aclasta strengthens the
men , Aclasta strengthens
be consistent among men and
be consistent among men
for males
in men ,
in men
men ,
men
in osteoporosis
in patients ( mean age
in patients ( particularly
in patients ( particularly overweight
in patients ( particularly overweight
, in patients (
in patients (
in patients
the
for patients
been seen in patients
been reported in patients
in patients
in patients with agitation and
in patients with agitation
used in patients with hypocalcaemia
for patients with hypocalcaemia (
for patients with hypocalcaemia
in renal failure patients ,
in renal failure patients
bipolar mania patients
in patients with bipolar disorder
in patients with bipolar
bei Patienten mit einer Adipositas
those with a recent
in patients with a manic
bei Patienten mit einer
in patients with a
those with a
patients with mixed episodes
patients with mixed
to patients with moderate anaemia
to patients with moderate
in patients with residual
in severe
bei Patienten mit stark eingeschränkter
and patients with
bei Patienten mit
for patients with
in patients at
in patients who
in patients with
in patients with
in patients
in
patients with associated risk
patients with associated
patients with
those with
used in patients with
with
bei Patienten ohne Adipositas (
bei Patienten ohne Adipositas
bei Patienten ohne
, in patients
and patients
bei Patienten
for patients
in patients who are
in patients
in patients
patients
those
used in patients
weight
in patients over 75
in patients over
in patients
in subjects with
in subjects
10 in the
10 in
in schizophrenia and
in schizophrenia
in pregnant women .
in pregnant women
in animals The safety
in animals The
in animals
Summary of vertebral fracture efficacy
are generally not well
are generally not well
in all patients were
in all patients
bei allen außer einer von
bei allen außer einer
bei allen außer
bei allen
in all
other antipsychotics
for other indications
with other potentially toxic compounds
with other potentially toxic
with other potentially
for other
in other
with other
in bipolar patients was 12.1
in bipolar patients was 12.1
in bipolar patients
in bipolar patients
in bipolar
in bipolar
in up to 10 %
in up to 10
in up to
and vascular
with chronic renal failure in
with chronic renal failure
with chronic
at the primary 2-hour endpoint
at the primary 2-hour
at the primary
at the
patients experience
patients
in whom the
patients scheduled for major elective
scheduled for major elective
patients scheduled for major
scheduled for major
patients scheduled for major
having a high
patients scheduled for
patients scheduled
scheduled
in whom
patients scheduled
scheduled
from the use of such
from the use of
in the treatment of post-menopausal
in the treatment of
in the treatment
treatment in
in Bipolar I Disorder :
in Bipolar I Disorder
for haloperidol ( 30
for haloperidol (
for haloperidol
in the placebo group .
in the placebo group
in reduction of manic symptoms
in reduction of manic
in reduction of
bei der die
at the maximum recommended clinical
at the maximum recommended
at the lowest
at the lowest
at the
bei der
in the
in
the
recommended in these patients .
recommended in these patients
bei diesen Patienten mit Vorsicht
bei diesen Patienten mit
, these patients
bei diesen Patienten
in these patients
these patients
in these
dopaminergic hyperactivity and agonist
with a maintenance dose of
with a maintenance dose
and suicide .
harm and suicide .
suicide .
and suicide
harm and suicide
suicide
in women
in
in isolated patients with normal
in isolated patients with
in isolated patients
in isolated
in adult dogs .
in adult dogs
in adult
during the course
similar between healthy non-smoking subjects
similar between healthy non-smoking subjects
between healthy non-smoking subjects and
between healthy non-smoking subjects
healthy
used concomitantly with mitratapide
used concomitantly with
used concomitantly
be used
experienced with their previous insulin
experienced with
at any dose in
, in manic patients who
in manic
in more than 30 %
in more than 30
in more than
in more
in patients treated with aripiprazole
in patients treated with aripiprazole
in
in post-menopausal women in men
in post-menopausal women in
in post-menopausal women in the
in post-menopausal women in
in post-menopausal women and
in post-menopausal women
in post-menopausal
in paediatric patients
in paediatric
in pregnant women .
in pregnant women
in pregnant
the Package
the Package
the Package
the
in four
less common with repeated infusions
with repeated infusions
with repeated
) for
, in
are
at
be consistent
be
bei
by the liver ,
by the liver
can occur
cases of
for the
for use in
for
in approximately
in case of
in case
in patients
in the
in
into
know
occur
of
patients
regresses
reported in
seen in
should carefully
the liver ,
the liver
treatment for
used in
values
when
with
patients have slightly
patients have
patients have
in elderly
remain at
both groups )
both groups
both
two medicines
both groups
both studies ,
both studies
both
two
awareness of the warning
awareness of
awareness
a
in humans is 0.25
in humans and may
humans and
body
body
Muttermilch ausgeschieden
body
human dose
human
humans
in human
in humans
in type 1 diabetes ,
in type 1 diabetes
in type 1
in type
81
includes
observed included lethargy , increased
included patients with or without
included patients with or
included patients with
included patients
included
example blood tests ,
for example blood tests ,
blood and nerve cells
example ,
example
blood
e. g.
example ,
example
for example
known if paclitaxel
known whether pioglitazone
known whether zoledronic acid
known if
known whether
well known and further
well known and
known as non
known as
known as non
known as
known
known complication of chronic
and depressive
depressive
given the known
known
the known
hypersensitivity to the active
of hypersensitivity to the active
hypersensitivity to the
of hypersensitivity to the
hypersensitivity to
of hypersensitivity to
notice any
drowsy or
drowsy
need
suggest
observed ( see sections 4.3
observed ( see sections
observed ( see
observed (
seen
observed but its occurrence
observed when erythropoiesis stimulating agents
observed when
observed
Me
observed
observed
.
been observed .
beobachtet . For lp
observed .
observed
were observed .
were
commonly dic
seen in
be observed .
may be observed .
be observed
may be observed
observed for
observed
should be observed
been observed
beobachtet
dic
observed for
observed in
observed over
observed
seen
were observed
were
observed mean improvement from baseline
observed mean improvement from
observed mean improvement
observed mean
observed
packs
provided
already
had already
previously
products you already
report
reported (
were reported (
reported
with
.
been reported .
treatment .
been reported ,
been reported
been reported
have been reported
reported
treatment
were reported
with
reported cases have been
reported cases
reported
bernsteinfarbene Glasflaschen mit 55
bernsteinfarbene Glasflaschen mit
amber
into
cancer patients .
in cancer patients .
cancer patients
in cancer patients
treated with
treated
insufficiency .
insufficiency
characteristic
described below
described
could damage
a possible warning signal .
a possible warning signal
especially in patients
especially in
especially when
especially when
especially important
especially important for patients
especially important for patients
especially important for the
especially important for
especially important in the
especially important in
especially important
especially
cannot be excluded .
cannot be excluded
comprising 5
comprising
hypertension and/ or dyslipidemia at
hypertension and/ or dyslipidemia
dyslipidemia at
dyslipidemia
existing treatment with metformin and
existing treatment with metformin
the existing treatment with metformin
existing treatment with
the existing treatment with
existing treatment
the existing treatment
take for high blood pressure
existing
the existing
consists of 10 % dissolved
consists of 10 %
consists of 10
consists of 165 amino acids
consists of 165
consists of 20 % dissolved
consists of 20 %
consists of 20
consists of 30 % dissolved
consists of 30 %
consists of 30
consists of 40 % dissolved
consists of 40 %
consists of 40
consists of 50 % dissolved
consists of 50 %
consists of 50
consists of
be at risk of pregnancy
be at risk of
be at risk
be at
with
regularly
subcutaneous route and is
subcutaneous route and
regularly and
check
regularly
been determined .
been determined
determined
measured
some of the ingredients of
some of the ingredients
some
spezifische Interaktionsstudien bestätigt , in
spezifische Interaktionsstudien bestätigt , in
spezifische Interaktionsstudien bestätigt ,
spezifische Interaktionsstudien bestätigt
had confirmed clinical fractures .
had confirmed clinical fractures
confirmed clinical fractures
confirmed clinical
confirmed
to
considered
and should not exceed 2
and should not exceed
not exceed
the
every
in
was 1.44 % for Aclasta-treated
was 1.44 % for
was 1.44 %
was 1.44
was 15 l/ hr/ m2
was 15
was 18.7
was 5.3 months ( 175
reduction was 51 % in
reduction was 51 %
reduction was 51
was 7.5 %
was 7.5
was 9.5 years .
was 9.5 years
was 9.5
, the incidence of akathisia
, the incidence of akathisia
the incidence of akathisia was
the incidence of akathisia
, the incidence of
, the incidence of
, the incidence of
the incidence of
the incidence of
, the incidence
, the incidence
, the incidence
the incidence
the incidence
of 2.8
mean weight increase with
mean weight increase
was
were 2 5 % .
were 2 5 %
were 2 5
were 39.5 % (
were 39.5 %
were 39.5
were
is 0.25 l/ kg .
is 0.25 l/ kg
is 0.25
is 10 or 15
is 10 or 15
is 10 or
is 10
is 15 mg or 30
is 15 mg or
is 15 mg
is 15 mg
is 15
is 15
is 150 IU/ kg
is 150
is 260
is 32,000 to 40,000 dalton
is 32,000 to 40,000
is 32,000 to
is 9.75 mg ( 1.3
is 9.75 mg (
is 9.75 mg
is 9.75
in man is 5
the recommended starting dose is
the recommended starting dose is
is between
is
.
assessed
before taking ABILIFY .
before taking ABILIFY
before taking ABILIFY .
before taking ABILIFY
before taking this medicine
before you
before the Abseamed treatment
starting before the Abseamed treatment
before the
starting before the
before you are
before you
before you
before
starting before
preferable .
preferable
follows :
follows
cause
relate
refers to the last
refers to the
refers to
refers
bilateral orchiectomy ( surgical castration
bilateral orchiectomy (
bilateral
Exkretion eliminiert. itte Only dic
Exkretion eliminiert. itte Only
bind
attaches to
attaches
biochemical marker
biochemical marker
biochemical
biological efficacy of epoetin alfa
biological efficacy of epoetin
biological efficacy of
biological efficacy
biological
,
bipolar patients was 12.1 %
bipolar patients was 12.1
bipolar patients
bipolar disorder , there were
bipolar disorder
bipolar
bipolar mania
bipolar disorder
bipolar disorder
bipolarer Störung
bipolar
bipolarer
10
and 10
10
and 10
to 12 g/ dl (
to 12 g/ dl
to 12
to 125,000
to 143
3 hours after dosing
3 hours
to 300 mg/ m2
to 300
at 36 months .
at 36 months
to 375
to 6 weeks )
to 6 weeks )
to 6 weeks
to 6 weeks
to 6
to IV )
to IV
proportional up to about 20
proportional up to about
of Abraxane until
until it
to yellow .
to yellow
to light yellow liquid .
to light yellow liquid
to years of treatment with
to years of treatment
to years of
to slightly yellow solution .
to slightly yellow solution
to slightly yellow
less severe
severe
until
until neutrophil counts recover to
until
have recently taken any other
recently taken any other
to off-white
up to 10 % ,
up to 10 %
up to 10
2 years
added to
up to 36
up to 48 kg for
up to 48 kg
up to 48
up to five years
up to five
for up to 12 weeks
for up to 12
for up to
thereafter
to
up to
up to
to 3 X
to
to disease progression [ 95
to disease progression [
to disease progression
to
Abraxane until
proportional up to
thereafter
to
until
up to
up
not
tell your doctor
the Scientific Discussion (
the Scientific Discussion
please
tell
pale mucosae .
pale mucosae
pale
blue , marked with
blue , engraved with
blue ,
blue
remain the
remain
concentration is unchanged .
concentration is unchanged
is
blocks the ability of
blocks the ability
blocks
hypovolemia
glucose lowering drugs ; Thiazolidinediones
glucose lowering drugs
.
need .
need
break .
break
and 34 % , respectively
insulin
and intra-subject variation for
and intra-subject variation
respectively , the plasma concentration
, respectively , the
respectively , the
, respectively ,
, respectively
respectively ,
respectively
and protracted absorption respectively .
and protracted absorption respectively
or sugary products
, respectively
and
insulin .
or
respectively
ca . 16
approximately 43-55 %
approximately 43-55 % bound
approximately 43-55 %
43-55
ca . Me
ca .
ca
approximately 1 %
approximately 1 %
approximately 1
approximately 18 %
approximately 18
about 20 mg
about 20
approximately 25
approximately 27 % of the
approximately 27 %
approximately 27
about 40 %
about 40
approximately 425 mg sodium per
approximately 425 mg sodium
approximately 425 mg
approximately 425
approximately 45 % of the
approximately 45 %
approximately 45
approximately 5 l/ kg .
approximately 5 l/ kg
approximately 5
approximately six weeks after
approximately six weeks
approximately six
approximately 86 %
approximately 86
about 90 %
about 90
about
approximately
by positron
cerevisiae ) .
cerevisiae )
cerevisiae
known marker
chemotherapy induced anaemia
chemotherapy induced
induce
induce
surgery patients in
surgery patients
surgery
chronic liver disease .
chronic liver disease
chronic liver
chronic renal failure in paediatric
chronic renal failure in
chronic renal failure and clinically
chronic renal failure and
chronic renal failure ,
chronic renal failure
chronic renal failure
chronic renal failure
chronic kidney failure ( renal
chronic kidney failure (
chronic kidney failure
chronic
be maintained during
be maintained
maintained during
maintained
i. e.
i. e. essentially sodium- free
i. e.
o. o Tel : +386
o. o Tel :
o. o Tel
o. o
because osteoporosis
because osteoporosis
since bioavailability
since
the
as
because
not acceptable
not
since
sure
powered
the product with the
the product with
the product
therefore a measure of the
therefore a measure
recommended , therefore
has to be administered intravenously
therefore reduced , coupled
and therefore its use is
Therefore
and therefore
has
therefore ,
therefore
feelings
feelings about hurting yourself
feelings
are having any thoughts or
are having any
, suggesting that
, suggesting
suggesting
should not exceed 30 mg
Abseamed has not
Aclasta must
pioglitazone should not
should also not be
darf bei Patienten mit
darf bei Patienten
darf bei
should not be used in
the medicinal product has
the medicinal product
this medicinal product must not
, this medicinal product should
, this medicinal product should
this medicinal product must
this medicinal product should
this medicinal product should
Do not use
should not be used in
Do not take
must not be less than
must not be less
Do not use
Do not
must not be
should not be
should not
Only solutions
should be used .
should be used
should not
darf
must
should not be
should
solutions
) Aclasta
)
concern .
concern
may require discontinuation of
may require discontinuation
the
the medicinal product has
about this medicinal product ,
about this medicine ,
about this medicinal product
about this medicine
the medicinal product
the product should
to
using machines Aclasta
use machines have been observed
use machines have been performed
or use machines have
use machines have
using machines
in maintaining weight loss
blood
the label to the physician
the label to the
overall survival
weight should be closely monitored
weight
body weight appeared
N-terminal
nurse if you are
nurse .
nurse .
nurse
nurse knows how to
nurse knows how
nurse
androgen independent ,
androgen independent
the powder
the risk of weight regain
the risk of
the risk of progression of
the risk of progression of
the risk of
increase the risk of oedema
reduces the risk
the risk of malformations and
the risk of malformations
, the risk of spine
, the risk of
risk
the risk of spine
the risk of
, the risk
risk
risk
the risk
the product
discontinuation of treatment
the volume of distribution is
an increased volume of distribution
as a mitosis-stimulating factor and
as a mitosis-stimulating factor
as a mitosis-stimulating
events the
trained in the handling of
trained in the handling
found in
authorisation . du
the nearest hospital and
the nearest hospital
the nearest
the potential risk
the potential risk
risk
therapeutic response
therapeutic response
therapeutic
authorisation .
authorisation
enter
medicinal product
of the
risk
the
these
which involved
which
that epoetin alfa
that epoetin
pioglitazone
is
need to
need to
need to
need to
have
sure
that ,
that
sustained haemoglobin exceeds 12
sustained haemoglobin exceeds
sustained haemoglobin level
15-minute infusions
duration , there were
duration ,
duration
materials derived from
be cautioned
cautioned
. de
defined by a decrease in
defined by a decrease
defined by a decrease in
defined by a decrease
defined as the patient
defined as the
defined as
defined
definitely related
16 to 81 times the
16 to 81 times
16 to 81 times
> 3 X the
> 3 X
the product
( N=70
N=70
was shown to be 36
was shown to be
was shown to
take it
the gastrointestinal
the heart or the
the heart or
the heart
the human insulin molecule
the bone tissue it is
the reference arm
the mouth is difficult .
the mouth is difficult
the mouth is
the PANSS Excitement Component score
the PANSS Excitement
the PANSS
protect the environment .
protect the environment
is eliminated in the urine
the active metabolite , represents
the active metabolite ,
the active metabolite
is the current standard of
is the current standard
the active substance or to
the active substance or
the active substance
the active
the recommended treatment schedule
the recommended
the primary 2-hour endpoint was
the primary 2-hour endpoint
the primary 2-hour
the primary
at
in the
on
the reference
the
to the
to
be advised accordingly .
be advised accordingly
advised accordingly
adipocytes (
daily
veterinary surgeon
eyes
in the eyes
the eyes
lower the blood pressure .
lower the blood pressure
the blood vessels
the cannabinoid type 1
the cannabinoid type
have the impression that
have the impression
the impression
results of a full range
results of a full range
results of a full
results of
results
to the foetus .
to the foetus
, the gluteal region or
the gluteal region or
, the gluteal region
the gluteal region
in order to protect
order to protect from
in order
order
reduce insulin requirement .
reduce insulin requirement
controls .
controls
regard to meals .
regard to meals as monotherapy
regard to meals as
regard to meals
humans is unknown
humans is
humans
the metabolism of substrates of
Paget s disease of the
Paget s disease
the Paget s disease
nurse
adipocytes ) that affects energy
the deltoid region may also
the deltoid region may
the thighs or the
the thighs or
the thighs
the non-diabetic
is excreted in human milk
is excreted in
is excreted
femoral neck bone
femoral neck
femoral neck bone
femoral neck
the studies
correct
be marketed .
be marketed
the
den
through the menopause
the active substance aripiprazole .
the active substance aripiprazole
the active substance paclitaxel (
the active substance paclitaxel
the active substance pioglitazone .
the active substance pioglitazone
the active substance or
the active substance
subsequent
the first 24 hours
the first
the first
the whole treatment period .
the whole treatment period
the gp-60 albumin receptor ,
the gp-60 albumin receptor
the gp-60 albumin
the gp-60
the clinical studies ,
the clinical studies
the clinical studies ,
the clinical studies
the clinical
the pooled results ,
the pooled results
data reveal no
the last day of
the last day
during the 3 weeks before
during the 3 weeks
the last
the
most cases , the ferritin
most cases ,
most of the cases ,
most of these patients
most of these
most clinical trials
most clinical
most of the
most
Abraxane should be vigilantly
Abraxane should be
be
should be
subsequent
the above indications
values above
unable to
dose regimens .
dose regimens
the four placebo-controlled studies
the four placebo-controlled
the four
the active ingredient insulin human
the active ingredient
D
For the
den
regard to effects
subsequent
the individual
the osteoporosis
the
through the
to the
to
used to
used
values
veterinary
vitamin D
metformin is contraindicated ,
metformin is contraindicated
cannot take metformin
metformin
denen Midazolam ( CYP3A4-Substrat )
denen Midazolam ( CYP3A4-Substrat
denen Midazolam (
denen Midazolam
the
whose first treatment
whose first treatment
whose first
whose manic symptoms had already
whose manic symptoms
whom the
whose
scheduled for major elective
scheduled for major
having a high
family history of
experiencing potentially clinically significant
experiencing potentially clinically
experiencing potentially
scheduled
where
whom
whose
same active substance
the same active substance
depressive illness and/ or
depressive illness
depressive
4.3 and
section 4.3 and
history of depressive disorders/ mood
4.3
section 4.3
the three-year
460 women with
460 women
460
ADT to minimize
for ADT to minimize
ADT to minimize
for ADT to minimize
of aripiprazole AUC
serum testosterone reduction
pituitary adenoma .
pituitary adenoma
of androgen suppression is
of androgen suppression
the proportion of patients
the proportion of
the proportion
from the use of such
of administration
use ABILIFY
use Abseamed
are given Aclasta :
are given Aclasta
Using
use of
use
used to treat
used to treat
Using
are
from the use of
of administration
of anaemia associated with chronic
of anaemia associated with
anaemia may
of anaemia with epoetin alfa
of anaemia with epoetin
of anaemia with
of anaemia and reduction
of anaemia and
anaemia
of anaemia associated
of anaemia
aripiprazole concentrations might be expected
maintaining the clinical
face
of precipitation of sulphate
from smoking upon
of the pancreas
pancreas
the pancreas
of the pancreas
pancreas
the pancreas
stopping
initiation of convulsions
initiation of
in the treatment
the treatment of post-menopausal osteoporosis
the treatment of post-menopausal
the treatment of
the treatment of diabetes
the treatment of
the treatment in this
the treatment of the
for the duration of therapy
for the duration of
be monitored .
be monitored
of the
treatment ,
treatment
in the management of overweight
,
of the
of
on treatment ,
on treatment
the treatment of
the treatment
the
treatment of
treatment
treatment
contribution
Bipolar I Disorder and for
Bipolar I Disorder and
in Bipolar I Disorder and
Bipolar I Disorder
in Bipolar I Disorder
Bipolar I Disorder ,
of Bipolar I Disorder ,
Bipolar I Disorder
blood pressure
blood
control decreases the risk
control decreases
the CHMP
the CHMP agrees
of CPK ( Creatine
of CPK (
of CPK
the CYP3A4 or CYP2D6 inhibitor
the CYP3A4 or
the CYP3A4
the CYP3A4 inducer
plasma clearance of zoledronic acid
of Cmax and AUC after
of Cmax and AUC
of Cmax and
of Cmax
of dosage may also
of dosage may
of dosage
( see
(
dose
the dose selector returns
of the blood donation procedure
of dosing .
of dosing
taking Actos 15mg
taking Actos 30mg
taking Actos 45mg
associated
associated
of the elimination per se
of the elimination
may be a moderate
be a moderate
Agency
the bottle ,
the bottle
Abraxane administration
administration
the administration of
the administration
the bile
of
total dose and rate of
to that seen
years
the HORIZON Pivotal Fracture Trial
the HORIZON Pivotal Fracture
the HORIZON Pivotal
the HORIZON
the HORIZON-PFT
half-life was due to
half-life was due
the main study , 72
the main study ,
the main study
the skin
the skin
your dog
the dog
of dogs
of dogs
conjugates of hydroxy metabolites of
the desired haemoglobin level may
of the target haemoglobin concentration
, the haemoglobin
the haemoglobin is rising by
the haemoglobin
the haemoglobin is
haemoglobin ( 1 to
haemoglobin ( 1
in haemoglobin ( 1 to
in haemoglobin ( 1
haemoglobin (
in haemoglobin (
haemoglobin
in haemoglobin
of hands ,
of hands
hip fracture
the indication increasing
the indication
reach room temperature
of the infusion lasts
timing of infusion was approximately
timing of infusion was
infusion
of the infusion
the infusion
timing of infusion
the injection needle .
the injection needle
of the injection site
site
the first trimester
of insulin resistance .
of insulin resistance
the level of calcium
bone remodelling
of controls .
of controls
concentration
disease
phosphokinase and rhabdomyolysis ,
phosphokinase and rhabdomyolysis
phosphokinase and
phosphokinase
the plasma concentration
the plasma concentration
the
the
body
the Long Term
by the liver primarily
by the liver
monitoring of liver enzymes .
monitoring of liver enzymes
lay
of the uptake
solution contains 0.05 mg
solution contains 0.05
solution contains
solution
, recovered label
recovered label
In addition the
the
the menopause ,
the menopause
of Product Characterisitics ,
of Product Characteristics ,
of Product Characteristics
of Product Characterisitics
of Product Characteristics
of Product
in mortality in this study
in mortality in this
in mortality in
the parent substance
the possibility
observation study
observation
Administration of
Administration of
parathyroid reserve , intestinal calcium
diminished parathyroid reserve ,
parathyroid reserve ,
diminished parathyroid reserve
parathyroid reserve
of the side effects ,
of the side effects
of renal function
the upper limit of normal
of osteoclast-mediated bone resorption .
of osteoclast-mediated bone resorption
of osteoclast-mediated
osteoporosis in men and
osteoporosis in men
of osteoporosis in post-menopausal women
osteoporosis in post-menopausal women
of osteoporosis in post-menopausal
osteoporosis in post-menopausal
of osteoporosis in
osteoporosis in
of osteoporosis
PROactive , a cardiovascular
PROactive , a
PROactive ,
PROactive
of the pack The ABILIFY
of the pack The
the carton .
the carton
of the pack
package leaflet of the
in the Package Leaflet )
the Package Leaflet )
see the Package Leaflet .
, see the Package Leaflet
, see the Package Leaflet
in the Package Leaflet
see the Package Leaflet
the Package Leaflet
patient should not
, the patient
, the patient
patient
the patient
of patients )
der Patienten , der
der Patienten ,
of the patients .
of the patients
of the patients .
of the patients
of patients received a
of patients were receiving insulin
of patients were receiving
of the patients received
of patients .
of the patients .
of patients
of the patients
of the patients had
of patients had a
of the patients had a
of the patients who received
der Patienten
of patients received
of patients
of the patients
of
patient population and
patient population
in
the pharmacokinetics of
the placebo group .
the placebo group
the placebo group .
the placebo group
the immediate packaging :
the immediate packaging
engraved
marked
the rat at doses
the rat
treatment-related
reconstitution ,
reconstitution
of the absorption rather than
of the absorption
into less pain from
into less pain
into less pain from
into less pain
less pain from
less pain
pain from
pain
pregnancy and
should
pregnancy only if the potential
pregnancy
dysmotility and aspiration have been
dysmotility and
dysmotility
the syringe onto a
the syringe onto
the syringe onto
the standard treatment
the standard
of the study .
the study of
the study of elderly women
the study of elderly
the trial for the prevention
of the study
the study of
of the population were women
of the population were
of the study population had
of the population
of suspension
of post-dose symptoms occurring within
of post-dose symptoms
the tablet formulation is 87
the tablet formulation is
of daily
into account and should
of therapy with pioglitazone
conditions ct
conditions
of therapy with
of therapy
therapy
from weight
from
TG in this
TG in
from
of tumour progression ,
of tumour progression
the refrigerated
the dose of Aclasta
administration of Aclasta
administration of
administration
following the administration
serum creatinine level
the administration
administration
following the administration
serum creatinine level
the administration
of
the past ,
the past
reduction of manic symptoms
reduction of manic symptoms over
reduction of manic
reduction of
the version 3.0
the levels of
the levels
of effect of zoledronic acid
of effect of
the present state
the condition is controlled
the condition
the condition
, the
the
of aliphatic methylene groups
of aliphatic
the other .
of the other ingredients .
of the other ingredients
the other face. .
the other face.
of the other clinical effects
of the other clinical
of the other
reported with
the other
the yield of autologous blood
of reported cases have been
of reported cases
of reported
bipolar disorder , Abilify was
of bipolar disorder
of bipolar
the sustained haemoglobin exceeds 12
the sustained haemoglobin exceeds
used
the body does not
the body
the
examining the combination of Actos
examining the combination of
examining the combination
der die
examining the
third
of a
the maximum recommended human
the maximum recommended
of increased insulin sensitivity
of weight regain .
of weight regain
the first 21 days of
the first dose .
the first
first infusion
the first infusion
first reconstitution ,
first reconstitution
the first three days after
the first three days
the first three
first
first
the first
der folgenden Tabelle 2
der folgenden Tabelle
following
co-administration were
its total active metabolites
the same dose
the same
according to standard medical practice
according to standard medical
according to standard
of potent CYP3A4
therapeutic
of in vitro solubility .
of in vitro solubility
pup
pup
of the cardiovascular
widened brain ventricles and
widened brain ventricles
of a full range of
of a full range
of a full range of
of a full range
of a full
works for a long time
of last
the limited number of
the limited number
the limited
the median timing of infusion
the median timing of
the median
) gene mutation assay .
gene mutation assay .
) gene mutation assay
gene mutation assay
) gene mutation
gene mutation
) gene
gene
metastatic disease has
metastatic disease
metastatic
of patients on Abraxane with
the Aclasta-treated group
the Aclasta-treated
of life parameters on the
of
those
times the mean steady-state
10 times the mean steady-state
3 times the mean steady-state
the mean
may
der nach einem Jahr 5
der nach einem Jahr
der nach einem
the lowest
the lowest
of the necessary amount
upper respiratory tract
the open-label study there was
the hip fracture repair
the use of oral aripiprazole
the use of oral
oral clearance of
the pharmacokinetic analysis
the pharmacokinetic
of post-menopausal osteoporosis ( PFT
of post-menopausal osteoporosis (
of post-menopausal osteoporosis
of post-menopausal
of the reconstituted suspension may
of the reconstituted suspension
of the reconstituted suspension
of the reconstituted
the rapid control of
the rapid control
the rapid
of the six identified metabolites
of the six identified
of the six
ensure the safe use of
factors such
risk factors such
with risk factors such
ensure the safe
factors such
risk factors such
with risk factors such
of excipients , see section
of excipients , see
of the other ingredients .
of the other ingredients
of excipients ,
of the excipients
of the other ingredients of
of the nursing
of symptomatic anaemia in
of symptomatic anaemia associated with
of symptomatic anaemia
of symptomatic
of the administered dose
of the administered
of the
on the published literature
on the published
of white
of white
white
the published literature .
the published literature
to
due to the pooled presentation
second trial utilised
, the
, the
,
Chest
accepted
associated with
associated
become
benefits and
benefits
der
due to the
due
in the
in the
its benefits and
its benefits
maintained their
occlusive
of Abraxane
of the
of the
of
on
patient s
prior
rate of
reported
s
safety of
simultaneously
the injection
the level of
the more
the patient s
the treatment of osteoporosis
the treatment of
the
their
times
timing of
to be
to
treatment ,
treatment
via the
of hypersensitivity reactions is
of hypersensitivity reactions
the
insufficient glycaemic control despite
with insufficient glycaemic
glycaemic control despite
and is usually maximal within
is usually maximal within
and is usually maximal
is usually maximal
insufficient
whose
currently
decreased appetite .
decreased appetite
of the medicine .
of the medicine
a summary of the European
of the medicine
summary of the European
has told you .
has told you
baseline levels at 12 months
baseline levels at
of consciousness and extrapyramidal symptoms
of consciousness and extrapyramidal
of consciousness and
of consciousness
the blood pressure is
the blood pressure is
is therefore recommended .
is therefore recommended
is therefore
the blood sugar .
the blood sugar
of the CHMP recommendations ,
of the CHMP recommendations
of the CHMP
of diabetes was 9.5 years
of diabetes was 9.5
of diabetes was
of diabetes is dietary
of diabetes is
of diabetes
the dialysis system is possible
the EPAR ) .
the EPAR )
of the EPAR ) .
of the EPAR )
of the EPAR
the EPAR
medicine works .
medicine works
of the event onset .
of the event onset
of progression of diabetic retinopathy
of progression of diabetic retinopathy
of progression of diabetic
of progression of diabetic
of progression of
of progression of
the food .
the food
up to 2 years .
up to 2 years
the level of HbA1c ,
the level of
absolute change in HbA1c
of the manufacturer
of the manufacturer of the
of the manufacturer
of the pharmacological effects
your immune system ) during
immune system ) during
system ) during
immune system )
system )
immune system
system
the
insulin
of insulin
of the bone .
of the bone
of the bone .
of the bone
of the bone
of mineral metabolism must also
of mineral metabolism must
of mineral metabolism
in bone turnover .
bone turnover
in bone turnover
of the body
mediastinal disorders
of mineral metabolism must also
of mineral metabolism must also
of mineral metabolism must
of that month .
of that month
Paget s disease of the
Paget s disease
of Paget s disease ,
of Paget s disease :
of Paget s disease
Nervous disorders :
Nervous disorders
Nervous
patient 's
the patient on
of the Marketing Authorisation Holder
of the Marketing Authorisation
of the Marketing
of the product per 8
of the product per
of the product
by the investigator
the investigator
of any powder
of any powder
of any powder
other erythropoietic therapy
of the stem cell compartment
of the stem cell
des Steady State ist bei
des Steady State ist
des Steady State
of the sulphonylurea .
of the sulphonylurea
of the sulphonylurea
of the veterinary medicinal product
of transfusion requirements in
of transfusion requirements
of the value ) .
of the value )
of the value
of manic episodes
of manic
of the biological active substance
of the compound or metabolites
of the compound or
microtubules throughout the
des
des
of the insulin it produces
of the Marketing Authorisation Holder
of the Marketing Authorisation
of the Marketing
the pre-menopausal range .
the pre-menopausal range
of the red blood
the second year had
's
bone metastases
bone
by the
des
from bone metastases
from bone
in
of any
of the
of
smoking
the level of
the peak
the
to
therefore weight
therefore
should therefore
dose reductions should therefore
similar dose reductions should therefore
similar dose reductions should
therefore
delivery system must be followed
delivery system must
delivery system
that
more
more
more
well below
well
diabetic ketoacidosis , diabetic hyperosmolar
diabetic ketoacidosis ,
diabetic ketoacidosis
diabetic
diabetic
diabetic ketoacidosis
diabetic hyperosmolar coma
diabetic hyperosmolar
undergoing dialysis ( See section
undergoing dialysis ( See
undergoing dialysis (
undergoing dialysis
undergoing dialysis does
(
the ABILIFY orodispersible
the ABILIFY tablet at the
the ABILIFY
ALT levels
ALT levels remain
the AUC after the
the AUC after
AUC
the AUC
the administration of recombinant human
the administration of
its use
the administration
the number of patients
the number of
at the number
the number
the anaemia
, aripiprazole solution for injection
aripiprazole solution for injection
the aripiprazole dose
the
excretion via the kidneys
abdominal wall .
abdominal wall
the abdominal wall
pancreas
considering stopping
should be considered .
should be considered
responds ,
responds
, treatment of anaemia
treatment of anaemia
the treatment of bipolar disorder
the treatment of bipolar
, treatment of
the treatment of
treatment of
the Abseamed treatment begins
the Abseamed treatment
, treatment with two other
, treatment with two
, treatment with
treatment with
the treatment of
, treatment
the treatment
treatment
treatment
precaustions for disposal and
, the formation of erythrocytes
abnormal arrays or bundles of
, the formation of
, the formation
binding is
binding
the bioavailability of mitratapide (
, the bioavailability of mitratapide
the bioavailability of mitratapide
, the bioavailability of
the bioavailability of
, the bioavailability
bioavailability
the bioavailability
blood levels of cyclosporin
intensify and prolong the
glucose levels had
Cmax
Cmax
Cmax
, the difference in total
the difference in total
, the difference in
the difference in
the disposition of paclitaxel
the disposition of
the disposition
, the dosage of ABILIFY
the dosage of ABILIFY
, the dosage of
the dosage of
, the dosage
dosing
the dosage
the dose of the sulphonylurea
the dose of the
the dose
, additional dose reduction
additional dose reduction
dose reduction
the dose
, the vial
the vial
the EMEA
the intake
you
pad .
pad
die Eliminationshalbwertszeit wegen des
die Eliminationshalbwertszeit wegen des
die Eliminationshalbwertszeit wegen
die Eliminationshalbwertszeit wegen
across endothelial cells .
across endothelial cells
although development of severe symptoms
although development of severe
although development of
, CYP3A4 and CYP2D6 enzymes
reduce the epoetin alfa
alfa therapy
who has experience
the disease is
the disease
diet was not restricted
the granting of
impair fertility in
drive
the ability of cancer cells
the ability of
to drive and use
drive
to drive and
drive
the ability
the faeces .
the faeces
the pooled atrial fibrillation incidences
the pooled atrial fibrillation
the pooled atrial
gliclazide .
gliclazide
the skin (
the skin
change in their usual
change in their usual
one-half of its
the haemoglobin target range of
the haemoglobin target range
the haemoglobin concentration should be
to maintain haemoglobin values
to maintain haemoglobin
, the frequency and severity
, the frequency and
the incidence of vertebral fractures
the incidence of clinical fractures
the incidence of clinical
the incidence of
, the frequency
the frequency
the incidence
hip
to give the Aclasta infusion
the injection
increasing insulin sensitivity .
increasing insulin sensitivity
treatment outcomes
, the incidence of EPS
the incidence of EPS was
the incidence of EPS
, the incidence of
the incidence of
, the incidence
the incidence
has made their bones weaker
made their bones weaker
the bone and therefore makes
a combination of
a combination
combination of
combination
the level of a substance
the level of a
the level
which is primarily hepatic .
which is primarily hepatic
liver enzymes should
not take the oral solution
, the solution
the solution
the majority of patients received
the majority of the
the majority of
the majority
of Aclasta
of Aclasta
the Montgomery-Asberg
N-dealkylation is
N-dealkylation
the needle quickly
the needle
effects
neutrophil counts recover to >
neutrophil counts recover to
the pack with
the pack
the Package Leaflet (
the package leaflet or
the Package
the package leaflet
declined in
declined
declined in
declined
to
patients
either the pharmacokinetics or pharmacodynamics
the pharmacokinetics or
the pharmacokinetics of aripiprazole .
the pharmacokinetics of aripiprazole
the pharmacokinetics of
the pharmacokinetics
pioglitazone
, the pipette
the pipette
those receiving placebo ( see
those receiving placebo (
those receiving placebo
the plasma concentration of pioglitazone
, the plasma concentration of
the plasma concentration of
, the plasma concentration
plasma concentration
the plasma concentration
the issues are resolved .
the issues are resolved
of the members within
the members within
of the members
the members
red blood cell production
stimulates red cell production
red blood cell
stimulates red cell
red
stimulates red
protein binding
the prevention of a new
enhance absorption
facilitate the re- suspension .
facilitate the re-suspension .
facilitate the re- suspension
facilitate the re-suspension
facilitate the
the entire orodispersible tablet on
the entire orodispersible tablet
the orodispersible tablet is fragile
the orodispersible tablet
the levels remain the
, serum levels of
serum levels of
, serum levels
serum levels
the levels
the safety of pioglitazone
the safety of
the safety
medicinal product at 52-weeks was
product at 52-weeks was
medicinal product at 52-weeks was
product at 52-weeks was
the suspension contacts the
the suspension contacts
, the suspension
the suspension
symptoms of hypocalcaemia
symptoms
could damage the tablet .
could damage the tablet
the tablet with water
the tablet with
the tablet
the tablet
, testosterone suppression
testosterone suppression
the action of the osteoclasts
the action of the
ability
aggravation of existing hypertension
aggravation of existing
the pen cap on
the metabolism of other medicinal
the metabolism of other
the metabolism of
vitamin D levels
to prepare and
less likely to break .
likely to break .
it less likely to break
less likely to break
likely to break
it less likely to
less likely to
likely to
warnings and precautions associated with
warnings and precautions associated
return rapidly
increase the effectiveness of Abseamed
increase the effectiveness of
that compared the effectiveness of
increase the effectiveness
that compared the effectiveness
the effect of Actos
the effect of medicines used
the effect of
the effect
the duration of the study
the duration of the
the duration
the cells cannot divide and
the cells cannot divide
the cells cannot
the cells
the tongue .
the tongue
the absolute change in HbA1c
the absolute change in
of the back of the
the most frequently
conducted in 375 anaemic patients
conducted in 375 anaemic
on
the most notable important
the most notable
clinical
die aus
from
, treated
related to 229 patients
where the observed
give the best control
the
the active substance zoledronic acid
the active substance
where the
are extensions
which produces three active metabolites
which produces three active
inadequately controlled by diet and
inadequately controlled by diet
by
the average duration of diabetes
the average duration of
the average duration
the average
response to
of one year or less
of one year or less
of one year or
of one year or
of one year
of one year
receiving radiotherapy .
receiving radiotherapy
receiving diuretic therapy
receiving diuretic therapy
a
given weekly
given weekly for three
, the recommended
recommended
the recommended
first treatment
first treatment
the first injection .
the first injection
first
the first
about
the following
androgen suppression in men
androgen suppression in
androgen suppression
die für
solution to reach
to reach
result
the geometric means of Cmax
the geometric means of
the geometric means
the entire dose is injected
the entire dose
the entire
die gleichzeitige Gabe von Rimonabant
die gleichzeitige Gabe von
,
the greater sensitivity of this
the greater sensitivity
that primarily stimulate
that primarily
whereas patients re-randomized to
but made
but
each
at combining
recent ( within
recent (
recent
manic symptoms had already
manic symptoms
treated with Abraxane
treated with aripiprazole were
treated with aripiprazole
treated with epoetin alfa
treated with haloperidol
4.3 and
section 4.3 and
4.3
section 4.3
with a bromobutyl/ polyisoprene
with
not necessarily in association with
not necessarily in association
insufficiency not yet undergoing dialysis
insufficiency not yet
which are normally
the next dose after
the next dose
taking the medicine by mouth
taking the medicine by
increase peripheral
, the pharmacokinetic characteristics
the pharmacokinetic characteristics
, the pharmacokinetic
the pharmacokinetic
the percentage
genotoxicity ,
to
the relative efficacy of M-II
the relative efficacy of
the relative efficacy
the relative
out the correct dose of
the correct dose
the correct
represent rapid
drink the resulting suspension
drink the resulting suspension
drink the
drink the
both fast-acting
both
is difficult
blood transfusions should be the
systemic exposure was generally
systemic exposure was
systemic exposure
systemic
which is potentially lethal .
which is potentially lethal
the missed dose
the anterior abdominal wall .
part of the abdominal wall
the anterior abdominal wall
which
the Scientific Discussion (
resulting in discontinuation
levels
levels
levels
( the
, in
, the doses that
, the overall
, the
, the
, who
,
58 The
70 The
The potential relevance of
The
a
are at
as low
as
at the
at
back
by
considering
die
dose of
dose
enhance
for
give
in the
in
increase the
increase
levels had
levels
not treated
of Abraxane
of the
of the
of
on
part of the
reduce the
related to
that of
that
the doses that
the major
the most
the overall
the same
the
therapy , the
to 15
to
which
who has
who
report hypoglycaemia
help to protect the environment
help to
to
is to check that
as being secondary to decreased
as being secondary to
this could damage the tablet
this
this is especially important for
this is especially important
this is especially
this is
this with
this will result in foaming
this will
based
take this
this
these findings
by these enzymes .
by these enzymes
these events
these side effects
this leaflet .
this leaflet
this leaflet
use in this patient population
experience these symptoms
these symptoms
these symptoms
that these effects are
these effects
it
of the
the
these
this
use in
this medicine is available
this product is available
on this product is available
in this area
in this
this area
this
you follow this advice carefully
these characteristics
this weight management programme ,
this weight management programme
diesen Patienten mit Vorsicht anzuwenden
diesen Patienten mit Vorsicht
diesen Patienten mit
these patients dosing should
diesen Patienten sollte
diesen Patienten
these patients
was 3.9 kg .
was 3.9 kg
these symptoms
eaten the complete portion
these two medicines
these two
, these
these
this
of age where
of age
this age group
of these applies to you
this basis
of these findings is unknown
of these findings is
of these findings
but this effect
this effect
of these events is
of these events
ready for use .
ready for use
this condition may also
this condition may
this condition
of these side effects
of these patients had signs
of these patients had
for these patients
these patients reported concurrent peripheral
of these patients , antibodies
of these patients
these patients
in this patient group .
in this patient group
this patient group .
this patient group
in this
of this population ,
of this population
this patient
this study .
this study
these trials , a
these trials ,
of these trials
these trials
of these symptoms decreased
of these symptoms were
of these symptoms
closely monitored throughout this
these limited data ,
these limited data
these limited
these hydroxylated metabolites is catalysed
these hydroxylated metabolites is catalysed
these hydroxylated metabolites
these hydroxylated
benefit
of these
of these
of this
of
these
this
not take this medicinal product
medicinal product
medicinal product
this medicinal product
this medicine
given this medicine .
of this product
this medicine
this product
veterinary medicinal product
this should be done in
this should be
, this
medicinal
of this
this
direct
direct effect of rimonabant
direct effect of
direct effect
acting and/
and/
direct
distal radius over 3
distal radius over
distal radius relative
distal radius
distal radius
dietary control .
dietary control
dietary
but it attaches to
but it attaches
but it
but
at how this loss could
how this loss could be
how this loss could
this loss could be
this loss could
documented risk factors
documented
randomised
dose-proportional .
dose-proportional
; leukopenia was reported in
; leukopenia was reported
dependent ; leukopenia was reported
dose-dependent increase in blood pressure
dose-dependent increase in
independent .
independent
three injections in
three injections
three years
three years .
three years
three years
three days after administration of
three days after administration
three days after
three days following the
three days after
three days following
three days
three days.
three days of the
three days
in the three days
the three days
three days
three weeks .
three weeks in a total
three weeks in
three weeks
produces three active metabolites .
produces three active metabolites
produces three active
in the three
the three
three
3 times a week by
3 times per week .
3 times per week
3 times per week .
3 times per week
3 times per week by
3 times per week
3 times per
three times a week .
, three times a
three times a
three times a week .
, three times a week
three times a week
, three times a week
three times a week
, three times
3 times
3
three times
every 3 weeks .
every 3 weeks
three week
pressure which requires urgent treatment
third infusion
third
ba , d. o. o
ba , d. o. o.
ba , d.
ba
amidohydrolase ( predominantly
by blocking
metabolized by both CYP3A and
catalysed by CYP3A4 .
catalysed by CYP3A4
in
in
administration
of the blood by heparin
by hydroxylation of aliphatic
by hydroxylation
by injection under the skin
by injection under the
give by injection under the
give by injection under
by injection
give by injection
injection
into less
into
durch Metabolisierung und anschließende biliäre
durch Metabolisierung und
by neurotransmitters ,
by neurotransmitters
by bilateral orchiectomy (
by bilateral
mediated by the gp-60 albumin
mediated by the gp-60
by the gp-60 albumin receptor
by the gp-60 albumin
by the gp-60
by the
durch den
of the EMEA
through the foil because
durch die gleichzeitige Gabe von
be treated by oral administration
, by
by the
by
durch die
of the
onset of late diabetic
is caused by a
by mild agitation before use
by mild agitation before
by mild
replaced with new bone material
by renal excretion .
by renal excretion
by renal
durch spezifische Interaktionsstudien bestätigt ,
durch spezifische Interaktionsstudien bestätigt
durch
durch
by
durch
in
into less
into
is caused by
of the blood by
of
studies looking at
studies of
studies
.
been performed .
been carried out .
been carried out
been conducted
been conducted
been performed
conducted
average duration of diabetes was
average duration of diabetes
average duration of
average duration
average steady-state
average
such patients .
such patients
dynamic
should not
also part
also part of the EPAR
also part of the EPAR
also part of
also part
also be effectively treated (
also be effectively treated
also
be effectively treated ( e.
be effectively treated (
be effectively treated
effectively treated
effectively
pens to function safely
cartridge to function safely
to function safely
a measure of the absorption
a measure of the
a measure
.
du
. du
.
ina
ein Anstieg des
ein Anstieg
an antimicrotubule agent
a medicine containing
a medicinal product
a medicine
medical
a finding
regimens including bisphosphonates
regimens including
regimens
a bisphosphonate .
a bisphosphonate
a cannabinoid receptor antagonist .
a cannabinoid receptor antagonist
a cannabinoid receptor
an antidiabetic medicine )
an antidiabetic medicine
one third of the patients
one third of the
one third
an average age of 62
follow a nutrition programme .
follow a nutrition programme
includes a nutrition programme .
includes a nutrition programme
a nutrition programme
a replacement insulin which
a replacement insulin which
a replacement insulin
naturally
a glycoprotein that stimulates ,
a glycoprotein that stimulates
a hormone
jaundice is observed ,
jaundice is observed
an inhibitor of osteoclast-mediated
an inhibitor of
an inhibitor
year after
year after
for a year or more
one year or less duration
one year or less duration
one year or less
one year or less
for a year or
one year or
one year or
one year ,
one year
for a year
one year
one year
year
NMS
of NMS
a maximum volume of 1
a maximum volume of
a maximum volume
rather
your carer/ relative
hypoglycaemia whilst driving .
hypoglycaemia whilst driving
a risk
of
some of
a growth factor
Another LHRH agonist
another antipsychotic medicine ) in
another antipsychotic medicine )
another antipsychotic medicine
another
a characteristic
a dose-dependent increase in
a
a clear-cut
for major elective
major elective
for major
major
an increased risk for thromboembolic
an increased risk of thrombotic
an increased risk for
an increased risk of
an increased risk
an increased risk of
an increased risk
increased risk of
increased risk
an increased
increased risk of
increased risk
risk
a
a potent inhibitor
a potent inhibitor of CYP3A4
a potent inhibitor of
a potent inhibitor
avoid invasive dental procedures
a mild
a new LHRH agonist and
a new LHRH agonist
a new LHRH agonist and
a new LHRH agonist
a new
normal quality
of normal quality
an antipsychotic medicine .
an antipsychotic medicine
a stable level
a sterile but unpreserved
a sterile but
a sterile
fatal outcome has been reported
fatal outcome has
fatal
and swallow it
apparent in animal studies with
apparent in animal studies
a cytotoxic anticancer medicinal product
a cytotoxic anticancer
a cytotoxic
, a
a
an
avoid
clinical
ein
for a
in
of a
year in
year
a similar significant
a similar
cardiotoxicity unequivocally
clearly
clear-cut
a 63 % reduction
an albumin-bound nanoparticle formulation of
an albumin-bound nanoparticle formulation
a multipack with
a multipack
receiving chemotherapy
may cause dehydration )
may cause dehydration
cause dehydration
a dose
a dose adjustment is necessary
a dose adjustment
one vial of 100 mg
one vial of 100
one vial of
one vial
one single-use
one single-use
permitted recovery from the
permitted recovery from
permitted
elevated creatine phosphokinase ,
elevated creatine phosphokinase
, exposure to
exposure to
containing 1 bottle
a glass ball to
half-life of approximately 6
half-life of approximately
a half-life of a few
revealed a half-life of approximately
a half-life of a
half-life of
half-life
to target a haemoglobin of
to target a haemoglobin
one infusion of Aclasta
a solution for infusion (
a solution for infusion
an injection
to be compatible .
to be compatible
a disease in which
a disease
a gradation in
a gradation
sites
a mixture of dissolved insulin
a mixture of dissolved
a mixture
an adverse reaction
an osmolality of
an osmolality
QT prolongation or
QT prolongation
a range of insulin suspensions
a range of
a range
planning to become pregnant .
planning to become pregnant
to become
one syringe from
a syringe
one syringe
a fixed-dose trial
one tablet
a reduction of insulin resistance
a reduction of
a 35 % reduction
a reduction
a different dose .
a different dose
antithrombotic prophylaxis
anti-erythropoietin , antibody-mediated PRCA is
adequate
a known complication of chronic
up to a 31
up to a
following
of the
one injection .
one injection
one
blood glucose monitoring is therefore
blood glucose monitoring
need to be treated
need to be
to be treated
to be
to
a colourless to slightly yellow
a colourless
a 2 ml calibrated dropper
a calibrated
a calibrated
demonstrated superior efficacy to placebo
with hypertension and/ or dyslipidemia
with
suggesting hepatic dysfunction
high in vitro permeability
high
a single intravenous infusion of
a single intravenous infusion
a single intravenous
to a calorie-controlled diet
a clear , colourless ,
a clear , colourless
a clear ,
as a clear ,
a clear and colourless solution
a clear and colourless
a clear and
a clear
as a clear
consider clinical
consider clinical monitoring
a cumulative dose
for a cumulative dose
a cumulative
for a cumulative
a long time
a long
mild renal impairment
mild
a mean total
moderate binding affinity for
moderate affinity for
moderate binding affinity for
moderate binding affinity
a negative impact on
a negative impact
a negative
grade 3 peripheral neuropathy at
peripheral neuropathy at any
peripheral neuropathy at
to allow proper dosing
a rapid initial effect together
a rapid initial effect together
a rapid
injection sites .
injection sites
allow the
significantly greater
specific treatment
specific
a statistically significant
a statistically
by physicians for
by physicians
by physicians for
by physicians
by physicians for the occurrence
symptomatic treatment should be initiated
symptomatic treatment
, symptomatic hypocalcaemia
symptomatic hypocalcaemia
symptomatic therapy should be administered
, symptomatic therapy should
symptomatic therapy should
, symptomatic
symptomatic
a concomitant systemic
a t½ of a few
a t½ of a
a 27 % higher
a 27 %
a 43 %
, a
If
a
an
as a
at any
at
by
demonstrated
due to the
due to
eine
for a
of a
of the
of
one
receiving
revealed
to take
to
, a similar decrease in
a similar decrease in
, a similar decrease in
a similar decrease in
a similar pattern of efficacy
a similar effect
, a similar
a similar pattern of
a similar pattern
a similar
the recommended human weekly dose
an anthracycline (
including an anthracycline (
an anthracycline
including an anthracycline
baseline
a baseline of 7.9 %
a baseline of 7.9
a baseline of
a baseline
a bromobutyl/ polyisoprene rubber stopper
a bromobutyl/ polyisoprene rubber
a bromobutyl/ polyisoprene
a dose range of 10
a dose range of
a dose range
an autologous predonation programme
a pre-filled pen .
a pre-filled pen
a glass of water
a glass of
a glass
it contacts
NMS , have also
a sulphonylurea ( another
a sulphonylurea (
a sulphonylurea .
a sulphonylurea , only in
a sulphonylurea , only
a sulphonylurea ,
a sulphonylurea
sulphonylurea
an animal model of familial
transfer from animal
transfer from animal
over
an autologous predonation programme :
an autologous blood predonation
an autologous predonation programme
an autologous blood
any of the excipients .
any of the excipients
to any of the excipients
of the
at increased risk of fracture
an increased risk of
at increased risk of
at increased risk
an increased
a lesser amount in urine
a lesser amount
a potent inducer
a cardiovascular
an apparent volume
it occurs , appropriate
a specialised genetic
a specialised
rubber
a body mass index
a body mass
a
an autologous
an
in
including an
it
one
rubber
the
using an
with
your doctor or pharmacist .
your doctor or pharmacist
your doctor or
a bromobutyl/ polyisoprene rubber stopper
a bromobutyl/ polyisoprene rubber
an infusion bag
one month
a PSUR
provide a PSUR
had had a stroke .
had had a stroke
one side and " 10
one side and " 15
one side and " 30
one side and "
one side and
one side
a portion of the food
a portion of the
a portion of
Abraxane over
not
over
experience a fast heart rate
any of the other ingredients
any of the other
ge reported with
to any of the other
to any of the excipients
any of the other ingredients
any of the other ingredients
to any of the excipients
to any of the excipients
to any of the excipients
any of the
ge reported
to any of the
both a calibrated
a minor trauma
a minor
a
a slight appetite decreasing effect
a slight appetite decreasing
a longer
a pH of 6-7.5 and
a pH of 6-7.5
a pH of
a pH
one additional 6
one additional
a
an
any of the
any
both a
ge
one
or
provide a
to any
to
were
a 3
a
in a
einer Adipositas infolge des höheren
einer Adipositas infolge des höheren
einer Adipositas ist die
einer Adipositas ist
einer Adipositas
a type of white
a type of white
a type of
a type of
a type
a type of
a type
Bipolar I Disorder , with
Bipolar I Disorder ,
of Bipolar I Disorder ,
Bipolar I Disorder
of Bipolar I Disorder
a blister .
a blister
of an increase in blood
of a multi-pack comprising 5
of a multi-pack comprising
recombinant DNA technology
an overseal ( aluminium )
an overseal ( aluminium
diet
of the
of
a dose of 600
a dose of
a dose
a vial .
a vial
a single
a pre-filled syringe ( injection
a pre-filled syringe (
a pre-filled syringe .
a pre-filled syringe The syringes
a pre-filled syringe The
a pre-filled syringe Epoetin alfa
a pre-filled syringe Epoetin
a pre-filled syringe
each containing 1 bottle .
, each containing 1 bottle
each containing 1 bottle
containing one bottle
a haloperidol-controlled trial
of heart failure ,
of heart failure
cardiovascular disorders
cardiovascular
hormonal therapy .
hormonal therapy
of hyperglycaemia ( such as
of hyperglycaemia (
of hyperglycaemia
of hypocalcaemia was
hypocalcaemia
of hypocalcaemia
of one infusion of 5
of one infusion of
one infusion
an initial dose of 450
of insulin resistance .
of insulin resistance
a 74-week extension
a meal or unplanned ,
a meal or unplanned
a meal or
a meal
of renal or hepatic dysfunction
a benefit-risk assessment with
a cartridge ( 3 ml
a cartridge ( 3
a cartridge (
a cartridge .
a cartridge
QT prolongation
a number of other
a number of
a number
and suicide .
harm and suicide .
suicide .
and suicide
harm and suicide
suicide
of pregnancy .
of pregnancy
one side .
one side
a standard scale for
a standard scale
a study in patients with
a study
of a substance
of a
a daily dose of 15
a daily dose of
a daily dose
by an improvement in
an interaction .
an interaction
a week .
a week
abrupt improvement in
a
another
otherwise decided by the
otherwise decided by
existing treatment with lithium
existing treatment with
existing treatment
cardiovascular
existing vertebral fracture(s ) .
existing vertebral fracture(s )
of existing vertebral fracture(s )
existing
of existing
diabetic retinopathy .
diabetic retinopathy
diabetic
one of these trials ,
one of these trials
one of these
dose dependent decreases in serum
a
with a
healthy
a large
controlled by systemic chemotherapy .
controlled by systemic chemotherapy
by systemic chemotherapy
higher than the
higher than
higher
a cardiovascular outcome study ,
a cardiovascular
a small study
a small study
a small
a clinical trial in healthy
a clinical trial
a clinical
a recent low-trauma hip fracture
a recent low-trauma hip fracture
a recent low-trauma
a recent
a recent
a more long-lasting effect
a more
a solvent-based
a manic or mixed episode
a manic or
a manic
einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch
einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde
einer ng Ethinylestradiol/Levonorgestrel-Kombination
einer ng
a recent low-trauma hip fracture
a recent low-trauma
a corresponding unit scale .
a corresponding unit scale
a corresponding
a prospective ,
a prospective
undergo periodic
of profound myelosuppression
of severe neutropenia or severe
of severe neutropenia or
of severe neutropenia
of severe
of
significant weight gain .
significant weight gain
one of two safety pharmacology
one of two
einer von
one of
a recent low-trauma
undergo dental surgery
of adding Abilify
of adding
, a
15 and 5
15 and
15
As an
In
a 5
a blood
a
an
and a
by an
by
deterioration
einer kürzlich erlittenen geringtraumatischen Hüftfraktur
einer kürzlich erlittenen geringtraumatischen
einer kürzlich erlittenen
einer kürzlich
einer
in Bipolar I
in a
in
incidence of
of a
of a
of
one of
one
ongoing
period
weight
with a
with a
be necessary
defined .
of overdose should
defined
of an overdose
of overdose
overdose
obtained with a prescription .
obtained with a prescription
of a CB1 antagonist
in these circumstances .
in these circumstances
of NMS are hyperpyrexia
after repeated dosing
after
who suffer from a
a known marker of
of each patient
of each patient
eines
signs of a sudden rise
signs of a
a specific type of receptor
of a
periods of a
treatment periods of a
a
eines
of a
of
periods of a
size of
treatment periods of a
an overall weight management programme
should be initiated
initiated
food .
food
tablets
take
taken
the tablets
2500
waren , wurde
waren ,
restricted
hepatic impairment .
hepatic impairment
impairment ,
impairment
patients with
is controlled .
is controlled
controlled
adverse
results
levels of the
levels of
levels
some of your ABILIFY tablets
some of your ABILIFY
some of your
some of the other clinical
some of the other
some of the
some or all of
some or all
some or
some of
some
some , but
some ,
some cases extreme and associated
some cases
few minutes .
few minutes
been experienced by some patients
some preclinical toxicological studies in
few
some
once every three
once every
once a year for 3
once a year for 3
once a year for
administered once a year ,
administered once a year
administered once a year
once a year
given once or twice daily
given once or twice daily
once or
once a year
once a
once daily )
once a day , but
once a day ,
once a day .
once daily .
taken once daily with or
taken once daily with
taken orally once daily with
administered once a day
once a day
once a day
once daily
once daily
taken once daily
taken orally once daily
given weekly
given weekly for three weeks
given
given weekly for three
administered once a
once a
once
taking
taking
taking
take
taking
take
taking
yearly
including ABILIFY ,
including ABILIFY
including bisphosphonates
including malformations ( see section
including malformations ( see
including malformations (
including malformations
including osteomyelitis , and the
including osteomyelitis , and
including osteomyelitis ,
including osteomyelitis
including parkinsonism , akathisia
including parkinsonism ,
including parkinsonism
including zoledronic acid
including all formulations of aripiprazole
including all formulations of
including all formulations
including those with a
including those with
including those
including the gastrointestinal
including the
including dose reduction
including
may include generalised skin rash
may include generalised skin
reported including rare cases of
, including
including
, inadequately treated
occurs , the treatment
occurs ,
occurs
isolated patients with normal or
isolated patients with normal
isolated patients with
isolated patients
isolated
.
each day .
each day
estimate
elective orthopaedic surgery
orthopaedic surgery
elemental
calcium and 400
eliminated
to reduce these side effects
recommended ( or if
recommended ( or
recommended ( see section 4.2
recommended ( see section
recommended ( see
recommended (
recommended that the
recommended ,
recommended that
recommended
, is recommended .
is recommended .
kidneys .
notify
recommended .
recommended
recommended for anyone
recommended for use in
recommended for use
recommended for
recommended for
, is recommended
is recommended
recommended
recommended starting dose is 15
recommended starting dose is
recommended starting dose for ABILIFY
recommended starting dose for ABILIFY
recommended initial dose for
recommended starting dose for
recommended initial dose
recommended starting dose
recommended dose is 600
recommended dosing regimen is
recommended dosing regimen
recommended dose of Abraxane is
recommended dose of Abraxane
recommended dose of
recommended dose is a
recommended dose is
recommended dose of
recommended dose
recommended weekly dose is between
recommended weekly dose
recommended total weekly dose
recommended weekly
recommended
recommended treatment schedule
maximum recommended human
maximum recommended
recommended human therapeutic exposure
recommended human therapeutic
maximum recommended clinical dose
recommended human
recommended
even
dated Final (
dated Final
endogenous human erythropoietin that
should be closely monitored .
should be closely monitored
closely
monitor closely
be monitored closely
remove the protective cap from
, but
,
contain 0.3 ml ( 3000
contain 0.3 ml (
contain 0.3 ml
contain 0.3
contain 0.4 ml ( 4000
contain 0.4 ml (
contain 0.4 ml
contain 0.4
contain 0.5 ml ( 1000
contain 0.5 ml ( 5000
contain 0.5 ml (
contain 0.5 ml
contain 0.5
contain 0.6 ml ( 6000
contain 0.6 ml (
contain 0.6 ml
contain 0.6
contain 0.7 ml ( 7000
contain 0.7 ml (
contain 0.7 ml
contain 0.7
contain 0.8 ml ( 8000
contain 0.8 ml (
contain 0.8 ml
contain 0.8
contain 0.9 ml ( 9000
contain 0.9 ml (
contain 0.9 ml
contain 0.9
contain 1 ml ( 10
contain 1 ml ( 2000
contain 1 ml (
contain 1 ml
contain 1
contain 15 , 30 or
contain 15 , 30
contain 15 ,
contain 15
contain lactose monohydrate and
contain lactose monohydrate
contain substances ( solvents )
contain substances ( solvents
contain
medicines
paclitaxel-
contains 0.05 mg zoledronic acid
contains 0.05 mg
contains 0.05
contains 1 bottle
contains 1 bottle
contains 1
contains 10 000 IU
contains 10 000 international units
contains 10 000 international
contains 10 000
contains 10 mg of aripiprazole
contains 10 mg of
contains 10 mg
contains 10 ml equivalent to
contains 10
contains 100 IU of insulin
contains 100 IU of
contains 100
contains 1000 international units (
contains 1000 international units
contains 1000 international
contains 1000
contains 15 mg of aripiprazole
contains 15 mg pioglitazone (
contains 15mg of pioglitazone (
contains 15 mg of pioglitazone
contains 15 mg pioglitazone
contains 15mg of pioglitazone
contains 15 mg of
contains 15 mg
contains 15mg of
contains 15mg
contains 15
contains 200 mg of fructose
contains 200 mg of
contains 200 mg
contains 200
contains 2000 IU
contains 2000 international units (
contains 2000 international units
contains 2000 international
contains 2000
contains 3 ml equivalent to
contains 3 ml equivalent to
contains 3 ml
contains 3
contains 30 mg of aripiprazole
contains 30 mg pioglitazone (
contains 30mg of pioglitazone (
contains 30 mg of pioglitazone
contains 30 mg pioglitazone
contains 30mg of pioglitazone
contains 30 mg of
contains 30 mg
contains 30mg of
contains 30mg
contains 30
contains 3000 international units (
contains 3000 international units
contains 3000 international
contains 3000
contains 40 IU of insulin
contains 40 IU of
contains 40
contains 4000 international units (
contains 4000 international units
contains 4000 international
contains 4000
contains 45 mg pioglitazone (
contains 45mg of pioglitazone (
contains 45 mg of pioglitazone
contains 45 mg pioglitazone
contains 45mg of pioglitazone
contains 45 mg of
contains 45 mg
contains 45mg of
contains 45mg
contains 45
contains 5 mg zoledronic acid
contains 5 mg zoledronic acid
contains 5 mg
contains 5 mg
contains 5
contains 5000 international units (
contains 5000 international units
contains 5000 international
contains 5000
contains 6000 international units (
contains 6000 international units
contains 6000 international
contains 6000
contains 7000 international units (
contains 7000 international units
contains 7000 international
contains 7000
contains 8000 international units (
contains 8000 international units
contains 8000 international
contains 8000
contains 9.75 mg ( 1.3
contains 9.75 mg (
contains 9.75 mg
contains 9.75
contains 9000 international units (
contains 9000 international units
contains 9000 international
contains 9000
Abraxane contains approximately 425 mg
, Abraxane contains approximately 425
Abraxane contains approximately 425
, Abraxane contains approximately
Abraxane contains approximately
, Abraxane contains
Abraxane contains
contains The active substance is
contains The active substance is
contains The active substance
contains The active substance
contains The active
contains The
contains metacresol , which
contains methyl parahydroxybenzoate and
contains methyl parahydroxybenzoate
vanillin and ethyl
contains approximately 425 mg sodium
contains approximately 425 mg
contains approximately 425
contains approximately
contains the active substance paclitaxel
contains the active substance
contains the active ingredient
contains the same active substance
contains one single-use
contains one single-use
contains a glass ball to
contains a
containing a bromobutyl rubber plunger
contains the following :
each ml of suspension contains
contains both fast-acting (
contains both fast-acting
contains both
contains the
contains
decide how long you
decide how long
decide how
decide
decided
household waste .
household waste
corresponding to 0.05330 mg
corresponding to 0.05330
equivalent to 300 IU .
equivalent to 300
corresponding to 5.330 mg
corresponding to 5.330
be disposed
products should be disposed
should be disposed
corresponding to the
corresponding to at least
corresponding to
equivalent to
of
appropriate dose adjustment
appropriate dose
corresponds to 0.035 mg
corresponds to 0.035
to 15 mg aripiprazole )
to 15 mg aripiprazole
to 15 mg
to 15
M-IV contribution to
corresponds to
to
such products
such
either Actos or placebo
either Actos or
either Actos
either CYP2C8
either valproate or lithium
either valproate or
either valproate
one infusion of Aclasta
one infusion of
either with
either
experienced the development
encephalopathy-like symptoms ( e. g.
encephalopathy-like symptoms (
encephalopathy-like symptoms can occur .
encephalopathy-like symptoms can occur
encephalopathy-like symptoms can
encephalopathy-like symptoms
encephalopathy-like symptoms
encephalopathy-like
uth Experience
er Die Steady-State-Pharmakokinetik eines oralen
er Die Steady-State-Pharmakokinetik eines oralen
er Die
reactions
Memory loss Dizziness
Memory loss
absolute change in HbA1c
in
lon ANNEX
er wünschen ,
er wünschen
er
it
lon As
lon
ra The
ra
uth
because of the limited
because of the
because of
because
be administered .
be used .
be administered
be used
rapid
is eliminated by renal excretion
is eliminated by renal
is eliminated by
is excreted unchanged
.
is catalysed
is catalysed by CYP2C8
is catalysed by
is rapid and mainly
is rapid and mainly via
is rapid and
is rapid
is catalysed
is eliminated
is
rapid
required ( see section 5.2
required ( see section
required ( see
required (
necessary your doctor may
necessary
for smokers .
is necessary .
necessary .
for smokers
is necessary
necessary
required
not generally
not
revealed no medically important differences
revealed no medically important
revealed no medically
revealed no
revealed
the following pharmacokinetic data
the following pharmacokinetic
the following
, the following weight
, no new
, no
,
the
?
dyslipidaemia .
, and
,
.
have been receiving
have received
dosing
been receiving
receive
received
will receive
will
were receiving insulin in combination
were receiving insulin in
were receiving insulin
were receiving
receiving
received risedronate once a day
received risedronate once a
received risedronate
received
received one infusion of
were receiving cardiovascular
were also receiving chemotherapy and
were also receiving chemotherapy
in patients
patients received
patients
received
were receiving
in men .
men .
in men
men
since 1993.
.
increase the risk of malformations
increase the risk of malformations
increase the risk of
increase the risk
increase
increased .
increase
increase
increased
to increase
increased Alanine Aminotransferase ( ALT
increased Alanine Aminotransferase (
increased Alanine Aminotransferase
increased Aspartate Aminotransferase ( AST
increased Aspartate Aminotransferase (
increased Aspartate Aminotransferase
increased exposure
increased exposure
increased Gamma Glutamyl Transferase (
increased Gamma Glutamyl Transferase
increased Gamma
increased insulin resistance
increased incidence of
increased Creatine Phosphokinase ,
increased Creatine Phosphokinase
increased production of saliva ,
increased production of saliva
increased pup mortality
how your
increased alkaline phosphatase
increased alkaline
increased
elevated post-menopausal
elevated
increased linearly from 2653
increased linearly from
increased linearly
increased
increased
at increased risk of
at increased risk
increased
an increased presence of
an increased
increased insulin sensitivity
increased risk of
increased risk of
increased risk
increased
blood glucose increased , blood
elevated liver enzymes and hepatocellular
elevated liver enzymes and
elevated liver enzymes
increased risk of death and
increased risk for thromboembolic events
increased risk for thromboembolic
increased risk of thrombotic vascular
increased risk of thrombotic
increased risk for
increased risk of
increased risk
increased risk of
increased risk of
increased risk
increased risk
increased
past
control group .
control group
evaluations .
evaluations
to learn how
to learn
learn
low-trauma hip fracture .
low-trauma hip fracture
low-trauma
lowest effective
be rechallenged with paclitaxel
rechallenged with paclitaxel
rechallenged
weight regain .
weight regain
low blood pressure : hypertensive
fracture incidence calculated was 1.9
fracture incidence calculated was 1.9
reach maximum concentration
reach
administration .
administration
is achieved ( this
is achieved (
is achieved .
is achieved
, was 18.7 µg/ ml
dosing .
dosing
achieved
plasma levels achieved
top .
top
of
first treatment
first treatment
first injection .
first injection
first
first 10 days after
first 10 days
first 10
first
first 21 days
first 24 hours
first Aclasta infusion
first Aclasta
first dose .
first
first infusion
first three days after administration
first three days after
first three days
first three
first
first opening the immediate packaging
first opening the
first opening
first
adult dogs .
adult dogs
with
adult patients :
adult patients
adult subjects , nor
adult
expected .
expected
be considered ( see section
be considered ( see
be considered (
be considered
considered
cycle
, adequate iron stores should
adequate iron stores should
, adequate
adequate
adequate
nine
In
report it to your doctor
it attaches to
it attaches
the
the bone remodelling process
the bone remodelling
the
are currently
are
essentially sodium- free .
essentially sodium- free
not pass it on
not pass it
unless the expected
unless
unless
has multiple well documented
has multiple well
In
even in
in
it on
it
not there
or not there
recently
eská
, etc. )
, etc.
races .
races
about 5-10 hours .
about 5-10 hours
adjusted approximately every four weeks
approximately every four weeks
approximately every four
approximately every
approximately one-half of its
about
approximately
about hurting yourself
about hurting yourself
.
evaluated and remains unknown
evaluated and
evaluated
evident ischaemic heart
5
extrapyramidal disorder , akathisia ,
extrapyramidal disorder , akathisia
extrapyramidal disorder , akathisia
extrapyramidal disorder ,
extrapyramidal disorder
extrapyramidal symptoms .
extrapyramidal symptoms
extrapyramidal
extensive extravascular distribution .
extensive extravascular distribution
extreme and associated with ketoacidosis
extreme and associated with
extreme and associated
if necessary
if
indicated
colourless and
colourless
colourless , aqueous solution .
colourless , aqueous solution
colourless , aqueous
colourless ,
colourless solution for injection in
colourless solution for injection
colourless solution .
colourless solution
colourless to light yellow liquid
colourless to slightly yellow solution
colourless to slightly yellow
colourless solution
colourless
farmacevtska dru ba , d.
farmacevtska dru
almost
screwed back on
screwed back on tightly .
screwed back on tightly
screwed back on
screwed back
reference laboratories .
reference laboratories
was detected .
festgestellt wurden
wurden
was detected
continue .
continue
decide whether
decide whether
experience
recommendations .
recommendations
decide , if
lipid soluble drugs used concomitantly
lipid soluble drugs
fat meal
sweet
filiaal Tel : +3726441100
filiaal Tel :
filiaal Tel
filiaal
, und sie
, und sie
.
Actos is available here
can be found here .
can be found here .
is available here .
can be found here
can be found here
is available here
can be found
is
sie
so
following side effects
the following side effects
following pharmacokinetic data
following pharmacokinetic
following adverse reactions
following clinical
following
the following
following information is
following undesirable effects occurred
following undesirable effects occurred
following reactions have also occurred
following reactions
folgenden Tabelle 2
Before
by
following adverse events have been
following adverse events
following adverse
folgenden Tabelle
folgenden
following diseases
following
the following
following : Physician educational material
following :
the following :
formally investigated .
formally investigated
formally
advanced prostate cancer
advanced solid tumours ,
advanced solid tumours
advanced solid
advanced
to look at the
to look at
androgen suppression in men with
androgen suppression in men
androgen suppression in
androgen suppression
from particles and
from particles
voluntarily
stops eating
early disposition phases ( and
early disposition phases (
early disposition phases
early
been previously exposed to anthracyclines
had
previous stroke who
previous stroke
previous
anthracyclines or have underlying
anthracyclines or have
have
market
tubulin
animal studies with pioglitazone .
animal studies with pioglitazone
might make you
might make
,
.
might
, reversal may be
, reversal
not result in accumulation of
not result in accumulation
is expected to reduce the
is expected to reduce
is expected to
is expected
results in blockage of the
results in blockage
results in
führt
results in
reversal
led to a decrease in
led to a decrease in
significant reductions in
resulted in
resulted
five years .
five years
were five short-term studies
on the total dose .
on the total dose
five large controlled studies
five large controlled
five large
five
for 3 weeks
for 3 consecutive
for 3
for 3 consecutive
for 3
for 4 weeks in rats
for 4 weeks in
for ABILIFY is 10 or
for ABILIFY is 10
for ABILIFY is 15 mg
for ABILIFY is 15
for ABILIFY is
for ABILIFY
für ABILIFY
for ACOMPLIA can be found
for ACOMPLIA
for Abilify can be found
for Abilify
of Abraxane is 260
of Abraxane is
of Abraxane
for Aclasta is available here
for Aclasta and risedronate
for Aclasta and
for Aclasta
for Aclasta-treated
for Aclasta-treated
for Actraphane can be found
for Actraphane
for aripiprazole .
for aripiprazole
for dehydro-aripiprazole the geometric means
, for dehydro-aripiprazole the
for dehydro-aripiprazole the
, for dehydro-aripiprazole
for dehydro-aripiprazole
for diabetes
for Medicinal products for
for dogs Mitratapide
for dogs
predispose patients to hypotension
for injections .
for injections Hydrochloric acid (
for injections Hydrochloric acid
for injections
for anyone
for lorazepam
for mitratapide versus
for mitratapide
for mitratapide
for patients experiencing
for patients
for patients experiencing
for patients
for people with phenylketonuria .
for people with phenylketonuria
in patients with less
in patients with
for patients
in patients
for patients with
for patients
for placebo .
for placebo
dosage adjustment
for rimonabant 20 mg (
for rimonabant 20 mg
for rimonabant 20
for rimonabant ; therefore ,
for rimonabant ; therefore
for rimonabant ;
for rimonabant
only to be supplied only
for Vantas
for all cancer patients
for all
for both groups )
for both groups
for both
of P-glycoprotein .
of P-glycoprotein
of
the foetus .
the foetus
to the foetus .
to the foetus
designed to be
for humans is
for humans
of Paget s disease
for
for use in children
for use in
for use
indicated for the treatment of
for the treatment of
for the treatment
responsible for batch release :
responsible for batch release
responsible for batch release
responsible for batch
responsible for dehydrogenation
to recommend dose modifications
to recommend dose
information on the infusion of
information on the infusion
for combination
for the receptors for the
the use of zoledronic acid
the use of
the use
of effectiveness was the
of effectiveness was
of effectiveness
for appropriate dose adjustment for
for the first injection .
for the first injection
for the first
for the
for
indicated for
information on the
of
the incidence of
the
for use in
for one year
for one injection .
for one injection
for one
works for a long time
for a long time
for a long
for a
of local infection including osteomyelitis
of local infection including
of local infection
of local
for
for at least 2
for at least
for placebo-treated patients
serious adverse events When
serious adverse events
serious cardiovascular events was observed
serious cardiovascular events was
for thromboembolic events in
for thromboembolic events
for thromboembolic
for cerebrovascular adverse events in
for cerebrovascular adverse events
for cerebrovascular adverse
, for
for
für
of
provide
g/ dl ( 0.62
g/ dl ( 1.25
g/ dl ( 5.9 -
g/ dl ( 5.9
g/ dl ( 6.2 -
g/ dl ( 6.2
g/ dl ( 7.5 mmol/
g/ dl ( 7.5
g/ dl ( 8.1
g/ dl (
g/ dl , the
g/ dl ,
g/ dl
g/ dl .
g/ dl - 12
g/ dl
g/ dl :
g/ dl
g/ dl
disorder .
there were no
there were
disorder
reduce the metabolic
reduce the
the metabolic
the
to reduce the metabolic
to reduce the
gastro-intestinal
gastrooesophageal reflux
ise Nervous disorders :
ise Nervous disorders
ise
Depressive disorders were
Population pharmacokinetic analysis
Population pharmacokinetic
or uth ra ge
Depressive disorders
ise
or uth
give
,
endorsed ( two relate
endorsed ( two
endorsed (
endorsed
indicated when Aclasta
indicated when
when
be used when
when
.
extraction .
medicinal products .
medicinal products
extraction
ready for use .
ready to use .
ready for use
ready to use
ready
broke
bound ) and
bound )
bound ) and binding
bound ) and
bound ) and
bound ) and
bound )
.
paclitaxel .
protein .
bound
protein
2 ml calibrated dropper are
2 ml calibrated dropper
calibrated
calibrated
calibrated measuring cup and a
calibrated measuring cup and
calibrated measuring cup
calibrated
suitable
appropriate doses for patients with
appropriate doses for patients
appropriate dose
appropriate doses for
appropriate dose
appropriate doses
, appropriate
appropriate
and than reinstitute epoetin
, followed by a
followed by a 74-week extension
followed by a
, followed by
followed by
about operating hazardous machines
about operating hazardous
energy requirements for
energy requirements
fed dogs ,
fed dogs
fed
administered intravenously
occurs ,
occurs
occurs .
occurs
administered
given
total administered dose with less
total administered dose with
total administered dose
administered
controlled as necessary .
treated , if necessary .
controlled as necessary
treated , if necessary
may
may do regular blood tests
may do regular
may be
may
medicines ) shortly
medicines )
medicines
to erythropoietins have been observed
to erythropoietins have been
time
time
to the active substance or
to the active substance
medicines
versus 0.8 % of
versus 0.8 %
versus 0.8
versus animal source insulin )
versus animal source insulin
to pioglitazone
to a stimulus ) .
to a stimulus )
to a stimulus
against the
the way back to
to
to a
to
versus
belongs to
belongs
reach
Use
yellow , marked with
yellow , marked with
yellow , marked with
yellow , engraved with
yellow , marked with
yellow ,
yellow
dissolved insulin and 50 %
dissolved insulin and 50
dissolved insulin and 60 %
dissolved insulin and 60
dissolved insulin and 70 %
dissolved insulin and 70
dissolved insulin and 80 %
dissolved insulin and 80
dissolved insulin and 90 %
dissolved insulin and 90
dissolved insulin and
dissolved insulin
dissolved
result
concomitant administration
concomitant
of
measured but a
measured annually
measured
infusion fluids .
infusion fluids
mixed episode of
mixed episode of
mixed episode
mixed episode of
mixed episode
mixed episodes or
mixed episodes
mixed
called
in
of action
of
exactly as your doctor
instruction for use to
advice
specific frequency can be presented
specific frequency can
approved on { date }
approved in { date }
.
approved on
generalised
of generalised
generalised hypersensitivity
of generalised hypersensitivity
produced by recombinant DNA technology
produced by
genetic
produce enough insulin to control
Insulin zur
produce enough insulin to
Insulin
produce enough insulin
produce enough red blood
enough
produce enough
geometric means of Cmax and
geometric means of Cmax
geometric means of
geometric means
geometric
planned G-CSF support .
planned G-CSF support
pooled data* ) :
pooled data* )
pooled data*
be advised
advised
important in those
mucositis
blood
small amount of
small amount
minor or moderate influence
minor or moderate
minor or
minor
increases
increases
can occur ( see section
can occur ( see
can occur (
occur ( see section
occur ( see
occur (
( see section
( see
(
( see section
( see
(
efficacy
lesser amount in urine (
lesser amount in urine
lesser amount
a
slightly between
slightly
entire dose is injected .
entire dose is injected
entire dose
entire
whole treatment period .
whole treatment period
total weight loss
total hip
for its total active metabolites
its total active metabolites
Ltd.
total
is predominantly via cytochrome
is predominantly via
in schizophrenic
estimated
estimated
estimated volume of distribution
estimated volume
reported estimated doses
reported estimated
be increased .
be increased
increased
agitation than
of agitation than
agitation
agitation
agitation or disturbed
agitation or
agitation and disturbed behaviours
agitation and
of agitation , and
agitation
of agitation ,
of agitation
of agitation
infants , Abraxane is
infants ,
infants
stopped
also occur in men .
occur in men .
also occur in men
occur in men
also occur in
also occur
occur in
occur
similar between healthy non-smoking subjects
similar between healthy non-smoking subjects
between healthy non-smoking subjects and
between healthy non-smoking subjects
healthy subjects
healthy
to healthy
healthy elderly and younger
healthy elderly and
healthy elderly
dose
dried and the cap
resulting
washed and
washed
circumstances
effectively .
effectively
be assured :
be assured
that usually develops in adulthood
usually transient , typically
transitory and disappear
transitory and
transitory
usually transient
usually
usual dose is between
usual dose is
usual dose
usual
values at the desired level
values
( G-CSF and GM-CSF
(
shown that pioglitazone has no
shown that pioglitazone has
shown
?
.
has
shown
be considered when
be considered
considered
Patients have
are currently
no experience in children
no experience in
no experience
no
are
have been accompanied by an
have been accompanied
think
think you may be pregnant
think
equal injections .
equal injections
equal
same dose
same
contribute equally to efficacy .
contribute equally to efficacy
contribute equally to
with hypertension and/ or dyslipidemia
were administered concomitantly with aripiprazole
was administered concomitantly with
is concomitantly administered .
is concomitantly administered
concomitantly administered
was administered concomitantly
with
gleichzeitige Gabe von Rimonabant
gleichzeitige Gabe von
concomitant administration
Concomitant osteoporosis therapy
,
Concomitant
concomitant nephrotoxic
concomitant
glycosylated haemoglobin ,
glycosylated haemoglobin increased
glycosylated haemoglobin
rate of
gp-60 albumin receptor ,
gp-60 albumin receptor
gp-60 albumin
gp-60
P- gp-Substrat ) untersucht wurden.
P- gp-Substrat ) untersucht
P- gp-Substrat ) untersucht
gp-Substrat
wide .
wide
large , open-label studies ,
systemic circulation
large controlled studies
large controlled
large
greater sensitivity of this population
greater sensitivity of this
greater sensitivity
more
more
take more ABILIFY
inject more Abseamed
take more Actos
inject more
take more
take more
more
for major orthopaedic surgery
for major
has multiple well documented
well-controlled studies in
well-controlled studies
well-controlled
well absorbed , with
is well absorbed and has
is well absorbed and has
was well
well
well tolerated in
well tolerated
has multiple well
was well
well
systemic chemotherapy
gynaecological , 23 lung
gynaecological , 23
gynaecological ,
gynaecological
gynaecological
)
longer
chemicals
on
( see section 5.1
( see section
( see
(
than you should
than you should
than you
than you
than
have
effects
have
.
doctor .
your doctor .
have an increased risk of
have an increased risk
have an increased
have an
have shown that pioglitazone has
not show an interaction between
did not show an interaction
not show an interaction
did not show
not show
cause
doctor
effects
have recently
have
to have
your doctor
.
pressure .
pressure
values
products .
has Abilify shown during the
has Abilify shown during
has Abilify
has Abraxane shown during the
has Abraxane shown during
has Abraxane
has Aclasta shown during the
has Aclasta shown during
has Aclasta
has Actos
has Actraphane shown during the
has Actraphane shown during
has Actraphane
aripiprazole has not been
aripiprazole has
also has a
also has
has a gradation in
has a gradation
has a
has a pH of 6-7.5
has a pH of
has a pH
has a
has minor or moderate influence
has minor or moderate
has minor or
has minor
in the blood stream has
has no known effects on
has no known effects
has no influence on the
has no influence
has no
has
products
but had no effect on
but had no effect
but had no
but had
also had a
also had a similar effect
also had a similar
also had
had a previous myocardial infarction
had a previous
had an
had
one .
had signs of local infection
had signs of local
had signs of
had signs
had a
had
had
had visceral metastases
had visceral
had
one
bound to bone tissue
hauptsächlich durch Metabolisierung und
mainly in faeces ( 55
mainly in faeces (
mainly in faeces
hauptsächlich
mostly
primarily
primarily by three biotransformation pathways
non-healing sores of
non-healing sores
non-healing
help
does not inhibit or induce
peripheral tissues
hepatic ) pathways in ina
hepatic ) pathways in no
hepatic ) pathways in
hepatic ) pathways
hepatic ) pathways in no
hepatic ) pathways in
hepatic ) pathways
hepatic metabolism and
hepatic metabolism
hepatic metabolism and
hepatic metabolism
hepatocellular dysfunction
hepatocellular
assessing
and apply pressure
apply
.
action .
feeding .
feeding
feeding
was maintained for up to
was maintained
will help to protect the
will help to
will help to protect the
will help
will help
.
suggest
presents
to lie down until you
to lie down until
lie down
lie down
is sufficiently investigated and
is sufficiently investigated
sufficiently investigated and
sufficiently investigated
is sufficiently
sufficiently
adequate data on the use
adequate data on the
adequate data on
hinreichenden oder gut kontrollierten
adequate and well-controlled trials of
adequate and well-controlled trials
adequate and well-controlled
adequate and
adequate
in strength ,
in strength
in serum testosterone reduction
in
alerted
alerted
high (
the insulin requirement ( see
the insulin requirement (
too high ,
the insulin requirement .
the insulin requirement
too high
high
highly protein-bound drugs are unlikely
highly protein-bound drugs are
of highly protein-bound drugs are
potent inhibitors of CYP3A4 ,
potent inhibitors of CYP3A4
potent inhibitors of
potent inhibitors
concomitant
potent
potent CYP3A4 inhibitors with ABILIFY
potent CYP3A4 inhibitors with ABILIFY
potent CYP3A4 inhibitors with
potent CYP3A4 inhibitors
potent CYP3A4
potent
potent
high
high fever
of
performed
high fever
sensitive
. emea .
. emea
. emea
emea
human ) .
human )
human , rDNA (
human , rDNA
human ,
human .
human
therapeutic exposure
therapeutic
human erythropoietin
human liver microsomes and tissue
human tumour samples ,
human tumour samples
human liver
human
hydroxylated metabolites is catalysed
hydroxylated metabolites is catalysed by
hydroxylated metabolites is catalysed
hydroxylated metabolites
hydroxylated
hyperosmolar coma or death
hyperosmolar coma or
hyperosmolar coma
hyperosmolar
lasts for a year or
lasts for a year
lasts for a
lasts
tumour biopsy specimens in vitro
common .
common
common side effects ( affecting
common
more often ( 1/ 100
more often (
more often
but more frequently
is more common
more common
is more common
more common
more frequently
most frequent adverse reaction is
most frequent adverse reaction during
most frequent adverse reaction
most frequent
most common side effects with
most common side effects
most common side effects
most common side effects
most common adverse lon reactions
most common adverse lon reactions
most common
highest nontumorigenic exposure in
highest
highest concentrations
at
of the art .
of the art
( 43 % )
( 43 %
( 43
higher ( 53 % )
higher ( 53 %
higher ( 53
higher (
higher than those observed after
higher than those
higher
higher Cmax and a
higher Cmax and
higher Cmax
higher dose to
higher dose
require higher maintenance doses than
require higher maintenance doses
higher
require higher
fluctuation
higher plasma concentrations
higher
patients
lon
.
ct
du
ideally starting before the
ideally starting before
ideally starting
ideally
identified metabolites are active (
identified metabolites are active
identified metabolites are
identified metabolites
identified
carbohydrate composition to
preventing
their internal skeleton that allows
their internal
illicit
{ date }
in 10-2007 . dic Me
in 10-2007
disposed of via wastewater or
disposed of via
commonly seen in schizophrenic
generally not
generally not be exceeded
therapy in general and the
generally
in
were consistent with biochemical
were consistent with
in the case of
in the case
in the brain .
in the brain
in the face
in urine (
in urine , blood
in urine , proteins
in urine ,
in either urine or faeces
in urine
in the infusion bag :
in the infusion bag
information or procedural aspects please
in the jaw .
in the jaw
the jaw
cells in the bone marrow
cells in the bone marrow
of the mouth or
the mouth or
mouth or
mouth
Vascular disorders Uncommon :
Vascular disorders Uncommon
Vascular disorders
im Nervensystem zu finden
in plasma .
in plasma
plasma
In
antagonist properties in
recovered in the urine ,
excreted in the urine and
excreted in the urine
recovered in the urine
compared to 21 %
compared to 21
compared with patients
versus placebo :
versus placebo
, compared
compared
, compared
compared
, compared
compared to
compared with
compared
female patients as compared to
patients as compared to
relative to baseline were
relative to baseline
, compared
compared
loss compared
patients as compared
versus
were
during continued treatment .
during continued treatment
during continued
widely distributed throughout the body
store them in
during the
during
in { MM/ YYYY }
and in
im
in the
in
involved in
levels and with
levels and
levels
of
plasma
state
were
in 1.3 ml
in 1.3
in 100 ml ready-to-infuse solution
in 100
in 6 % of
in 6 %
in 6
at least one to
at least one
in Abilify , aripiprazole ,
in Abilify , aripiprazole
in Abilify ,
in Abilify
in Abraxane
described in section 6.6 .
described in section 6.6
in section 6.6
in section
in Aclasta , zoledronic acid
in Aclasta ,
in Aclasta
in
in
be included in Braille .
be included in Braille
at doses up to
at doses
supplied in vials , cartridges
supplied in vials ,
supplied in vials
in bottles
as white ,
as white
as
as
of
in kilograms .
in kilograms
taken in combination with alcohol
in combination with insulin
used in combination with insulin
in combination with metformin
in combination with sulphonylureas or
in combination with sulphonylureas
taken in combination with other
in combination with
taken in combination with
used in combination with
in combination
taken in combination
used in combination
presented in Module
in bacterial and mammalian cell
in bacterial
in PVC-aluminium perforated
in Prozent angegeben : Me
in Saccharomyces cerevisiae ) .
in Saccharomyces cerevisiae )
in Saccharomyces cerevisiae
in Saccharomyces
in increments of 2
in increments of
done in
in increments
a risk in situations where
effects listed in table 1
listed in table 1
in table 1
presented in Table 4.
presented in Table 4.
in table
in subsets ranging from 517
in subsets ranging from
in subsets
be marketed .
in Verkehr gebracht . Me
be marketed
as described in version 3.0
described in version 3.0
in water and
in water
related to the first
related to the
related to
related
in all of whom it
in all of whom
in all of
in all
in both groups
similar in both groups
in both
uncommon in the
found in adipocytes (
the enterocytes may be followed
the enterocytes may be
the enterocytes
uptake into bone and
uptake into bone
the Paget s disease
in the thighs or the
in the thighs or
in the thighs
of the non-diabetic
that of the non-diabetic
shown during the studies ?
comparator groups ( sulphonylurea
be marketed .
be marketed
reported in the individual studies
in the individual studies
in the individual
during the 3 weeks
the
back into the systemic circulation
into the systemic circulation
in the
of the
that of the
the
uptake into
in denen Midazolam ( CYP3A4-Substrat
in denen Midazolam (
in denen Midazolam
in
history of
in maintaining the clinical
in the treatment of
in treatment of
in the bile
in the HORIZON-PFT
in half-life was due to
in half-life was due
in the main study ,
in the main study
included in the carton .
included in the carton
in the pharmacokinetics of
in the placebo group .
in the placebo group
in pregnancy and
in pregnancy
be administered to breast-feeding women
breast-feeding (
breast-feeding
the pharmacokinetics
the
by hepatic metabolism and
by hepatic metabolism
by hepatic metabolism and
by hepatic metabolism
in the Aclasta-treated
in the pioglitazone treated
in the pioglitazone
in the
in the
in
in the
in
by
in the
in
in
included due to the
included in the
mentioned in
of
where prophylaxis against
where prophylaxis
where
is excreted in human milk
is secreted in human milk
excreted into human breast milk
in
shown during the studies ?
shown during the studies
shown during the
shown during
in this age group
listed in this leaflet
in this patient group .
in this patient group
in this patient
in this
every 3 weeks .
every 3 weeks
into a vein (
into a vein )
into a vein
to
in a dose range of
in a dose range
in a pre-filled pen .
in a pre-filled pen
in an autologous predonation programme
in a
into an infusion bag
into an
in a blister .
in a blister
in a pre-filled syringe .
in a pre-filled syringe The
in a pre-filled syringe Epoetin
in a pre-filled syringe
studied in one main study
studied in one main study
in a cartridge .
in a cartridge
case in a population of
case in a population
in one of these trials
in one of these
in a large
studied in a small
found in one of two
found in one of
case in a
found in one
in a
in one of
in some cases
in some
that primarily stimulates red
that primarily
described in the following diagram
in cold-formed aluminium perforated
in clinical trials of
in clinical trials
in clinical trials with oral
in clinical trials with
in clinical trials , uncommon
in clinical trials
in clinical
did not
did
did not
did
periodically
achieved and periodically thereafter
increase in haemoglobin
of increase in haemoglobin
in very rare cases
in very rare
in very
in rare cases
in rare
second-line therapy .
second-line therapy
the freezer section or
excreted unchanged
in vitro (
in vitro .
in vitro findings
did not show potential for
did
in vitro
in vitro
vitro
in vitro solubility .
in vitro solubility
in vitro studies
in vivo appears
in vivo
in other indications .
in other indications
in other
in
in two 6-month comparative trials
, in
a
are given in the
are given in
are
as described in
as
at
described in
did not
did
found in
given in
in milk
in other
in steady
in
included in
included
into
of
present in
supplied in
that of
the
uncommon in
where prophylaxis against
where prophylaxis
where
in line with the recommended
in line with the
in line with
in line
lymphocytes
by pinching the
by pinching
by
six
individual insulin requirement is
individual
basis of individual clinical status
individual clinical
of individual clinical
individual patient
individual
of individual
indicated for the
indicated for
is indicated
indicated
been shown to alter laboratory
been shown to
shown to
shown
infolge des höheren
infolge des höheren
consequence
inform your doctor or
tell your doctor or
inform your doctor
tell your dentist
tell your doctor
inform your
inform your doctor
please tell your doctor
inform your
please tell your
inform
please tell
tell your
inform
tell
potential for inhibition of CYP2C8
potential for inhibition of
potential for inhibition
initial effect together with a
initial effect together with
initial effect together
injectable
injected
injected
has been injected .
is injected .
has been injected
is injected
injected
including PANSS and the Montgomery-Asberg
including PANSS and the
including PANSS and
including PANSS
include continuous electrocardiographic
include continuous electrocardiographic monitoring
occur within the first three
occurring within the first three
occur within the first
occurring within the first
occurring within the
within the
within the pre-menopausal range .
within the pre-menopausal range
within the
within a week .
within a week
within a
within a
, use within 3 months
use within 3 months
within 90 days ) low-
within 90 days )
within 90 days
within 90
away within three days.
within three days.
away within three
within three
within two weeks following
within two weeks
within two
away within
given
within
within
given
occurring within
within
part
especially infections and
especially infections
specifically to the unique
specifically to the
especially in patients
especially in
especially those
especially
especially in the face
particularly
particularly if
at the start of treatment
at the start of
at the start
especially
particularly
particularly overweight patients )
particularly overweight patients )
particularly overweight patients )
particularly overweight patients )
particularly overweight patients
particularly overweight patients
particularly overweight
particularly overweight
a total of 1,900 patients
a total of
a total
a total of 357 patients
a total of 357
total more
a total of
a total of
a total
total
inter- and intra-subject variation for
inter- and intra-subject variation
inter- and
inter-
inter-individual variation .
inter-individual variation
inter-individual
intermediate-acting combined with
intermediate-acting combined
intermediate-acting
intestinal calcium malabsorption ) .
intestinal calcium malabsorption )
intestinal calcium malabsorption
intestinal calcium
intra-abdominal fat . ct
intra-subject variation for
intra-subject variation
intramuscular .
intramuscular
intramuscular
the intramuscular
administered intramuscularly
intramuscular injection was 90 %
intravenously ) .
intravenously )
to be administered intravenously (
to be administered intravenously
given by the intravenous route
to be administered intravenously .
administered intravenously
to be administered intravenously
be administered intravenously or subcutaneously
given
single intravenous infusion of 5
single intravenous infusion of
single intravenous infusion
intravenous
single intravenous
intravenous bolus
the intravenous bolus
intravenous infusion of
intravenous infusion
intravenous
the intravenous
intravenous
the intravenous route ,
the intravenous route .
intravenous administration
intravenous route
the intravenous route
intravenous administration of Abraxane
intravenous administration of
intravenous administration
intravenous
the intravenous
invasive dental procedures if possible
invasive dental procedures
below
infertility
second year .
second year
second
ischaemic
ischaemic
anaemic
of anaemic
tubing
should be
, it is
,
is
. It
.
is 15 mg once a
is 15 mg
is 15
is 150 International Units (
is 150 International Units
is 150 International
is 150
are 3.3-fold higher than those
are 3.3-fold higher
are 3.3-fold
is 5 mg ,
is 5 mg
is 5
is 50 International Units (
is 50 International Units
is 50 International
is 50
contributes about 58 % and
contributes about 58 %
contributes about 58
is 600 International Units (
is 600 International Units
is 600 International
is 600
ABILIFY is and
ABILIFY is
, Abraxane is
Abraxane is
Abseamed is and
Abseamed is
Aclasta is and
Aclasta is
Actos is and
Actos is
is aripiprazole .
is aripiprazole
is fever .
is fever
paclitaxel is
is pioglitazone .
is pioglitazone
is part of
Caution is
is indicated when Aclasta is
is indicated as an aid
is indicated as
is also indicated for
is also indicated
is also
ina
ist bei Patienten mit einer
ist bei Patienten mit
ist bei Patienten
routine volume replacement should
4
ist bei
is well known and
is especially important
is especially important for patients
is especially important for the
is especially important for
is especially important in the
is especially important in
is especially important
is especially
is therefore a measure
is therefore
, see the Package Leaflet
is available in the
prior
times
the treatment should be discontinued
the treatment
ist die Eliminationshalbwertszeit wegen des
ist die Eliminationshalbwertszeit wegen
ist die Eliminationshalbwertszeit wegen
in general , hypoglycaemia is
therapy should be discontinued .
therapy should be discontinued
therapy
is dietary control .
is dietary control
is dietary
is
ist die
this is superfluous
this is
by symptoms
is an antimicrotubule agent
is a medicine containing
is a medicine
is a bisphosphonate .
is a bisphosphonate
is a cannabinoid receptor antagonist
is a cannabinoid receptor
is a glycoprotein that stimulates
is an inhibitor of osteoclast-mediated
is an inhibitor of
is an inhibitor
is a growth factor
is a characteristic
is a dose-dependent increase in
is a new LHRH agonist
is a new LHRH agonist
is a new
is an antipsychotic medicine .
is an antipsychotic medicine
is a sterile but
is a sterile
is a cytotoxic anticancer
is a cytotoxic
is a
is an
ist ein
is an albumin-bound nanoparticle formulation
is a solution for infusion
is a disease in which
is a disease
is a mixture of dissolved
is a mixture
is a range of
is a range
, close medical
close medical
is a colourless
is a single intravenous infusion
is a single intravenous
is a clear , colourless
is a clear ,
is a clear and colourless
is a clear and
is a clear
is presented as a clear
treatment with flu-like symptoms
no specific treatment is
is a
is presented as a
ist eine
it is
a blood transfusion may be
a blood transfusion may
is designed to be
is indicated for
is ready for use .
is ready to use .
is ready for use
is ready to use
is ready
slightly
.
technology is glycosylated and is
is high (
is high
is described in section 6.6
is supplied in vials ,
is supplied in vials
is available as white
is available as
is available as
in the first
breast-feeding
is ready for use
is
is available
is supplied in
is
is indicated for the
is indicated for
is indicated
is not a substrate of
is not a substrate
is not a
ist keine Anpassung der Dosis
ist keine Anpassung der Dosis
, the data available are
ist keine
the data available are
is contraindicated for patients with
is contraindicated for patients
is contraindicated for
is contraindicated
ist mit
may occur .
may occur
may
is not known if
is not known whether
is unknown .
is , therefore , not
is not known
is unknown
is required ( see
is required (
is required
is necessary
is not
is
can only be obtained
only be obtained with
can only be
only be
is very wide .
is very wide
is very
is a characteristic of
is a characteristic
is concentration independent
is unknown , but it
is unknown , but
is unknown ,
is unknown .
is unknown
is unclear and
is similar to
is similar
is similar
skin fold minimises the
skin fold minimises
remains unknown .
remains unknown
is less common .
is less common
is less
is important that
is important to take calcium
is important
is effective in
is effective
be
,
25
After
It
are not known
are
be
is ,
is a
is available in
is available
is presented
is the
is
ist
known
not known
of
patients
.
ct
dic
years
x 3 ml .
x 3 ml
x 3
per square metre of body
per square metre of
per orodispersible tablet
per ml
per ml 0.2 mg
per ml 0.2
per ml 1.8 mg
per ml 1.8
per ml 400 mg sucrose
per ml 400 mg
per ml 400
per ml
per
x
each syringe
each patient
at the same time
tablet at the same time
at the same
tablet at the same
at the
each
tablet at the
, epistaxis , pharyngolaryngeal pain
any dose
each dose ,
each dose
epistaxis , pharyngolaryngeal pain
any insulin therapy , injection
, each ml of suspension
each ml of suspension
, each ml of
each ml of
, each ml
each ml
any confirmed or suspected
any confirmed or suspected overdose
, each
, epistaxis , pharyngolaryngeal pain
any
each
epistaxis , pharyngolaryngeal pain
but made
If
but this is superfluous
but this is
but not other bisphosphonates .
but not other bisphosphonates
but not other
but not
but not clinically significant
but not clinically
did not
, but
However ,
However
but
did
fibrosis of any origin .
fibrosis of any origin
fibrosis of
,
39.5 % ( 95
39.5 % (
39.5 %
39.5
, each
after
each
by CYP2C8
by
young subjects .
young subjects
year for 3 consecutive
year for 3
year for 3 consecutive
year for 3
year for
year
annual infusion of Aclasta
September 2005
in September 2005
annual dose of
annual dose
annual
young patients .
younger adult subjects , nor
younger subjects .
younger subjects
younger subjects
younger
cold-formed aluminium perforated
allowed to come into
was
have also occurred in isolated
have also occurred in
have also occurred
.
ABILIFY can
Abseamed can
Aclasta can
Aclasta may
, your doctor may consider
your doctor may consider
may cause side effects
may be
may be
may also be necessary
may also
may also want
can occur .
can occur
may reduce insulin requirement .
may reduce insulin requirement
may intensify and prolong the
the dose may be adjusted
the dose may
to concentrate and react may
may increase the effect of
may increase the effect
may result
may increase the
may
it may
may be
comparable with the clinical
with the clinical
it may also be
appetite may occur during treatment
appetite may occur
may occur
may be followed by
may be followed by
may be followed
may be
it may
may be followed
may be
can decide whether
can decide whether
may occur in combination with
may occur in combination
may occur in
may be associated with an
can be
can be
can
may be associated with
cannot be ruled out .
cannot be excluded .
cannot be excluded
increased tactile hyperesthesia were ro
tactile hyperesthesia were ro
increased tactile hyperesthesia were
tactile hyperesthesia were
may be necessary when
may be necessary
may be harmful for
may be harmful
can result in sudden and
can result in sudden
can result in
can result
may be
food and drink
with food and drink
may produce effects that
can be translated
which can be translated
can be added to metformin
can be added to
, may
can be
can
may be
may increase
may occur
may
cardiac events .
of cardiac events .
cardiac events
of cardiac events
cardiac events
of cardiac events
cardiac
of cardiac
cardiorespiratory depression .
cardiorespiratory depression
cardiovascular outcome study of pioglitazone
cardiovascular outcome study of
cardiovascular outcome study
cardiovascular
cardiovascular outcome study , 5238
cardiovascular outcome study ,
cardiovascular therapy ,
cardiovascular therapy
cardiovascular
increase in mortality from
are not iron deficient .
are not iron deficient
not show potential for
no difference in
vitro genotoxicity assays .
vitro genotoxicity assays
no
not
keine Anpassung der Dosis notwendig
keine Anpassung der Dosis
keine Anpassung der Dosis
no effect on the
no effect on
no effect
no data in
no data available
no data
receiving dialysis
is no experience of acute
is no experience of
no information on the
no information on
is no accumulation : the
is no accumulation :
is no accumulation
no osteomalacia , marrow fibrosis
not other bisphosphonates .
not other bisphosphonates
not other
no adequate and well-controlled
no adequate and
keine ausreichenden Daten am
no adequate
no known effects on the
no known effects on
no known effects
require any special storage conditions
no specific frequency can
no adequate data on the
no adequate data on
no adequate and well-controlled trials
no adequate and well-controlled
no adequate and
no adequate
no clinically significant change in
no clinically significant
no clinically
no clinically
no medically important differences .
no medically important differences
no medically important
no medically
no appreciable affinity
no appreciable affinity for
no appreciable
no relevant
homogenous without visible precipitates .
homogenous without visible precipitates
significant improvement in quality
no significant
insulin cannot be defined
insulin cannot be
no adverse
not using effective contraception
not using effective
, no
No
any
cannot
did not receive
keine
no information
no new
no
not receive
not using
not
of no
no influence on the
no influence
no evidence of clinically significant
no evidence of clinically
no evidence of
no evidence
no relevant effect on
no relevant effect
no relevant
no significant effect on
no significant effect
no significant
did not
no
none
did not
kg ) .
kg )
kg over 2
kg .
kg BW 120 ml :
kg BW 120 ml
kg BW 120
kg BW 210 ml :
kg BW 210 ml
kg BW 210
kg BW
kg for the 120
kg for the
kg for
kg require higher maintenance doses
kg require higher
kg and adults .
kg and adults
kg and
kg over 2 years
kg over 2
kg
m² with
m²
m²
m²
child resistant polypropylene closure and
a child resistant polypropylene closure
child resistant polypropylene closure
polypropylene child-resistant closure
clear , colourless , aqueous
clear , colourless ,
clear , colourless solution
clear , colourless
clear ,
clear and colourless solution .
clear and colourless solution
clear and colourless
clear and
clear
small study
small study
small
metabolites , 3
minor metabolites , 3
metabolites ,
metabolites
minor metabolites ,
minor metabolites
metabolites ,
metabolites
minor metabolites ,
minor metabolites
study ( 19.5
19.5
clinical judgement .
clinical judgement
durch spezifische Interaktionsstudien bestätigt
durch
durch
durch
clinically evident ischaemic heart
not clinically significant
not clinically
clinically significant hypocalcaemia , reversal
clinically significant hypocalcaemia
clinically significant
clinically important change in valproate
clinically significant change in
clinically significant changes
clinically significant
clinically
of clinically significant
clinically
of clinically
clinical factors warrant (
clinical factors warrant
clinical fractures
clinical relevance of these findings
clinical relevance of these
clinical relevance
clinical trial of pioglitazone vs.
clinical trial of pioglitazone
clinical trial of
clinical trial
clinical
consider clinical
consider clinical monitoring
clinical dose
clinical effects of aripiprazole
clinical effects of
clinical effects
widened brain ventricles and
widened brain ventricles
clinical fractures The incidence
in clinical fractures in men
in clinical fractures in
clinical fractures was 7.5 %
clinical fractures was 7.5
clinical fractures was
clinical fractures following a
clinical fractures following
clinical fractures
clinical fractures over the duration
clinical fractures over the
clinical fractures over
clinical fracture variables are
clinical fracture variables
clinical pharmacology
clinical trials , treated
clinical trials
clinical trials
clinical situations
clinical trials in osteoporosis ,
clinical trials in osteoporosis
clinical trials in
clinical trial in healthy
clinical trial
clinical trials of
clinical trials in which
clinical trials
clinical studies for other indications
clinical studies for other
clinical studies for
clinical trials that
clinical trials aripiprazole has
clinical trials with aripiprazole ,
clinical trials of aripiprazole ,
clinical trials of aripiprazole
clinical trials with aripiprazole
clinical trials with pioglitazone
clinical trials with oral
clinical trials with
clinical trials and
57 clinical trials
clinical trials and
clinical studies , use
clinical studies ,
clinical studies
clinical studies ,
clinical studies
clinical trials , an increased
clinical trials , an
clinical trials , uncommon cases
clinical trials , uncommon
clinical trials , rare cases
clinical trials , rare
clinical trials ,
diagnosed
clinical studies ,
clinical studies
clinical trials of
clinical trials
diagnosed
one year clinical trials
one year clinical trials
Clinical Study Report :
Clinical Study Report
III clinical
clinical trials
clinical
cognitive
cognitive
combined with fast-acting ,
combined with fast-acting
combined with
combined
combining
during treatment .
used .
during treatment
epoetin alfa .
used
, the skin should be
occurs ,
occurs
complete resuspension of any powder
complete resuspension of any powder
complete resuspension of any
complete resuspension
complete
a full range of standard
a full range of
a full range
a full range of standard
a full range of
a full range
a full
therapeutic response
therapeutic response
therapeutic
causal relationship has not
causal relationship has
could be
could not be detected .
could not be detected
could
contact
contraindicated for patients with hypocalcaemia
contraindicated for patients with
contraindicated for patients
contraindicated for
is contraindicated ,
is contraindicated ,
is contraindicated
contraindicated
all
all
be monitored and the
be monitored and
be monitored
be monitored
monitored
randomised , controlled ,
, controlled ,
controlled
long-term 26-week controlled trial ,
long-term 26-week controlled trial
Studien bei Schwangeren
well-controlled trials of aripiprazole in
well-controlled trials of aripiprazole
well-controlled trials of
active comparator controlled trials
controlled studies
controlled trials
well-controlled trials
controlled clinical studies ,
controlled clinical studies
controlled clinical
, controlled
Schwangeren
controlled
well-controlled
conventional paclitaxel-containing medicines .
conventional paclitaxel-containing medicines
safety data revealed no
corrected for dose
corrected for dose
corrected for
corrected
corrected for
corrected
paresis
taxanes
the taxanes
a quick
quick
cumulative dose
cumulative
cumulative
cumulative toxicity
cumulative
shortly following
shortly
, insulin requirements
insulin requirements
( see section
( see
(
. It can
.
, Actos 15mg tablets can
, Actos 30mg tablets can
, Actos 45mg tablets can
reactions may
may vary with age
may vary with
may cause allergic reactions (
may cause allergic reactions
may also
may occur .
may occur
may
may feel dizzy ,
may feel dizzy
can be
can
may eat
may have
may
might lead to severe complications
may
insulin it produces .
insulin it produces
be used in patients
be used in
be used
used in patients
used in
used
exercise
increased exercise
they were advised
physical activity , non- smoking
physical activity , non-
physical activity
flavour ( including
shortened overall survival and increased
shortened overall survival and
shortened overall survival
shortened
recent ( within 90
recent ( within
recent (
recent low-trauma hip fracture .
recent low-trauma hip fracture ,
recent low-trauma hip fracture
recent low-trauma hip fracture
recent low-trauma
recent
recent
l/ hr/ m2 .
l/ hr/ m2
l/ kg .
l/ kg
The printed
or The printed
or Depressive disorders or
For a full list of
For a full list
This summary was last updated
This summary was
This summary
la Es werden möglicherweise nicht
la Es werden möglicherweise
la Es werden
la Es
la Industria 30 28108 Alcobendas
d
d
d
d
d
ge
la
.
1.3 % for
was 10 % (
was 10 %
was 10
was approximately six weeks
was approximately six
was approximately
was
was
in 2.3 %
in 2.3
in
.
the
. This veterinary medicinal product
. This
.
3 days.
and transport refrigerated ( 2°C
and transport refrigerated (
and transport refrigerated
and rimonabant may inhibit the
and rimonabant may inhibit
rimonabant may inhibit the
rimonabant may inhibit
either Actos or placebo for
long-acting insulin
long-acting
for
long you
long time
long
long bones
works for a long time
long
support long-term safety
and slowly
slowly be
slowly
as assessed by the investigator
as assessed by the
as assessed by
as assessed
as packaged for sale :
as packaged for sale
as packaged
empty , sterile ,
empty
Limited data suggest
slight appetite decreasing effect
slight appetite decreasing
mild to moderate and resolved
mild to moderate and go
mild to moderate
mild to
hepatic impairment does
mild and transient .
mild and transient
mild and
mild and do
mild
in mild ( Clcr
in mild (
mild ( Clcr
mild (
mild renal impairment
minor symptoms
in mild
mild
minor
mild or moderate liver problems
mild or moderate
normal
Mildly anaemic
mild to moderate
mild pain reliever such as
mild agitation before use .
mild agitation before use
mild agitation before
mild
disease .
disease
read the Package
read the
read
lesen Sie bitte
read
read
to read
non-lethal
last day of that month
last day of
last day
last renewal :
DATE
last
.
are insufficient
liegen keine ausreichenden Daten am
are
liegen keine
not been studied .
not been studied
not been studied
.
are
liegen
are extensively
is always well below
is always well
is always
is between 75 and 300
is between 75 and
is between 75
is between
is
limited number of
limited number
limited
linear and dose-proportional .
linear and dose-proportional
linear and
linearly from 2653 to 16736
linearly from 2653 to
linearly from 2653
linearly from
linear
linearly
805
RIO-Diabetes
805
RIO-Diabetes
. no
.
ro
local infection including osteomyelitis ,
local infection including osteomyelitis
local infection including
local infection
local safety of Vantas is
local safety of Vantas
local safety of Vantas is
local safety of Vantas
local safety of
local safety
local
local )
local
ina
60
supplied
2.
for longer than one year
for longer than one year
for longer than
more .
more
more long-lasting effect is needed
more prolonged effect is desired
more long-lasting effect
longer .
longer
for longer
more
prolonged
longer
soluble insulin 10 % and
soluble insulin 10 %
soluble insulin 10
soluble insulin 20 % and
soluble insulin 20 %
soluble insulin 20
soluble insulin 30 % and
soluble insulin 30 %
soluble insulin 30
soluble insulin 40 % and
soluble insulin 40 %
soluble insulin 40
soluble insulin 50 % and
soluble insulin 50 %
soluble insulin 50
soluble insulin
soluble
solvent-based paclitaxel
solvent-based
solvent-based
)
.
usually did not require
emea . europa . eu
. europa . eu
receive appropriate training for you
receive appropriate training for
receive appropriate training
When
receive appropriate training for
receive appropriate training
sometimes severe irritability .
sometimes severe irritability
sometimes
manic episodes (
manic episodes
manic symptoms
manic
manic episode in patients
manic episodes
manic episodes in
manic episodes
manic or mixed episode of
manic or mixed episode of
manic or mixed episode
manic or mixed episode of
manic or mixed episode
manic or
manic
manic episodes in patients
manic episodes in
manic episodes and
manic episodes
manic symptoms
manic symptoms over 3 weeks
manic symptoms over 3
manic symptoms over
being placed
by being placed
manic
maternal body weight gain .
maternal body weight gain
maternal
maximum of 30 mg (
maximum of 30 mg
maximum of 30
maximum of
maximum
maximum dose should
maximum dose
peak plasma
maximum daily dose should
maximum daily dose
maximale Tagesdosis
maximum concentration
maximum
median time to
median
medically important differences .
medically important differences
medically important
medically serious signs and
medically serious signs
medically serious
medically important signs and symptoms
medically important signs and
medically important signs
medically
medically
healthcare professionals in
healthcare professionals
injected by medical staff .
injected by medical staff
injected by
medical practice .
medical practice
medical
more ABILIFY oral solution
more ABILIFY orodispersible tablets
more ABILIFY tablets
given more ABILIFY
more ABILIFY
more units of
more units
been reported while taking
while taking
more weeks after your
more weeks after
more weeks after
more weeks after
more weeks
more than 1
more than 1 patient
more than 1
greater than 2 g/ dl
more than 2 g/ dl
greater than 2
more than 2
3 sites of metastases .
3 sites of metastases
3 sites of
3 sites
3
more than 30 % of
more than 30 %
more than 30
greater than
more than
exercise
increased exercise
more in every 100 patients
more
given more
greater
has stopped
more
stopped
different time zones
in 3.2
several controlled studies
several controlled
several
accumulation
be avoided when taking ABILIFY
be avoided when taking
be avoided when
be avoided
usually
Most side effects with Aclasta
Most side effects with
Most side effects
Most
most of
most
mellitus ( see section 4.4
mellitus ( see section
mellitus ( see
mellitus (
mellitus , diabetic ketoacidosis ,
mellitus , diabetic ketoacidosis
mellitus , diabetic
mellitus ,
Mellitus : hyperglycaemia , in
Mellitus : hyperglycaemia ,
Mellitus : hyperglycaemia
mellitus and heart disease or
mellitus and heart disease
mellitus and
mellitus
) gene mutation assay .
gene mutation assay .
) gene mutation assay
gene mutation assay
) gene mutation
gene mutation
) gene
gene
human
source insulin
source
balance ,
balance
balance ,
balance
measure
measure
enrolled in
metabolised and is
metabolised and
metabolised
enzymes .
metabolised
enzymes
metabolised
of substances
substances
metastatic breast cancer , around
metastatic breast cancer
metastatic breast cancer
metastatic breast cancer
metastatic breast cancer
metastatic breast cancer
metastatic
metastatic disease has
metastatic disease
metastatic
mg ( 0.7 ml )
mg ( 0.7 ml
mg ( 0.7
mg ( 1.3 ml )
mg ( 1.3 ml
mg ( 1.3
mg ( baseline 7.3 %
mg ( baseline 7.3
mg ( baseline
mg ( i. e.
mg ( once daily )
mg ( once daily
mg ( once
mg (
mg )
mg , 10 mg ,
mg , 10 mg
mg , 10
mg , 15 mg and
mg , 15 mg
mg , 15
mg , 30
mg ,
mg Aclasta .
mg Aclasta
mg aripiprazole ) once a
mg aripiprazole )
mg of aripiprazole .
mg aripiprazole as the
mg aripiprazole as
mg aripiprazole
mg of aripiprazole
mg aspartame ( E951 )
mg aspartame ( E951
mg aspartame (
mg aspartame
mg Fe2+/ day for paediatric
mg Fe2+/ day is
mg Fe2+/ day
mg fructose per ml 400
mg fructose per ml
mg fructose per
mg of fructose and 400
mg of fructose and
mg fructose
mg of fructose
mg solution for infusion is
mg solution for infusion is
mg solution for infusion
mg calcium twice a day
mg calcium
mg methyl parahydroxybenzoate ( E218
mg methyl parahydroxybenzoate (
mg methyl parahydroxybenzoate
mg mitratapide/ kg bodyweight results
mg mitratapide/ kg bodyweight
mg mitratapide/
mg sodium per dose .
mg sodium per dose
mg sodium per
mg sodium
mg of paclitaxel .
mg paclitaxel .
mg of paclitaxel
mg paclitaxel
mg pioglitazone ( as hydrochloride
mg pioglitazone ( as
mg pioglitazone (
mg of pioglitazone .
mg of pioglitazone as hydrochloride
mg of pioglitazone as
mg of pioglitazone
mg pioglitazone
mg propyl parahydroxybenzoate ( E216
mg propyl parahydroxybenzoate (
mg propyl parahydroxybenzoate
mg orodispersible tablets ( tablets
mg orodispersible tablets (
mg orodispersible tablets are round
mg orodispersible tablets are
mg orodispersible tablets
mg of sucrose .
mg sucrose per ml 1.8
mg sucrose per ml
mg sucrose per
mg of sucrose
mg sucrose
mg tablets , as 10
mg tablets , as
mg tablets ,
mg tablets may
mg tablets are rectangular and
mg tablets are rectangular
mg tablets are round and
mg tablets are round
mg tablets are
mg tablets
mg zoledronic acid ( anhydrous
mg zoledronic acid anhydrous
mg zoledronic acid (
mg zoledronic acid
mg zoledronic acid .
mg zoledronic acid must be
mg zoledronic acid
mg zoledronic acid monohydrate .
mg zoledronic acid monohydrate
mg
mg
mg
mg
mg once a year for
mg once a year
mg once a day ,
mg once a day .
mg once daily .
mg administered once a day
mg once a day
mg once a day
mg once daily
mg once daily
mg once a
mg once
mg elemental
mg
mg in 1.3 ml
mg in 1.3
mg in 100
mg in
mg intramuscular .
mg intramuscular
mg intramuscular
mg per square metre of
mg .
mg
mg .
mg
mg or 30 mg once
mg or 30 mg
mg or 30
mg or
mg should be
mg daily .
mg daily
mg and 30 mg tablets
mg and 30 mg
mg and 30
mg and
mg reduced the risk of
mg reduced the risk
mg reduced
mg were
mg
mg of anhydrous human insulin
mg of anhydrous
mg has not
mg has
mg ,
mg of
mg
20
mg/ day ( i. e.
mg/ day (
mg/ day .
mg/ day
mg/ day for four days
mg/ day for four
mg/ kg daily was
mg/ kg daily
mg/ kg
mg/ kg/ day .
mg/ kg/ day
mg/ m ) .
mg/ m2 ) .
mg/ m )
mg/ m2 )
mg/ m2 ; 95 %
mg/ m2 ; 95
mg/ m2 ;
mg/ m
mg/ m2 , paclitaxel
mg/ m2
mg/ ml ) .
mg/ ml )
mg/ ml ) and as
mg/ ml ) and
mg/ ml )
mg/ ml Butylated hydroxyanisole (
mg/ ml Butylated hydroxyanisole
mg/ ml solution for injection
mg/ ml oral solution for
mg/ ml oral solution
mg/ ml oral solution is
mg/ ml oral solution
mg/ ml
avoid microbial
microcrystalline cellulose , hydroxypropyl cellulose
microcrystalline
reorganisation
at least 10 days following
take at least 15 minutes
at least 15 minutes .
at least 15 minutes
at least 15
for at least 15
at least 2
at least 30 % .
at least 30
at least 500 mg calcium
at least 500 mg elemental
at least 500 mg
at least 500
kept under
at least 75
at least five
at least two weeks
at least two
at least
for at least
is minimal .
is minimal
minimal
.
0.3 ml solution for injection
0.3 ml
of 0.3 ml
0.3
of 0.3
0.6 ml solution for injection
0.6 ml
of 0.6 ml
0.6
of 0.6
0.8 ml solution for injection
0.8 ml
of 0.8 ml
0.8
of 0.8
1.7 % of women
1.7 % of
1.7 %
of 100 mg paclitaxel .
of 100 mg paclitaxel
of 100 mg
with 100 ml of solution
with 100 ml of solution
with 100 ml of
with 100 ml
of 100
with 100
containing 28 , 98 and
containing 28 , 98
containing 28 , 98 and
containing 28 , 98
containing 28 ,
containing 28
be 36 %
be 36
: significant loss of appetite
: significant
with ABILIFY
with ABILIFY and with other
with ABILIFY and with
with ABILIFY
associated with Abilify ?
associated with Abilify
using Abilify
be treated with Abraxane .
be treated with Abraxane
treated with Abraxane
patients on Abraxane
patients treated with Abraxane
patients receiving Abraxane
patients on Abraxane with
Abraxane with
on Abraxane with
reported with Abraxane
occurs frequently with Abraxane .
occurs frequently with Abraxane
with Abraxane
with Abseamed may be
Abseamed
with Abseamed
being treated with Aclasta .
should be treated with Aclasta
be treated with Aclasta
being treated with Aclasta
treated with Aclasta
Aclasta-treated group
patients treated with Aclasta ,
patients treated with Aclasta
patients treated with Aclasta ,
patients treated with Aclasta
Aclasta-treated
treated with Aclasta ,
treated with Aclasta
reported with Aclasta
with Aclasta .
with Aclasta
Aclasta
Aclasta-treated
with Aclasta ,
with Aclasta
treated with Actos and insulin
with Actos and insulin
with Actos and
with Actos are visual disturbance
with Actos are
with Actos are
with Actos
in
patients presenting with agitation and
patients presenting with agitation
with agitation and disturbed behaviours
with agitation and
patients presenting with agitation
with agitation
with alcohol or other
with alcohol or
with alcohol
aripiprazole ( 30 mg
aripiprazole ( 30 mg
aripiprazole ( 30
aripiprazole ( 30
oral aripiprazole
oral aripiprazole
aripiprazole (
aripiprazole (
aripiprazole
with aripiprazole , there were
with aripiprazole ,
aripiprazole alone was
of aripiprazole alone was
patients treated with aripiprazole .
patients treated with aripiprazole
treated with aripiprazole
of aripiprazole in pregnant
of aripiprazole in
with aripiprazole and 3.0 %
with aripiprazole and 3.0
with aripiprazole and 3.2 %
with aripiprazole and 3.2
with aripiprazole and
aripiprazole ,
aripiprazole
aripiprazole
of aripiprazole ,
of aripiprazole
of aripiprazole
of aripiprazole
with aripiprazole ,
with aripiprazole .
with aripiprazole
with medicinal products
with some medicines ,
with some medicines
with renal impairment (
with renal impairment
with bisphosphonates
carbamazepine ,
occurs with carbamazepine .
occurs with carbamazepine
carbamazepine
carbamazepine
with quinidine occurs .
with quinidine occurs
with quinidine
with cyclosporin ,
with cyclosporin
with oral formulations of ABILIFY
with diabetes mellitus
with diabetes
life parameters on
and repeat-dose
with epoetin alfa alters
with epoetin alfa .
with epoetin alfa
with epoetin alfa is a
with epoetin alfa is
epoetin alfa
with epoetin alfa
with epoetin alfa
with epoetin
of
in women with
with gemfibrozil ( an
with gemfibrozil ( an
with gemfibrozil (
with gemfibrozil
with haloperidol
with hypocalcaemia ( low blood
with hypocalcaemia ( low
with hypocalcaemia (
with hypocalcaemia
with hypocalcaemia ( see section
with hypocalcaemia ( see
with hypocalcaemia (
with hypocalcaemia
with haematological malignancies (
with haematological malignancies .
with haematological malignancies
have broken their hip
for you to
for you
you to
you
you to do this .
for you to do this
you to do this
with your doctor
with your
your
be added to infusion fluids
be added to
with insulin or
with insulin ,
with insulin
with insulin syringes with a
with insulin syringes with
with insulin syringes
with ketoacidosis or hyperosmolar coma
with ketoacidosis or hyperosmolar
with ketoacidosis or
with ketoacidosis
of seizure
used to achieve androgen
with hepatic impairment
with impaired liver function .
with impaired liver function
with hepatic impairment : no
with hepatic impairment :
with hepatic impairment
with liver problems
with lithium
with metformin and /
with metformin and
with metformin and/ or
with metformin
with mitratapide has not been
with mitratapide
with Paget s disease
with food and drink :
with food and drink
with kidney disease
with renal
with renal impairment :
with renal impairment
with renal
used with NovoFine needles .
used with NovoFine needles
with osteoporosis
be treated with paclitaxel .
be treated with paclitaxel
treated with paclitaxel
with paclitaxel
patients with a manic
patients with a
in patients with advanced solid
in patients with advanced
in patients with
patients with
treated with pioglitazone
treated with pioglitazone
women treated with pioglitazone and
women treated with pioglitazone
treated with pioglitazone
of pioglitazone vs. gliclazide as
of pioglitazone vs. gliclazide
of pioglitazone vs.
with pioglitazone there was
with pioglitazone in all
with pioglitazone in all patients
with pioglitazone in all
with pioglitazone in
of pioglitazone
with pioglitazone
with placebo .
placebo-treated patients .
placebo-treated patients
with placebo
used in combination with products
marked with A-007 and
marked with A-007
marked with A-008 and
marked with A-008
marked with A-009 and
marked with A-009
marked with A-011 and
marked with A-011
marked with
marked with
marked with
with rifampicin ( an inducer
with rimonabant was associated with
with risk factors for diabetes
with risk factors for
with risk factors
with schizophrenia .
with schizophrenia
Fever and chills ,
Fever and chills
with sulphonylureas or insulin
with sulphonylureas or
with sulphonylureas
with type 2 diabetes mellitus
with type 2 diabetes
with type 2
with type
with either valproate or lithium
treated with Vantas
with Vantas
be monitored closely .
used with caution in
be monitored closely
used with caution
mit Vorsicht anzuwenden
used with caution in patients
used with caution in
be monitored
mit Vorsicht
used with caution
with caution
with water
with active malignant disease
with other drug types
with medicines
other medicines Please tell
other medicines Please
with medicines known
with medicines known
mixed with other medicinal products
with other medicinal products and
with medicines
with other medicinal products
with other medicinal products
other
with other
and biliary excretion .
biliary excretion .
and biliary excretion
biliary excretion
with atypical antipsychotic agents ,
with atypical antipsychotic agents
with hepatic impairment may be
with hepatic impairment
with bipolar disorder
with bipolar
chronic renal failure patients :
with chronic renal failure and
chronic renal failure patients
with chronic renal failure ,
with chronic renal failure
with chronic renal failure
with chronic
pipettes provided with the product
with the product
take it with or
take it with
of the heart or the
of the heart or
of the heart
with the recommended treatment schedule
with the recommended
of the
with the
the local representative
the local representative
markedly with subsequent
with subsequent
with the
4.3 and
section 4.3 and
4.3
section 4.3
in the
associated with
associated with
to that seen
at long-term use of Actos
at long-term use of
at long-term use
marked with " A
engraved with " A-007
engraved with " A-008
engraved with " A-009
engraved with " A-011
engraved with "
marked with "
debossed with 20 on
debossed with 20
debossed with
engraved with
marked with
with the syringe onto a
with the syringe onto
with the syringe onto
micro-ophthalmia
the use of oral
at
micro-ophthalmia
the
to
treatment with
with the
with
with these characteristics
with this weight management programme
with this weight management programme
with these
with this
with this
with this condition may also
with this condition may
with this condition
with this
using an alcohol wipe .
using an alcohol wipe
a doctor or pharmacist
a doctor or
a doctor
with baseline
with a baseline of 7.9
with a baseline of
with a baseline
with a bromobutyl/ polyisoprene
with a bromobutyl rubber plunger
with a glass of water
with a glass of
with a glass
a sulphonylurea
and a sulphonylurea
with a sulphonylurea
at increased risk of
associated with an increased
with an apparent volume
a
associated with an
the
using a
using an
with a
with
mit einer Adipositas ist die
mit einer Adipositas ist
mit einer Adipositas
with an overseal ( aluminium
at dose levels of 80
at dose levels of
at dose levels
at dose
associated with fluid retention
administered to target a haemoglobin
administered to target a
with a cartridge ( 3
with a cartridge (
with a cartridge
with a number of other
with a number of
with a number
treated with comparator
with abrupt improvement in
with a recent low-trauma
with a recent
with a more
with a manic or
with a manic
mit einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde
mit einer ng Ethinylestradiol/Levonorgestrel-Kombination
mit einer ng
with a recent low-trauma
with a corresponding unit scale
with a corresponding
with significant weight gain
a similar
a
mit einer
to a similar
to a
weight
with a 5
with a
with an
a similar mix
to a similar mix
with encephalopathy-like symptoms (
with encephalopathy-like symptoms can occur
with encephalopathy-like symptoms can
with encephalopathy-like symptoms
with encephalopathy-like symptoms
with encephalopathy-like
fixed-dose
following
the following
with mixed episodes or
with mixed episodes
with mixed
with reported estimated doses
with reported estimated
in healthy subjects the
in healthy subjects ,
in healthy subjects
in healthy
with high fever
intravenous bolus
the intravenous bolus
intravenous
the intravenous
packs of 14
packs of
, each
each
with polypropylene child-resistant closure
with mild or moderate
with mild to moderate
with metastatic breast cancer
with metastatic breast cancer
with metastatic breast cancer
with metastatic
5.3
with residual
with normal or
with normal
2.5 with or without evidence
with or without food
with or without
with or without food
with or without psychotic features
with or without psychotic
with or without
with or
with oral
developing sudden lack of efficacy
developing sudden lack of efficacy
with
with
with
treated with recombinant human erythropoietin
with renal anaemia ,
with renal anaemia
with renal
quickly with racing ideas and
quickly with racing ideas
with fast-acting , insulin
with fast-acting ,
with fast-acting
with severe
with severe agitation ,
with severe agitation
with severe hepatic impairment should
with severe hepatic impairment
with severe renal
with severe
with rare hereditary problems of
with rare hereditary problems
with overlapping undesirable effects
with solid tumours (
with solid tumours
with solid
mit stark eingeschränkter
with severe
both via subcutaneous administration .
subcutaneous administration .
via subcutaneous administration .
both via subcutaneous administration
subcutaneous administration
via subcutaneous administration
both via subcutaneous
subcutaneous
via subcutaneous
patients with symptomatic anaemia
patients with symptomatic anaemia
with less
increased with increasing dose .
increased with increasing dose
with increasing study duration :
with increasing study duration
increased with increasing
with increasing
with two other antidiabetic medicines
with two other
with two
, with
a
administered
agreed with
and treatment with
associated with
at
be
decreases with
have
in addition to
in addition
in patients
in
micro-ophthalmia
mit
of
patients presenting with
patients with
patients
significant
start of
start
supplements
those mentioned in
those mentioned
those
to patients with
treated with
treatment with
treatment
used to
used
using
with a
with a
with associated risk
with associated
with less
with
with a similar rate and
, with a similar rate
with a similar rate
, with a similar
with a similar
condition with
interphase
tell
by the intravenous route .
by the intravenous route
by the intravenous
by
existing
mean improvement from baseline on
mean improvement from baseline
mean improvement from
mean improvement
mean Cmax of paclitaxel ,
mean Cmax of paclitaxel
mean Cmax of paclitaxel ,
mean Cmax of paclitaxel
mean difference to placebo -2.9
mean difference to placebo
mean difference to
mean difference
mean total clearance was 15
mean total clearance was
mean total clearance
mean plasma elimination half-life of
mean plasma elimination half-life
mean volume of distribution
mean total
mean
in mean
mean
ml ( 10 000
ml ( 10
ml ( 1000
ml ( 2000
ml ( 3.5
ml ( 3000
ml ( 4000
ml ( 5000
ml ( 6000
ml ( 7000
ml ( 8000
ml ( 9000
ml (
ml ) .
ml ) aripiprazole .
ml ) aripiprazole
ml )
ml ) for the first
ml ) for the
ml ) for
ml ) may be
ml ) may be
ml ) ,
ml )
ml .
ml
ml 0.2 mg propyl parahydroxybenzoate
ml 0.2 mg
ml 0.2
ml 1.8 mg methyl parahydroxybenzoate
ml 1.8 mg
ml 1.8
ml 400 mg sucrose per
ml 400 mg sucrose
ml 400 mg
ml 400
ml 6 pre-filled syringes of
ml 6
ml : 10 kg BW
ml : 10 kg
ml : 10
ml : 22 kg BW
ml : 22 kg
ml : 22
ml : 40 kg BW
ml : 40 kg
ml : 40
ml :
ml 120 ml
ml 120
ml 210 ml
ml 210
ml ready-to-infuse solution ) is
ml ready-to-infuse solution ) is
ml ready-to-infuse solution )
ml ready-to-infuse solution
ml bottle
ml solution for injection contains
ml solution for injection in
ml solution for injection
ml solution ( corresponding to
ml solution ( corresponding
ml of solution contains 5
ml of solution contains 5
ml of solution contains
ml of solution contains
ml solution contains
ml oral solution 150
ml oral solution 480
ml oral solution
ml of solution
ml of solution
ml solution
ml
ml glass cartridge (
ml glass cartridge
ml Component of a
ml Component
ml calibrated dropper
ml calibrated dropper
ml calibrated dropper
ml at one injection site
ml solution contains 0.05
ml solution contains
ml solution
ml of suspension
ml of
ml
ml of the product per
ml of the product
ml contains 10 000 international
ml contains 10 000
ml contains 10
ml contains 100 IU of
ml contains 100
ml contains 1000 international units
ml contains 1000 international
ml contains 1000
ml contains 2000 international units
ml contains 2000 international
ml contains 2000
ml contains 3000 international units
ml contains 3000 international
ml contains 3000
ml contains 40 IU of
ml contains 40
ml contains 4000 international units
ml contains 4000 international
ml contains 4000
ml contains 5000 international units
ml contains 5000 international
ml contains 5000
ml contains 6000 international units
ml contains 6000 international
ml contains 6000
ml contains 7000 international units
ml contains 7000 international
ml contains 7000
ml contains 8000 international units
ml contains 8000 international
ml contains 8000
ml contains 9000 international units
ml contains 9000 international
ml contains 9000
ml contains
ml equivalent to 1000
ml equivalent to 300
ml equivalent to 300
ml equivalent to 400
ml equivalent to
ml equivalent to
or 480 ml per bottle
ml per
ml and a multipack with
ml and a multipack
ml and a
ml and
ml of
ml
mm
mmol/ l ) .
mmol/ l ) to 12
mmol/ l ) to
mmol/ l )
mmol/ l )
mmol/ l )
mmol/ l ) or the
mmol/ l ) or
mmol/ l ) per month
mmol/ l ) per
mmol/ l ) should
mmol/ l ) should
mmol/ l ) .
mmol/ l )
mmol/ l ) .
mmol/ l )
mmol/ l ) in
mmol/ l )
mmol/ l
mmol/
liver problems or with
liver problems or
liver problems
months to
rarely reported in
rarely reported
morphometric vertebral fractures Aclasta
morphometric vertebral fractures
morphometric
motor neuropathy , ataxia ,
motor neuropathy , ataxia
motor neuropathy ,
motor neuropathy
motor
a multiphasic manner .
in a multiphasic manner .
a multiphasic manner
in a multiphasic manner
multiphasic manner
multiphasic
multiple
multiple medicinal
multi-centre trial was
multi-centre trial
multi-centre
must be followed .
must be followed
drug therapy should be discontinued
has to be
counts should be performed during
, the solution must
the solution must
must be conducted
must be
followed
must be
must
should be
myocardial ischaemia , myocardial
male patients
healthy male and female subjects
male and female
male and
male
moderate and
moderate
moderate hepatic impairment .
moderate hepatic impairment
moderate and go away within
moderate and go away
moderate and go
5.3
moderate
moderate influence on the
moderate influence
moderate renal impairment
moderate
possible , even several weeks
possible , even several
be used .
may occur .
to store ABILIFY 6.
be used
may occur
may
possible ,
possible
benefit clearly justifies
take possible interactions
take possible
observed for orthostatic hypotension .
observed for orthostatic hypotension
for orthostatic hypotension
possible
possibly protein disulfide isomerase .
possibly protein disulfide isomerase
possibly delayed ) .
possibly delayed )
possibly delayed
possibly
longstanding diabetes .
longstanding diabetes
all pack sizes may
all the pack sizes may
möglicherweise nicht alle Packungsgrößen in
möglicherweise nicht alle Packungsgrößen
möglicherweise nicht alle
all pack
möglicherweise nicht
to
possibly delayed ) .
possibly delayed )
possibly delayed
all the
all
may
möglicherweise
possibly
to
full list of all
full list of all
attention should be paid
attention should
blood
blood
blood
it
tired or
, tell
,
them .
iron stores should be assured
iron stores should be ensured
iron stores should
must also be effectively treated
must also
should be carefully
should be carefully monitored .
should be carefully monitored
medicinal
must
should be
them
marked
n = 131 )
n = 131
n = 132 )
n = 132
n = 135 )
n = 135
n = 136 )
n = 136
n =
.
This medicinal product
This
reported : infections
d Name and
d Name
. ct
.
d ise or
d ise or uth
d ise
d
n oder ohne ( behandelte
n oder ohne (
n oder ohne
n oder
Based
. du
Renal
d
dic
du
in
n
reported :
n= 938 ; mean age
n= 938 ;
n= 938 ;
at 12 ,
12 months
after 12 weeks the level
after 12 weeks the
after 12 weeks
after 12
at 12
24 months
after 6 months
at six months
after 6
administered after the completion
after dosing .
after administration
after dosing
dose reflected differences
for dose reflected differences
dose
for dose
dose
for dose
following the end of treatment
following the end of treatment
after the same dose
after the same
after the
after
following treatment with aripiprazole alone
after administration of Aclasta
after administration of
after administration
after treatment
after
following tooth extractions or other
following tooth extractions or
following tooth extractions
following
been through the menopause
after the first
been through the
following the administration of
following the administration
do not appear uniformly
after administration of Aclasta
after administration of
after the first
after the first
after receiving
after the
after your
after
after
following the
observed after the
increased after one or two
be increased after one or
increased after one or
be increased after one
increased after one
nach einem Jahr 5 %
nach einem Jahr 5
nach einem Jahr
after transfer from animal
nach einem
be administered after a meal
following a recent
administered after a
following a
a few days to
a few
after first opening the
after first opening
intravenous
intravenous
after at least five weeks
reported after months to years
after months to
reported after months to
reported after months
observed in clinical trials after
in accordance
after subcutaneous administration .
after subcutaneous administration
after repeated dosing
after repeated oral
after repeated
administered after
after an
after
at
been
following
in
observed after
severity
state
after opening and
after opening
after you have received Aclasta
you
subsequent courses
been demonstrated although individual patients
been demonstrated although individual
been established .
dose .
suckling reflex .
the suckling reflex .
treatment dose .
been established .
been established
been established
demonstrated
dose
suckling reflex
the suckling reflex
treatment dose
used in humans .
used in humans
all
decreased markedly with subsequent
decreased
of in accordance with
natural hormone erythropoietin .
natural hormone erythropoietin
natural hormone
natural course of peripheral neuropathy
natural course of
natural course
natural
investigate
treatments
negative impact
negative
negative impact on overall survival
negative impact on
negative impact
negative
take the pack with you
take the
take
take
appreciable affinity for muscarinic receptors
appreciable affinity
appreciable affinity for
appreciable
new vertebral fracture (
new vertebral fracture
new
re-schedule
in new
new
new information is received
new information is
new LHRH agonist and this
new LHRH agonist and
new LHRH agonist
new LHRH agonist and
new LHRH agonist
new
replaced with new
new
nine
neuropathic pain , tremor Common
neuropathic pain , tremor
neuropathic pain ,
neuropathic pain
neuropathic
ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch die
ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch
ng Ethinylestradiol/Levonorgestrel-Kombination wurde
ng Ethinylestradiol/Levonorgestrel-Kombination
. The pharmacokinetic profile demonstrates
The pharmacokinetic profile demonstrates that
The pharmacokinetic profile demonstrates
pharmacokinetic profile demonstrates that a
pharmacokinetic profile demonstrates that
pharmacokinetic profile demonstrates
ng
ng/ ml ; Ctrough =
ng/ ml ; Ctrough
ng/ ml ;
ng/ ml
ng/ ml
without treatment in between
without treatment in
without treatment
without
without treatment in between
without treatment in
without treatment
without
nicht alle Packungsgrößen in
pack sizes may
the pack sizes may
nicht alle Packungsgrößen
nicht alle
is not appropriate .
is not appropriate
not appropriate
nicht angewendet werden (
not be administered
not be used
Leaflet .
nicht angewendet werden
not be administered
not be used
nicht angewendet
not indicated
not use
increased tactile hyperesthesia were ro
tactile hyperesthesia were ro
increased tactile hyperesthesia were
tactile hyperesthesia were
has not sufficiently Me
has not sufficiently
is too weak , talk
not sufficiently
to insufficient data on safety
insufficient data
concomitantly .
concomitantly
not known if paclitaxel
not known whether pioglitazone
not known whether zoledronic acid
not known if
not known whether
unknown .
considered not known (
considered not known
not known
therefore , not
unknown
insufficiency .
insufficiency
not been determined .
not been determined
not powered
renal insufficiency not yet
not been carried out .
not been carried out
not been conducted
not
not restricted
not take
not take
not recommended
is not recommended .
not recommended
not recommended for anyone
not recommended for use
not recommended for
not recommended for
is not recommended .
is not recommended
is not recommended
not recommended
not necessary .
not necessary
not receive
not evaluated and
not evaluated
not
does not produce enough insulin
does not produce enough
nicht
do
non-healing sores of
non-healing sores
non-healing
not included due to the
tell your
tell
not included
in man .
in man
but not in monkeys ,
but not in monkeys
but not in
but not
cannot be controlled ,
cannot be controlled , epoetin
non-lethal single intravenous dose
carton .
carton
not metabolised and
not metabolised
not be treated with Abraxane
not be added to
not be treated with paclitaxel
is not appropriate .
mouth is not appropriate .
is not appropriate
mouth is not appropriate
not
not been demonstrated although individual
not been established .
not been established .
not been established
not been established
not necessary .
not necessary
if heparinisation is not optimum
not routinely measured but a
not routinely measured
not routinely
not specifically investigated .
not specifically investigated
not specifically
not highly
not systemically
cannot divide and
cannot divide
not been evaluated .
not been studied .
not evaluated .
not been studied .
has not been studied
not been studied
not been evaluated
not been studied
not evaluated
not be used if
not be used
does not matter
not lead to an increase
not lead to an increase
not lead to further
not lead to
not to be expected .
not to be expected
not to be
not
not satisfactorily controlled
not satisfactorily
cannot
do not
do
does not
is not
nicht
not been
not pass
not take
not to
not
with
without treatment in between
without treatment in
without treatment
without
not greater than 12
not greater than
not be exceeded .
not be exceeded
receiving non-platinum chemotherapy
receiving non-platinum
non-renal clearance .
non-renal clearance
non-selective beta- blocking agents ,
non-selective beta- blocking agents
non-steroidal
too low
recent low-trauma hip fracture ,
recent low-trauma hip fracture
recent low-trauma
low blood calcium levels )
low blood calcium levels
low blood calcium
low blood
low
associated with hypocalcaemia
associated with
associated
low
lower in a
lower in
lower
lower dose of 5.25 mg
lower dose of 5.25
lower dose of
lower dose
lower
lowest
lowest available dose
lowest available
lowest
are never to
decreases with subsequent doses
decreases with subsequent
with subsequent doses
with subsequent
in patients with liver problems
in patients with
in patients
in
not
not yet undergoing
not yet undergoing
residual
yet undergoing
normal .
normal
are
normal
normal and anaemic rats ,
normal and anaemic rats
normal and anaemic
normal and
normal
normal or
normal
normal dynamic
normal reference
normal
normal
of normal
not normally exceed 200 IU
not normally exceed 200
are usually
normally
usually
normal-weight subjects . lp
brain ,
brain
resolved .
of
resolved
( see section 5.2
( see section
( see
(
ACOMPLIA should be
.
may be needed .
necessary .
is necessary ,
.
is necessary
be necessary when
be necessary
may be needed
necessary in
necessary
notwendig
necessary amount
only 0.01
only 3 patients with
only 3 patients
only 3
only on reports
only on reports
only on
limited experience in
of the limited experience in
the limited experience in
limited experience
of the limited experience
the limited experience
limited
of the limited
the limited
in Paget s disease only
restricted to patients with moderate
, only in patients who
only in patients who
, only in
only in
restricted
only at the
a few
only one infusion of Aclasta
only minor symptoms
only minor
only
very limited data
few minutes ) .
per se
few minutes )
per se
few minutes
few
for single use only
only intended for
, only
Only
few
only be
only
unable
unable
next appointment and discuss
next appointment
next
required .
required
whether you
considered
if
whether
above indications .
above indications
above
upper respiratory tract
upper respiratory tract
upper respiratory tract
upper
although
, or 13
or 13
or 15 mg/ day (
or 15 mg/ day
or 15 ml solution/
or 15
of 10 or 15
of 10 or
or 2 ) at
or 2 )
or 2 ) at
or 2 )
or 2
or 24 hours after the
or 24 hours after
or 24 hours
or 24
or 30 mg once daily
or 30 mg once
or 30 mg
or 30
or 45 mg of pioglitazone
or 45 mg of
or 45 mg
or 45
or 450 IU/ kg
or 450
or 480 ml per
or 480 ml
or 480
or 49 orodispersible tablets .
or 49 orodispersible tablets
500 film-coated tablets .
and 500 film-coated tablets .
500 film-coated tablets
and 500 film-coated tablets
500
and 500
98 film-coated tablets .
and 98 film-coated tablets .
98 film-coated tablets
and 98 film-coated tablets
or 98 tablets
98
and 98
or ABILIFY oral solution
or ABILIFY
or ASL/ ALT > 10
or ASL/ ALT >
or ASL/
or waste material should
or nurse if you
or pharmacist if you are
or nurse if
or pharmacist .
or pharmacist
or pharmacist if
or pharmacist
or pharmacist for advice
or nurse
or pharmacist
or blood pressure , tachycardia
or blood pressure ,
or blood pressure
or CYP2D6
or CYP2D6 inhibitor
or telithromycin or
or diuretics that
or diuretics
or dyslipidaemia ( abnormal
human dose or exposure
or exposure
or obesity is caused by
or obesity
Cardiovascular
or joints
or glucose-galactose
wastewater or household waste .
wastewater or household waste
wastewater or
or Hb increase 1
or Hb increase
or history of cardiac failure
your liver or heart .
your liver or heart
or ibuprofen ( anti-inflammation medicines
or ibuprofen ( anti-inflammation
or ibuprofen shortly following
or ibuprofen shortly
or ibuprofen
or insulin .
or insulin
or coma ,
or coma
or combination therapy ( see
or combination therapy (
or combination therapy
or hospital as
or hospital
or body weight .
or body weight
or hepatic impairment may
or hepatic impairment
or lithium
or lithium concentrations .
or lithium concentrations
or pulmonary
or paracetamol
patients or
patients or
or nurse
or placebo (
or placebo
or stroke in
or stroke
or if you
or settling are
or settling
or sucrase-isomaltase insufficiency should
or sucrase-isomaltase insufficiency
or death
or urticaria )
or urticaria
or valproate
or disturbed
or worsening
or dentist .
or dentist
or snack containing carbohydrates .
or snack containing carbohydrates
or disposed
or intentional acute
or intentional
or all of
or all
other bisphosphonates or
or other symptoms of
or other symptoms
or other
other relevant
or other dental surgeries .
or other dental surgeries
or to other antidiabetic medicines
or other potent CYP3A4 inhibitors
or other CNS medicinal products
or other CNS
, or to other
or other
or to other
or tense .
or tense
or tense .
or tense
or without food
or without
or stored at room temperature
or stored at
or in case of HIV
or in case of
or in case
or
or chronic liver disease .
or chronic liver disease
or chronic liver
or chronic
or the label to the
or nurse .
or nurse .
or nurse
or nurse
or discontinuation of treatment
or 16 to 81 times
or 16 to 81 times
or the blood vessels
or the deltoid region may
or the
or lay
or
or diabetic ketoacidosis
or aggravation of existing
or the anterior abdominal wall
or the
or
or
or any of the
or to any of the
or any of the
or any
or to any
or obesity
sweet or fatty foods
sweet or
or previous stroke who
or previous stroke
or previous
or mixed episode of
or mixed episode of
or mixed episode
or mixed episode of
or mixed episode
or mixed
or planned G-CSF support .
or planned G-CSF support
or hyperosmolar coma or death
or hyperosmolar coma or death
or hyperosmolar coma or
or hyperosmolar coma
or hyperosmolar
or higher dose to
or higher dose
or higher
, or as
or as
or placebo
or
, or
or
or of no
or more .
or more
or longer .
or longer
or more
or more units of
or more units
or more weeks after your
or more weeks after
or more weeks after
or more weeks after
or more weeks
or more
or more
or with risk factors for
or with risk factors
or with
or moderate influence on the
or moderate influence
or moderate
oder ohne ( behandelte )
oder ohne ( behandelte
oder ohne (
or without food .
or without food
or without
or without food .
or without food
or without a rapid-cycling course
or without psychotic features and
or without psychotic features
or without psychotic
oder ohne
or without
or peripheral
Antidepressants or herbal
untreated , inadequately treated
untreated
or severe sensory neuropathy ,
or severe sensory neuropathy
or severe sensory
or severe
or very rapid or irregular
or very rapid or
or very rapid
or very
or
or they received risedronate
or they received
or they
side
or unplanned ,
or unplanned
or irregular heart beat .
or irregular heart beat
or irregular
below the
below
or insufficient
or less duration ,
or less duration
or less
or if you are
, or if the
or if the
or if they
, or if
or if
, or were
, or were
or were
or during lactation .
or during lactation
or during lactation .
or during lactation
or additional risk factors (
compromise or additional risk factors
or additional risk factors
compromise or additional
or additional
, or might apply ,
or might apply
or two weeks
or two
, or to
, or
10 or 15
10 or
2 or
; or
compromise or
oder
or 15
or 5
or disposed
or if
or in
or liquid faeces
or liquid
or obesity
or of
or overweight
or the
or to
or
to
open-label study there was no
open-label study there was
open-label studies
open-label
occurs frequently
ohne ( behandelte )
ohne ( behandelte
ohne (
ohne Adipositas (
ohne Adipositas
or in Asian/ Oriental
years or in Asian/ Oriental
or in Asian/
years or in Asian/
Excluding finger , toe
without food .
without food
without
without food .
without food
without a rapid-cycling course .
without a rapid-cycling course
without psychotic features and with
without psychotic features and
without psychotic features
without psychotic
without steroid pre- treatment or
without steroid pre- treatment
without steroid
ohne
or
with no
without
years or
oncology indications , and a
oncology indications , and
oncology indications ,
oncology indications
oncology
orchiectomy
hip fracture repair
hip repair surgery
your hip repair surgery
repair
to ensure optimum response
to ensure optimum response
, oral
oral
absorb orally administered mitratapide .
absorb orally administered mitratapide
absorb orally administered
, oral
oral
oral bioavailability of the
oral bioavailability of
oral therapy is not appropriate
oral therapy
by mouth
by
oral
oral aripiprazole :
oral aripiprazole
oral
use of oral aripiprazole
use of oral
oral clearance
Kontrazeptivums mit einer ng
Kontrazeptivums mit einer
Kontrazeptivums mit
Kontrazeptivums
oral
oral administration of
oral administration
oral
oral administration ,
oral administration
oral
elective orthopaedic surgery :
elective orthopaedic surgery
for orthopaedic surgery
elective
orthostatic hypotension Rare :
orthostatic hypotension Rare
orthostatic hypotension
orthostatic hypotension* ,
orthostatic hypotension*
orthostatic
in patients
patients
p rst vniec ba Latvij
p rst vniec ba
p rst vniec
p rst
p
pH of 6-7.5 and an
pH of 6-7.5 and
pH of 6-7.5
pH of
pH
be a palliative treatment .
be a palliative treatment
to be a palliative treatment
administration site conditions
administration site
parenteral benzodiazepine may be
parenteral benzodiazepine
parenteral
parenteral benzodiazepine therapy
being
corresponding unit scale .
corresponding unit scale
corresponding
pectoris , increased risk of
pectoris , increased risk
pectoris , increased
pectoris ,
pectoris
per se of insulin
per se
perforated
have to be adjusted periodically
peripheral coldness , orthostatic hypotension
peripheral coldness , orthostatic
peripheral coldness ,
peripheral coldness
experiencing grade 3 peripheral neuropathy
grade 3 peripheral neuropathy
peripheral neuropathy
peripheral arterial
peripheral motor neuropathy , ataxia
peripheral motor neuropathy ,
peripheral motor neuropathy
peripheral motor
peripheral
peripheral oedema
peripheral neuropathy to resolution
peripheral neuropathy to
peripheral neuropathy
individual situation
genotoxic agent at
genotoxic agent
pharmacokinetic data
pharmacokinetic
pharmacokinetic analysis
pharmacokinetic characteristics of aripiprazole and
pharmacokinetic characteristics of aripiprazole
pharmacokinetics of insulin products
pharmacokinetic characteristics of
pharmacokinetics of
pharmacokinetic characteristics
pharmacokinetic parameters
pharmacokinetic
pharmacological
hemmt.
hemmt.
short-
short-
placebo-controlled trial
placebo-controlled studies ,
placebo-controlled studies
placebo-controlled
Due to
is therefore
planning
800 to 1,200 IU of
800 to 1,200 IU
800 to 1,200
to sudden stabbing migraine-
to sudden stabbing migraine-like
to sudden stabbing
to sudden
sudden and
sudden
signs
sudden unexplained death
sudden unexplained
sudden
polycythaemic mice ) .
polycythaemic mice )
polycythaemic mice
Based
post-menopausal women ,
post-menopausal women in men
post-menopausal women in
post-menopausal women in the HORIZON-PFT
post-menopausal women in the
post-menopausal women in
post-menopausal women and
post-menopausal women
post-menopausal osteoporosis ( PFT )
post-menopausal osteoporosis ( PFT
post-menopausal osteoporosis (
post-menopausal osteoporosis
osteoporosis
post-menopausal
of post-menopausal osteoporosis ,
post-menopausal osteoporosis ,
of post-menopausal osteoporosis
post-menopausal osteoporosis
post- menopausal osteoporosis
development were assessed in the
development were assessed in
development were assessed
development
postprandial
postural dizziness , neuropathic pain
postural dizziness , neuropathic
postural dizziness ,
postural dizziness
postural
CYP3A4 inhibitor
CYP3A4
potentially medically serious signs and
potentially medically serious signs
potentially medically serious
serious adverse reactions in
serious adverse reactions
serious
potentially toxic compounds ,
potentially toxic compounds
potentially toxic
potentially carcinogenic
potentially
potential risk for humans
potential risk for
potential risk
potential
self harm and
self harm
self
primary efficacy variable was the
primary efficacy variable was
primary efficacy variable
primary
primary 2-hour endpoint was 5.8
primary 2-hour endpoint was
primary 2-hour endpoint
primary 2-hour
primary
per 100
per 8 kg
per 8
per dose , i. e.
per dose ,
per dose .
per dose
per kilogram .
per kilogram bodyweight .
per kilogram bodyweight
per kilogram ,
per kilogram
per month ) with
per month )
per month , or if
per month , or if
per month , or
per month ,
per month
per month
per month or the
per month or
per month
per day .
per day
times per week )
times per week )
times per week , the
times a week by injection
times a week by
times per week .
times per week
times per week .
times per week
per week by the intravenous
per week by
times per week by
per week
times per week ,
times per week
times per week
per ml
per
times per
sensitive to
sensitive
proconvulsant activity of rimonabant was
proconvulsant activity of rimonabant
proconvulsant activity of
proconvulsant activity
proconvulsant
prospective , randomised , double-blind
prospective ,
prospective
during the second year
the second year
during the second
the second
during the
the
percentage
percentage
loss percentages were obtained :
loss percentages were obtained
pre- and post-natal development
pre- and post-natal
the pre- and post-natal
predispose
preclinical toxicological studies in dogs
preclinical toxicological studies in
pre-menopausal range .
pre-menopausal range
use of epoetin alfa
use of
use
ge Depressive reactions may occur
psychotic features
psychotic
psychotic illnesses and mood disorders
psychotic features and with or
psychotic features and with
psychotic features and
psychotic features
psychotic symptoms
psychotic
paediatric haemodialysis patients
paediatric patients
paediatric
rDNA ( produced by
rDNA (
rDNA
;
rDNA ) .
rDNA ) or to any
rDNA ) or
rDNA )
rDNA
radiolabelled pioglitazone to man ,
radiolabelled pioglitazone to man
to
randomised
randomised , double-blind
randomised
smoke .
smoke
ACOMPLIA ,
ACOMPLIA ,
rectangular and blue ,
rectangular and blue
rectangular and pink ,
rectangular and pink
rectangular and
rectangular
.
be reduced .
be reduced
reduced with
reduced
reduced BSAP
pioglitazone reduced total plasma triglycerides
reduced visual acuity ,
reduced visual acuity
rapidly reduced
reduced
your levels of the
your levels
measured on a regular basis
be monitored regularly .
be monitored regularly
monitored regularly
regularly
copious amounts of water .
copious amounts of water
copious amounts of
copious amounts
in CHO cell line by
in CHO
recombinant human erythropoietin
recombinant human
reconstituted medicinal product contains approximately
reconstituted medicinal product contains
reconstituted medicinal product
reconstituted suspension has a pH
reconstituted suspension has a
reconstituted suspension has
reconstituted suspension
reconstituted
reconstituted suspension in the
reconstituted suspension may occur .
reconstituted suspension may occur
reconstituted suspension may
reconstituted suspension
reconstituted suspension
reconstituted
rectal
relative efficacy of M-II
relative efficacy of
relative efficacy
relative
relevant effect on
relevant effect
relevant
renal excretion .
renal excretion
renal effects
renal
renal
renal anaemia ,
renal anaemia
renal
presumably represent rapid
presumably
presumably
republika Eli
republika OncoEurope Tel : +
republika OncoEurope Tel :
republika OncoEurope Tel
republika OncoEurope
republika
absorbed , with peak plasma
absorbed , with
, discard any remaining contents
, discard
remaining amount of
remaining amount
time
reversible and dose dependent
reversible and dose
reversible and
reversible
methods
rats , dogs ,
correct dose
correct amount
correct
pink , marked with
pink , marked with
pink , marked with
pink , engraved with
pink , marked with
pink ,
pink
red blood pigment ( haemoglobin
red blood pigment ( haemoglobin
red blood
blood cell production .
blood cell production
cell production .
cell production
blood cell
cell
routinely measured but a
routinely measured
in routine laboratory parameters
in routine laboratory parameters
in routine
routinely
rst vniec ba Latvij Tel
rst vniec ba Latvij
rst vniec ba
rst vniec
rst
minimum
minimum
round and yellow ,
round and yellow
round and pink ,
round and pink
round and
round
off
round tablets contain 15 ,
round tablets contain 15
round tablets contain
round tablets
round
sc use
sc
gently inverted
sanofi-aventis S. p. A. ,
sanofi-aventis
do not seem
seem
appears to be low .
appears to be low
appears
concentration
seems comparable to that
seems comparable to
seems comparable
seems
appears to act via
appeared to be reversing ,
schizophrenia patients the incidence
schizophrenia patients
schizophrenia
mesolimbic system modulates
painful
quickly and apply pressure
rapidly reversible and dose dependent
rapidly reversible and dose
rapidly reversible and
rapidly reversible
with a quick
with
fast-acting , insulin (
fast-acting , insulin
fast-acting ,
fast-acting
fast-acting (
fast-acting
quickly
rapidly
with
rapid initial effect together with
rapid initial effect together with
rapid initial effect together
rapid initial effect together
rapid
represent rapid
rapid or irregular heart beat
rapid or irregular
rapid or
rapid
rapid onset of effect of
rapid onset
rapid control of agitation
the rapid control of agitation
rapid control of
the rapid control of
the rapid control of
rapid control
the rapid control
rapid
the rapid
Quincke
had
are pregnant ,
are pregnant
are pregnant or
are pregnant
pregnant
pregnant women .
pregnant women
pregnant or
pregnant
Black .
Black
severe dehydration )
severe dehydration )
severe dehydration
severe weight loss , emaciated
severe weight loss ,
severe weight
and severe
severe
severe neutropenia or severe sensory
severe neutropenia or severe
severe neutropenia or
severe neutropenia
severe manic episodes in
severe manic episodes
severe manic
severe sensory neuropathy , additional
severe sensory neuropathy ,
severe sensory neuropathy
severe sensory
severe
severe agitation ,
severe agitation
severe renal impairment
severe hepatic impairment should not
severe hepatic impairment should
severe hepatic impairment
severe renal
severe
severe symptoms is less common
severe symptoms is less
severe symptoms is
severe symptoms
severe manic episodes and
severe manic episodes
severe manic
severe
serious
weaker than normal .
weaker than normal
weaker than normal
weaker than
weaker
be harmful for
be harmful
environment .
from light .
environment
from light
six months
six identified metabolites are active
six identified metabolites are
six identified metabolites
six identified
six
6-month comparative
6-month
observed in clinical trials
very wide .
very wide
very
mesolimbic system modulates
very rapid or irregular
very rapid or
very rapid
is very rare ( see
is very rare (
is very rare
very rare cases of
very rare cases
very rare
very rare cases fatal
very rare cases
very rare
becomes very significant
is severe and rapid
is very
very
antihypertensive treatment .
antihypertensive treatment
be
may be
of
always ask his patients
its
accordance
its application for the use
its application for the
withdraw its application
its application for
its application
its metabolites are
its metabolites
its
its 1-adrenergic receptor
been available as an
been available
post-marketing experience , accidental
post-marketing experience
postmarketing
state
inject
rare - Refraction disorders
rare -
rare ( see section
rare ( see
rare (
rare
rare
rare cases of NMS
rare cases of
rare cases
rare
rare hereditary problems of
rare hereditary problems
rare cases fatal outcome has
rare cases fatal
rare cases
rare
rare cases of bronchoconstriction
rare cases of
rare cases
rare
significantly decreased
sensory neuropathy , headache ,
sensory neuropathy , headache
sensory neuropathy ,
sensory neuropathy
sensory disturbance , somnolence .
sensory disturbance , somnolence
sensory
sensory neuropathy , additional
sensory neuropathy ,
sensory neuropathy
sensory
grade 3 sensory neuropathy withhold
sensory neuropathy
please contact
please contact
sicca , madarosis Eye disorders
sicca , madarosis
sicca ,
sicca
, suggest that
that
, 39
, 39 ± 16 %
, 39 ± 16
, 39 ±
found to be
to be
normally on the day
regresses
feel drowsy or dizzy
feel better .
feel better
to the possibility
to the
an increase in extra-abdominal
in place , the cells
in place , the
of heart failure .
of heart failure
undergo dental surgery
a blood
a
about hurting yourself .
about hurting yourself
experience
in all of whom it
in all of whom
in all of
in all
to the tissues .
to the tissues
in
formulation
If
, no new
, no
linearly from 2653 to
linearly from 2653
linearly from
linearly
feel tired or dizzy
are not sure
feel dizzy , especially
feel dizzy ,
feel dizzy
probably need
,
a
an
formulation
found to
have an
in place ,
on treatment
on
or
to
overlapping undesirable effects such as
overlapping undesirable effects
factors such
risk factors such
with risk factors such
factors such
risk factors such
with risk factors such
treatment .
treatment
safety pharmacology studies .
safety pharmacology studies
safety pharmacology
concerns
make sure that your haemoglobin
ensure
ensure
make sure the entire
make sure the
ensure that
make sure
ensure
to ensure
ensure
to ensure
visible
to
sie durch den
sie durch
they received risedronate once a
they received risedronate
they received
However ,
it becomes very significant
whole .
whole
it
sie
they
see section 4.2 ) .
see section 4.2 ) The
see also section 4.2 )
see section 4.2 )
see section 4.2 Treatment of
see section 4.2 Treatment
see section dic
see also section 4.2
see section 4.2
see section dic
see section 4.3 ) .
see section 4.3 )
see section 4.3
see section 4.3 ) .
see section 4.3 )
See section 4.4 ) .
see section 4.4 ) .
See section 4.4 )
see section 4.4 )
please see section 4.4 -
see section 4.4 -
see section 4.4 and 5.2
siehe Abschnitt 4.4 und 5.2
see section 4.4 and section
see section 4.4 and
siehe Abschnitt 4.4 und
See section 4.4
please see section 4.4
see section 4.4
siehe Abschnitt 4.4
see section 4.5 ) .
see section 4.5 )
see section 4.5 .
see section 4.5
nefazodone)(see section 4.5 )
nefazodone)(see section 4.5 )
nefazodone)(see section 4.5
see section 4.6 ) .
see section 4.6 )
see section 4.6
see section 4.8 ) .
see section 4.8 )
see section 4.8
see section 5.1 ) .
see section 5.1 ) :
see section 5.1 ) ,
see section 5.1 )
see section 5.1
see section 5.2 ) .
see also section 5.2 )
see section 5.2 )
see also section 5.2
see section 5.2
see sections 4.4 and 5.2
siehe Abschnitt 5.2
see section 5.3 ) .
see section 5.3 )
see section 5.3
see section 6.1 ) .
see section 6.1 )
see 6.1 .
see section 6.1 .
see 6.1
see section 6.1
, see section 6.3 .
, see section 6.3
, see section 6.6 .
see section 6.6 .
, see section 6.6
see section 6.6
, see section
See section
is
please see section
section 4.5
see also section
see section 4.4 )
see section
see section
see sections 4.4 and
see sections 4.4
see
see sections 4.3 and 4.4
see sections 4.3 and
see sections 4.3
see sections 4.8 and 4.9
see sections 4.8 and
see sections 4.8
see sections
see Annex I )
See Annex I :
See Annex I
see Annex I
see Table 2 ) .
see Table 2 )
see Table 2
see Table
See also section 4.4 )
See also section 4.4
See also section
See also
siehe auch Abschnitt
see the
, see
See
please see
see also
see sections
see
siehe Abschnitt
significantly impact
significantly
signifikant verändert. t lä
signifikant verändert.
improvement in
improvement
significant
significantly
signifikant
significant effects were
significant effects
significant risk factors such as
significant risk factors
significant differences in hip fracture
significant differences in
significant differences
significant change in aripiprazole concentrations
significant change in
significant changes in routine
significant changes
significant
significant effect on
significant effect
shown significant benefits
shown significant benefits
significant benefits
by significant intra- and inter-individual
by significant intra- and
by significant intra-
significant
significant
are
are
.
are
are sulfobutylether -cyclodextrin
are lactose monohydrate ,
are lactose monohydrate
are :
interactions resulting from displacement of
interactions resulting from displacement
are mannitol , sodium citrate
are mannitol ,
are mannitol
are neutropenia (
are neutropenia
are growth factors
are active ( M-II
are active (
are active
are ready to use (
are ready to use
on the European Medicines Agency
is limited .
is limited
should be checked prior to
should be checked prior to
should be checked
should be checked
with repeated infusions
with repeated
have
tablet is bioequivalent to aripiprazole
tablet is bioequivalent to
tablet is bioequivalent
are not necessary .
are not necessary
are not
are
should be alerted about
should be alerted about
liver enzyme levels should
liver enzymes should be checked
the
these effects are mild and
these effects are mild
these effects are
corresponding to the
corresponding to
are extrapyramidal
are transitory and
are transitory
are presented in Table 4.
are included in the carton
are included in the
are included in
are no data available
does not require any special
does not require any special
not require any special
not require any special
does not require any special
are no
cannot
have occurred in post-marketing experience
are not to be expected
are not to be
, are not
are not
a few
few
are rectangular and blue ,
are rectangular and blue
are rectangular and pink ,
are rectangular and pink
are rectangular and
are rectangular
are round and yellow ,
are round and yellow
are round and pink ,
are round and pink
are round and
are round
which are unusual
are shown below .
are shown below
are white to off-white
are white
also be
also
respected .
respected
are for use with
are for use
are for
, are
also
are not
are shown
are
have
which are
are usually mild to moderate
are usually mild to
are usually
and the effect of
and the effect
and the
started as soon as possible
started as soon as
drink
and
if applicable
doctor at once .
doctor at once
be discontinued immediately .
be discontinued immediately
discontinued immediately
immediately after opening
should be used immediately .
should be used immediately .
should be used immediately
should be used immediately
immediately
discontinuation of treatment .
discontinuation of treatment
antipsychotic medicine .
antipsychotic medicine
solid tumours ( 172 breast
solid tumours ( 683 breast
solid tumours (
solid tumours ,
solid tumours
solid
should
should not exceed 200
should not exceed 30 mg
Abseamed should be discontinued immediately
Abseamed should
, Aclasta should
Aclasta should
, aripiprazole should
aripiprazole should be
aripiprazole should
epoetin alfa should be used
epoetin alfa should
, your dog should
should be considered on
, these patients should avoid
these patients should avoid
, these patients should
these patients should
the medicinal product should be
should be in accordance
should be in
should be
the patient should
should be
the aripiprazole dose should
dosing should
the dose should
the dose should
, the vial should
the vial should
alfa treatment should be discontinued
the pipette should be washed
, the pipette should be
the pipette should be
, the suspension should
the suspension should
resuspension should be ensured by
resuspension should be ensured
the reconstituted suspension if
should be
should consider clinical
should consider clinical monitoring
should be considered ( see
should be considered (
should be considered
should be
should be advised
should be advised
should generally not
should generally
should be done in
should be administered intravenously
should be given
should be used with caution
should be used with caution
Take special care with
should not be administered
should not be administered
should not be
should not
should not normally exceed 200
should be restricted
should only be administered
should only be given
should only be
should be carefully weighed
should be avoided .
should be avoided
should not be diluted with
should not be diluted
,
should be weighed
should be
should
sollte
should :
should not use ABILIFY
should not take ABILIFY
your haemoglobin-levels and your
your haemoglobin-levels and
your haemoglobin-levels
should you attempt
should you
should be
should be advised accordingly .
should be advised accordingly
therefore should not be
therefore
blood levels of cyclosporin should
patients should
should consider clinical
should consider clinical monitoring
should
should
should be monitored closely
their
should be
should be
should not be
should not
should be monitored regularly .
should be monitored regularly
should
should be
should
should be
should receive
should seek
should
dose reductions should
thus not necessary .
thus not necessary
thus not
thus restoring
thus
of the ingredients of ABILIFY
of the ingredients of Abseamed
of the ingredients of
of the ingredients of
ingredients
of the ingredients
of the ingredients
other forms of interaction
forms of interaction
forms of
other forms of
excipients or to any bisphosphonates
excipients or to any
excipients , see section 6.1
of excipients , see 6.1
excipients , see section
of excipients , see section
of excipients , see
excipients , see
of excipients , see
other ingredients .
other ingredients are lactose monohydrate
other ingredients are disodium
other ingredients are lactose
other ingredients are mannitol ,
other ingredients are mannitol
other ingredients are
other ingredients
other ingredients of ABILIFY
other ingredients of Actos 15mg
other ingredients of Actos 45mg
excipients ,
excipients
of excipients ,
of excipients ,
of excipients
other ingredients of
other ingredients
other ingredients
carefully all instructions given to
carefully all instructions given
carefully all
carefully weighed against the
carefully weighed
carefully weighted
carefully
carefully monitored .
should be closely monitored .
carefully monitored
should be closely monitored
source
and very rare cases of
and very rare cases
and very rare
and very
, and
and
as
metabolic and
the metabolic and
both fast-acting (
both fast-acting
both
surgery , and :
surgery , and
surgery ,
surgery
specifically investigated .
studied specifically .
specifically investigated
studied specifically
specifically
specialized DEHP-free
specialized
specific treatment
spezifische Interaktionsstudien bestätigt , in
spezifische Interaktionsstudien bestätigt ,
spezifische Interaktionsstudien bestätigt
specific
special warnings and
special warnings
specific
activation of
activation
reflected differences in
reflected differences
rodents
second-line therapy .
second-line therapy
sse Der Anteil der Patienten
sse Der Anteil der
sse Der Anteil
sse Der
ise Sanofi Winthrop Industrie ,
ise Sanofi Winthrop Industrie
ise Sanofi Winthrop
ise Sanofi
ise or uth ra ge
ise or
ise or uth
gastrointestinal
ge
ise
sse
preventing
bone markers stabilised within
bone markers stabilised
,
highly bound to plasma proteins
stark eingeschränkter
is severe and
is severe
becomes
highly
severe
severe irritability .
severe irritability
statistically significant greater improvements in
statistically significant greater improvements
improvement in
improvement
statistically significant greater improvements in
statistically significant greater improvements
statistically significant
statistically
migraine-like headaches as a
migraine-like
are supplied in blister
in proportion to
proportion to
in proportion
proportion
educational
represents a
mother presents no risk
mother presents no
represents
they eventually die .
they eventually die
sterile syringe ,
sterile syringe
sterile
sterile but unpreserved product
sterile but unpreserved
sterile but
sterile
increased by 77
are breast-feeding .
are breast-feeding
breast-feeding women
nursing mother presents no
nursing
the Package
the Package
the Package
breast-feeding
the
compartment .
specifically and
compartment
specifically
stops the action of the
stops the
stops
physicians for
physicians
physicians for
physicians
physicians for the occurrence of
physicians for the occurrence
, Aclasta strengthens the
Aclasta strengthens the
, Aclasta strengthens
Aclasta strengthens
strengthens
given subcutaneously (
subcutaneously ) .
subcutaneously ) .
subcutaneously )
subcutaneously ) .
subcutaneously )
to be administered subcutaneously !
given subcutaneously 3
administered subcutaneously in the
given subcutaneously
difficult
subcutaneous (
subcutaneous erythropoietin
subcutaneous
subcutaneous tissue .
subcutaneous tissue
subcutaneous use of Abseamed
subcutaneous use of
subcutaneous use
both via subcutaneous administration .
subcutaneous administration .
via subcutaneous administration .
both via subcutaneous administration
subcutaneous administration
via subcutaneous administration
subcutaneous administration .
subcutaneous administration
subcutaneous injection ,
subcutaneous injection
both via subcutaneous
subcutaneous
the subcutaneous
via subcutaneous
symptomatic
symptomatic anaemia in
symptomatic anaemia associated with
symptomatic anaemia
symptomatic
symptomatic
systemically
concomitant systemic disease such as
concomitant systemic disease
concomitant systemic
systemic exposure was generally
systemic exposure was
systemic exposure
systemic
systemic
highly palatable
)
2.
keeping airways
t lä
)
t lä
made
divide and they eventually die
divide and
Tell
divide
57
programme , the
programme ,
programme .
1800 ml .
1800 ml
programme
or embryo/ foetal effects
embryo/ foetal effects
embryo/
terminal half-life ( t½ )
terminal half-life ( t½
terminal half-life (
terminal half-life is determined by
terminal half-life is determined by
terminal half-life is determined
terminal half-life is determined
terminal half-life
terminal
therapeutic response
therapeutic response
therapeutic margin of epoetin alfa
therapeutic margin of epoetin
therapeutic margin of
therapeutic margin
therapeutic
mutation assay .
mutation assay
mutation
thromboembolic events in
thromboembolic events
thromboembolic
thrombotic events
of thrombotic vascular events
thrombotic vascular events
of thrombotic vascular
thrombotic vascular
of thrombotic
thrombotic
can
maximus
deep venous thrombosis )
thrombosis ( DVTs ) .
thrombosis ( DVTs )
deep vein thrombosis
deep venous thrombosis
deep vein thrombosis , arterial
deep vein thrombosis ,
deep vein thrombosis
deep vein
thrombosis
animal studies , epoetin
Foetal
doses
toxic compounds ,
toxic compounds
toxic
zur pharmakologischen Aktivität bei. ln
enhanced transendothelial transport
enhanced transendothelial
transient ischaemic attacks ,
transient ischaemic attacks
transparent plastic ( cycloolefinic polymer
transparent plastic ( cycloolefinic
transparent plastic
occurred in 24 % of
occurred in 24 %
occurred in 24
occurred in 29 % of
occurred in 29 %
occurred in 29
occurred in 32 % of
occurred in 32 %
occurred in 32
occurred in four
occurred in
aripiprazole has not been
has not been
has been
has not
occurred
reported concurrent peripheral
reported concurrent peripheral oedema
occurred
reported
signs of
tend to
tend
occurs frequently with Abraxane
nasal dryness , wheezing
teardrop- shaped tablets . no
teardrop- shaped tablets .
teardrop- shaped tablets
cloudy after resuspension .
cloudy after resuspension
characteristic of Paget s disease
characteristic of
characteristic
t½ ) is therefore
t½ ) is
t½ )
t½ 1.87
t½ of
t½
daily )
daily .
day .
1,000 to 1,500 mg elemental
15mg or
15mg
daily .
daily
daily was
day for two months .
day for two months
daily
day
daily insulin requirement may be
daily insulin requirement
daily
unable
dose by 25 %
27 % higher
27 %
by 32 % and
by 32 %
by 32
43 %
47 % .
47 %
47
um 5 % ansteigt .
um 5 % ansteigt
um 5 %
um 5
by 61 % below
by 61 %
by 61
for advice before
for advice
draw conclusions regarding
approximately 2.5 mm less
by approximately 25
by approximately
to minimise the risk of
accordingly to minimise the risk
to minimise the risk
carton in order to protect
carton in order
in order to maintain haemoglobin
determine the safety of pioglitazone
determine the safety of
determine the safety
to
determine the
in order to
to
possible to re-schedule
to decide , if
rising by more than 2
rising by more than
rising by more
by at least 30
fell by at least 75
by at least
fell by at least
3.6
by
determine
draw conclusions
fell by
in order
increased
to
um
of overdoses , such as
overdoses , such as
methylene groups .
methylene groups
included only 3 patients with
included only 3 patients
included only 3
included only
included
immediately if you are breast-feeding
immediately if you
immediately if
your doctor immediately if
your doctor immediately
immediately
concentration independent .
concentration independent
independent
independent
independent
uncomfortable feeling in the stomach
unaffected
unknown , but it attaches
unknown , but it
unknown , but
unknown ,
is unknown .
unknown .
is unknown
unknown
subject to confounding factors
and " 10 " on
and " 10 "
and " 10
and " 15 " on
and " 15 "
and " 15
and " 30 " on
and " 30 "
and " 30
and " 5 " on
and " 5 "
and " 5
and "
and +0.1 on placebo (
and +0.1 on placebo
and +0.1
and , with
and ,
and -3A4 respectively .
and -3A4 respectively
and /
and 0.8 % for placebo
and 0.8 % for
and 0.8 %
and 0.8
and 1.1
and 10 cartridges x
and 10 cartridges
and 10 on one side
and 10 on
and 10 pre-filled pens
and 10
und 10
and 11 g/ dl (
and 11 g/ dl
and 11
and
and 11
and 12 g/ dl (
and 12 g/ dl
and 12
and 15 on one side
and 15 on
and 15
and
and 15.7 % for
and 15.7 %
and 15.7
and 16 mg zoledronic acid
and 16 mg
and 16
and 180-minute infusions of Abraxane
and 180-minute infusions of
and 180-minute infusions
and 180-minute
and 19 %
and 19
and 2.47 in favour of
and 2.47 in favour
and 2.47 in
and
and 3 -p-hydroxypaclitaxel ,
and 3 -p-hydroxypaclitaxel
and 3
and 3.0 % with placebo
and 3.0 % with
and 3.0 %
and 3.0
and 3.2 % with placebo
and 3.2 % with
and 3.2 %
and 3.2
and 30 on one side
and 30 on
and 30 mg orodispersible tablets
and 30 mg tablets ,
and 30 mg tablets
and 30 mg
to 30 mg/ day (
to 30 mg/ day .
to 30 mg/ day
and 30
to 30
and 300 IU per kilogram
and 300 IU per
and 300 IU
and 300 IU/ kg given
and 300
and 33 IU/ kg ,
and 33 IU/ kg
and 33
and 36 months ) .
and 36 months )
and 36 months
and 36
and 3A4 ( dextromethorphan )
and 3A4 ( dextromethorphan
and 3A4 (
, and 3A4
, and 3A4
and 3A4 .
and 3A4
and 4.4
.
patient .
and 4.9 ) .
and 4.9 )
and 4.9
and 400 mg of sucrose
and 400 mg of
and 400 mg
and 400
and 42 %
and 42
mg and 45 mg
and 45
and 5 vials x
and 5 vials
and 5 on one side
and 5 on
and 5
and 5-hydroxytryptamine are involved
and 5-hydroxytryptamine are
and 5-hydroxytryptamine
and 5.2 ) . dic
und 5.2 ) .
und 5.2 )
and 5.2
und 5.2
and 50 % isophane insulin
and 50 %
and 50 IU/ kg 2
and 50
and 53.3 % for
and 53.3 %
and 5HT2a receptors and
and 6
and 6.1 months ( 300
and 6.1 months (
and 6.1 months
and 6.1
and 60 % isophane insulin
and 60 %
and 60
and 7 )
and 7
and 70 % isophane insulin
and 70 %
and 70
and 76 % had >
and 76 % had >
and 76
and 8.7 for aripiprazole .
and 8.7 for aripiprazole
and 8.7 for
and 8.7
and 80 % isophane insulin
and 80 %
and 80
and 802 with haematological malignancies
and 802 with
and 802
and 8167 patients ) .
and 8167 patients )
and 8167 patients
and 8167
and
and 90 % isophane insulin
and 90 %
and 90
and 98 tablets .
and 98 tablets
and 98
, and :
and :
and AUC after
and AUC
and analogues for injection ,
and analogues for injection
and analogues for
and angioedema
and address of
and address of
and address of the manufacturer
and address of the
and address
and address
and swelling of hands ,
and swelling of hands
and swelling of
and swelling
and aspiration have been
breathlessness .
or breathlessness .
breathlessness
or breathlessness
and beta-sympathomimetics , growth hormone
and beta-sympathomimetics ,
and beta-sympathomimetics
and exercise
and level of consciousness should
and level of consciousness
and Bipolar I Disorder
and blood pressure
and CYP2D6
and CYP3A4
and CYP3A4
and Cancer Linear Analogue Scale
and Cancer Linear
and Cancer
and Cmax of dehydro-aripiprazole ,
and Cmax of dehydro-aripiprazole
and Cmax of
and Cmax
and danazol .
and danazol
and method of
and method
and dehydro-aripiprazole , but
and dehydro-aripiprazole ,
and dehydro-aripiprazole did
and dehydro-aripiprazole are
and dehydro-aripiprazole
and diabetes mellitus ( see
and diabetes mellitus (
and Diabetes Mellitus : hyperglycaemia
and diabetes mellitus : hyperglycaemia
and diabetes mellitus :
and diabetes mellitus
and family history of diabetes
and diabetes mellitus ( see
and diabetes mellitus (
and Diabetes Mellitus : hyperglycaemia
and diabetes mellitus
and Diabetes
and diabetes
and differentiating hormone , the
and differentiating hormone
and dopamine
and dosing pipette .
and dosing pipette
and doses
and doses above 45 mg
and doses above 45
and doses above
and diarrhoea .
patients and diarrhoea in 25
patients and diarrhoea in
the patients and diarrhoea in
and diarrhoea
and dyskinesia
and E216 .
and E216
and inflammation .
and inflammation
and vomiting .
and vomiting .
and vomiting
and vomiting
and adults .
and adults
and adult patients on
and adult patients
and obesity in adult dogs
and obesity in adult
overweight and obesity in adult
and obesity in
of overweight and obesity in
overweight and obesity in
and obesity
of overweight and obesity
overweight and obesity
and women
and death in utero .
and death in utero
and G-CSF or GM-CSF
and G-CSF or GM-CSF
and gliclazide .
and gliclazide
and haloperidol 73 % )
and haloperidol 73 %
and haloperidol 73
and haloperidol
and Manufacturer Marketing authorisation holder
and Manufacturer Marketing authorisation
and Manufacturer
and heart disease or previous
and heart disease or
and heart disease
and dogs rapidly
and hypoaesthesia ( decreased sensitivity
and hypoaesthesia ( decreased
and hypoaesthesia (
and hypoaesthesia
and your blood pressure
and your blood pressure should
and your haemoglobin
and your
in vivo and in
and infections
and infiltration were observed .
and infiltration were observed
and infiltration were
and contents of the pack
and contents of the pack
and contents of the
and contents
and insulin
and isophane ( NPH )
and isophane ( NPH
and isophane (
and isophane
and isophane insulin 50 %
and isophane insulin 50
and isophane insulin 60 %
and isophane insulin 60
and isophane insulin 70 %
and isophane insulin 70
and isophane insulin 80 %
and isophane insulin 80
and isophane insulin 90 %
and isophane insulin 90
and isophane insulin
and itching
under 18 years of age
and adolescents has not
and adolescents has
and adolescents under
and potassium in
and bone marrow fibrosis of
and bone marrow
and headache ( 5.1 %
and headache ( 5.1
and headache (
and headache in the
and headache in
and headache
and headache in the
and headache in
and headache
and corticosteroids .
and corticosteroids
and lactation .
and lactation
and M-IV ) .
and M-IV )
and M-IV
stomach discomfort , diarrhoea
stomach discomfort ,
stomach discomfort
and magnesium stearate .
and magnesium stearate
and N-dealkylation .
and N-dealkylation
jejunum and kidney
and NovoFine needles .
and NovoFine needles
and osteonecrosis (
infusion and osteonecrosis (
and osteonecrosis
infusion and osteonecrosis
and Package Leaflet and
and Package Leaflet and
and paranoia .
and paranoia
and patients with diabetes
and bipolar mania patients
and patients with
in patients less than 65
in patients less than
that in patients less than
and patients
in patients
that in patients
to that in patients
and pioglitazone
and placebo ( 2.1 %
and placebo ( 2.1
and placebo ( 29 [
and placebo ( 29
and placebo (
and placebo
studied in patients being
and placebo over three
and placebo over
and polyps ) :
and polyps )
and polyps
and protein intake .
and protein intake
and protein binding
and rats , but not
and rats ,
and rats
and reduction of transfusion requirements
and reduction
and rhabdomyolysis ,
and rhabdomyolysis
and risedronate
and severity
and weakness )
and weakness
and chills , pain in
and chills , pain
and safety of Aclasta 5
and safety of Aclasta
and safety of
and safety
reach and sight of children
reach and sight of
reach and sight
and you will
and you will
and sulphonamides .
and sulphonamides
and symptoms reported
and symptoms
and symptoms of heart failure
and symptoms of hyperglycaemia (
and symptoms of hyperglycaemia
and symptoms of
and symptoms
and safety .
and safety of rimonabant
and safety of
and safety
and Vantas
and disturbed behaviours ,
and disturbed behaviours
and multiply .
and multiply
and
and
and
and vitamin D supplementation ,
and vitamin D supplementation
and vitamin D
and vitamin
and precautions
and precautions for use
and precautions for
and precautions
and water for injection .
and water for injections .
and water for injection
and water for injections
and water for
and water
and efficacy .
and efficacy .
and efficacy
and efficacy of rimonabant
and efficacy of
and efficacy
and forefinger .
and forefinger
and time to
and acute renal failure .
and acute renal failure
and all active metabolites
and all active
and all
and as
and anaphylactic reaction .
and anaphylactic reaction
and other forms of interaction
and other antipsychotic drugs
and other
and other erythropoiesis-stimulating agents (
and other erythropoiesis-stimulating agents
and other erythropoiesis-stimulating
and other
and administered
and approximately 20 %
and approximately 20
and approximately 60 % in
and approximately 60 %
and approximately 60
and approximately
September 2005 and
in September 2005 and
and
and anaemic rats ,
and anaemic rats
and anaemic
on
and completed suicide ( see
and completed suicide (
and completed suicide
and treated
and adult patients
for
and consists of 165
and consists of
, was 18.7
, was
and pale mucosae .
and pale mucosae
and pale
and blue ,
and blue
and approximately 18 %
and approximately 18
and approximately 45 %
and approximately 45
and approximately
and
and using machines
or use machines have
use machines have
and
, and that ,
, and that
and that ,
and that
and
and controls .
and controls
and dose regimens .
and dose regimens
face and ACTOS on
face and ACTOS
face and
and TG in this
and TG in
and the median timing of
and the median
and of the
and the
and
insufficient glycaemic control despite
and whose
insufficient
and mediastinal disorders
and Paget s disease
and similar dose reductions should
and AUC
and binding is
and binding
drive and
drive and
drive and
and the majority of the
and the majority
and the Montgomery-Asberg
and drink the
and drink the
and the
and
and dose-proportional .
and dose-proportional
and a multipack with
and a multipack
and an osmolality of
and an osmolality
with
and a negative impact on
and a negative impact
and a negative
and a 27 %
and a 43 %
and a
and an
and a bromobutyl/ polyisoprene rubber
and a sulphonylurea ,
and a sulphonylurea
and healthy
and decide how long
and decide how
and decide
and increased
cycle and multiple
cycle and
and a
and
and extrapyramidal symptoms .
and extrapyramidal symptoms
and extrapyramidal
and colourless solution .
and colourless solution
and colourless
and for the
and for
for
and controlled as necessary .
and controlled as necessary
and treated , if necessary
and yellow , marked with
and yellow ,
and yellow
and dried and the cap
and well-controlled studies in
and well-controlled studies
and well-controlled
and hepatocellular dysfunction
and hepatocellular
and preventing them from returning
and preventing them
and the Paget s disease
and in
and in clinical
, and
and in
and
physician and intensive medical care
and inter-individual variation .
and inter-individual variation
and inter-individual
and is not a substrate
and is not a
and remains unknown .
and remains unknown
and is
and young subjects .
and young subjects
and younger
and cardiorespiratory depression .
and cardiorespiratory depression
and cardiovascular therapy ,
and cardiovascular therapy
and no appreciable affinity
and no appreciable affinity for
and no appreciable
and no
and clinically evident ischaemic heart
and clinically
and well-controlled trials of aripiprazole
and well-controlled trials of
and well-controlled trials
and well-controlled
a quick
quick
and usually did not require
and sometimes severe irritability .
and sometimes severe irritability
and sometimes
and manic
and the
and with or without
and with or
and with
and
and male patients
and male
and possible
and possibly protein disulfide isomerase
and after
and following
and take
and new
is usually reversible .
is usually reversible
taken with or without liquid
with no
and administration site conditions
and administration site
and parenteral benzodiazepine may be
and parenteral benzodiazepine
and parenteral
mucositis and peripheral neuropathy
and peripheral
and postprandial
and paediatric haemodialysis patients
rats , dogs , and
and pink , marked with
and pink ,
and pink
and its
and its metabolites are
and its metabolites
and its
and post-marketing experience
und
, becoming
,
brain function or even death
brain function
and should
and should be advised accordingly
and therefore should not be
and should
and thus not necessary .
and thus not necessary
and thus not
, thus restoring
and thus
and other forms of interaction
and other forms of
and they eventually die .
and they eventually die
and cloudy after resuspension .
and cloudy after resuspension
and 47 % .
and 47 %
and 47
and discard any unused amount
and discard any
other
following repeated phlebotomy .
following repeated phlebotomy
and therefore
and resolved within a week
and resolved within a
and resolved within
and resolved
and go away within three
and go away within
and disappear
and go away
and go
and blurred vision .
and blurred vision
and blurred
and distribute
and mainly
and mainly via the faeces
and mainly via the
and mainly via
and transient .
and transient
and was rapidly reversible and
, and was rapidly reversible
and was rapidly reversible
, and was rapidly
and was rapidly
, and was
and was
and female
and for four days
with
and
, and when
and when
and , as with other
and , as with
and , as
and works in
and acts
and works
and what it is used
and what it is
and was
which was
and seek
50
and a lesser amount
and a
and
and additional pharmacovigilance activities
and additional
, and
, becoming
,
1.0
; and
albumin receptor , and
and ,
and 4.3
and a
and all
and any
and dose dependent
and dose
and in
and is
and multiple
and rate
and the
and tissue
and via
and vitamin
and weight
and
are
brain and
disorganised thinking and
drug and
hormone
infusion and
other
potentially
receptor , and
reduced and
studied
thinking and
to
und
which
who are
worse and
and oedema
and extent of absorption .
and extent of absorption
and extent of
and eliminated via the kidney
in
and/ or pain
and/ or ongoing antidepressive treatment
and/ or ongoing antidepressive
and/ or a sulphonylurea .
and/ or a sulphonylurea
and/ or non-healing sores of
and/ or non-healing sores
and/ or non-healing
and/ or
and/ or
and/
or
last very long .
last very long
unexplained death
unexplained
unexpected
adverse events which
adverse events : in the
adverse events : in
adverse events in patients
adverse events
cerebrovascular adverse events in
cerebrovascular adverse events
cerebrovascular adverse
adverse
adverse drug reactions from
adverse events have been
adverse events
adverse lon reactions
additional adverse reactions
adverse lon reactions
adverse reactions
of rimonabant
rimonabant
adverse reactions
adverse
discard any unused amount .
discard any unused amount
discard any
approximately
unexplained
unexplained nausea
a disordered
disordered
in a disordered
unplanned ,
unplanned
;
unusual tiredness , feeling dizzy
unusual tiredness , feeling dizzy
unusual
unclear whether or not there
unclear whether or
unclear whether
unclear and pioglitazone
unclear and
unclear
unpreserved product and is
unpreserved product and
unpreserved product
unpreserved
immediately
irregular heart beat .
irregular heart beat
irregular
irregular heart rhythm
malignant and unspecified ( including
malignant
listed below is
listed below
below .
shown below .
below
shown below
listed below .
listed below
below 100 ng/ ml
below 100
below 12 g/ dl (
below 12 g/ dl
below 12
below 15 mg were
below 15 mg
below 15
are under 18 years of
are under 18 years
under 18 years of
under 18 years
below age 18 years due
below 18 years of age
below age 18 years
less than 18 months
below 18
less than 18
below 25°C ) .
below 25ºC ) .
below 25°C )
below 25ºC )
below 25°C
below 25ºC
under 30 kg require higher
under 30 kg
under 30
below 30°C ) .
below 30°C )
below 30°C
less than 65 years
less than 65
, see section 6.1
see section 6.1
, see section
see section
in Aclasta
Aclasta
aripiprazole ( 43 %
aripiprazole ( 43
for aripiprazole-treated
conducted according to standard medical
conducted according to standard
conducted
receiving chemotherapy ,
receiving chemotherapy
develop PRCA
for haloperidol-treated
haloperidol-treated
is controlled .
is controlled .
is controlled
is controlled
controlled
controlled
olanzapine-treated
on peritoneal dialysis ( See
with pioglitazone .
receiving pioglitazone
with pioglitazone
receiving placebo ( 139
on placebo ( baseline 7.2
on placebo ( baseline
on placebo (
receiving placebo (
placebo , or were
placebo , or were
placebo , or
on placebo
placebo ,
placebo
receiving placebo
adipose regions ,
adipose regions
defined using the following convention
followed during preparation of the
followed during preparation of
followed during preparation
chronic kidney failure and clinically
chronic kidney failure and
chronic kidney failure
under the supervision of a
under the plasma concentration
under the
under the
below the
under the skin (
injection under the skin )
injection under the skin
under the skin
under the
emea
with oral aripiprazole :
with oral aripiprazole
with oral
%
been
below
less than
on
receiving
under
with
corrected .
corrected
interrupted and
interrupted
human milk .
in human milk .
human milk
in human milk
CHO/ HGPRT ) gene mutation
( CHO/ HGPRT ) gene
CHO/ HGPRT ) gene
( CHO/ HGPRT )
( CHO/ HGPRT
CHO/ HGPRT )
CHO/ HGPRT
below baseline levels
below baseline levels at
( CHO/ HGPRT )
( CHO/ HGPRT
CHO/ HGPRT )
CHO/ HGPRT
below
, patients
patients
are therefore affected
overall burden of disease ;
overall burden of disease ;
overall burden of disease
causes of deaths were
causes of deaths
ise peripheral volume of distribution
,
investigated and further comparative studies
.
been evaluated .
been studied .
evaluated .
investigated .
investigated and
investigated
studied
should be investigated .
should be investigated
been studied .
been studied
wurden. er Die
wurden. er
wurden.
been evaluated
been studied
evaluated
investigated
studied
treatment
immediately if you
immediately if
your doctor immediately if
your doctor immediately
immediately
remain unchanged .
remain unchanged
unchanged
unchanged pioglitazone
unchanged
active substance
unlikely to reduce
unlikely to
unlikely
therefore unlikely .
unlikely .
therefore unlikely
unlikely to reduce
unlikely to
unlikely
effective , and doses
effective , and doses above
effective , and
effective ,
effective
and sight of children .
and sight of children
and sight of children .
and sight of children
and sight of
and sight
for whom
blood
insufficient
monotherapy
insufficient safety information
incoherent speech
utero and via
utero and
utero
vascular events ) .
vascular events )
vascular events
vascular and
vascular
ventricular arrhythmias , sudden unexplained
ventricular arrhythmias , sudden
ventricular arrhythmias ,
ventricular arrhythmias
ventricular
thrombosis , arterial
thrombosis ,
thrombosis
.
between .
.
given .
.
be administered intravenously .
be given .
are
be administered intravenously
be given
are given
administered
given to
given
administered over
administered zoledronic acid
administered
obsolete
release :
release
? er Die
? er
?
associated
appointment .
appointment
. europa . eu/
europa . eu/
available dose
available
missed dose as soon as
missed dose
similar
similar
similar to
similar
comparable to placebo .
comparable to placebo
similar to that
similar to
comparable to
comparable between
comparable to that
comparable to
comparable
similar
.
compared to 1.7 % of
compared to 1.7 %
compared with those
compared with those
treatment with placebo
compared
with placebo
compared to
compared
placebo
mass .
mass
should be rotated
also prevents this
also prevents
from returning .
from returning
Table 3.
in Table 3.
requests the inclusion ,
requests the inclusion
of
insulin .
insulin
increased fatty deposition and
increased fatty deposition
increased production of saliva ,
increased production of saliva
increased primary
of increased primary
increased
of increased
potassium and protein intake
potassium and
potassium
be avoided .
be avoided
avoided
l
decreased sensitivity to a stimulus
decreased sensitivity to a
decreased sensitivity
of
decreased locoregional control
decreased maternal body weight gain
decreased
reduce the exposure of rimonabant
reduce the exposure of
reduce the exposure
reduce the
reduce
mix
mix
prior to administration .
and
5HT2a receptors .
5HT2a receptors
mediated
has been proposed that
suspected , therapy with
has been proposed
is expected to reduce the
is expected to reduce
is expected to
is expected
prescribers
prescribers should be alert to
prescribers should be alert
commits to performing the
commits to provide
commits to
commits to performing
commits
reduce
reduced , coupled with a
reduced , coupled
therefore
, Abilify
reduced the risk of
reduced the risk
decreased by
,
reduced
,
reduced sample size .
reduced sample size
reduced
of
several different receptors on the
different receptors on
different receptors
different
various
tamper-proof cap.
a day .
a day
prescribe
prescribed
prescribed dose when concomitant
resolved within a week .
resolved within a week
resolved within a
resolved within
resolved
disappear during continued
disappear
blurred vision , dry eye
blurred vision ,
blurred vision
, blurred vision , dyspepsia
, blurred vision ,
blurred vision .
blurred vision Gastrointestinal disorders
verschwommenes Sehen aufgrund einer Schwellung
blurred vision
blurred
a visual aid indicating
visual aid indicating
with a visual aid indicating
has been accidentally frozen .
has been accidently frozen .
has been accidentally frozen
has been accidently frozen
accidentally
case of accidental
case of accidental
case of accidental
case of accidental
case of accidental overdosing ,
case of accidental overdosing
: Educational leaflet
:
pressure .
pressure
chest pain )
chest pain
Benommenheit
attempt
vs. gliclazide as monotherapy was
vs. gliclazide as monotherapy
vs. gliclazide as
vs. gliclazide
vs. placebo ) was
vs. placebo )
vs. placebo
active comparator
versus
vs.
distribute to the tissues
distribute
per week into 2 equal
per week
tolerated in
tolerated
can cause
can cause
cause
been
devices for repeated use )
devices for repeated use
system . lp
used
be used , but
be used if they
be used if
be used ,
be used .
be used
used
veterinary medicinal product or waste
unused product
any remaining contents .
any remaining contents
delayed ) .
delayed )
complications .
may be
be
complications
delayed
delayed
not alter rimonabant exposure .
not alter rimonabant exposure
alter rimonabant exposure
warning symptoms of hypoglycaemia and
warning symptoms of hypoglycaemia
verändert. t lä
verändert.
altered mental status
much ABILIFY solution for injection
much ABILIFY
much less
much
has multiple well documented
has multiple well
four carbohydrate chains are
four carbohydrate chains
four weeks
four placebo-controlled studies
four placebo-controlled
Four
four of
four week
four
visceral metastases
visceral
essential
vitro ( mouse spleen cell
vitro (
vitro .
vitro findings from
vitro findings
vitro
vitro studies have shown no
vitro studies have shown
vitro studies have
vitro studies
vivo appears to be low
vivo appears
vivo
vniec ba Latvij Tel :
vniec ba Latvij Tel
vniec ba Latvij
vniec ba
vniec
full list is available in
full list is available
full list
schedule .
treatment schedule .
schedule
treatment schedule
3 The full EPAR for
3 The full EPAR
from baseline on the PANSS
from baseline on the
from baseline on
from baseline
basis of individual clinical status
individual clinical
of individual clinical
individual
of individual
by
calculated by
from
" A
sulphone 0.0471 µg/ ml
of 0.63 mg mitratapide/
of 0.63 mg
of 0.63
out of 1,062 ) .
out of 1,062 )
out of 1,062
of 1 ml
of 1
out of
1,000 , less than
1,000 , less
1,000 ,
1,000
of 10 g/ dl (
of 10 g/ dl
of 10
of 100 % .
of 100 %
100
of 100
of 12 - 14
of 12 -
of 12 g/ dl (
of 12 g/ dl
of 12
of 15 mg has not
of 15 mg has
of 15 mg
of 15 mg/ day
of 15
of 2 units .
of 2 units
of 2
from 2653 to 16736
from 2653 to
from 2653
3.5
out of 3,852 ) .
out of 3,852 ) in
out of 3,852 )
out of 3,852
out of 3,862 )
out of 3,862
of 30 minutes , every
of 30 minutes ,
of 30 minutes
doses of 30 mg risedronate
of 30 mg should be
of 30
of 300 mg/ m2
of 300
of 300-360 mOsm/ kg .
of 300-360 mOsm/ kg
35 %
35
of 45 mg
of 45
of 5 mg Aclasta .
of 5 mg Aclasta
of 5 mg zoledronic acid
of 5 mg
of 5
of 5.25 mg ( 0.7
of 5.25 mg (
of 5.25 mg
of 5.25
of 50 IU/ kg 2
of 50 IU/ kg
of 50
aged
ranging from 517 to
ranging from 517
of 6-7.5 and an osmolality
of 6-7.5 and an
of 6-7.5 and
of 6-7.5
Within 60 days of
Within 60 days of
60 days of an
60 days of
of 600 IU/ kg
of 600
from 65 to 200 kg
from 65 to 200
from 65 to
from 65
of 7.9 % for both
of 7.9 % for
of 7.9 %
of 7.9
of 789 patients
levels of 80 to 375
of 80 to 375
levels of 80 to
of 80 to
levels of 80
of 80
ABILIFY solution for injection
of ABILIFY solution for injection
receiving ABILIFY solution for injection
of ABILIFY Each ml of
of ABILIFY .
of ABILIFY
ABILIFY
ABILIFY
of ABILIFY
receiving ABILIFY
ACOMPLIA , rimonabant ,
in ACOMPLIA , rimonabant ,
ACOMPLIA
taking ACOMPLIA with some medicines
taking ACOMPLIA with
of ACOMPLIA were
ACOMPLIA
as type 2 diabetes or
in ACOMPLIA
monitor ACOMPLIA
of ACOMPLIA in
of ACOMPLIA
taking ACOMPLIA
of Abilify and placebo
of Abilify and placebo over
of Abilify and
of Abilify
of Abraxane (
of Abraxane as first-line
of Abraxane as
of Abraxane at dose levels
of Abraxane at dose
of Abraxane has not been
of Abraxane has been
of Abraxane were
Abraxane
of Abraxane
of Abseamed in patients at
of Abseamed .
of Abseamed
of Abseamed between 17 and
of Abseamed between 17
of Abseamed between 25 and
of Abseamed between 25
of Abseamed between
of Abseamed
of Aclasta 5 mg
of Aclasta 5
given Aclasta :
of Aclasta can be
of Aclasta ( see
of Aclasta (
of Aclasta .
of Aclasta
given Aclasta
of Aclasta in children and
of Aclasta in children
of Aclasta in
administer Aclasta
account when assessing Aclasta .
account when assessing Aclasta
doses of Aclasta .
doses of Aclasta
of Aclasta , see section
of Aclasta , see
Aclasta
with Aclasta tend to
with Aclasta tend
Aclasta
Aclasta
given Aclasta
of Aclasta ,
of Aclasta
with Aclasta
of Actos .
in Actos 15mg tablets
of Actos 15mg tablets
in Actos 15mg
of Actos 15mg
in Actos 30mg tablets
of Actos 30mg tablets
in Actos 30mg
of Actos 30mg
in Actos 45mg tablets
of Actos 45mg tablets
in Actos 45mg
of Actos 45mg
Actos with
of Actos and insulin
of Actos and
Actos 15mg
Actos 30mg
Actos 45mg
Actos
in Actos
of Actos
of Actraphane .
of Actraphane
Actraphane
of agitation and disturbed behaviours
agitation/ behavioural
in agitation/ behavioural
of akathisia was 6.2 %
of akathisia was 6.2
of akathisia in bipolar patients
of akathisia in bipolar patients
of akathisia in bipolar
of akathisia in bipolar
of akathisia in
of akathisia was
of akathisia
of angioedema and anaphylactic reaction
of angioedema and
of angioedema
of aripiprazole ) .
of aripiprazole )
of aripiprazole .
of aripiprazole .
of aripiprazole
of aripiprazole and
aripiprazole
of aripiprazole
of medicines used to
of medicines used
to
bisphosphonates in
bisphosphonates
of blood clots/ blood
of bronchoconstriction
of CYP3A4 ( ketoconazole )
of CYP3A4 ( ketoconazole
of CYP3A4 ( e. g.
of CYP3A4 ( e.
of CYP3A4 (
of CYP3A4 ,
of CYP3A4
of CYP3A4 inducers is expected
of CYP3A4 inducers
of CYP3A4 inducers
of dehydro-aripiprazole ,
of dehydro-aripiprazole increased by 77
of dehydro-aripiprazole
of diabetes
of diabetes
of digoxin , warfarin ,
of digoxin , warfarin
of digoxin ,
of digoxin
dose modifications in patients with
dose modifications in patients
dose modifications in
dose modifications
of EPS was 19 %
of EPS including parkinsonism ,
of EPS including parkinsonism
of EPS including
of EPS was
of EPS
blisters .
blisters
of epoetin alfa on
of epoetin alfa is very
of epoetin alfa is
of epoetin alfa may
of Epoetin alfa and other
of Epoetin alfa and
of epoetin alfa has been
of Epoetin alfa
of epoetin alfa in
of epoetin alfa
of epoetin alfa
of Epoetin
of epoetin
of adult patients scheduled
of adult patients
of adult
of adult
of erythrocytes from precursors
of erythrocytes from
of erythrocytes
of the warning signs of
of the warning
of sex
of glucose
hip fracture event
by your doctor
by your
battery of
hypoglycaemic effect of insulin
hypoglycaemic effect of
of insulin
of insulin suspensions for injection
of insulin suspensions for
of insulin suspensions
of insulin products with fast
of ketoconazole or other
of ketoconazole or
of ketoconazole
of children .
of children
of bone tissue )
of bone tissue
with repeated annual dosing .
with repeated annual dosing
with repeated annual dosing
to co- morbidities
be stopped . du
be stopped
be stopped
of seizure
of cancer cells to
of cancer cells
cooling element .
cooling element
agonists ( LH-RHas )
agonists ( LH-RHas
of M-II is minimal
of M-II
of NMS
to avoid
to avoid
operate machinery .
operate machinery
of metformin and a sulphonylurea
of monotherapy with metformin
of metformin and
of metformin
of malformations and
of malformations
of mitratapide ( parent
of mitratapide (
of mitratapide
of Paget s disease
of nerve cells in the
of nerve cells
of orlistat , ethanol
osteoporosis
of paclitaxel , which
of paclitaxel , which
of paclitaxel ,
of paclitaxel in patients
of paclitaxel
of paclitaxel contain
of paclitaxel .
of paclitaxel
of paclitaxel following Abraxane administration
of paclitaxel is
of paclitaxel has not been
of paclitaxel has
of paclitaxel
paracetamol or
paracetamol
of patients with the
of Black patients
in patients with
number of patients .
number of patients
of patients with
of patients
patients
who are breast
of pioglitazone ( see section
of pioglitazone ( see
of pioglitazone (
pioglitazone and
of pioglitazone
pioglitazone and
of pioglitazone during
of pioglitazone
pioglitazone
of placebo (
of placebo
placebo
of rimonabant treatment in
of rimonabant has not
of rimonabant has
of rimonabant was found in
of rimonabant was
failure of
of rimonabant
of
of stroke or
of stroke
of cleavage (
of cleavage
excluded in the studies for
excluded in the studies
in the studies for
in the studies
of symptoms
analyses
of standard genotoxicity tests ,
of standard genotoxicity tests
of standard
Vantas
unique Vantas
of Vantas is sufficiently
of Vantas is
of Vantas
Vantas
of Vantas is
of Vantas
unique Vantas
of vertebral fractures did
of vertebral fractures
of zoledronic acid in
of zoledronic acid
zoledronic acid
of anaphylactic reaction/ shock
other medicinal products to affect
other medicinal products
of other
other medicinal
appropriate
of approximately 6 hours
of approximately 6
of approximately
recovery from the
of whom
concentration
on the published literature
on the published
of
the
three
in
in
in
benefit from a higher dose
of lipid soluble drugs
of advanced prostate cancer
of agitation and disturbed behaviours
of agitation and
of agitation
of injectable
of clinical fractures was 7.5
of clinical fractures was
of clinical fractures following a
of clinical fractures following
of clinical fractures
of clinical fractures over the
of clinical fractures over
of clinical
solvent-based paclitaxel 175 mg/ m2
solvent-based paclitaxel 175
solvent-based paclitaxel
may be injected by
of multiple medicinal
in new
new
of peripheral neuropathy to resolution
of peripheral neuropathy to
of peripheral neuropathy
of recombinant human erythropoietin
of recombinant human
methods
with
of adverse
less than 18 months of
of unchanged pioglitazone
of unchanged
white ,
white
of two safety pharmacology studies
of two safety pharmacology
of two
. of
2 diabetes
2
account when
are
be
dose
for
from
greater than
greater
have
in
infusions of
is not
is
levels of
may be
may result in loss of
may
months of
number of
of on
of spine
of such
of the
of the
of whom
of
out of
over
presence of
ranging from
recovery from
taking
ten
than its
than
to
type 2 diabetes
type 2
von
was
with
of greater than 12
of greater than
established related to conditions other
established related to conditions
established related to
to draw conclusions regarding
to draw conclusions
to
.
to prevent dehydration .
to prevent dehydration
prior to the initiation of
diluted
to protect from moisture .
to protect from moisture .
to protect from moisture
to protect from moisture
to protect from
to protect
before your surgery .
before your surgery
before your
to protect from light .
to protect from light .
to protect from light .
to protect from light
to protect from light
to protect from light
to protect
to protect from
to protect
mainly
to act mainly
than in those with
than in those
, before breakfast .
before breakfast .
, before breakfast
before breakfast
prior to surgery
prior to
for reconstitution before use
before
donating your own blood before
recently
have recently taken any other
recently taken any other
recent low-trauma hip fracture ,
recent low-trauma hip fracture
recent low-trauma hip fracture
recent low-trauma
recently
more
before and
before
prior to
prior
to
pre-existing
pre-existing
reports of
reports
abdominal wall .
anterior abdominal wall .
abdominal wall
anterior abdominal wall
pre-filled pens x 3
pre-filled pens x
pre-filled pens
be applied .
be applied .
therefore be applied .
be applied
be applied
therefore be applied
applied
be ensured .
be ensured
ensured
not
their previous insulin .
their previous insulin
steroid pre- treatment or
steroid pre- treatment
steroid
group .
group
be managed cautiously .
be managed cautiously
mainly
mainly via the faeces .
mainly via the faeces
mainly via the
mainly via
preferably
monthly intervals unless
monthly intervals
monthly
physician .
physician
transient , typically
transient .
transient and asymptomatic , were
transient and asymptomatic ,
transient and asymptomatic
transient
" mini " stroke
temporary
transient
transient loss of consciousness and
transient loss of consciousness
transient loss
transient
" mini " stroke have
and discuss
androgen-
mediated by a reduction of
mediated by a reduction
mediated by a
mediated by
was whether
was 5.8 for placebo
was 5.8 for
was 5.8
, Abilify was
Abilify was
, Aclasta was
Aclasta was
Aclasta was more effective than
, Aclasta was more effective
Aclasta was more effective
, Aclasta was
Aclasta was
was the number of patients
was the number of
was the number
aripiprazole solution for injection was
weight loss was less pronounced
was the incidence of clinical
was the incidence of
was the incidence
was the most notable important
was the most notable
, in
, the patients were
in
the patients were
was the most
was the same
was the
was
can occur ( see section
can occur ( see
can occur (
occur ( see section
occur ( see
occur (
( see section
( see
(
( see section
( see
(
were linear and dose-proportional .
were linear and dose-proportional
were linear and
were linear
was not powered
was not
was lower in a
was lower in
was lower
was rapidly reversible and dose
was rapidly reversible and
was rapidly reversible
was rapidly
improvement in
improvement
healing was comparable between
was comparable between
healing was comparable
was comparable
was more effective than
was more effective
area was
healing was
patients were
was generally
was
were
was generally similar between the
were :
were : nausea
were women , 87 %
were women , 87
were women ,
were women
visual disturbance ,
visual disturbance
excluded
almost
were usually transient , typically
were usually transient
were usually
and were
were similar to that
were similar to
were excluded in the studies
were excluded
were
of which were
waren
were excluded
were
which were
which can cause side effects
indicating extensive
which
however
indicating
which
anhydrous , corresponding to 0.0533
anhydrous , corresponding to 5.330
anhydrous , corresponding to
anhydrous ) .
anhydrous )
anhydrous
of anhydrous human insulin .
of anhydrous human insulin
of anhydrous
altered mental
unregelmäßiger Puls oder
due to vomiting
groups
groups
des
des
due to
female rats
female rats
female and male patients
female and male
female and
female
softened stools
softened
irreversible metabolism-dependent
direct- acting
direct-
irreversible metabolism-dependent
is usually in those with
medicine .
medicine
of the hormone .
of the hormone
for four days
four
need another dose of
need another dose
have any further
have further
further information is
any information
need more information about
with
any
further
have any
need another
need
indications .
other indications .
indications
other indications
further reduction of bone
further
course of continued therapy .
continuing to
continuing
continuing to
continuing
remains
white to off-white
white and cloudy after resuspension
white and
white
white HDPE bottles containing 28
white HDPE bottles
white tablets debossed with
white tablets
white
white , round tablets contain
white , round tablets
white , round
white , teardrop- shaped tablets
white ,
of white
white
on the type of food
the type of food
type of food
on the type of
the type of
type of
of
conjunction
in conjunction
of
Oriental
permitted recovery from the
permitted recovery from
permitted
,
little ,
little
data
affecting less than 1
less than 1
less than 1
affecting less than 10
less than 15 minutes
less than 15
less than 6 months ago
less than 6
less than three
less than
less duration , there were
less duration ,
less duration
species at plasma
less common .
becoming less common
less common
affecting less
becoming less
less
at least 211 patients in
at least 211
at least
if your dog has
if your dog
. if your
if your
when administering paclitaxel concomitantly with
when administering paclitaxel concomitantly
when administering paclitaxel
when pioglitazone was
when pioglitazone
when taking ABILIFY .
when taking ABILIFY
people with phenylketonuria
while you are using Abseamed
while you are using
if you are pregnant
if you have high blood
if you have high
If you
if you are
if you are
if you have developed
if you
you are
you
for example , if you
for example , if you
if you cannot receive
if
if the sustained haemoglobin exceeds
if the
if the solution
if the
an
when oral therapy
when oral
when
if they
, if
. if
if
the treatment of obese
unless
when administering
when
( see section 4.2
( see section 4.4
werden ( siehe Abschnitt 4.4
( see section 5.2
( see section 5.3
( see section
( see section
( see
werden ( siehe Abschnitt
werden (
that pioglitazone
that
, particularly at
be considered
should be
if you have
if you are
be
if
,
are advised
,
be
) .
.
Abraxane therapy .
Leaflet .
are observed .
be
before swallowing .
if possible .
period .
therapy .
use .
be
be
be
you may not
werden auf die
werden auf
the next dose after
the next dose
are taken orally once daily
cancer
( see section
( see
(
. It can be
may be
for infusion should slowly be
for infusion should slowly
infusion should slowly be
infusion should slowly
should slowly be
should slowly
werden mit
werden möglicherweise nicht alle Packungsgrößen
werden möglicherweise nicht alle
werden möglicherweise nicht
werden möglicherweise
in man .
in man
probably need
should be
and patients with diabetes
and patients with
and patients
and preventing them
and
be
be mediated by a reduction
be mediated by a
be mediated by
are being taken to
to treat
.
Abraxane therapy
all
are being
are observed
are
be
become
before
cancer
dosing
for infusion should
if possible
infusion should
period
should be
should
the
therapy
werden
with
. lp
can significantly impact
significantly impact
important
important that
important to take calcium
important for patients
important for patients
important for the
important for
important in the
important in
important
most
anticipated toxicities
5-hydroxytryptamine and dopamine
5-hydroxytryptamine and
5-hydroxytryptamine
function
fructose intolerance , glucose-galactose malabsorption
fructose intolerance ,
of fructose intolerance ,
fructose intolerance should
of fructose intolerance should
fructose intolerance
of fructose intolerance
haloperidol .
haloperidol and
haloperidol
how your anaemia
how your anaemia
how your
such as itraconazole and HIV
, such as ketoconazole or
such as ketoconazole or
, such as ketoconazole
such as ketoconazole
as metformin and gliclazide .
as metformin and gliclazide
as metformin and
as metformin
such as tiredness
such as redness , swelling
such as redness ,
such as redness
such as sedation (
such as sedation
, as with other potentially
as with other potentially
, as with other
as with other
, as with
as with
, as
as
such as a
such as
how
how
zu Empfehlungen bezüglich der
how the anaemia
how the
benefit
of how well the
how well
in milk
how long you
how long
as possible
as
these outcomes might apply
such as fever
such as unusual
such as
, such as
as
disease such as
how
may include
same as
such as
from the mouth is
from
screwed back on tightly .
screwed back on tightly
screwed back on
screwed back
repeat-dose
the repeat-dose
based on conventional studies of
based on conventional studies
repeated dosing
repeated oral
based on
repeat-dose
repeated
the repeat-dose
demonstrated a
demonstrated
,
( approximately 1/ 20th
to
,
and is
,
when
.
is needed .
receptors .
will receive
will advise you on the
will advise you on
will advise you
will advise you on the
will advise you on
will advise you
will receive
your doctor may
will
doctor will
pioglitazone is rapidly
pioglitazone is
will ask you
is given by injection under
is given by injection
is considered not known
is considered to
is considered
is given when
is used :
is used
is given
is used
is recommended in these patients
is reported
is recommended , therefore
optimised glycaemic control delays the
its use is
the treatment will
of Aclasta is
of Aclasta is
the use of
the use
the
will take this
is given 3
is catalysed by CYP3A4 .
is catalysed by CYP3A4
is
, a
a
recommended dose is a
monitoring of
is taken once daily with
is taken once daily
, it is recommended
it is recommended
will decide when you
will decide when
is endorsed ( two relate
is endorsed ( two
is endorsed (
is endorsed
is estimated
is estimated
is well absorbed , with
is well
wird hauptsächlich durch Metabolisierung und
wird hauptsächlich
will help to
will help
undergoes extensive hepatic metabolism by
undergoes extensive hepatic metabolism
wird in der folgenden Tabelle
wird in der
is eliminated by a triphasic
wird in
is individual and determined
no information will
is not recommended for anyone
is not recommended for
is not recommended for
is not recommended
is not metabolised
is not systemically
is not
is usually
is adjusted to
is adjusted
is
is given subcutaneously (
is administered subcutaneously in the
is given subcutaneously
accepted .
accepted
is given 2
is given twice
, approximately
activity
approximately
by
given
is given
is needed
is on
is
receptors
there is
use of
use
will
wird
is metabolised by multiple
is metabolised
is extensively metabolised
,
effective in maintaining the clinical
effective in a dose range
effective in
effective as metformin and gliclazide
effective as metformin and
effective as metformin
effective as
be
effective
substance in ACOMPLIA
substance in
substance
effective contraception
using effective contraception
effective
using effective
substance rimonabant .
substance rimonabant
substance or to
substance or
substance
more effective than risedronate .
more effective than risedronate
effective than
more effective than
effective
more effective
works by
works
fall
Aclasta works for one year
Aclasta works for
Aclasta works
also affects
acts by blocking
acts by
works in
is thought to act mainly
is thought to
is thought
acts
affects
works
and behaviour and emotional flatness
and behaviour and emotional
speech
know if
know how ABILIFY
know how
knows how to
knows how
know
Scientific Discussion (
published literature .
published literature
scientific advice from
scientific advice
scientific
the Summary of
the Summary
the
and this
this
and this
this
unit dose blisters
unit dose
what it is used
what it is
of
whilst the relative efficacy of
whilst the relative efficacy
whilst the relative
of
whilst the
whilst
.
been
been
similar
been
similar
been
the request of the
, there was no
, there was
the request of the
prescribed by
prescribed
prescribed by
prescribed
,
.
patients ,
prescribed by
prescribed
, ACOMPLIA 20 mg was
ACOMPLIA 20 mg was
Abilify
, Aclasta has been
Aclasta has been
has been prescribed for you
at the end of the
were assessed in the rat
were assessed in the
has been studied in
were assessed in
also looked at combining
also looked at
also looked
was observed in 45 %
was observed in 45
was evaluated in 7 patients
was evaluated in 7
was observed in 90 %
was observed in 90
has been reported in children
has been reported in patients
was evaluated in
was observed in
has been observed
.
has not been established
osteoporosis
, recovered label was
recovered label was
was
and looked at the number
looked at the number
, testosterone suppression was
testosterone suppression was
was
wurde durch die
wurde durch
wurde ein Anstieg des
wurde ein Anstieg
was apparent in animal studies
a similar significant increase
was
is sufficiently investigated and
is sufficiently investigated
sufficiently investigated and
sufficiently investigated
is sufficiently
sufficiently
in
was studied in a small
was found in one of
was found in one
were determined in clinical studies
has been detected in
was found in
no osteomalacia , marrow fibrosis
, no
no
wurde
has been associated with
have been associated with
has
demonstrated that
demonstrated
treatment was not evaluated and
was not evaluated and
treatment was not evaluated
was not evaluated
has not been formally investigated
has not been formally
has not been established .
has not been established
has not been studied specifically
has not been investigated .
has not been investigated
has not been
has not
treatment was not
was not
was significantly
was last approved on
was last approved
was last updated in 10-2007
was last updated
was last
,
6
Four studies
and looked
been
has been detected
has been studied
has been
has
have been
looked
osteoporosis
patients ,
population was
prescribed by
prescribed
the use of
there was
treatment was
use of
was assessed
was evaluated
was observed
was
were assessed
were
wurde
have not been evaluated beyond
( 57.3 % )
( 57.3 %
( 57.3
included somnolence ,
been
were
study .
2697
508 men were randomised
508 men were
, antibodies
, there were eight main
, there were eight
, elevated creatine phosphokinase
, elevated creatine
were
following adverse reactions were
, uncommon cases of seizure
, uncommon cases of
, uncommon cases
, uncommon
were
studies ,
were not specifically investigated .
were not specifically investigated
were not specifically
were not evaluated .
were not evaluated
were not
were
were treated without steroid
were treated without
, accidental or intentional acute
, accidental or intentional
, accidental or
, accidental
, cerebrovascular adverse events (
, cerebrovascular adverse events
, cerebrovascular adverse
was recovered unchanged in the
have
, there were
3 trials
been reduced
been
cases reported
festgestellt wurden
have been
have
studies ,
studies
study
trials
were carried out ,
were observed
were treated
were
wurden
wurden. er Die
wurden. er
wurden.
2 months was
while approximately 86 %
while approximately 86
while approximately
for the duration of therapy
for the duration of
during treatment with aripiprazole .
during treatment with aripiprazole
during treatment with epoetin
during treatment with
during treatment
during lactation .
during lactation
reported during post-marketing surveillance
treatment during the assessment
during puberty or due to
adequate clinical monitoring during the
administered during pregnancy
administered during pregnancy
during pregnancy and
during pregnancy
during pregnancy
während der
during therapy
during pregnancy , lactation
during pregnancy ,
during pregnancy and lactation
during pregnancy and
during pregnancy
during lactation .
during lactation
during the
during
during
while the
während der
while Cmax was unchanged
during and
develop such
develop
during
while
whilst
aqueous solution .
aqueous solution
aqueous
a week .
week by injection
week by
a week
week
weekly dose is between 75
weekly dose is between
weekly dose
total weekly dose is between
total weekly dose
weekly
recommendations , read
recommendations , read
wünschen , lesen Sie bitte
recommendations ,
wünschen ,
recommendations
wünschen
x 1 , 49 x
x 1 , 49
x 1 , 56 x
x 1 , 56
x 1 , 98 x
x 1 , 98
x 1 ,
x 1 film-coated tablets in
x 1 film-coated tablets
x 1 orodispersible tablets 28
x 1 orodispersible tablets 49
x 1 orodispersible tablets
x 1 tablets .
x 1 tablets 28 x
x 1 tablets 28
x 1 tablets 49 x
x 1 tablets 49
x 1 tablets 56 x
x 1 tablets 56
x 1 tablets 98 x
x 1 tablets 98
x 1 tablets in
x 1 tablets
x 1
x 109/ l and
x 109/ l
x 109/ l.
iron oxide ( E172 )
iron oxide ( E172
x ULN ) should not
x ULN ) should
x ULN )
x ULN or ASL/
x ULN or
x ULN
x
e. g. aminoglycosides or diuretics
e. g. aminoglycosides or
e. g. aminoglycosides
e. g. rifampicin
e. g. stenoses
e. g. diminished parathyroid reserve
e. g. diminished
e. g. diminished
e. g. increased exercise
e. g. increased
e. g.
e. g.
.
e. g. increased
e. g.
e. g.
e. g.
e.
swelling and inflammation .
e.
e. g. stroke
e. g. gemfibrozil
e. g. hypothermia , pyrexia
e. g. hypothermia ,
e. g. hypothermia
e. g. ,
e. g.
e. g.
e.
e. g.
e. g. anaphylactic reaction ,
e. g. anaphylactic reaction
e. g. anaphylactic
e. g. prior
dental surgery
dental
dental treatment or
dental treatment or
dental treatment
; the incidence of
; the incidence
; the
shows that pioglitazone improves
displays high
displays
, aripiprazole failed
, aripiprazole failed
aripiprazole failed
exhibited antagonist properties in
devoid of genotoxic potential in
did not show any changes
did not show any
, pioglitazone consistently gave
a
exhibited
failed
in
showed
substance in
shown no
showed
shown
CNS medicinal products with
CNS medicinal products
CNS
is fragile ,
is fragile
fragile
cerebrovascular
seek
Subjects
2
to 21 % of
to 21 %
to 21
up to 25°C )
50
8.7 % for
8.7 %
8.7
ABILIFY tablets
ABILIFY
ra ge
to aripiprazole tablets , with
to aripiprazole tablets ,
to aripiprazole tablets
to aripiprazole
treated patients .
treated patients
resulted in recovery in all
resulted in recovery in
resulted in recovery
The
to diet
vomiting , diarrhoea ,
vomiting
exposures
in exposures
or ACOMPLIA has not
muscarinic receptors .
muscarinic receptors
to male patients (
to male patients
to placebo -2.9 kg )
to placebo -2.9 kg
to placebo -2.9
to placebo .
placebo :
placebo
to placebo
free fatty
Obesity is
produce effects that
other
be preferable .
be preferable
to that
to
to tablets .
to tablets
to
three injections in
three injections
three
a lesser amount
a
one
following dosing from 80
following dosing from
the inhibition of the normal
the inhibition of the
may lead to hyperglycaemia .
may lead to hyperglycaemia
lead to hypoglycaemia .
lead to hypoglycaemia
lead to an increase
lead to an increase
otherwise decided by
to existing treatment with
to existing treatment
to existing
dose dependent decreases in serum
controlled by systemic chemotherapy .
controlled by systemic chemotherapy
by systemic chemotherapy
to reduce the exposure of
to reduce the exposure
to reduce the
to reduce
lead to further
by
greater
lead to
to a
to
, but
,
local requirements .
local requirements
to increase their
re- suspension .
re-suspension .
re- suspension
re-suspension
lowest effective
l
unlikely to
to be expected .
to be expected
benefit to be derived from
with excessive sedation and
with excessive sedation
with excessive
Public Assessment Report ( EPAR
mild inhibitory effect on
mild inhibitory effect
.
values
to the insulin requirement (
to the insulin requirement .
to the insulin requirement
too high .
are too high
are too high
too high
x 10 ml and
x 10 ml
x 10
x
in all
therapy .
all
in all
therapy
Limited data suggest
difficult .
difficult
to low
from light .
from moisture .
light .
moisture .
from light
from moisture
light
moisture
to be low .
to be low
episodes of hypoglycaemia .
episodes of hypoglycaemia
zu um 5 % ansteigt
zu um 5 %
zu um 5
zu um
treatment in between .
without treatment in between .
take too many tablets
to know if
to know
Packungsbeilage zu entnehmen .
Packungsbeilage zu entnehmen
Packungsbeilage zu
advice
be
greater
high
in
is
or the
or
ra This document is a
ra This document is
relative to
show
the
this to
to be
to
too
treatment in between
treatment in
with
without treatment in between
without treatment in
zu entnehmen .
zu entnehmen
zu
satisfactorily controlled
satisfactorily
for osteoporosis , but not
for osteoporosis , but
for osteoporosis ,
psychosis .
for
psychosis
indication of
indication
on tightly .
tightly .
on tightly
tightly
underlying
favour of controls .
favour of controls
favour of
favour
comparisons .
comparisons
last approved on
last approved
last updated in 10-2007
product , scientific
last updated
last
product , scientific
to break down their internal
to break down
to resolution
in discontinuation
relative to baseline
dopamine D4 ,
dopamine D4
dopamine
oral
oral
, the oral
oral doses of
oral doses
oral
the oral
H1 receptors .
H1 receptors
, serotonin 5HT1a
serotonin 5HT1a
serotonin 5HT2c and 5HT7
, serotonin
serotonin
, in part , by
in part , by
, in part
in part
adrenergic and histamine H1 receptors
adrenergic and histamine
carcinogenic potential of paclitaxel has
carcinogenic potential
, in
in
relative to
to
zum Einnehmen
zum
As weight increases from 65
As weight increases from
As weight increases
increasing study duration :
increasing study duration
increasing
increases , inform
increases ,
increases
orally during
orally
unit dose blister packs .
unit dose blisters .
unit dose blister packs
unit dose blisters
unit dose
to aripiprazole solution for injection
to aripiprazole
used to treat osteoporosis in
used to treat diabetes
to treat type 2
to treat metastatic breast cancer
for the treatment of
to treat
used to treat
for the treatment
to treat
used to treat
to recommend dose modifications in
to recommend dose modifications
to recommend dose
to recommend
taken to ensure the safe
taken to
to detect possible arrhythmias .
to detect possible arrhythmias
to detect possible
for infusion
for injection .
for injection
reduction in new
reduction in
reduction
reduction in
reduction
to reduce side effects
to reduce
to
to control the blood sugar
to control the
to control
for reconstitution is
for reconstitution
reproductive toxicity studies .
reproductive toxicity studies
minimisation
the serotonin reuptake site and
for the serotonin reuptake site
the serotonin reuptake site
safety and
safety
not affect your ability
not affect your
them to divide and multiply
them to divide and
them to divide
medicine to suppress
improvement
to starting Abseamed therapy .
to starting Abseamed therapy
to prevent
to
in order to
order to
to
by decreased appetite
followed by decreased appetite
by
followed by
by
followed by
for use with insulin syringes
for use with
for use
to prevent
for the prevention
efficacy and safety .
efficacy and safety
efficacy and
efficacy
to the existing treatment with
to the existing treatment
to the existing
for pH-adjustment ) ,
for pH-adjustment ) Sodium hydroxide
for pH-adjustment )
for pH-adjustment
significant
acid
for the
for
in
medicine to
of
to prevent
to the
to treat
to
used
zur
with rimonabant in overdosage
.
back into the systemic circulation
into the systemic circulation
is given concomitantly with cyclosporin
with food and drink
concomitantly with medicines known
together with two other
together with two
concomitantly with
is given concomitantly with
together with
concomitant administration of
concomitant administration
concomitantly
is given concomitantly
together
pooled presentation are :
pooled presentation are
pooled presentation
added to metformin in patients
added to metformin in
added to metformin
added to
to
addition to aripiprazole
in addition to aripiprazole
addition to
in addition to
addition
in addition
placebo
additional 6
additional pharmacovigilance activities
additional benefit .
provide additional benefits .
provide additional benefits
additional benefit
additional risk factors ( e.
additional risk factors (
additional risk factors
adding
additional
might apply
much Abseamed has been injected
much Abseamed
much
in two main studies
in two main
two main studies
two main
two years
two years
for two months .
for two months
two species , both via
two species , both
two species ,
two species , both via
two species , both
two species ,
two species
in two studies was
in two studies
two studies , where
two studies ,
two studies
two weeks following
two weeks
two other antidiabetic medicines
two other
for two consecutive days
for two consecutive days
for two consecutive
two relate
two of the cardiovascular
two of the
in two equal injections .
into 2 equal injections .
two equal injections .
in two equal injections
into 2 equal injections
two equal injections
in two equal
into 2 equal
two equal
two large
two minor metabolites , 3
two minor metabolites ,
two minor metabolites
two minor metabolites ,
two minor metabolites
two minor
two
two or more weeks after
two or more weeks
two or more
two or
two short-
two short-
two 6-month comparative
two 6-month
two safety pharmacology studies .
two safety pharmacology studies
two safety pharmacology
comparing
in two
two minor
two
2 times per week by
2 times per week
2 times per
twice a day for
twice a day
twice daily is
twice daily
2 times
2
given 2
given twice
twice a
twice
second year
second trial utilised
second trial
second
between 1.25 and 2.47 in
between 1.25 and
between 1.25
between 10 g/ dl
between 10 g/ dl
between 10 and 12
between 10 and
between 10
between 17 and 33
between 17 and
between 17
between 25 and 50
between 25 and
between 25
between 9.5 and 11
between 9.5 and
between 9.5
Cmax and Cmax corrected for
Cmax and Cmax corrected
Cmax and Cmax
Cmax and
between thumb and forefinger
between thumb and
between thumb
between epoetin alfa and
between epoetin alfa
between epoetin
between the
between
between
. du
between healthy
between healthy elderly and younger
between healthy elderly and
between healthy elderly
between
concentration
12 weeks .
12 weeks
12
cytotoxic anticancer medicinal product and
cytotoxic anticancer medicinal product
cytotoxic anticancer
cytotoxic
{ month/ year }
month/
One study also
One study
One
± 16 % of the
± 16 %
± 16
± 2.5
196 ± 28.1 ng/ ml
196 ± 28.1
± 33 %
± 33
±
µ : +44 ( 0)20
µ : +44 (
µ : +44
µ :
µ
APPEAR ON THE OUTER
APPEAR ON THE
APPEAR ON
OUTER
THE OUTER PACKAGE
APPEAR
Elderly patients ( 65 years
Elderly patients ( 65
Elderly patients (
Elderly : the effectiveness
Elderly The efficacy and
Elderly The efficacy
Elderly The
Elderly patients
Elderly
Elderly
deterioration of
deterioration
of deterioration of
of deterioration
includes appropriate dietary changes .
includes appropriate dietary changes
medical or healthcare professionals
Physicians should consider clinical
Physicians should consider clinical monitoring
Physicians should
should be alert to the
should be alert to
should be alert
Physicians
alert
Ísland VISTOR HF Sími :
Ísland VISTOR HF Sími
Ísland VISTOR HF
Ísland VISTOR
Ísland
Oedema Oedema may
oedema ) .
oedema )
oedema , mucosal
oedema ,
oedema .
oedema
reports of oedema were
oedema
158 Do
164 Do
170 Do
opening the bottle ,
opening the bottle
opening the
opening
opening
oesophagitis , toothache
oesophagitis ,
oesophagitis
BRISTOL-MYERS SQUIBB GESMBH Tel
Österreich BRISTOL-MYERS SQUIBB GESMBH Tel
BRISTOL-MYERS SQUIBB GESMBH
Österreich BRISTOL-MYERS SQUIBB GESMBH
BRISTOL-MYERS SQUIBB
Österreich BRISTOL-MYERS SQUIBB
BRISTOL-MYERS
Österreich BRISTOL-MYERS
Medice Arzneimittel Ges . mbH
Österreich Novartis Pharma GmbH Tel
Österreich Novartis Pharma GmbH
Österreich Novartis Pharma
Österreich Novartis
Österreich
Nausea , diarrhoea , vomiting
Nausea , diarrhoea ,
Nausea , diarrhoea
nausea , vomiting , an
nausea , vomiting ,
nausea , vomiting and diarrhoea
nausea , vomiting and
nausea , vomiting
nausea , constipation ,
nausea , constipation
Nausea ,
nausea ,
Nausea occurred in 29 %
Nausea occurred in 29
Nausea occurred in
Nausea occurred
nausea and vomiting .
nausea and vomiting
nausea and vomiting
nausea and
Nausea
experience nausea
nausea
Osteonecrosis of
Allergic reactions have been
Allergic reactions have
A half-life of approximately
A half-life of
A half-life
Pioglitazone or
Thrombotic/ vascular events ,
Thrombotic/
, little
,
A
Allergic
Pioglitazone
Overdose ( symptoms ,
Overdose ( symptoms
Overdose (
overdose with aripiprazole ,
overdose with aripiprazole
overdose with
Overdose of epoetin alfa may
Overdose of epoetin alfa
Overdose of epoetin
Overdose of
Overdose
of overdose
overdose
overdosing
line with the recommended
line with the
line with
line
Hypersensitivity :
Hypersensitivity to the active substance
hypersensitivity to the active substance
Hypersensitivity to
Hypersensitivity
hypersensitivity
of hypersensitivity
Hypersensitivity reactions including rare cases
Hypersensitivity reactions including rare
Hypersensitivity reactions including
hypersensitivity reactions ,
hypersensitivity reactions is
Hypersensitivity reactions
hypersensitivity reactions
overweight or obesity
overweight or
overweight
Survival [ 95 % CI
Survival [ 95 %
Survival [ 95
Survival [
Survival and
Survival
clear-cut
the occurrence of cardiac events
the occurrence of cardiac events
for the occurrence of cardiac
the occurrence of cardiac
for the occurrence of
for the occurrence
the occurrence of
the occurrence
supervision and monitoring should
supervision and monitoring should
monitoring to detect possible arrhythmias
monitoring to detect possible
monitoring
similar
were similar
generally similar between the
similar between the
similar decrease in
similar decrease in
similar increase
similar effect
similar
extent of absorption .
extent of absorption
extent of
mix
similar mix
a similar rate and
a similar rate
similar significant
a similar
similar
elderly women ,
elderly women
älteren Patienten ist keine
älteren Patienten ist
elderly patients with
among elderly patients who
elderly patients
patients
älteren Patienten
elderly and younger
elderly and
elderly
älteren
old
anxious or tense .
anxious or tense
anxious or tense .
anxious or tense
anxious or
anxious
medical prescription (
medical prescription
attention
medical
the occurrence of cardiac events
for the occurrence of cardiac
the occurrence of cardiac
for the occurrence of
for the occurrence
the occurrence of
the occurrence
seek medical
seek
symptoms of
the symptoms of
symptoms
the symptoms
do this .
to do this .
do this
to do this
over " 640 "
over " 641 "
over " 643 "
one year
greater than 12 g/ dl
greater than 12
of greater than 12
greater than 14 g/ dl
greater than 14
for 2 weeks
for 2
24
over 24
26-week ,
26-week ,
26-week
over 3 weeks .
over 3 weeks
over 3
over 30 minutes
over 30 minutes
over 30 kg and adults
over 30 kg and
over 30 kg
over 30
above 45 mg ( once
above 45 mg (
above 45 mg
above 45
aged over 50 years
aged over 50 years
over 50
aged over 65
over 75 years of age
over 75 years and
over 75
by CYP2C8
CYP2D6 .
CYP2D6
bestimmte sonstige Bestandteile von
over the whole treatment period
over the
the
via the faeces .
via the faeces
mediated through a combination of
mediated through a combination
via the kidney .
eliminated via the kidney .
eliminated via the kidney
via the kidney
over the duration of the
over the duration
over the
via the
by three biotransformation pathways :
by three biotransformation pathways
for three weeks (
over three weeks in
for three weeks
for three
over three
over
three
one year
over one year
over 15
over a period of 30
over three
over at least
over a period of
over
over a period
over
dosing for a longer
for a longer
beyond
dosing for a
for a
through
than a daily dose of
than a daily dose
than a
metabolised by multiple
metabolised
for four days ,
for four days
for four
over 12 weeks
over 12
,
above
beyond
by
dosing for
for
greater than
of greater than
over
than
via
allergic ( hypersensitive ) to
are hypersensitive ( allergic )
full list of
are hypersensitive ( allergic
full list of
full list
list
, orchidectomy
orchidectomy
overweight or obesity
overweight or obesity
overweight
overweight patients )
overweight patients )
overweight patients
in
overweight and
overweight
" high "
exceed
week .
exceed
week
be exceeded .
in section 4.2 .
be exceeded
in section 4.2
exposure produced
exposure
condition
therapy .
monitor
therapy
monitored and controlled as necessary
monitored and
monitored .
period .
monitored
period
monitored
should
.
extensively metabolised by the liver
extensively metabolised
predominantly
usual starting dose is 150
usual starting dose is 50
usual starting dose is 600
usual starting dose is
usual starting dose
usual dose is 9.75 mg
usual dose is 9.75
usual dose is
usual dose is 15 mg
usual dose is 15
usual dose is 5 mg
usual dose is 5
usual dose is
usual dose
usual
employed
usually in
usually mild to moderate
usually mild to
usually
